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ABSTRACT 
Aims: The overall aim of the thesis is to study the Health-Related Quality of Life 
(HRQoL) in Adult Congenital Heart Disease (ACHD). The thesis examines the 
impact of ACHD on HRQoL, the demographic, clinical, and psychosocial factors 
associated with HRQoL, and changes in these factors over time. 
Methods: The thesis consists of three studies, including a cross-sectional, a 
longitudinal, and a qualitative. Three hundred and fourteen individuals, from four 
diagnostic groups (Simple, Tetralogy of Fallot-ToF, Transposition of the Great 
Arteries-TGA, & Single Ventricle-SV) were recruited from The Heart Hospital, 
London and completed the cross-sectional study. Clinical measures were collected 
by a consultant cardiologist and participants completed a range of psychosocial 
measures, including generic and disease-specific measures of HRQoL. One-sample 
t-tests were conducted to examine differences between the whole sample and 
diagnostic groups and general population norms and ANOVAs for differences 
between the four diagnostic groups in HRQoL. Hierarchical multiple regressions 
were employed to examine the factors associated with HRQoL. One hundred and 
eighty eight participants completed the longitudinal study (mean follow-up: 3.3 
years). Changes in HRQoL and other psychosocial variables were explored using 
Hierarchical Linear Models (HLM). Semi-structured interviews were conducted with 
twelve participants to explore their experiences. 
Results: Participants reported diminished HRQoL in some physical and 
psychosocial domains. The SV group reported poorer physical and psychosocial 
HRQoL in various domains compared with the general population norms and some 
of the other diagnostic groups, whilst the Simple group reported impaired 
psychosocial HRQoL. Illness perceptions explained the largest proportion of 
variance in generic (physical and psychosocial) and disease-specific HRQoL. After 
accounting for demographic and clinical characteristics, psychosocial factors 
including perceptions about the symptoms and consequences of ACHD, the use of 
self-blame as a coping strategy, and mood were independently associated with 
HRQoL. Clinical factors, HRQoL, coping, and social support remained stable over 
time, whilst some changes were observed in illness perceptions and anxiety. The 
qualitative interviews provided further insight into the physical, psychosocial, and 
occupational consequences of ACHD, the people’s efforts to adjust to their condition 
and treatment and gain perspective, and the role of their social environment. 
Discussion: The theoretical and clinical implications of the findings are discussed. 
People with ACHD may benefit from routine psychological assessment and 
provision of clear and timely information and interventions addressing negative 
illness perceptions, depression, and anxiety. 
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CHAPTER 1 – CONGENITAL HEART DISEASE, ITS 
TREATMENT, AND IMPACT 
1.1. Prologue 
The overall aims of the thesis are to study the Health-Related Quality of Life 
(HRQoL) and the factors associated with HRQoL in Adult Congenital Heart Disease 
(ACHD). To capture the potential changes in HRQoL and psychosocial factors over 
time, these were assessed on two occasions in a sample of participants. In addition, 
the thesis consisted of a comprehensive set of studies including both qualitative and 
quantitative studies so as to provide a more comprehensive understanding of HRQoL 
in this group of people with ACHD. This chapter provides a brief description of the 
heart and its function followed by a description of Congenital Heart Disease (CHD) 
and the emergence of ACHD as a sub-specialty. The aetiology, epidemiology, 
survival and mortality rates in CHD are described. This chapter also includes a 
description of the classification initiatives in CHD. The most common defects, their 
treatment, and prognosis are also presented. The chapter concludes with an overview 
of complications in ACHD.  
1.2. The heart: structure and function 
To understand CHD and its types it is important to understand the structure and 
function of the normal heart. The heart is a muscular, fist-sized organ weighing 
between 200 and 400 grams that lies in the middle to the left of the thorax and is part 
of the cardiovascular system. It is comprised of four chambers, the upper left and 
right atria and the lower ventricles, separated by a muscular wall called the septum. 
The atria and ventricles work together with the four valves pumping blood around 
the body through the arteries and veins.  
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Every time a heart beats, two actions take place: diastole and systole. Blood is 
collected in the left and right atria and a contraction pushes blood through the 
tricuspid and mitral valves into the respective left and right ventricles (diastole). 
When the ventricles are filled with blood another contraction takes place (systole). 
Oxygen-poor blood is pushed from the right ventricle through the pulmonary artery 
into the lungs, which oxygenate the blood. Oxygen-rich blood is simultaneously 
pumped from the left ventricle through the aortic valve to the heart and other body 
parts. This cycle is repeated many times, with the heart beating 60-80 times a minute 
during rest. Every day the heart beats approximately 100,000 times, pumping more 
than 7 litres of blood. 
1.3. Congenital heart disease: definition and diagnosis 
CHD refers to abnormalities in the structure or the function of the heart, which are 
present at birth. Most defects are characterised by an ill-formed heart, structural 
deficiencies of the valves and vessels, or small holes on the septum. 
Many defects do not have obvious or even noticeable symptoms and may be 
diagnosed later in life. Symptoms normally depend on the severity of a specific 
defect. A number of typical symptoms may be observed in people with CHD: 
 Cyanosis: oxygen de-saturation caused by the persistent mixing of systemic 
venous blood (oxygen-rich) and pulmonary blood (oxygen-poor) 
 Shortness of breath 
 Dizziness or fainting (syncope) 
 Arrhythmias: irregular heartbeat/rhythm 
 Palpitations: heartbeat abnormalities 
 Fatigue 
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 Reduced exercise capacity 
CHD may be diagnosed at any point from the antenatal period to adulthood. 
Antenatal diagnosis was introduced more than 30 years ago and approximately 60% 
of CHD is now diagnosed during the antenatal and new-born period (Knowles & 
Hunter, 2014). Antenatal screening is usually conducted using ultrasound (foetal 
echocardiography) at the mid-trimester anomaly scan and appears to be useful in 
planning successful postnatal management (Brown & Sullivan, 2014). Recent data 
for 2013-2014 suggest that in the UK, up to 45.7% of major CHD is diagnosed 
during the antenatal period in those undergoing intervention in infancy (National 
Institute for Cardiovascular Outcomes Research [NICOR], 2014). However, up to 
40% of CHD may be diagnosed later in life including adulthood (Petersen, Peto, & 
Rayner, 2003). When CHD is suspected in the postnatal period and following an 
initial physical examination, diagnostic tests are carried out to confirm the presence 
of a cardiac defect. In the past, diagnosis was established through cardiac 
catheterisation. This involved a long thin tube (i.e. catheter) being inserted into an 
artery in the arm or leg and guided to the heart in order to map it using contrast dye 
and an x-ray machine. Due to recent diagnostic advances the presence of CHD may 
be identified through less invasive approaches, including transthoracic or 
transoesophageal echocardiography (TOE), electrocardiography (ECG), chest 
radiography, exercise stress testing, magnetic resonance imaging (MRI), and 
computerised tomography (CT) (Popelová, Oechslin, Kaemmerer, & Sutton, 2008).  
The combination of advanced diagnostic procedures and developments in surgical 
and interventional techniques along with the increase in quality of care led to a large 
population of affected children surviving well into adulthood. The result is a 
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continuously increasing population of adults with CHD and the development of a 
new cardiovascular sub-specialty, ACHD (Perloff, 1991), which includes all adults 
aged 16 and above, who have successfully transitioned from paediatric to adult care 
(Watson & Rana, 2009). In the past, the adult population of people with CHD was 
referred to as Grown-Up Congenital Heart (GUCH), but this has been superseded by 
the term ACHD. 
For the purposes of the present thesis the term ACHD is used throughout to refer to 
the adult population under study. The general term CHD is used within the context 
of the child and adolescent literature and when referring to the condition in general.  
1.4. Nomenclature and classification 
The inherent diversity that characterises CHD is attributed to the large number of 
different defects and their subtypes. A standardised system of nomenclature of CHD 
has only recently emerged. The International Society for Nomenclature of Paediatric 
and Congenital Heart Disease (ISNPCHD) created a comprehensive international 
nomenclature system by cross-mapping several existing lists from across the world. 
The International Paediatric and Congenital Cardiac Code (IPCCC) (Franklin et al., 
2008) is the result of meticulous research and meetings between several specialists 
from all over the world. The aim of this initiative is to name and categorise CHD and 
its treatment for the purposes of risk stratification, comparison of outcomes between 
specialised centres, and for the overall improvement of patient care. Although the 
IPCCC is currently only used by individual specialist cardiologists, there is great 
potential for its adaptation in research.  
Complexity of surgery has also been the focus of efforts to produce a standardised 
system. The Risk Adjustment in Congenital Heart Surgery-1 (RACHS-1) method 
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and the Aristotle Basic Complexity (ABC) score are two independent systems for the 
classification of treatment complexity. The future aim is the unification of these two 
systems (Jacobs et al., 2007).  
The following description of the most common defects is organised in four groups 
(Figure 1.1). The terminology used in the thesis is based on the clinical literature and 
previous studies in ACHD. For the purposes of the present thesis, the term used to 
describe these four groups will be “diagnostic groups”, with differing structural 
changes in the heart. This term is also used throughout the analyses described in the 
thesis.  
1. “Simple” 
 The following defects were collapsed into this group:  ventricular septal defect  atrial septal defect  right ventricular outflow tract obstruction (pulmonary valve stenosis)  left ventricular outflow tract obstruction (valvular aortic stenosis, 
coarctation of the aorta) 
2. Tetralogy of Fallot  
3. Transposition of the Great Arteries  
4. Single Ventricle  
Figure 1.1. Description of the four diagnostic groups 
The four diagnostic groups are described in the next sections. The most common 
long-term complications are discussed in more detail in section 1.8 (page 40). 
1.4.1. “Simple” 
Various defects were categorised under this diagnostic group and each is described 
in more detail in the following subsections. The term “Simple” was adopted to 
reflect the relative complexity of this group compared with the other three groups 
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included in the study and to relate the study to the large clinical literature and 
guideline reports which use the same terminology (Baumgartner et al., 2010; Billett, 
Cowie, Gatzoulis, Vonder Muhll, & Majeed, 2008a; Srinathan et al., 2005; Warnes 
et al., 2001; Warnes et al., 2008). 
1.4.1.1. Ventricular septal defect 
Ventricular Septal Defect (VSD) is characterised by a hole between the two heart 
ventricles that leads to an increase in blood flow to the lungs (Figure 1.2). It may 
occur as an isolated defect or as part of a more complex defect, such as Tetralogy of 
Fallot (see section 1.4.2, page 32). VSD is the most common acyanotic CHD, 
accounting for 30 to 40% of all CHD cases as an isolated defect (Baumgartner et al., 
2010). It is less common in the adult population due to the frequency of spontaneous 
closure (40-60% of children) (Popelová et al., 2008). 
 
© Texas Heart Institute [www.texasheart.org]1   
Figure 1.2. Image representation of VSD 
The natural history of VSD depends on the magnitude of the defect and the presence 
of pulmonary hypertension. Patients with small defects and no pulmonary 
                                                          
1 The right to use copyrighted images was granted through e-mail correspondence with the Texas 
Heart Institute. A copy of the correspondence can be found in Appendix A. 
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hypertension are usually asymptomatic and do not require treatment, yet are typically 
at higher risk for complications (Silversides et al. 2010a). Most patients have a 
reparative surgery before adulthood. The most common surgical intervention is the 
use of a patch to cover the hole and requires an open-heart surgery and the use of 
cardiopulmonary bypass. The operative mortality rate for surgical repair is 1-2% and 
it offers a relatively good long-term outcome (Baumgartner et al., 2010). Less 
commonly used is the transcatheter intervention, where devices are inserted into the 
heart through catheters and is performed in a catheterisation lab. This procedure is 
performed for patients who are at high risk for surgical mortality or those with 
previous surgical interventions (Baumgartner et al., 2010). 
The ten-year survival rate for unrepaired small VSD is 75% (Harris & Foster, 2009). 
The outlook for patients having the repair before the age of two is considered to be 
very good (Warnes et al., 2008). 
1.4.1.2. Atrial septal defect 
Atrial Septal Defect (ASD) is characterised by a hole between the two heart atria 
(Figure 1.3). In some cases the opening may develop during adulthood. This usually 
causes oxygen-rich blood from the left atrium to flow to the right atrium (shunt) thus 
increasing the pressure in the lungs (Popelová et al., 2008). ASD accounts for 9 to 
11% of all CHD cases. The most common subtype (based on the location of the 
hole) is secundum Atrial Septal Defect (ASDII), which accounts for 75% of all ASD 
cases. Ostium primum ASD is less common accounting for approximately 15% of 
ASD cases.  
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© Texas Heart Institute [www.texasheart.org] 
Figure 1.3. Image representation of ASD 
Because of its asymptomatic nature ASD is usually diagnosed in adulthood 
(Baumgartner et al., 2010). A large unrepaired ASD may lead to symptoms such as 
reduced exercise capacity, palpitations, shortness of breath, arrhythmias, and heart 
failure during the fourth decade of life (Silversides et al., 2010a). 
Depending on the size of the ASD, surgical closure through open-heart surgery may 
be required (Brickner, Hillis, & Lange, 2000). Reparative open-heart surgery has low 
operative mortality (1%) and patients generally have good long-term outcomes, 
especially if they do not experience other co-morbidities (Baumgartner et al., 2010). 
Transcatheter intervention is the common practice for ASDII closure and offers 
similar outcomes to surgical intervention (Silversides et al., 2010a). 
The survival rates for unrepaired ASD beyond the age of 50-60 years do not exceed 
50%, with subsequent attrition of about 6% per year (Perloff, 2009). The outlook for 
patients having the repair before the age of 25 is considered to be excellent, whereas 
patients having the repair after the age of 40 are at increased risk of long-term 
complications (Phillips, 2009).  
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1.4.1.3. Right ventricular outflow tract obstruction 
Right Ventricular Outflow Tract Obstruction (RVOTO) is an obstruction in the 
blood flow of the right ventricle. The most common (90%) subtype is valvular 
Pulmonary Stenosis (PS). PS is characterised by a narrowing of the pulmonary valve 
and therefore a problematic blood flow to the lungs (Figure 1.4). PS is usually 
isolated but can also appear alongside other congenital defects. As an isolated defect, 
PS accounts for 10% of CHD cases (Foster & Lease, 2009). 
The severity depends on blood flow rate, heart rate, and right ventricular function. 
Patients with mild PS may be asymptomatic, while severe PS may lead to shortness 
of breath, fatigue, or even chest pain (Brickner et al., 2000). Patients with mild PS 
may reach adulthood without requiring treatment, yet severe PS is usually treated in 
childhood (Popelová et al., 2008). 
 
© Texas Heart Institute [www.texasheart.org] 
Figure 1.4. Image representation of PS 
The preferred method of treatment of PS is transcatheter, with the aim to widen the 
narrowed part and improve blood flow. The alternative approach is surgical 
treatment, which is indicated for patients with associated defects and for whom 
transcatheter intervention is not possible (Baumgartner et al., 2010).  
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The survival rate for unrepaired mild PS is 95% at 20 years after diagnosis (Brickner 
et al., 2000). The long-term survival for repaired PS is considered excellent with 
rates close to the general population (97% survival at 25 years) (Popelová et al., 
2008). However, long-term complications and reoperations are common in patients 
with PS (Warnes et al., 2008). 
1.4.1.4. Left ventricular outflow tract obstruction 
Left Ventricular Outflow Tract Obstruction (LVOTO) is an obstruction in the blood 
flow of the left ventricle. A number of subtypes may be categorised as LVOTO-
specific, including valvular aortic stenosis and coarctation of the aorta. 
Valvular Aortic Stenosis (AS) is the narrowing of the aortic valve, which leads to an 
obstruction of blood flow from the heart to the rest of the body (Figure 1.5). 
Depending on the position of the narrowing AS may also be Sub-Aortic (SAS) or 
Supravalvar (SVAS) (Aboulhosn & Child, 2006). AS accounts for 8% of all cases of 
CHD (Popelová et al., 2008).  
 
© Texas Heart Institute [www.texasheart.org] 
Figure 1.5. Image representation of AS 
Symptoms may develop gradually in a period of 10 to 20 years and may include 
shortness of breath, chest pain, and syncope (Harris & Foster, 2009). Depending on 
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the severity and the experience of symptoms, patients may not need to undergo an 
intervention. Transcatheter and surgical approaches may be used as temporary 
palliative procedures in childhood, yet the only reparative treatment for AS is 
considered to be surgical Aortic Valve Replacement (AVR) (Popelová et al., 2008).  
Unrepaired and asymptomatic patients are considered to have a normal life 
expectancy, but patients that develop symptoms in adulthood generally have reduced 
survival (Brickner et al., 2000). The mortality timeline for unrepaired and 
symptomatic patients is 5 years after chest pain symptoms, 3 years after syncope 
symptoms, and 2 years after heart failure symptoms develop (Brickner et al., 2000). 
The 25-year survival rate for repaired AS patients is 75% (Hoffman, Kaplan, & 
Liberthson, 2004). Owing to the progressive nature of AS, long-term complications 
are possible after repair (Silversides et al., 2010b).  
Coarctation of the Aorta (CoA) is a narrowing (coarctation) of part of the main artery 
leading out of the heart (aorta) (Figure 1.6). CoA may present with other congenital 
heart defects (complex) as well as independently (simple) in 6 to 8% of all CHD 
cases (Gurvitz, 2009).  
The degree of narrowing generally varies, and depending on severity, patients may 
not be diagnosed until adulthood. Patients usually present with symptoms such as 
headaches, shortness of breath, leg fatigue, and nose bleeding (Harris & Foster, 
2009).  
Most CoA patients typically have surgery to relieve narrowing soon after birth. 
Operative mortality for surgical intervention in neonates and infants is high (4-50%), 
while that for older children is low (0-5%) (Doshi & Syamasundar Rao, 2012). 
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Transcatheter approaches to treating CoA are less common (Aboulhosn & Child, 
2006). 
 
© Texas Heart Institute [www.texasheart.org] 
Figure 1.6. Image representation of CoA 
The survival rate for unrepaired CoA is 10% at the age of 40 (Brickner et al., 2000). 
The 44-year survival rate for CoA repaired in childhood is approximately 73% 
(Popelová et al., 2008). Re-coarctation (recurring narrowing of the aorta) occurs in 
5-10% of surgically treated patients. Patients with CoA are thought to be at risk of 
late complications (Popelová et al., 2008). 
1.4.2. Tetralogy of Fallot 
Tetralogy of Fallot (ToF) is characterised by the presence of four problems in the 
heart (Figure 1.7): 
i) VSD: Hole between the two heart ventricles; 
ii) Over-riding of the aorta: The artery that carries oxygen-rich blood to the 
body is shifted over the right ventricle and VSD, instead of exiting only 
from the left ventricle; 
iii) Right ventricular outflow obstruction (PS): Narrowing of the valve and 
artery that connect the heart with the lungs; 
iv) Right ventricular hypertrophy: Thickened wall of the right ventricle. 
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ToF is the most common cyanotic defect, prevalent in 10% of children after the age 
of 1 year (Therrien, 2009). ToF has different severity levels; the mild form does not 
typically cause cyanosis at birth (“pink Fallot”) and it is sometimes diagnosed during 
adulthood (Silversides et al., 2010b). The classic form of ToF is characterised by 
cyanosis, and the severe form includes pulmonary atresia (under-developed 
pulmonary valve) (Popelová et al., 2008). 
 
© National Heart, Lung, and Blood Institute (NHLBI) [http://www.nhlbi.nih.gov/]2 
Figure 1.7. Image representation of normal heart and heart with ToF 
The majority of babies with ToF present cyanosis at birth and, if left untreated, they 
may experience symptoms ranging from hypoxic spells during childhood to stroke 
and endocarditis (see section 1.8, page 40) during adulthood (Brickner et al., 2000).  
In the past, treatment for ToF involved a stepwise approach, with a temporary 
palliative intervention followed by a complete repair. The main goal of the palliative 
intervention is to increase pulmonary blood flow (Baumgartner et al., 2010). Due to 
                                                          
2 NHLBI is part of the National Health Institute (NHI) and U.S. Department of Health and Human 
Services. The right to use images was granted through e-mail correspondence with the NHLBI. A 
copy of the correspondence can be found in Appendix B. 
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the long-term complications resulting from palliative procedures (Brickner et al., 
2000) such stepwise approaches are increasingly being abandoned in favour of 
complete repair early in a baby’s life. Typically, complete surgical repair is carried 
out in the first year of life (Therrien, 2009). The operative mortality for complete 
ToF repair is 1% (Baumgartner et al., 2010). 
The survival rate for untreated ToF is very low with only 11% at age 20 years, 6% at 
age 30 years, and 3% at age 40 years (Brickner et al., 2000; Perloff, 2009). The 
survival rate after 36 years is approximately 85% for repaired patients (Warnes et al., 
2008). Ten to fifteen percent of patients with ToF will eventually require re-
operation and long-term complications are considered common (Silversides et al., 
2010b). 
1.4.3. Transposition of the great arteries 
Transposition of the Great Arteries (TGA) is characterised by ventriculo-arterial 
discordance, with the aorta arising from the right ventricle and the pulmonary artery 
arising from the left ventricle (Figure 1.8). It is prevalent in 5% of all new-borns 
with CHD and it may present as an isolated defect or in complex forms with a VSD 
(Meijboom & Webb, 2009).  
Cyanosis is usually evident within hours from birth and heart failure is common 
during the new-born period. Due to the high cyanosis-related mortality rate (90%) 
during the first year of life, it is generally uncommon for TGA to be left untreated 
(Brickner et al., 2000). 
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© Texas Heart Institute [www.texasheart.org] 
Figure 1.8. Image representation of TGA 
Most patients undergo at least one operation during childhood. Critically hypoxic 
patients may initially undergo a transcatheter palliative procedure to improve blood 
mixing, yet ultimately surgical repair is required (Popelová et al., 2008). Until 
recently, the most common surgical procedures were the Mustard and Senning 
operations (atrial switch: creation of channels in atrial chambers to redirect blood 
flow), which were superseded by the Jatene operation (arterial switch: main arteries 
are switched to the right ventricles) around 1990. In complex cases of TGA with 
VSD and PS, the Rastelli operation (use of tubes to redirect blood flow) may be 
performed (Hornung, 2011). Most of the current adults with TGA have undergone 
one of the atrial switch operations. In the Mustard and Senning operations (using 
different techniques) the aim is to divert the blood and get oxygen rich blood to 
circulate around the body.  
Atrial switch operations have a 75 to 85% survival rate at 25 years post-intervention, 
whereas data for the arterial switch operation are only currently beginning to emerge 
and suggest a 10-year survival rate of 85 to 97% (Villafañe et al., 2014). The Rastelli 
operation offers less favourable outcomes, with only 70% of patients surviving after 
15 years (Silversides et al., 2010c). Long-term complications are considered 
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common after repair for TGA (Popelová et al., 2008). Arrhythmias may lead to the 
need for pacemaker insertion for up to 25% of patients (Meijboom & Webb, 2009). 
1.4.4. Single ventricle physiology 
The umbrella term “Single Ventricle” (SV) encompasses all the complex defects, 
which may range from cases where one of the two ventricles is missing or is 
underdeveloped resulting in a single functional ventricle (Hypoplastic Right 
Ventricle-HRV or Hypoplastic Left Ventricle-HLV) (Figure 1.9) to the closure or 
absence of one of the atrioventricular valves (Tricuspid Atresia-TA or Mitral 
Atresia-MA) (Figure 1.10). The common characteristic of all SV defects is that 
biventricular (two-ventricle circulation) repair is not typically feasible (Popelová et 
al., 2008). Patients are cyanotic from birth and with a median survival of 14 years, 
the prognosis for untreated SV is considered very poor (Silversides et al., 2010c).  
 
© British Heart Foundation, 2014. Reproduced with kind permission of the British Heart Foundation3 
Figure 1.9. Image representation of HLV 
                                                          
3 The right to use images was granted through e-mail correspondence with the British Heart 
Foundation. A copy of the correspondence can be found in Appendix C. 
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 © British Heart Foundation, 2014. Reproduced with kind permission of the British Heart Foundation.  
Figure 1.10. Image representation of TA 
Most patients are treated in childhood with a stepwise procedure towards the Fontan 
operation. Depending on the level of pulmonary blood flow, patients undergo 
various temporary palliative procedures followed by the first stage of the Fontan 
operation (Gatzoulis & Swan, 2009). The second stage may involve different 
modifications of the Fontan procedure or the more recent Total Cavopulmonary 
Connection (TCPC). These procedures are generally aimed at separating systemic 
and pulmonary blood flow and therefore minimising cyanosis, but they are 
considered palliative (Gatzoulis, Swan, Therrien, & Pantely, 2005).  
Research suggests that the survival rates after the Fontan operation are 86 to 94% at 
ten years and 82 to 87% at 15-20 years (Silversides et al., 2010c). SV defects have a 
multi-systemic character, which can result in serious complications (Warnes et al., 
2008). 
1.5. Epidemiology 
CHD is the most common congenital birth defect and in the UK it is estimated that 
eight in 1,000 babies are born with CHD. This results in an incidence of 5,000 babies 
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with CHD in the UK every year (Cardio & Vascular Coalition [CVC], 2008). Recent 
official reports on the prevalence of CHD in the adult population are not available 
but estimations have indicated a population of approximately 185,000 adults in 2010, 
a figure that is expected to be higher at this time (Petersen et al., 2003). Moreover, 
the majority of people with ACHD are in the younger spectrum of adulthood 
(Watson & Rana, 2009). 
In Europe there are approximately 1.2 million people with ACHD (Verheugt et al., 
2010). Wren and O’Sullivan (2001) estimated that the adult population consists of 
approximately 28% complex, 54% moderate, and 18% minor defects, yet the 
percentages for moderate and complex defects including ToF, TGA, and SV are 
expected to rise (Department of Health [DoH], 2006).  
1.6. Aetiology 
In 80 to 90% of cases the causes of CHD still remain unclear but these cases appear 
to have multifactorial origin. Only 10 to 20% of cases are attributed to specific 
causes that have been identified (Buskens, Grobbee, Frohn-Mulder, Wladimiroff, & 
Hess, 1995). Some defects have a genetic basis, with higher incidence observed in 
babies whose parents (especially the mother) have CHD (Deanfield et al., 2003). 
Approximately 6 to 10% of all cases of CHD originate from chromosomal 
abnormalities (Buskens et al., 1995). For instance, higher rates of CHD are evident 
in babies with chromosomal abnormalities such as Down’s syndrome (Petersen et 
al., 2003). Five to 10% of CHD cases are attributed to genetic disorders. Moreover, 
maternal diseases such as Type I diabetes, phenylketonuria, systemic lupus 
erythematosus and viral infections such as rubella account for about 1% of diagnosed 
cases of CHD (Bernier, Stefanescu, Samoukovic, & Tchervenkov, 2010). Finally, 
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another 1% of the cases are caused by environmental factors such as excessive 
maternal alcohol consumption, use of antiepileptic drugs, and use of other drugs such 
as lithium during pregnancy (EUROCAT, 2009). Increasing evidence suggests that 
maternal obesity may cause CHD and limited research indicates maternal smoking 
during pregnancy and air pollution as potential causal factors, yet more research is 
needed in these areas (Dolk, Loane, Garne, & EUROCAT, 2011).  
1.7. Survival patterns and mortality rates 
The medical and surgical advances of the past few decades in the diagnosis and 
treatment of CHD have led to increasing survival well into adulthood, especially for 
moderate and complex defects, including ToF, TGA, and SV. Specifically, the 
introduction of new diagnostic procedures, the improvement of intensive care, and 
the development of more efficient anaesthetic approaches are some of the factors that 
contributed to increased survival in CHD (Tan, 2006). In addition, the advances in 
surgical interventions and the increase in reparative surgeries being performed earlier 
in people’s lives, have led to an adult population with different disease physiology 
and clinical outcomes than the earlier survivors (Warnes et al., 2001).   
Currently, approximately 85% of people with CHD survive into adult life, compared 
with less than 20% fifty years ago (Deanfield et al., 2003). More recently, it has been 
reported that up to 90% of people with CHD may survive into adulthood (Stuart, 
2012). Nonetheless, CHD leads to reduced life expectancy even with simple defects 
(Watson & Rana, 2009). The combined rate of perinatal mortality and pregnancy 
terminations in Europe is currently 0.7 per 1,000 births and is mainly attributed to 
complex defects, such as SV (EUROCAT, 2009). 
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In the adult population overall mortality rates are not very clear. However, the Euro 
Heart Survey, which involved 79 European centres, revealed that there is a 2.8% 
mortality rate after a five-year follow-up in a population of individuals with ACHD. 
The lowest and highest mortality rates were observed in the simple defects such as 
VSD and the more complex such as SV respectively (Engelfriet et al., 2005). 
Cardiovascular causes (chronic heart failure, sudden cardiac death) account for 
approximately 45% of deaths in people with ACHD (Zomer et al., 2012a), with 
increased mortality when late complications are present (Verheugt et al., 2010). 
Increasing survival and decreasing mortality rates have resulted in an adult 
population larger than the paediatric population, with the adult population expected 
to rise by 5% every year (Tan, 2006). 
1.8. Long-term complications and healthcare utilisation 
Most individuals with ACHD will be eventually faced with long-term complications 
resulting from an “ageing repaired heart” and will require further interventions due 
to recurring problems (Ellison et al., 2013). A study of surgeries conducted in an 
ACHD specialised unit in Birmingham indicated that reoperations account for 34.2% 
of all ACHD-related operations (Srinathan et al., 2005). Some of the most common 
reoperations in ACHD include AVR after previous AS surgery, Pulmonary Valve 
Replacement (PVR) after surgery for PS or ToF, and recurring narrowing of the 
aorta after surgery for CoA. Reoperations are generally less common for TGA and 
Fontan-operated (SV) adults (Shore & Prapa, 2011).  
For these reasons, the majority of people with ACHD require long-term outpatient 
care by specialised cardiologists. Table 1.1 presents some of the most common long-
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term complications in ACHD, their prevalence, people at risk, and current 
management strategies.  
Many individuals with ACHD will eventually suffer from arrhythmias. As a late 
complication, arrhythmias occur in 18-20% of people with ACHD and are the most 
common cause of sudden cardiac death (52-84%) (Deal, 2009). Arrhythmias pose 
significant burden on individuals due to the frequent need for hospitalization and 
possible adverse effects of anti-arrhythmic medication (Triedman & Walsh, 2011). 
Heart failure is characterized by symptoms of exercise intolerance in the presence of 
any abnormality in the structure and/or function of the heart (Dimopoulos, Alonso-
Gonzalez, Thaulow, & Gatzoulis, 2011). Heart failure is the second most common 
cause of sudden cardiac death in ACHD (Deal, 2009). 
Most individuals with ACHD are also vulnerable to Infective Endocarditis (IE), an 
infection in the heart. IE can lead to further complications, including heart failure, 
thus vulnerable groups are regularly monitored by blood testing (Child, Pegues, & 
Perloff, 2009). 
Pulmonary Artery Hypertension (PAH) is defined as resting mean pulmonary artery 
pressures greater than 25mm Hg or exercise-induced pressures greater than 30mm 
Hg and is present in approximately 4% of people with ACHD (Owusu-Ansah, Lim, 
& Veldtman, 2009). An extreme manifestation of PAH is Eisenmenger Syndrome 
(ES), which occurs when pulmonary hypertension is presented with a persistent 
right-to-left shunt (reversal of blood flow) and cyanosis. PAH may lead to increased 
morbidity and mortality especially in people with complex defects (D'Alto & Diller, 
2014).   
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Table 1.1. Common long-term complications in ACHD 
Long-term 
complication 
Prevalence People at high risk  Prevention  Treatment 
Arrhythmias Most common 
complication 
evident in 18-20% 
of people with 
ACHD  
- TGA, SV, VSD, ASD, ToF, AS  - Modifications and advancements in 
surgical techniques 
- Prophylactic arrhythmia surgery 
- Anti-arrhythmic medication 
- Catheterisation procedures 
- Pacemakers 
- ICDs 
- Surgery 
Heart failure 1/3 of people with 
ACHD experience 
exercise 
intolerance, the 
main feature of HF 
- Cyanotic ACHD (especially those with 
PAH/ES) 
- SV (especially Fontan operated) 
- TGA (especially Mustard & Senning 
operated) 
- People with arrhythmias and 
ventricular dysfunction 
- Prevention is associated with attempts to 
treat the underlying ACHD  
- Heart (& lung) transplantation 
- Mechanical hearts 
- Palliative treatments (ICDs & pacemakers) 
- Medication, including diuretics (promote 
passing of urine), steroids, hypertension 
medication, anti-arrhythmic medication 
- Exercise training 
Infective 
endocarditis 
Accounts for 4% 
of admissions to a 
specialised ACHD 
service 
- Previous IE 
- Complex cyanotic ACHD  
- Unrepaired CoA, VSD, PS, AS, ToF 
- Prosthetic valves and conduits  
- Surgically created shunts (blood flow 
pattern that deviates from the typical) 
- Skin and oral hygiene 
- Antibiotic prophylaxis when undergoing 
surgical procedures, including oral surgery 
and natural childbirth 
 
- Antibiotic medication 
- Anticoagulant medication (“blood thinners”) 
- Surgery 
 
Pulmonary 
artery 
hypertension 
Affects 4% of 
people with 
ACHD 
- ASD, VSD, CoA, ToF, TGA, cyanotic 
ACHD 
- Earlier repairs 
- Prevention is also associated with 
attempts to treat the underlying ACHD 
- Hypertension medication 
- Oxygen therapy 
- Surgery 
- Heart (& lung) transplantation 
High-risk 
pregnancy 
Complications in 
11% of 
pregnancies 
- ES, TGA 
- Palliated or unrepaired cyanotic ACHD  
- Mechanical valves 
- Risk assessment 
- Medication adjustment 
- Surgical repair of ACHD 
- Maternal and foetal monitoring 
- Delivery planning 
- Contraception 
- Termination in already pregnant high-risk 
women 
- Elective delivery before 39 weeks gestation 
- Antibiotic prophylaxis during delivery for 
women with history of IE 
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Although pregnancy is believed to be well tolerated by women with ACHD, it is 
contraindicated for women with severe PAH/ES because of the high mortality risk 
(50%) (Warnes et al., 2008).  
In addition to the above complications, ACHD may cause significant reduction in 
exercise capacity. Generally, competitive sports are contraindicated for cyanotic 
individuals (Warnes et al., 2008). The benefits of physical activity are well 
documented, yet the feasibility of safe exercise programs in ACHD has not been 
sufficiently studied. Recent trials indicate that tailored exercise training in people 
with ACHD can be both safe and effective (Dua, Cooper, Fox, & Graham Stuart, 
2010; Findlow & Doyle, 1997; Holloway et al., 2011; Martínez-Quintana, Miranda-
Calderín, Ugarte-Lopetegui, & Rodríguez-González, 2010; Thaulow & Fredriksen, 
2004). 
As mentioned earlier, chronic cyanosis can lead to multiple complications affecting a 
number of different organs. At the cardiovascular level cyanosis may lead to 
progressive heart failure, infective endocarditis, and syncope (Gatzoulis et al., 2005). 
People with cyanosis may also experience orthopaedic problems, renal dysfunction, 
scoliosis, gallstones, and bleeding (Petersen et al., 2003). Neurological 
complications have also been reported in people with cyanosis, resulting from stroke 
and cerebral abscesses (Gatzoulis et al., 2005). Effective management of chronic 
cyanosis is considered to be very important due to the increased morbidity and 
mortality risk. 
The high morbidity in ACHD is evident in the increasing number of hospital 
admissions. In the UK, the proportion of all hospital admissions with a primary 
diagnosis of ACHD has increased from 21.5% in 1995/1996 to 27.3% in 2003/2004 
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in patients over 25 years (Billett, Majeed, Gatzoulis, & Cowie, 2008b). The main 
reasons for hospitalization are arrhythmias and interventional or diagnostic 
catheterization (British Cardiac Society Working Party, 2002). In addition, 
healthcare utilisation in people with ACHD is high, with increased number of GP 
visits and prescriptions compared with controls (Billett et al., 2008a). 
1.9. Loss to follow-up 
Despite the risk for long-term complications and the high healthcare utilisation in 
ACHD a significant number of people are currently not being followed-up at 
specialist ACHD centres and are therefore lost to follow-up (Wren & O’Sullivan, 
2013). A study conducted in a single centre in Canada indicated that up to 47% of 
their cohort failed to receive outpatient cardiology follow-up between the age of 18 
and 22. Lack of follow-up was also observed in 21% of people with severe defects 
(e.g. SV) (Mackie, Ionescu-Ittu, Therrien, Pilote, Abrahamowicz, & Marelli, 2009). 
In a Belgian study by Goossens et al. (2011) 10% of people did not receive follow-
up at the recommended level of care. Both of these studies found that male sex and 
no prior surgery were associated with loss to follow-up. Wray, Frigiola, and Bull 
(2011) reported that 24% of people who had undergone repair of ToF in Great 
Ormond Street Hospital London since 1964 were lost to follow-up. The authors 
reported that 48% of late deaths occurred in this group of people. Reasons for loss to 
follow-up were assessed through telephone interviews and included lack of 
knowledge, anxiety, and ambivalence. It is likely that significant rates of people lost 
to follow-up also exist in other defects (Wray et al., 2011).  
These data suggest that people who are currently followed-up in specialist adult 
clinics do not represent the whole spectrum of people with ACHD. Structured 
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transition from paediatric to adult clinics has been recommended in order to address 
this problem (Wren & O’Sullivan, 2013). 
1.10. Summary 
The increasing survival rates in babies born with CHD and the progression of this 
group into adulthood has led to the emergence of a new sub-specialty in cardiology, 
namely ACHD. People surviving well into their adult lives are faced with long-term 
complications and repeat interventions, which require them to attend regular 
appointments in specialist clinics. The chronic nature of ACHD poses significant 
challenges for people who are not only at high risk for mortality but also 
psychosocial consequences. The next chapter will review the evidence regarding the 
impact of ACHD on health-related quality of life by presenting the findings of the 
systematic review of the literature conducted as part of the present thesis. 
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CHAPTER 2 – IMPACT OF ADULT CONGENITAL 
HEART DISEASE ON HEALTH-RELATED 
QUALITY OF LIFE: A SYSTEMATIC REVIEW OF 
THE LITERATURE 
2.1. Prologue 
The first chapter provided the clinical context of the thesis by describing CHD, its 
treatment, and long-term complications. This chapter presents a systematic review4 
of studies that have examined HRQoL in people living with ACHD. The chapter 
begins with a brief overview of the increasing interest in patient-reported outcomes 
and especially HRQoL. Conceptualization and measurement issues in HRQoL 
research are then discussed followed by the rationale for the systematic review. The 
final section of this chapter consists of a description and discussion of the findings of 
the systematic review.  
2.2. Background 
2.2.1. Patient-reported outcome measures in chronic illness 
The growing population of people surviving into adulthood resulted in the 
recognition of ACHD as a chronic illness. Chronic illnesses are “prolonged, do not 
resolve spontaneously, and are rarely cured completely” (National Center for 
Chronic Disease Prevention and Health Promotion [NCCDPHP], 2009). The 
increased survival has led to a shift of focus towards endpoints beyond mortality. 
People with chronic illnesses are progressively faced with not just physical but also 
psychosocial challenges resulting from their illness (Petrie & Revenson, 2005).  
                                                          
4 The systematic review was published in February 2013 (Fteropoulli, Stygall, Cullen, Deanfield, & 
Newman, 2013) (see Appendix D). 
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This shift of focus is reflected in the widespread introduction of Patient-Reported 
Outcome Measures (PROMs) in evaluating the effects of healthcare. It links clearly 
to the UK DoH and the National Health Service (NHS) generic guidelines for the 
adoption of PROMs, in which the routine assessment of psychosocial outcomes and 
especially HRQoL in healthcare is promoted (DoH, 2008). The assessment of 
HRQoL outcomes is important because it is considered a major indicator of 
adjustment to chronic illness (Hoyt & Stanton, 2012).  
2.2.2. Conceptualizing health-related quality of life 
The concept of quality of life (QoL) and its definition has been the focus of a vast 
number of studies. The prefix “health-related” is now used to distinguish quality of 
life measurements carried out in the medical context of health and illness (Testa & 
Nackley, 1994). Nevertheless, a clear and agreed definition of health-related quality 
of life remains largely elusive. Although investigators disagree as to what domains 
or dimensions constitute the concept, there is an agreement that HRQoL is a 
complex, subjective, and multi-dimensional concept (Fayers & Machin, 2009). 
The conceptualization of life domains that comprise HRQoL has been primarily 
based on the World Health Organisation’s (WHO) definition of health: “a state of 
complete physical, mental, and social well-being and not merely the absence of 
disease or infirmity” (WHO, 1948). In the present thesis, the definition by the 
International Society for Quality of Life Research (ISOQOL) was adopted, whereby 
HRQoL is the functional consequences of a condition and its treatment on a person 
and encompasses physical, occupational, psychological, interpersonal, and somatic 
sensation elements (Schipper, Clinch, & Olweny, 1996). However, it should be 
noted that QoL and HRQoL are not defined well in the ACHD literature. Therefore, 
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the systematic review presented in this chapter aimed to be over-inclusive by 
studying (HR)QoL in general (see section 2.4.2.2, page 53). 
2.2.3. Measuring health-related quality of life 
Much as its definition, the measurement of HRQoL has been a source of 
disagreement. Generally, there are three approaches in measuring HRQoL, namely 
generic, disease-specific, and individual. 
Generic measures can be used beyond the bounds of illness and disability and many 
were initially developed to assess HRQoL in healthy populations (Fayers & Machin, 
2009). These measures may include multiple items that address various dimensions 
such as physical, emotional, and social functioning. The most widely used generic 
measure is the short-form 36 (SF-36) (Ware, Snow, Kosinski, & Gandek, 1993). One 
of the advantages of such generic measures is that they allow comparisons between 
the target patient group and normative data that has been acquired from the general 
population. The generic nature of such measures carries some inherent limitations, 
such as limited sensitivity and responsiveness to changes in HRQoL, specific to 
various illnesses (Guyatt, Feeny, & Patrick, 1993). 
Some of the limitations of generic measures are potentially addressed by disease-
specific measures, which are specific to an illness, its associated symptoms, and 
challenges. These measures focus on specific aspects of peoples’ lives that are 
considered to be influenced by their illness and therefore in many cases are assumed 
to be more responsive to changes in the condition (Fletcher, Gore, Jones, Fitzpatrick, 
Spiegelhalter, & Cox, 1992). Their limitation is that they cannot be used to compare 
HRQoL between different illnesses and with the general population. At present, 
there is only one disease-specific measure for ACHD, namely the Congenital Heart 
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Disease-TNO-AZL Adult Quality of Life (CHD-TAAQOL) questionnaire 
(Kamphuis et al., 2004). Details of this measure are discussed in Chapter 5. 
Individual measures of HRQoL have been developed in order to capture what is 
most important from the patients’ perspective. In such measures, people nominate 
the most significant areas of their lives and rate their functioning in these areas. One 
such measure is the Schedule for the Evaluation of Individual Quality of Life-Direct 
Weighting (SEIQoL-DW) (Hickey et al., 1996). Although these measures offer 
personalised insight about people’s HRQoL, they are time consuming and do not 
allow comparisons between people because the areas of the lives that are important 
are determined by the individual (Wood-Dauphinee, 1999).  
Generally, it is suggested that both generic and disease-specific measures are 
included in studies to capture comparisons to other conditions and normative data of 
a healthy population and also to be sensitive to the specific symptoms of the 
condition under study (Fletcher et al., 1992). 
2.2.4. Rationale for systematic review 
HRQoL has become one of the major PROMs in ACHD research (Moons, 2010). 
When the present study commenced, studies on HRQoL had been reviewed in four 
papers all of which focused in children and adolescents with CHD. Two were 
systematic reviews and two were overviews of the literature. The earliest systematic 
review was published in 2009 and focused on psychological adjustment and HRQoL 
in children and adolescents after open-heart surgery (Latal, Helfricht, Fischer, 
Bauersfeld, & Landolt, 2009). The second systematic review described and 
compared the HRQoL of children and young adults that were either born pre-term or 
born with CHD (Dahan-Oliel, Majnemer, & Mazer, 2011). Of the two overviews one 
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was an overview of neuropsychological, psychosocial, and HRQoL outcomes in 
children and adolescents with CHD (Bellinger & Newburger, 2010), while the other 
described the measurement of HRQoL and the status of the literature in children with 
CHD (Marino, Uzark, Ittenbach, & Drotar, 2010). 
The reviews reported mixed findings in the literature with some of the reviewed 
studies indicating impaired HRQoL in children and adolescents with CHD, while 
others did not support this notion. There were also differences between proxy and 
self-reported HRQoL with parents usually reporting greater impairment compared to 
the children themselves (Latal et al., 2009). The difficulty of using proxy and self-
reported HRQoL assessments has been identified in the overviews by Bellinger and 
Newburger (2010) and Dahan-Oliel et al. (2011).  
Disease complexity was associated with poorer HRQoL in the review by Dahan-
Oliel (2011). Latal et al. (2009) did not support this conclusion but reported that 
other clinical characteristics such as medication and co-morbidities were associated 
with impaired proxy-reported HRQoL (Latal et al., 2009). The review by Marino et 
al. (2010) also identified the methodological limitations of the child literature, which 
included small samples, variability of measures, and discrepancies between patient 
and proxy assessments. 
One literature review which was published in 2005 focused on the biopsychosocial 
experiences of the adult population, including HRQoL (Kovacs, Sears, & Saidi, 
2005). Similarly to the reviews in the child and adolescent literature, this study 
reported mixed findings on the HRQoL of people with ACHD. In addition, the 
impact of disease complexity on HRQoL in the adult population remained unclear. 
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The review by Kovacs et al. (2005) was not specifically focused on HRQoL in 
ACHD and identified only a small number of studies (n=  8). Although some of the 
studies included measures of disease complexity and other clinical characteristics, 
the review provided only a brief summary about their impact on HRQoL and did not 
examine these associations in detail. In addition, since the publication of the review 
by Kovacs et al. (2005) several new studies had been published. A more detailed 
examination of HRQoL in people with ACHD and the role of disease complexity 
and clinical factors was therefore considered necessary to gain an up to date and 
comprehensive understanding of this area of work.  
2.3. Aims of the systematic review 
The focus of the systematic review was HRQoL, thus papers that were restricted to 
an examination of psychosocial factors and did not include HRQoL were not 
considered. The literature on psychosocial variables, change over time in these 
variables, and their relationship with HRQoL is addressed in Chapter 3 within the 
context of the theoretical framework of the thesis. The aims of the systematic review 
were:  
1) To examine the impact of ACHD on the HRQoL of patients compared with 
healthy controls and/or normative data. 
2) To establish whether disease complexity and clinical variables are associated 
with HRQoL in ACHD. 
2.4. Methodology 
In accordance with reporting guidelines for systematic reviews, a Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist 
(Moher, Liberati, Tetzlaff, & Altman, 2009) can be found in Appendix E. According 
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to the PRISMA checklist, the report consists of methodological aspects including the 
search strategy, eligibility criteria (e.g. participants, comparisons, outcomes, and 
study design), information sources, selection process, plan of analysis, synthesis of 
the results, and quality assessment. The report also includes a flow diagram of the 
selection process, results of individual studies in table form, summary of evidence, 
and the limitations of the included studies and the systematic review. 
2.4.1. Search strategy 
The electronic databases outlined below were searched from inception through to 
November 2011.  
 Science Direct 
 Pubmed 
 Embase, Amed, and PsycInfo through OVIDSP 
 CINAHL Plus and Medline through EBSCO 
Articles published after the review completion, between November 2011 and August 
2014, were also identified and the findings from these studies are summarised in the 
results section. The findings of newer articles identified in 2014 did not differ from 
the overall conclusions of the review completed in 2011. The synthesis of the 
findings includes the studies identified in the original search and recent studies are 
addressed in an addendum.  
A scoping search revealed that studies in ACHD did not distinguish between QoL 
and HRQoL. For this reason, and to avoid excluding relevant studies, the general 
term quality of life was used to search the literature. The search did not include terms 
relating to specific indices of (HR)QoL (e.g. social functioning, mood, see section 
2.4.2.2, page 53). Initial search terms were specific, (e.g. “quality of life AND 
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GUCH”) but as the search did not retrieve many relevant articles, it was broadened 
by using various word combinations i.e. (“quality of life” OR “life satisfaction” OR 
“well being”) AND (GUCH OR ACHD OR congenital heart disease OR congenital 
cardiac disease OR congenital heart defect OR congenital cardiac defect). Where 
the search yielded too many results, additional filter terms were used (e.g. AND 
adult). In addition, the bibliographies of selected articles were reviewed for relevant 
titles. The search strategy was conducted in a single stage and it was the same for all 
electronic databases. An example of the full electronic search strategy for one of the 
databases is provided in Appendix F. 
2.4.2. Inclusion and exclusion criteria 
2.4.2.1. Publication type 
Articles written in English and published in peer-reviewed journals were included.  
2.4.2.2. Study design and purpose 
Studies were included if they used quantitative methods to measure HR(QoL), while 
qualitative studies, literature reviews, meta-analyses, opinion articles, commentaries, 
and reports were excluded. Studies were included if their purpose was to: a) describe 
the patients’ (HR)QoL compared with normative data or healthy controls and/or b) to 
study associations between disease complexity or individual clinical variables and 
(HR)QoL. Studies were excluded if their purpose was to study associations between 
psychosocial variables and HR(QoL). As mentioned earlier, (HR)QoL is not well-
defined in the ACHD literature. Thus, the review aimed to examine the literature on 
(HR)QoL in general and be over-inclusive during searches. Only studies that 
mentioned and described (HR)QoL were included and those that solely described 
what may be considered related components of (HR)QoL or other PROMs (e.g. 
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cognitive functioning, mood, social functioning) without referring to (HR)QoL were 
excluded. For example, a study was included if it presented data on cognitive 
functioning as part of its (HR)QoL measurement but a study was excluded if it 
described cognitive functioning independently outside the context of (HR)QoL. 
2.4.2.3. Measures 
Only studies using (HR)QoL measures validated in previous research with adult 
samples were included. These measures included validated multidimensional 
questionnaires and single-item measures assessing (HR)QoL. Studies that used 
measures of other PROMs such as social functioning, mood, or measures of 
psychosocial functioning were excluded (see section 2.4.2.2, page 53). Studies were 
excluded if they used non-validated measures such as author-designed single-item 
measures or question sets. 
2.4.2.4. Participants 
People with ACHD were defined as those aged ≥14 years. Initially age was set at 
≥16 years; however, it was changed to ≥14 to reflect the increasing number of 
studies that include younger individuals in primarily adult samples. Such studies 
were included if they provided data on HRQoL using questionnaires designed for 
adults (see section 2.4.2.3). Furthermore, when studies with mixed samples 
distinguished between paediatric and adult samples in terms of (HR)QoL assessment 
and reporting, only the adult data was included in the systematic review. Studies that 
were exclusively on paediatric samples and assessed (HR)QoL using paediatric 
measures were excluded as the review was focused on adults. Studies were excluded 
if they consisted solely of Marfan syndrome samples. Marfan syndrome is a 
hereditary connective tissue disorder that can affect the heart among other body 
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organs in 80% of cases (Child, 1997), hence it is not considered to be a congenital 
heart defect exclusively. 
2.4.3. Assessment of relevance 
Relevance was assessed based on the article title, then on the abstracts, and finally by 
reviewing full-text articles. An initial review of the titles was conducted by the 
researcher and articles were excluded if the condition under study was not relevant 
(i.e. other medical conditions such as coronary heart disease). Articles were retained 
for abstract assessment when there was uncertainty about their relevancy based on 
title alone. The abstracts were then assessed using the eligibility criteria by the 
researcher along with a member of the supervisory team. When there was 
uncertainty about the relevance of articles these were discussed and cross-checked 
by the whole supervisory team using the inclusion and exclusion criteria. Overall, 
there was agreement in the assessment of article relevance and there were no grey 
areas in deciding the relevance of articles because the search was intended to be 
over-inclusive and it was clear whether the articles were on the topic or not. 
2.4.4. Analysis plan 
 A quantitative meta-analysis was not conducted as part of this review. A narrative 
synthesis was considered appropriate due to the anticipated heterogeneity among 
studies in terms of participant characteristics, outcome measures and study design. 
The extracted information was tabulated for ease of synthesis of the data. 
2.4.5. Data extraction and synthesis 
A data extraction form (Appendix G) was used to record general article information 
(title, author(s), and source), sample characteristics (target population, 
inclusion/exclusion criteria, and demographic information for the ACHD group and 
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the normative data/control group), study characteristics (aim(s), design, (HR)QoL 
definition, measures, and statistical analysis), and main findings. 
For the purpose of describing the findings, the scales or subscales of each (HR)QoL 
instrument used in the studies were categorised into three broad domains, namely 
physical, psychosocial, and environmental/occupational HRQoL and related 
subdomains (Table 2.1). Therefore, Table 2.1 represents the measurement rather than 
the operationalization of (HR)QoL in the studies. The categorisation was conducted 
by the researcher and cross-checked by the supervisory team. Physical HRQoL 
included all scales or subscales measuring concepts relating to physical functioning 
and physical health, while psychosocial HRQoL included those that measured 
concepts relating to psychological and social functioning, and mental health. 
Environmental/occupational HRQoL included all scales and subscales measuring 
physical and home environment, access to healthcare, daily activities, work, and 
financial resources. 
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Table 2.1. Categorisation of scales and subscales into domains of HRQoL for the systematic review data synthesis 
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occupational 
HRQoL 
Ph
ysi
cal
 
fun
ctio
nin
g 
Ro
le p
hys
ica
l 
Pai
n 
Ge
ner
al h
eal
th 
Sy
mp
tom
s 
Gr
oss
 m
oto
r 
fun
ctio
nin
g 
Fin
e m
oto
r 
fun
ctio
nin
g 
Co
gni
tiv
e 
fun
ctio
nin
g 
Sle
ep 
Psy
cho
log
ica
l/ 
me
nta
l h
eal
th 
Ro
le e
mo
tio
nal
 
Vit
alit
y 
Ha
ppi
nes
s 
Sex
ual
 
fun
ctio
nin
g 
So
cia
l 
fun
ctio
nin
g 
En
vir
onm
ent
 &
 
dai
ly 
act
ivi
ties
 
SF-36                 
WHOQOL-Bref                 
DUKE                 
SIP                 
TAAQOL                 
SQoL                 
CHD-TAAQOL                 
LAS                 
SEIQoL-DW                 
GBB                 
WHOQOL-Bref= World Health Organization Quality of Life- Bref, DUKE=DUKE Health Profile, SIP= Sickness Impact Profile, TAAQOL= TNO-AZL Adult’s Health-Related Quality of Life, 
SQoL= Subjective Quality of Life, LAS= Linear Analogue Scale, GBB= Giessener Complaints Questionnaire.  
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2.4.6. Quality assessment 
To assess the quality of each study a checklist was created based on the Quality 
Index proposed by Downs & Black (1998). The checklist assessed the quality of a 
study in four areas: reporting, external validity, bias, and selection bias (Appendix 
H). Each item on the scale was given a score of 2, 1 or 0. The quality of each study 
was calculated by summing up the score points. The best possible score was 36, with 
0-9=  poor quality, 10-18=  low quality, 19-27=  moderate quality and 28-36=  high 
quality. 
2.5. Results 
2.5.1. Identified articles 
A total of 431 potential articles were identified. The details of the article selection 
process are presented in Figure 2.1. After exclusions based on title relevance, the 
abstracts of 201 articles were examined. After further exclusions, the full-texts of the 
remaining 58 articles were examined in detail for inclusion in the systematic review. 
In addition, examination of the bibliographies of these articles resulted in 3 relevant 
articles. A total of 31 articles were included in the systematic review.
CHAPTER 2 – SYSTEMATIC REVIEW 
59 
 
 
Figure 2.1. Flow chart of article selection for the systematic review 
Articles identified and assessed 
for title relevance 
n=  431 
Excluded n= 230 
Not ACHD sample 
Articles assessed for abstract 
relevance  
n=  201  
Excluded n= 143 
Clinical outcomes (n=  32) 
Qualitative studies (n=  11) 
Child samples (n=  17) 
No measure of (HR)QoL (n=  57) 
Conference abstracts/editorials (n=  22) 
Not ACHD sample (n=  4) 
 
Articles assessed for full-text 
relevance  
n=  58  
Excluded n= 30 
No intention to measure (HR)QoL (n=  3) 
No measure of (HR)QoL (n=  10) 
Purpose of the study not relevant (n=  11) 
Not (solely) ACHD sample (n=  6) 
Total number of articles included in 
the systematic review 
n=31 
Total from bibliography 
search (n=3) 
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2.5.2. Article characteristics  
The characteristics of all reviewed studies are presented in Table 2.2. Twenty-six 
studies examined HRQoL in people with ACHD in comparison with normative data 
or healthy controls and 22 examined the relationship between disease complexity or 
clinical variables and HRQoL. The reviewed articles were published between 2001 
and 2011. The majority of studies originated from Europe (n=  23, 74%). The 
remaining originated from North America (n=  6, 19%) and Asia (n=  2, 7%). 
2.5.3. Study quality 
The methodological quality of all studies is reported in Table 2.2. The majority of 
studies (n=  27, 87%) were of moderate quality, while the remaining (n=  4, 13%) 
were low. The main reasons for low quality were poor reporting and insufficient 
sample size. Most studies failed to report whether the sample size resulted from 
power calculations, thus it is not known whether the studies had sufficient power to 
answer the research questions. Some studies did not clearly describe the participant 
selection process, making it difficult to assess whether the individuals that took part 
were a representative sample of the population they were recruited from. Of 
particular note is the study by Ternestedt et al. (2001) in which the statistical analysis 
was not described. It was therefore difficult to evaluate the validity of the findings. 
This study and those by van den Bosch et al. (2004), Cohen, Daniela, Yalonetsky, 
Gagin, and Lorber (2010), and Jefferies, Noonan, Keller, Wilson, and Griffith (2004) 
were rated as low quality due to poor methodological reporting and small sample 
size.
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Table 2.2. Characteristics of the studies included in the systematic review 
 Authors (year) Design Participants Comparison group (HR)QoL 
measure 
Study 
quality 
  N, Mean age (S.D., range), 
gender 
Diagnosis or patient group    
1 Bol Raap et al. 
(2007) 
Retrospective 
13yrs follow-up 
(QoL cross-
sectional) 
N=  28 (Follow-up N=  25) 
Mean age (at surgery): 34 (19-50) 
Gender: 15 male, 13 female 
All VSD Normative data 
N=  4410 
TAAQOL 
 
Moderate 
(22) 
2 van den Bosch 
et al. (2004) 
 
Cross-sectional N=  22 for (HR)QoL assessment 
(total N=  36) 
Mean age (at operation): 12 (2-34) 
Gender: 18 male, 18 female 
21 TA, 9 DILV, 6 other Normative data SF-36  
  
 
Low (18) 
3 Bruto et al. (2007) Prospective  
(cross-sectional) 
N=  912 
Mean age: 30 (11) 
Gender: 474 male, 438 female 
 
Obstructive lesions (79 CoA, 67 
AS), shunt lesions (99 VSD, 55 
ASD, 45 AVSD), 9 complex 
acyanotic, complex cyanotic (169 
ToF, 87 TGA) and other 
Normative data SF-36 
 
Moderate 
(22) 
4 Chen et al. (2011) Prospective  
(cross-sectional) 
N=  289 
Mean age: 33.2 (10.6) 
Gender: 105 male, 184 female  
*86 ASDII, 64 VSD, 60 ToF Controls age- and 
gender-matched 
 
WHOQOL-
Bref-Taiwan 
Moderate 
(27) 
5 Cohen et al. (2010) 
 
Cross-sectional N=  27 
Mean age: 68.6 (5.7, 60-87) 
Gender: 10 male, 17 female 
All ASDII Controls age- and 
gender-matched N= 27 
Mean age: 69.9(±8.2, 60- 
78) 
Gender: 10 male, 17 
female 
CHD-
TAAQOL 
only 
symptoms 
subscale 
Low (17) 
*Only conditions diagnosed in more than 10% of the sample were listed and compared 
S.D.= Standard Deviation, DILV= Double Inlet Left Ventricle, AVSD= Atrioventricular Septal Defect. 
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Table 2.2 Continued 
 Authors (year) Design Participants Comparison group (HR)QoL 
measure 
Study 
quality 
  N, Mean age (S.D., range), 
gender 
Diagnosis or patient group    
6 Daliento et al. 
(2005)  
Cross-sectional N=  54 
Mean age: 32 (4) 
Gender: 24 male, 30 female 
All ToF Normative data SF-36  
 
Moderate 
(22) 
7 Ebenroth & 
Hurwitz (2007) 
 
Longitudinal 
10yrs follow-up 
 
N=  35  
Mean age: 25.4 (19-37) 
Gender: 23 male, 12 female 
All TGA Normative data SF-36 
only 
physical 
component 
Moderate 
(24) 
8 Gratz et al. (2009) Cross-sectional N=  564 
Median age: 24 (14-37) 
Gender: 309 male, 255 female 
 
32 cyanotic, 31 Fontan circulation, 
98 TGA with arterial switch, 38 
TGA no arterial switch, 96 ToF, 47 
Ebstein anomaly, 33 PS/PR, 66 
left-heart obstruction AS/CoA, 62 
isolated shunt, 61 other 
Normative data and 
controls N= 53 
Median age: 25 (14-57) 
Gender: 33 male, 18 
female 
SF-36 Moderate 
(24) 
9 Hager & Hess 
(2005) 
 
Prospective  
(cross-sectional) 
N=  149 
Median age: 23.8 (14-59.8) 
Gender: 89 male, 60 female 
13 SV, 47 TGA, 9 CCTGA, 32 
ToF, 7 CoA, 3 AS, 6 PS, 7 
Ebstein’s anomaly, 5 VSD, 3 ASD, 
14 other 
Normative data SF-36  
 
Moderate 
(22) 
10 Immer et al. (2005) Cross-sectional N=  233 [(HR)QoL-N=  154] 
Mean age: 35 (16) 
Gender: n/a 
125 ASD, 34 AVD/PVD, 21 CoA, 
17 ToF/TGA (cyanotic), 7 AVSD 
Normative data 
age- and gender-matched 
SF-36 Moderate 
(22) 
11 Irtel et al. (2005) Cross-sectional N=  67 
Median age: 25 (16-62) 
Gender: 39 male, 28 female 
32 TGA, 35 ToF Normative data 
age- and gender-matched 
SF-36  
 
Moderate 
(24) 
PR= Pulmonary Regurgitation, CCTGA= Congenitally Corrected TGA, AVD= Atrial Valve Diseases, PVD= Pulmonary Valve Diseases. 
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Table 2.2 Continued 
 Authors (year) Design Participants Comparison group (HR)QoL 
measure 
Study 
quality 
  N, Mean age (S.D., range), 
gender 
Diagnosis or patient group    
12 Jefferies et al. 
(2004)  
Cross-sectional N=  32 
Mean age: 27 (9) 
Gender: 15 male, 17 female 
17 acyanotic (3 ASD, 2 MVP, 2 
Marfan, 3 VSD, 3 AS, 2 CoA, 2 
PS) & 15 cyanotic (4 ToF, 3 TGA, 
5 SV, 2 Down Syndrome, 1 TA) 
Normative data from two 
studies age-matched 
SF-36  
 
Low (17) 
13 Kamphuis et al. 
(2002a) 
Cross-sectional N=  82 with mild CHD 
Mean age: 24.6 (17-32) 
Gender: 31 male, 51 female  
20 VSD, 7 PS, 6 ASD, 6 AS, 3 
BAV, 2 APVD, 1 MVP, 37 
spontaneous resolution 
Controls 
N=  361 (SF-36) 
N=  831 (TAAQOL) 
TAAQOL 
& SF-36 
Moderate 
(25) 
14 Kamphuis et al. 
(2002b) 
Cross-sectional N=  78 with complex CHD 
Mean age: 24.3 (18-32) 
Gender: 44 male, 34 female
  
Surgery type: 39 SRV, 23 conduit 
or mechanical prosthesis, 11 SV, 5 
palliative operation shunt 
Controls age- and 
gender-matched  
N=  361 (SF-36) 
N=  831 (TAAQOL) 
TAAQOL 
& SF-36 
Moderate 
(25) 
15 Lane et al. (2002) Cross-sectional N= 276  
Median age: 31 (16-85) 
Gender: 41.7% male, 58.3% 
female 
Treatment groups: 68 cured, 105 
corrected, 23 palliated, 70 medical, 
10 inoperable 
Normative data SF-36  
 
Moderate 
(24) 
16 Loup et al. (2009) Cross-sectional N=  153 
Mean age: 26 (11) 
Gender: 94 male, 59 female 
43 ToF, 59 TGA, 51 VSD Normative data age- and 
gender-matched 
SF-36 
 
Moderate 
(21) 
17 Lu et al. (2010) Cross-sectional N=  62 
Median age: 28.5 (14-69) 
Gender: 37 male, 25 female 
All ToF Normative data SF-36 
 
Moderate 
(22) 
MVP= Mitral Valve Prolapse, BAV= Bifoliate Aortic Valve, APVD= Abnormal Pulmonary Venus Drainage, SRV= Systemic Right Ventricle.  
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Table 2.2 Continued 
 Authors (year) Design Participants Comparison group (HR)QoL 
measure 
Study 
quality 
  N, Mean age (S.D., range), 
gender 
Diagnosis or patient group    
18 Mokhles et al. 
(2011)  
Cross-sectional N=  509 
Mean age: 19 (0-66) 
(SF-36 ≥14yrs) 
Gender: 301 male, 208 female 
170 AVD, 152 ToF, 63 PA/ PS or 
VSD, 51 TGA with PA or PS, 26 
CAT, 26 PA/PS with intact septum, 
3 AA with biventricular heart 
Normative data SF-36 
 
Moderate 
(22) 
19 Moons et al. (2004)  Cross-sectional N=  89 
Median age: 24 (20- 26.5) 
Gender: 52 male, 37 female 
76.4% simple TGA, 23.6% 
complex TGA 
N/A LAS 
& CHD-
TAAQOL 
QoL 
determinants 
Moderate 
(22) 
20 *Moons et al. 
(2006)  
Cross-sectional N=  404 
Median age: 13 (18-56) 
Gender: 221 male, 183 female 
79 VSD, 68 ToF, 62 CoA, 42 AS, 
31 PS, 20 TGA, 17 mixed AVD, 17 
ASDII, 15 mitral insufficiency, 12 
SV, 7 DORV, 34 other 
Controls age- and 
gender-matched  
N=  404 
Median age: 23 (18-58) 
Gender: 221 male, 183 
female 
LAS 
&  CHD- 
TAAQOL 
QoL 
determinants 
Moderate 
(24) 
21 *Moons et al. 
(2005) 
Cross-sectional N=  629  
Median age: 24 (18-66) 
Gender: 378 male, 251 female 
112 ToF, 108 VSD, 89 CoA, 65 
AS, 48 PS, 37 TGA, 170 other 
N/A LAS & 
SEIQoL- 
DW 
Moderate 
(23) 
22 Müller et al. (2011) Cross-sectional N=  58 
Median age: 27.9 
Gender: 28 male, 30 female 
23 PS group (9 DILV, 5 TGA, 5 
CCTGA+VSD, 1 TA, 1 PA, 1 
HLHS, 1 AVSD), 35 ES group (21 
VSD, 9 ASD, 6 AVSD) 
Normative data SF-36 Moderate 
(23) 
*Studies with common sample. 
PA= Pulmonary Atresia, CAT= Common Arterial Trunk, AA= Aortic Atresia, DORV= Double Outlet Right Ventricle, HLHS= Hypoplastic Left Heart Syndrome, ES= Eisenmenger Syndrome. 
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. Table 2.2 Continued 
 Authors (year) Design Participants Comparison group (HR)QoL 
measure 
Study 
quality 
  N, Mean age (S.D., range), 
gender 
Diagnosis or patient group    
23 Rietveld et al. 
(2002)  
Cross-sectional N=  82 
Mean age: 30.2 (17-77)  
Gender: 40 male, 42 female 
13 mild CHD (small VSD, ASDII, 
mild PS), 44 moderate (CoA, ToF, 
AS), 25 severe (Fontan, Rastelli, 
Mustard, inoperable) 
N/A SF-36 Moderate 
(19) 
24 Rose et al. (2005) Cross-sectional N=  111 
Mean age: 33 (12) 
Gender: 56 male, 55 female 
21 ToF, 16 ASD, 12 VSD, 11 AS, 10 
CoA, 7 TGA, 6 aortic insufficiency, 5 
PR, 4 PDA, 4 ES, 15 other 
Normative data WHOQOL-
Bref & GBB 
Moderate 
(19) 
25 Saliba et al. (2001) Cross-sectional N=  67 
Enrolled=  89 
Mean age: 22.7 (17-49) 
Gender: 42 male, 47 female 
35 TA, 13 MA, 24 DIV, 17 other Normative data Duke Heart 
Profile 
Moderate 
(22) 
26 †Simko & 
McGinnis (2003) 
Cross-sectional, 
case-control 
N=  124 
Mean age: 26.4  
Gender: 54 male, 70 female 
 
23 ToF, 21 VSD, 11 CoA, 20 TGA, 6 
SV, 12 ASD, 7 TA, 10 AS, 14 PS 
Controls age-, gender-, 
race- & socio-economic 
status-matched 
N=  124 
Mean age: 26.5 
Gender: 54 male, 70 
female 
SIP Moderate 
(21) 
27 †Simko & 
McGinnis (2005) 
Cross-sectional N=  124  
Mean age: 26 (8.5) 
Gender: 54 male, 70 female 
cyanotic (23 ToF, 20 TGA, 6 SV, 7 
TA) & acyanotic (21 VSD, 11 CoA, 
12 ASD, 10 AS, 14 PS) 
Controls age- and 
gender-matched  
N=  124 
Mean age: 26.5 
Gender: 54 male, 70 
female 
SIP Moderate 
(23) 
†Studies with common sample. 
DIV= Double Inlet Ventricle. 
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Table 2.2 Continued 
 Authors (year) Design Participants Comparison group (HR)QoL 
measure 
Study 
quality 
  N, Mean age (S.D., range), 
gender 
Diagnosis or patient group    
28 Ternestedt et al. 
(2001) 
 
Longitudinal (20 
& 30yrs post-
surgery) 
N=  26 
Mean age: 20yrs: 28.7, 
30yrs: 38.7 
Gender: 15 male, 11 female 
¥12 ToF, 14 ASD N/A SQoL Low (13) 
29 Vandekerckhove et 
al. (2009) 
Cross-sectional N=  39 
Median age: 19.9 (15.8-28.1) 
Gender: 29 male, 10 female 
24 simple TGA, 7 TGA+VSD, 4 
Taussig-Bing anomaly, 4 TGA/VSD 
with arch obstruction 
Normative data TAAQOL Moderate 
(19) 
30 Winter et al. (2008) Cross-sectional N=  47 
Mean age: 35 (21-69) 
Gender: 20 male, 17 female 
All SRV (31 TGA, 16 CCTGA) Normative data age- and 
gender-matched 
SF-36 Moderate 
(22) 
31 Winter et al. (2010) Cross-sectional N=  133 
Mean age: 38 (18-75) 
Gender: 69 male, 64 female 
43 CoA, 42 TGA, 36 Marfan, 12 ES Normative data age- and 
gender-matched 
SF-36 Moderate 
(22) 
¥Diagnostic groups age- and gender-matched at operation and follow-up. 
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2.5.4. Study design and sample demographics 
Most studies (n=  29, 94%) were cross-sectional and 2 were longitudinal. All but four 
studies (n=  27, 87%) included a comparison group of either normative data or 
healthy controls. The number of participants ranged from 22-912 and more than half 
of the studies (n=  17, 55%) had fewer than 100 participants. Age ranged from 14-85 
years and gender was roughly balanced within the studies. The majority (n=  23, 
74%) included people with a range of diagnoses, 7 (23%) included people with a 
single diagnosis and 1 (3%) categorised people in terms of the treatment they had 
received.  
2.5.5. (HR)QoL instruments 
A variety of instruments were used (Table 2.2). Generic instruments included the SF-
36 (n=  19), TAAQOL (n=  4), SIP (n=  2), WHOQOL-Bref (n= 2), Duke Health 
Profile (n=  1), and Subjective Quality of Life (SQoL, n=  1). Single-item generic 
QoL was assessed by the Linear Analogue Scale (LAS, n=  2). Disease-specific and 
individual measures included the CHD-TAAQOL (n=  2) and the Schedule for the 
Evaluation of Individual Quality of Life-Direct Weighting (SEIQoL-DW, n=  1) 
respectively. 
2.5.6. The impact of ACHD on HRQoL 
Table 2.3 presents the findings of the 26 studies that compared the HRQoL of people 
with ACHD with either normative data or healthy controls. 
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Table 2.3. Studies that examined HRQoL in people with ACHD in relation to a comparison group 
Authors (Year) Physical HRQoL Psychosocial HRQoL Environmental/ 
occupational HRQoL 
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Bol Raap et al. 
(2007) 
  =    =  =  ↓ ↓ =   =  =  =  =  =  
van den Bosch et al. 
(2004) 
↓ ↓ =  ↓      ↓ =  =    =   
Bruto et al. (2007) ↓ =  ↑ ↓      =  =  =    =   
Chen et al. (2011) ↓         ↓     =  ↑ 
Cohen et al. (2010)     ↓            
Daliento et al. (2005) ↓ =  =  =       =  =  =    =   
Ebenroth & Hurwitz 
(2007) 
↓ =  =  ↓        ↓   =   
Gratz et al. (2009) ↓ =  =  ↓      =  =  =    =   
Hager & Hess (2005) ↓ =  =  ↓      =  =  ↓   =   
Immer et al. (2005) =  =  =  =       =  =  =    =   
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Table 2.3 Continued 
Authors (Year) Physical HRQoL Psychosocial HRQoL Environmental/ 
occupational HRQoL 
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Irtel et al. (2005) ↓ ↓ ↓ ↓      ↓ ↓ ↓   ↓  
Jefferies et al. (2004) ↓ ↓ =  ↓      =  =  =    =   
Kamphuis et al. 
(2002a) 
=  =  =  =   =  =  =  =  =  =  =  =  =  =  =  
Kamphuis et al. 
(2002b) 
↓ ↓ =  ↓  ↓ =  =  =  =  =  ↓ =  =  =  =  
Lane et al. (2002) ↓ ↓ ↓ ↓      ↓ ↓ ↓                                                                                                                                                                                                                                                                                             ↓  
Loup et al. (2009) =   =  =  =       =  =  =    =   
Lu et al. (2010) =   =  ↓ ↓      =  =  =    =   
Mokhles et al. (2011) ↓ =  ↑ ↓      =  ↑ =    =   
Moons et al. (2006)    ↑             
Müller et al. (2011) ↓ ↓ =  ↓      =  =  ↓   =   
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Table 2.3 Continued 
Authors (Year) Physical HRQoL Psychosocial HRQoL Environmental/ 
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Rose et al. (2005) ↓   ↓ ↓     ↓     =  
Saliba et al. (2001) =   =  =       =      =   
Simko & McGinnis 
(2003) 
↓        ↓ ↓      ↓ 
Vandekerckhove et 
al. (2009) 
  =    =  =  =  =  ↓  ↓ =  =  =  =  
Winter et al. (2008) ↓ ↓ ↑ ↓      =  =  =    =   
Winter et al.(2010) ↓ ↓ ↓ ↓      =  =  =    =   
Total no. 17↓ 
5= 
8↓ 
10= 
4↓ 
14= 
3↑ 
15↓ 
5= 
1↑ 
2↓ 1↓ 
3= 
4= 1↓ 
3= 
2↓ 
3= 
7↓ 
16= 
2↓ 
14= 
1↑ 
7↓ 
13= 
4= 4= 2↓ 
21= 
1↓ 
4= 
1↑ 
Note. ↓ means poorer HRQoL, ↑ means better HRQoL, =  means similar HRQoL (in relation to comparison group), blank means not measured. 
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2.5.6.1. Physical HRQoL 
Twenty-two studies examined physical functioning. Seventeen (77%) studies 
reported poorer physical functioning in people with ACHD than the comparison 
group, whereas 5 (23%) studies reported no differences. Risk factors for poorer 
functioning included younger age (Bruto, Harrison, Fedak, Rockert, & Siu 2007; 
Mokhles et al., 2011) and female gender (Chen et al., 2011).  
Eighteen studies examined role limitations due to physical problems. Eight (44%) 
studies found greater role limitations due to physical problems in people with ACHD 
than the comparison group, whereas 10 (56%) studies found no differences.  
Twenty-one studies examined pain. Four (19%) studies reported greater pain and 3 
(14%) reported less pain in people with ACHD than the comparison group, while 
fourteen (67%) studies reported no differences.  
Twenty-one studies examined general health perception. Fifteen (71%) studies 
suggested poorer and one (5%) study suggested better general health perception in 
people with ACHD than the comparison group, while 5 (24%) studies found no 
differences.  
Both studies that examined symptoms reported more cardiac-related (e.g. shortness 
of breath) symptoms in people with ACHD than the comparison group.  
Four studies examined gross motor functioning. One (25%) study indicated poorer 
gross motor functioning in people with ACHD than the comparison group whereas 3 
(75%) found no differences.  
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All (n=  4) studies that examined fine motor functioning reported no differences 
between people with ACHD and the comparison group. 
Four studies examined cognitive functioning. One (25%) study reported poorer 
cognitive functioning in people with ACHD than the comparison group, while 3 
(75%) reported no differences. 
Five studies examined sleep. Two (40%) studies reported poorer sleep functioning in 
people with ACHD than the comparison group, whereas 3 (60%) found no 
differences.  
2.5.6.2. Psychosocial HRQoL 
Twenty-three studies examined psychological/mental functioning. Seven (30%) 
studies indicated compromised psychological/mental functioning in people with 
ACHD, whereas 16 (70%) reported no differences in comparison with the general 
population or healthy controls.  
Seventeen studies examined role limitations due to emotional problems. Two (12%) 
studies reported greater and 1 (6%) study reported fewer role limitations due to 
emotional problems in people with ACHD than the comparison group, whereas 14 
(82%) studies reported no differences.  
Twenty studies examined vitality. Seven (35%) studies indicated less vitality in 
people with ACHD than the comparison group, while 13 (65%) indicated no 
differences.  
All (n=  4) studies that examined either happiness or sexual functioning indicated no 
differences between people with ACHD and the comparison group. 
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Twenty-three studies examined social functioning. Two (9%) studies reported 
reduced social functioning in people with ACHD than the comparison group, while 
21 (91%) reported no differences.  
2.5.6.3. Environmental/occupational HRQoL 
Six studies examined environment and daily activities. One (17%) study reported 
poorer and one (17%) reported better environmental circumstances in people with 
ACHD than the comparison group, while 4 (66%) reported no differences. 
2.5.7. The relationship between disease complexity and clinical variables and 
HRQoL in ACHD 
HRQoL was most commonly explored in relation to cyanosis (n=  9, 41%), followed 
by diagnosis (n=  7, 32%), functional status (n=  7, 32%), exercise capacity (n=  6, 
27%), ventricular dysfunction (n=  5, 23%), arrhythmias (n=  4, 18%), and treatment 
type (n=  2, 9%). Table 2.4 presents the findings of the reviewed studies that 
examined the relationship between clinical variables and HRQoL. 
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Table 2.4. Studies that examined associations between clinical variables and HRQoL 
Clinical variable 
    Authors (Year) 
Physical HRQoL Psychosocial HRQoL Environmental/ 
occupational 
HRQoL 
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CYANOSIS  
    Bruto et al. 2007 Y Y --- Y      Y --- Y   Y  
    Jefferies et al. 2004 Y Y --- Y      --- --- Y   ---  
    Lane et al. 2002 Y Y Y Y      Y --- Y   Y  
    Saliba et al. 2001 Y  --- ---      ---     ---  
    Gratz et al. 2009 Y --- --- Y      --- --- ---   ---  
    Simko & McGinnis 2005 ---        --- ---      Y 
    Daliento et al. 2005 --- --- --- ---      --- --- ---   ---  
    Loup et al. 2009 --- --- --- ---      --- --- ---   ---  
    Moons et al. 2005    ---             
DIAGNOSIS  
    Gratz et al. 2009 --- --- --- Y      --- --- ---   ---  
    Irtel et al. 2005 --- --- --- ---      Y --- Y   ---  
    Müller et al. 2011 Y --- --- ---      --- --- ---   Y  
    Saliba et al. 2001 ---  --- Y      ---     ---  
    Simko & McGinnis 2005 Y        Y Y      Y 
    Winter et al. 2010 Y Y Y Y      --- --- ---   ---  
    Ternestedt et al. 2001          Y     Y Y 
EXERCISE CAPACITY                 
    Gratz et al. 2009 Y --- --- Y      --- --- ---   ---  
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Table 2.4 Continued 
Clinical variable 
    Authors (Year) 
Physical HRQoL Psychosocial HRQoL Environmental/ 
occupational 
HRQoL 
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    Hager & Hess 2005 Y --- --- Y      --- --- ---   ---  
    Irtel et al. 2005 Y Y Y Y      --- Y ---   ---  
    Müller et al. 2011 Y Y --- Y      --- --- Y   ---  
    Rose et al. 2005 Y   Y ---     ---     ---  
    Ebenroth & Hurwitz 
    2007 
--- --- --- ---        ---   ---  
FUNCTIONAL STATUS                 
    Chen et al. 2011 Y         ---     --- Y 
    Ebenroth & Hurwitz  
    2007 
Y Y --- ---        ---   ---  
    Kampuis et al. 2002b Y Y Y Y  Y Y Y Y Y Y Y --- Y Y Y 
    Moons et al. 2005    Y             
    Rietveld et al. 2002 --- --- --- ---      --- --- ---   ---  
    Cohen et al. 2010     ---            
    Daliento et al. 2005 --- --- --- ---      --- --- ---   ---  
VENTRICULAR 
DYSFUNCTION 
                
    Lu et al. 2010 Y Y Y Y      --- --- ---   ---  
    Moons et al. 2005    ---             
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Table 2.4 Continued 
Clinical variable 
    Authors (Year) 
Physical HRQoL Psychosocial HRQoL Environmental/ 
occupational 
HRQoL 
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    Daliento et al. 2005 --- --- --- ---      --- --- ---   ---  
    Ebenroth & Hurwitz  
    2007 
--- --- --- ---        ---   ---  
    Irtel et al. 2005 --- --- --- ---      --- --- ---   ---  
ARRHYTHMIAS                 
    Bruto et al. 2007 --- --- --- Y      --- Y ---   ---  
    Irtel et al. 2005 Y Y Y Y      Y Y Y   Y  
    Loup et al. 2009 --- --- --- ---      --- --- ---   ---  
    Daliento et al. 2005 --- --- --- ---      --- --- ---   ---  
TREATMENT TYPE                 
    Loup et al. 2009 --- --- --- Y      Y --- Y   ---  
    Lane et al. 2002 Y Y Y Y      Y Y Y   Y  
Note. Y means association with HRQoL, --- means no association with HRQoL, blank means not measured. 
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Cyanosis 
The majority of studies (n=  5, 63%) reported poorer physical functioning in cyanotic 
compared with acyanotic individuals, while the remaining (n=  3, 37%) reported no 
differences. One study (100%) reported poorer environmental circumstances for 
cyanotic than acyanotic individuals. There were mixed findings regarding the 
relationship between cyanosis and the following domains: role limitations due to 
physical problems, general health perception, and vitality. In all other domains, the 
general pattern of findings indicated that there were no HRQoL differences between 
cyanotic and acyanotic individuals. 
Diagnosis 
The majority of studies (n=  3, 60%) reported poorer general health perception in 
people with complex than those with simpler diagnoses, while the remaining (n=  2, 
40%) reported no differences. One study (100%) reported poorer sleep functioning in 
people with complex than those with simpler diagnoses. Mixed findings were 
evident regarding the relationship between diagnosis and physical functioning and 
environmental/occupational HRQoL. Of note, the study by Ternestedt et al. (2001) 
reported better HRQoL in the more complex (ToF) compared with the simpler 
(ASD) diagnosis. In all other domains, the majority of studies indicated that there 
were no differences in HRQoL in terms of diagnosis.  
Exercise capacity 
The findings indicated that there was no association between exercise capacity and 
most HRQoL domains except for physical functioning and general health. The 
majority of studies (n=  5, 83%) reported that poorer exercise capacity was associated 
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with poorer physical functioning and poorer general health perception, while the 1 
study (17%) reported no significant associations.  
Functional status 
Functional status was measured by the following indexes: New York Heart 
Association (NYHA), Ability, Warnes, and Somerville. The majority of studies (n=  
3, 60%) reported that people who had poor functional status had poorer physical 
functioning compared with those who had good functional status, while 2 (40%) 
reported no differences. One study (100%) indicated that people who had poor 
functional status had poorer gross motor, fine motor, cognitive, sleep, and sexual 
functioning, than those who had good functional status. Two studies (100%) reported 
poorer environmental HRQoL in people who had poor functional status compared 
with those who had good functional status. Mixed findings were reported regarding 
the relationship between functional status and role limitations due to physical 
problems. In all other domains, the findings suggested that there were no differences 
in HRQoL in terms of functional status. 
Ventricular dysfunction 
The general pattern of findings suggested that there was no association between 
ventricular dysfunction and HRQoL. 
Arrhythmias 
There were mixed findings regarding the association between arrhythmias and 
general health perception and role limitations due to emotional problems. In all other 
domains, the findings indicated that there were no differences in HRQoL between 
individuals who experienced arrhythmias and those who did not. 
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Treatment type 
Two studies examined the relationship between treatment type and HRQoL. One 
study reported better general health perception, better psychological/mental health, 
and greater vitality in people with TGA who were treated with modern surgical 
techniques (arterial switch) compared with those treated with older techniques 
(Mustard & Senning). There were no differences between the two groups in physical 
functioning, role limitations due to physical problems, pain, role limitations due to 
emotional problems, and social functioning. Contrary to expectations, the second 
study reported that patients who had curative surgery had poorer 
psychological/mental health and social functioning compared with patients who had 
corrective surgery (further operation possibility) and those who did not have surgery. 
In addition, patients who had palliative surgery (further operation possibility) and 
patients who did not have surgery were similar in terms of HRQoL. Patients who 
were deemed inoperable had poorer HRQoL than all other groups, except that they 
had similar social functioning and vitality when compared to patients who had 
curative surgery. 
Disease complexity 
A few studies used broader categorisations of disease complexity, such as the Task 
Force 1 (Table 2.5). The majority of studies (n=  4, 67%) indicated no differences in 
HRQoL between the groups, where broad disease complexity categorisations were 
used. 
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Table 2.5. Studies that examined associations between disease complexity 
categorisations and HRQoL 
Authors (year) Categorisation Association with 
HRQoL 
Bruto et al. (2007) Diagnosis, native cyanosis, surgery 
type (obstructive, shunt, complex) 
No 
Moons et al. (2004) Diagnosis (simple, complex) No 
Moons et al. (2005) Diagnosis and need for follow-up 
appointments (Task Force 1: mild, 
moderate, severe) 
No 
Rietveld et al. (2002) Diagnosis (cardiologist: mild, 
moderate, severe) 
No 
Chen et al. (2011) Diagnosis and need for follow-up 
appointments (Task Force 1: mild, 
moderate, severe) 
Physical HRQoL 
Kamphuis et al. 
(2002b) 
Cyanosis, arrhythmias, heart failure, 
residual defects (Objective physical 
index: score 0-4) 
Gross motor & 
cognitive 
functioning 
 
2.5.8. Summary of studies published after the review completion 
An additional 21 studies were identified after the completion of the systematic 
review. The characteristics of the newer studies are presented in Table 2.6. All 
studies were cross-sectional and the number of participants ranged between 24 and 
2360. Fourteen (67%) studies had a sample size smaller than n=  100. Compared with 
the studies that were included in the published systematic review most of which 
consisted of mixed samples, the majority 14 (67%) of newer studies tended to focus 
on a single diagnosis, while 6 (29%) included people with various diagnoses, and 1 
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(4%) included two diagnoses. The majority of studies (n=  18, 86%) used the SF-36 
to measure HRQoL. Other measures used were the CHD-TAAQOL (n=  1), the EQ-
5D (n=  1), the psychological General Well-Being Index (n=  1), and the WHOQOL-
BREF (n=  1).  
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Table 2.6. Characteristics of the studies published after the review completion 
 Authors (year) Design Participants Comparison group (HR)QoL 
measure 
Study 
quality 
  N, Mean age (S.D., range), 
gender 
Diagnosis or patient group    
1 Angeli et al. 
(2012) 
Cross-sectional N=  62 
Mean age: 24 (7, 16-58) 
Gender: 32 male, 30 female 
All SV Not reported SF-36, CHD-
TAAQOL 
Low (13) 
2 Berghammer et 
al. (2013) 
Cross-sectional N=  1274 
Median age: 33.1 (15-87)  
Gender: 647 male, 627 female 
126 aortic anomalies, 122 
aortic valve lesions, 97 
pulmonary valve anomalies, 26 
mitral valve anomalies, 26 
tricuspid valve anomalies, 92 
ToF/RV anomalies, 89 TGA, 
17 SV, 5 truncus arteriosus, 
542 shunt lesions, 132 other 
Normative data EQ-5D Moderate 
(26) 
3 Buys et al. 
(2014) 
Cross-sectional N=  73 
Mean age: 27.3 (7.9, 16-46) 
Gender: 53 male, 20 female 
All ToF Normative data 
N=  1742 
SF-36 Moderate 
(22) 
4 Buys et al. 
(2013) 
Cross-sectional N=  103 
Mean age: 28.7 (6.3, 18-50) 
Gender: 70 male, 33 female 
All COA Normative data 
N=  1742 
SF-36 Moderate 
(21) 
5 Bygstad et al. 
(2012) 
Cross-sectional N=  53 for (HR)QoL assessment 
(total N=  55) 
Median age: 32.2 (18.4-60) 
Gender: All male 
All ToF Controls age-matched 
N=  33.5 (19.9-57.1) 
SF-36 Moderate 
(21) 
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Table 2.6 Continued 
 Authors (year) Design Participants Comparison group (HR)QoL 
measure 
Study 
quality 
  N, Mean age (S.D., range), 
gender 
Diagnosis or patient group    
6 Callus et al. 
(2014) 
Cross-sectional N=  143 
Mean age: 39.1 (14.6, 16-73) 
Gender: 63 male, 80 female  
18 conotruncal defects, 
6 aortic valve anomalies, 1 
endocardial cushion defects, 88 
septal defects, 1 pericardial 
anomalies, 7 great vessel 
anomalies, 1 coronary 
anomalies, 15 SV, 1 pulmonary 
venous return anomalies, 3 other 
Normative data Psychological 
General Well-
Being Index 
Moderate 
(23) 
7 Cotts et al. 
(2012) 
Cross-sectional N=  25 
Mean age: 42.6 (16) 
Gender: 11 male, 14 female 
All CCTGA Normative data & 
Controls with mild 
ACHD (11 ASD, 14 
VSD) 
N=  25 
Mean age: 39.7 
Gender: 11 male, 14 
female 
SF-36 
 
Moderate 
(22) 
8 Enomoto et al. 
(2013) 
Cross-sectional N=  72 
Mean age: 26.1 (5.5, 18-39) 
Gender: 41 male, 31 female 
13 simple (10 ASD/VSD, 2 
AVD, 1 other), 39 moderate (17 
ToF, 4 VSD+ valve 
problems/obstruction, 4 
Ebstein’s, 3 AVSD, 8 other), 20 
complex (5 CCTGA, 4 TGA, 4 
TA, 2 PA, 2 truncus arteriosus, 1 
other) 
Normative data 
 
SF-36 Moderate 
(24) 
9 Frigiola et al. 
(2014) 
Cross-sectional N=  34  
Mean age: 37.4 (11.8, 18.1-
57.6) 
Gender: 17 male, 17 female 
All ToF Normative data WHOQOL-
Bref 
Moderate 
(27) 
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Table 2.6 Continued 
 Authors (year) Design Participants Comparison group (HR)QoL 
measure 
Study 
quality 
  N, Mean age (S.D., range), 
gender 
Diagnosis or patient group    
10 Hanninen et al. 
(2011) 
Cross-sectional N=  67 
Mean age: 68 (60-86) 
Gender: 28 male, 39 female 
All ASD Normative data age-
matched 
SF-36 Moderate 
(19) 
11 Hickey et al. 
(2012) 
Cross-sectional N=  396 for (HR)QoL 
assessment (total N=  840) 
Median age: 29.5 (18-64.9) 
Gender: 511 male, 329 female 
All ToF Normative data age- 
and gender-matched 
SF-36 High (29) 
12 Idorn et al. 
(2013) 
Cross-sectional N= 60 
Mean age: 20.7 (17.8-27.4) 
Gender: 28 male, 32 female 
All SV (Fontan) Age- and gender-
matched controls 
N=  172 
Mean age: 21.7 (18.4-
28.7) 
Gender: 84 male, 88 
female 
SF-36 Moderate 
(26) 
13 Kahya Eren et 
al. (2013) 
Cross-sectional N= 69 
Mean age: 39.7 (14.2) 
Gender: 18 male, 51 female 
All ASD Age-, gender-, and 
socioeconomic status-
matched controls 
N=  69 
Mean age: 40.2  
Gender: 18 male, 51 
female 
SF-36 Moderate 
(24) 
14 Knowles et al. 
(2012) 
Cross-sectional N= 224 
Median age: 33 (18-60) 
Gender: 112 male, 112 female  
All ToF Normative data  
 
SF-36 Moderate 
(24) 
15 Müller et al. 
(2013b) 
Cross-sectional N= 546 
Median age: 26.9 (16-71) 
Gender: 310 male, 236 female 
85 simple, 154 moderate, 307 
complex 
Normative data age- 
and gender-matched 
SF-36 Low (17) 
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Table 2.6 Continued 
 Authors (year) Design Participants Comparison group (HR)QoL 
measure 
Study 
quality 
  N, Mean age (S.D., range), 
gender 
Diagnosis or patient group    
16 Müller et al. 
(2013c) 
Cross-sectional N= 56 
Median age: Senning: 18.9 
(17.7-20), ASO: 18.8 (17.1-
19.5) 
Gender: 40 male, 16 female 
All TGA (28 Senning, 28 ASO) Normative data age- 
and gender-matched 
SF-36 Moderate 
(21) 
17 Müller et al. 
(2014) 
Cross-sectional N= 2360 
Mean age: 28.6 (11.2, 14-75) 
Gender: 1302 male, 1058 
female 
112 cyanotic, 149 Fontan, 106 
TGA Rastelli, 214 TGA Senning 
& Mustard, 59 TGA ASO, 399 
ToF, 128 Ebstein, 144 PS/PR, 
206 CoA, 295 AS, 287 shunt, 
261 other 
Normative data SF-36 Moderate 
(21) 
18 Opić et al. 
(2014) 
Cross-sectional N= 79 
Mean age: 27.5 (3.4, 20-35) 
Gender: 53 male, 25 female 
48 ToF, 31 TGA Normative data SF-36 
 
Moderate 
(24) 
19 Pike et al. 
(2012) 
Cross-sectional N= 54 
Mean age: 25.6 (9, 15-50) 
Gender: 26 male, 28 female 
All SV Age-, gender-, 
ethnicity-, marital 
status-, educational 
level-, and geographic 
region-matched 
controls 
N=  66 
Mean age: 24.5 
Gender: 26 male, 40 
female 
SF-36 
 
Moderate 
(26) 
20 Riley et al. 
(2012) 
Cross-sectional N= 99 
Mean age: 37.2 (17-67) 
Gender, 54 male, 45 female 
30 simple, 55 moderate, 14 
complex 
Normative data SF-36 Moderate 
(22) 
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Table 2.6 Continued 
 Authors (year) Design Participants Comparison group (HR)QoL 
measure 
Study 
quality 
  N, Mean age (S.D., range), 
gender 
Diagnosis or patient group    
21 Ruys et al. 
(2013) 
Cross-sectional N=  18 for (HR)QoL 
assessment (total N=  30) 
Median age: 22 years (20-25) 
Gender: 17 male, 13, female 
 
All TGA ASO Normative data age- 
and gender-matched 
and control group of 
Mustard patients (N=  
58, Median age: 27, 
Gender: 40 male, 18 
female) 
SF-36 Low (17) 
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A summary of the findings from these recent studies regarding the impact of ACHD 
on HRQoL can be seen in Table 2.7. In terms of physical HRQoL, out of 20 studies 
examining physical functioning, 9 (45%) reported poorer physical functioning and 1 
(5%) study reported better physical functioning in people with ACHD than the 
comparison group, while 10 (50%) reported no differences. Seventeen studies 
examined role limitations due to physical problems, with 5 (29%) reporting greater 
role limitations in people with ACHD than the comparison group and 12 (71%) 
reporting no differences. Out of 17 studies examining bodily pain, 3 (18%) found 
less pain and 1 (6%) found greater pain in people with ACHD than the comparison 
group, whereas 13 (76%) reported no differences. Seventeen studies examined 
general health perception and 11 (65%) reported poorer general health perception in 
people with ACHD than the comparison group and 6 (35%) found no differences. 
In terms of psychosocial HRQoL, out of 21 studies examining psychological/mental 
health, 3 (14%) found poorer and 1 (5%) found better psychological/mental health in 
people with ACHD than the comparison group, while 17 (81%) found no 
differences. Out of 16 studies examining role limitations due to emotional problems, 
1 (6%) reported greater and 1 (6%) reported fewer role limitations in people with 
ACHD than the comparison group, while 14 (88%) found no differences. 
Seventeen studies examined vitality and 6 (35%) reported less and 1 (6%) reported 
more vitality in people with ACHD than the comparison group, while 10 (59%) 
found no differences. Out of 18 studies examining social functioning, 2 (11%) found 
better social functioning in people with ACHD than the comparison group and 16 
(89%) found no differences. In terms of environmental/occupational HRQoL 1 
(100%) study found better environmental circumstances in people with ACHD than 
the comparison group. Overall, the pattern of findings regarding the impact of 
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ACHD on HRQoL remained unchanged with the inclusion of newer studies (Table 
2.7).  
Since the majority of the recent studies focused on a single diagnostic group rather 
than mixed samples, their inclusion enabled the examination of HRQoL in various 
diagnostic groups compared with the general healthy population. Three studies 
focused on people with diagnoses categorised in the Simple group (CoA: n=  1, 
ASD: n=  2). Together, the findings from these studies reported no differences in any 
HRQoL domain between people with ACHD and the comparison group. 
Interestingly, the study by Buys et al. (2013) which focused on people with CoA 
found poorer general health in the physical domain and poorer psychological/mental 
health and lower vitality in the psychosocial domain compared with normative data. 
Five studies focused on people with ToF and the majority found poorer physical 
functioning, poorer general health, and poorer vitality in this group compared with 
the general population but no differences in other physical and psychosocial 
domains. One of these studies examined environmental/occupational HRQoL and 
found better HRQoL in people with ToF compared with normative data. Three 
studies focused on people with TGA and the majority found no differences in any 
domain of HRQoL between this diagnostic group and the comparison group. Of 
note, the findings regarding role limitations due to emotional problems were mixed 
across the three studies. Three studies focused on people with SV and the majority 
found poorer physical functioning, greater role limitations due to physical problems, 
and poorer general health in this group compared with the general population but no 
differences in other physical and psychosocial domains. 
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Table 2.7. Summary of findings from studies published after the systematic review completion 
Authors (year) Physical HRQoL Psychosocial HRQoL Environmental/ 
occupational HRQoL 
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Angeli et al. (2012) = = =  ↓      ↓ = ↓   =  
Berghammer et al. 
(2013) 
= = ↑       =     =  
Buys et al. (2014) ↓ = =  ↓      ↓ = ↓   =  
Buys et al. (2013) = = = ↓      ↓ = ↓   =  
Bygstad et al. (2012) ↓ = = ↓      = = =   =  
Callus et al. (2014)    =      =  =     
Cotts et al. (2012) = = = =      = ↓ =   =  
Enomoto et al. 
(2013) 
↓ ↓ = ↓      = = =   =  
Frigiola et al. (2014) =         =     ↑ ↑ 
Hanninen et al. 
(2011) 
= = = =      = = =   =  
Hickey et al. (2012) ↓ ↓ ↑ ↓      = = ↓   =  
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Table 2.7 Continued 
Authors (year) Physical HRQoL Psychosocial HRQoL Environmental/ 
occupational HRQoL 
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Idorn et al. (2013) ↓ ↓ = ↓      = = =   =  
Kahya Eren et al. 
(2013) 
= = = =      = = =   =  
Knowles et al. (2012) ↓ = ↑ ↓      = = ↓   =  
Müller et al. (2013b) =         =       
Müller et al. (2013c) = = = =      = = =   =  
Müller et al. (2014) ↓         =       
Opić et al. (2014) = = ↓ ↓      ↑ = ↓   ↑  
Pike et al. (2012) ↓ ↓ = ↓      = = =   =  
Riley et al. (2012) ↓ ↓ = ↓      = = =   =  
Ruys et al. (2013) ↑ = = =      = ↑ ↑   =  
Total no. (including 
initial systematic 
review studies) 
26↓ 
10= 
1↑ 
13↓ 
22= 
5↓ 
27= 
6↑ 
26↓ 
11= 
1↑ 
2↓ 1↓ 
3= 
4= 1↓ 
3= 
2↓ 
3= 
10↓ 
33= 
1↑ 
3↓ 
28= 
2↑ 
13↓ 
23= 
1↑ 
4= 4= 2↓ 
37= 
2↑ 
1↓ 
4= 
2↑ 
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Very few studies (n=  2) with mixed diagnostic samples investigated HRQoL 
differences between diagnostic groups. Two studies (100%) reported poorer physical 
functioning in people with complex than those with simpler diagnoses. One study 
(100%) found greater role limitations due to physical problems and poorer social 
functioning in people with complex than those with simpler diagnoses. In all other 
domains, the majority of studies indicated that there were no differences in HRQoL 
in terms of diagnosis. 
Two studies used broader categorisations of disease complexity (i.e. Task Force 1). 
Enomoto et al. (2013) reported poorer physical functioning in moderate and severe 
groups compared with the mild and poorer general health perception in the severe 
group compared with the moderate group. Müller, Hess, and Hager (2013b) found 
poorer physical functioning but better psychological/mental health with increasing 
complexity. 
2.6. Discussion 
This review is the first to have systematically examined the evidence regarding 
HRQoL in ACHD. A total of 31 studies were systematically reviewed and an 
additional 21 studies were identified after the review completion. Although the 
review findings on the HRQoL in people with ACHD were mixed, some initial 
inferences can be made.  
In the majority of studies there was a lack of conceptualization of HRQoL. There 
was also an evident variability in the measurement of HRQoL between the studies. 
This was reflected in the use of generic, disease-specific, and individual measures of 
HRQoL. However, the majority of studies used the generic SF-36 measure. In order 
to facilitate the synthesis of the findings the scales/subscales of different measures 
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were categorised in three broad HRQoL domains: physical, psychosocial, and 
environmental/occupational and related sub-domains. The systematic review 
followed a different approach to previous reviews in that it provided a summary of 
the literature by examining the weight of evidence in various HRQoL domains. This 
coupled with the larger number of studies reviewed, provided a clearer picture on the 
magnitude of evidence. 
2.6.1. HRQoL comparisons with normative data or healthy controls  
The first objective of this review was to investigate the HRQoL of people with 
ACHD in comparison to normative data or healthy controls. The general pattern of 
findings indicated that people with ACHD experience reduced physical functioning, 
poorer general health, and greater symptoms than the comparison group of either 
normative data or healthy controls. In some domains of physical HRQoL (i.e. role 
limitations due to physical problems, pain, sleep, gross/fine/cognitive/motor 
functioning) as well as psychosocial and environmental/occupational HRQoL the 
majority of studies indicated no differences between people with ACHD and the 
comparison group. This pattern of findings in the published systematic review was 
supported by the findings of recent studies in ACHD identified after the review 
completion. 
The majority of recent studies focused on a single diagnostic group compared with 
older studies, the majority of which examined mixed samples. This likely reflects the 
increased recognition of the need to distinguish between diagnostic groups due to the 
heterogeneity of the ACHD population. Most of the older studies with mixed 
samples did not distinguish between diagnostic groups when examining HRQoL 
possibly due to their limited sample sizes that precluded such analyses. The review 
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of recent studies provided some insight into HRQoL in various diagnostic groups 
compared with the general healthy population. The pattern of findings indicated that 
people with ToF and SV appear to experience poorer HRQoL than the comparison 
group but only in certain domains pertaining to physical HRQoL (physical 
functioning, general health). On the other hand, the findings indicated that there were 
no differences in HRQoL between people in the Simple and TGA diagnostic groups 
and the comparison group. These findings suggest that certain groups (i.e. ToF, SV) 
may be vulnerable to experiencing reduced physical HRQoL. This finding is in line 
with the findings of the systematic review regarding the ACHD population as a 
whole, which appears to experience diminished HRQoL in certain physical domains 
but not psychosocial and environmental/occupational domains. 
It was difficult to compare the findings of the present systematic review with the 
literature review by Kovacs et al. (2005). The latter identified only 8 studies 
conducted in ACHD and did not distinguish between different domains of HRQoL. 
The authors concluded that there were mixed findings with some studies reporting 
poorer HRQoL and others reporting normal HRQoL in people with ACHD. Mixed 
findings were also reported in reviews conducted in child populations (Bellinger & 
Newburger, 2010; Latal et al., 2009; Marino et al., 2010). Dahan-Oliel et al. (2011) 
reported similar findings to the present systematic review, indicating that young 
adults with CHD experience impaired physical HRQoL.  
The findings of the present study however, suggest that these individuals are mostly 
concerned with the physical limitations and practical issues arising from their 
condition. A chronic condition like ACHD introduces significant physical challenges 
with individuals experiencing cardiac-related symptoms and impaired physical 
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functioning. However, the physical impact of ACHD does not appear to extend to 
people’s ability to carry on with their typical role activities, considering the number 
of studies indicating lack of impact on the role physical subscale. Although the 
evidence on cognitive, fine motor, gross motor, and sleep functioning were limited to 
a few studies, the general pattern of findings indicated that people with ACHD were 
not impaired in these domains.  
These findings are likely to reflect the impaired physical state of people with ACHD. 
Continuous cardiac surveillance coupled with unexpected health deterioration can 
have a significant physical burden. However, these findings also raise an important 
issue regarding expectations. Given that HRQoL is patient-reported, it is possible 
that the findings reflect a perceived lack of understanding leading people to develop 
unrealistic expectations and misconceptions about their physical functioning. In 
addition, the somewhat unclear disease course in ACHD may leave people feeling 
uncertain and insecure about their condition and prognosis (Claessens et al., 2005).  
The evident lack of impairment in psychosocial HRQoL across most of the reviewed 
studies suggests that despite experiencing significant physical limitations, people 
with ACHD find ways to cope. Some authors proposed that these individuals 
successfully adjust to their condition because they develop adaptive coping strategies 
early in their lives. One such coping mechanism is normalization, whereby people 
accept and incorporate their illness and treatment in their daily lives from an early 
age (Deatrick, Knafl, & Murphy-Moore, 1999). This form of normalization has been 
reported in qualitative studies with children and adolescents with CHD but also 
adults (Berghammer, Dellborg, & Ekman, 2006; Claessens et al., 2005). In the study 
by Claessens and colleagues (2005), people with ACHD struggled to live a “normal” 
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life, adjusting their daily life to their functioning and matching their lifestyle to that 
of their healthy peers. 
Other authors proposed that people with ACHD cope with the stressors of living 
with a chronic condition because of an increased sense of coherence. For example, 
Moons and Norekvål (2006) attributed the lack of HRQoL impairment in their earlier 
study (Moons et al., 2006) to an increased sense of coherence. They argued that 
growing up with ACHD has made people understand, manage, and find meaning in 
their experiences. This helps them gain perspective which facilitates better 
psychosocial adjustment. 
Some authors have argued that lack of psychosocial impairment in people with 
ACHD can be attributed to a change in internal standards, values, and priorities (i.e. 
response shift) (Schwartz & Sprangers, 1999). The response shift phenomenon has 
been typically proposed as an explanation of changes in HRQoL over time in 
longitudinal studies. However, some authors argued that response shift may also be 
evident in cross-sectional studies. Specifically Moons et al. (2009) argued that 
individuals who grow up with ACHD may develop different internal values from 
healthy individuals. In one of the studies included in the present systematic review, 
younger individuals reported poorer HRQoL compared to their peers, whereas older 
individuals reported normal HRQoL compared to their healthy counterparts (Bruto et 
al., 2007). This may signify that response shift is taking place over time leading 
older individuals to redefine of their standards, values, and priorities and therefore 
modify their expectations of HRQoL.  
Although a limited number of studies examined environmental/occupational 
HRQoL, the evidence indicated a lack of impairment in this HRQoL domain. This 
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finding suggests that people with ACHD do not generally have problems with work, 
access to healthcare, and their environment. It is unsurprising that these individuals 
did not experience problems with access to healthcare considering that the samples 
in the reviewed studies mostly consisted of individuals monitored regularly in 
specialist ACHD clinics. On the other hand, many guideline reports have suggested 
that people with ACHD may face occupational problems, including career and 
insurance problems (Perloff, 1991). The lack of impairment in occupational HRQoL 
in the reviewed studies can be attributed to its assessment in already employed 
individuals. However, there was a limited number of studies examining this 
particular HRQoL domain; hence, more studies are needed to establish whether 
people with ACHD experience limitations in the occupational domain of their lives. 
2.6.1.1. Changes in HRQoL over time 
It is worth noting that because the reviewed studies were mostly cross-sectional, it 
was not possible to examine whether changes in HRQoL occur over time. Only two 
longitudinal studies were identified in the systematic review. Ternestedt et al. (2001) 
reported mean scores in HRQoL for two groups (ToF, ASD; n=  26) at two follow-
ups, specifically 20 and 30 years after surgery. However, they did not provide a 
description of any statistical analysis conducted to study changes over the two time 
points and the results and discussion sections lacked clarity about changes in 
HRQoL. Thus it was not possible to extract the relevant information. The study by 
Ebenroth and Hurwitz (2007) reported minimal changes over time in a sample of 35 
people with TGA, with lower energy at a 10-year follow-up. Two additional 
longitudinal studies were identified after the review completion. One study consisted  
of mostly people with ToF (n=  103) and indicated a decrease in general health 
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perception at a 3-year follow-up but no changes in the subscales of the EQ-5D, 
including mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression (Skoglund et al., 2014). Another study with a mixed sample (n=  
349) reported that social inhibition (feeling unpleasant among other people) 
decreased while negative emotions increased over a period of 10 years (van Rijen et 
al., 2005a). The evident lack of studies examining changes in HRQoL in ACHD 
point to the need of more research that includes longitudinal assessments of HRQoL.  
2.6.2. Relationship between disease complexity and clinical variables and 
HRQoL 
The second objective of the review was to study the relationship between disease 
complexity as well as clinical variables and HRQoL. The findings indicated no 
differences in HRQoL between groups in studies that used broad disease complexity 
categorisations such as the Task Force 1 by Warnes et al. (2001). Two of the most 
recent studies however, found that physical HRQoL diminished with increased 
disease complexity. Taking into account older and more recent studies, the findings 
with regards to disease complexity using broad categorisations were mixed. These 
findings are in agreement with a recent meta-analysis of the impact of disease 
complexity on emotional functioning in adolescents and adults with CHD (Jackson, 
Misiti, Bridge, Daniels, & Vannatta, 2015). The authors concluded that this 
heterogeneity in findings across studies may be due to the failure of broad 
categorisations (e.g. Task Force 1: simple, moderate, complex) in capturing the true 
impact of illness on people’s experiences. The main criticism is that broader 
categorisations do not sufficiently differentiate between the most complex SV and 
the comparatively less complex TGA diagnoses because both are categorised as 
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“complex”, although the TGA group do not typically experience the same morbidity 
and mortality risk as the SV group (Jackson et al., 2015).  
However, the same meta-analysis suggested that individual clinical variables need to 
be explored in order to explain heterogeneity across studies in emotional functioning. 
In the present systematic review there was an evident impact of individual clinical 
variables on physical HRQoL, whereby being cyanotic, having a more complex 
diagnosis, experiencing reduced exercise capacity and poorer functional status were 
associated with a poorer general health perception and greater physical limitations. 
This finding is in agreement with the review by Dahan-Oliel et al. (2011) who found 
that disease complexity was associated with poorer physical HRQoL in adolescents 
and young adults with CHD. There was either a lack of association or mixed findings 
in other physical subscales as well as psychosocial and environmental/occupational 
HRQoL. This finding is in agreement with previous reviews in children and 
adolescents (Latal et al., 2009; Marino et al., 2010). The review by Kovacs et al. 
(2005) was inconclusive regarding the impact of disease complexity on HRQoL in 
ACHD. The findings of this review suggest that disease complexity and clinical 
factors may be associated with certain domains of physical HRQoL but not 
psychosocial or environmental/occupational HRQoL.  
These findings, coupled with the variability in HRQoL differences between people 
with ACHD and the general population discussed in the previous section, suggest 
that clinical factors alone may be a poor explanation for variability in HRQoL in 
ACHD and that other psychosocial processes may help explain some of this 
variability. The limited ability of clinical factors in explaining people’s HRQoL 
emphasizes the importance and supports the adoption of biopsychosocial approaches 
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to health and illness research (Skevington, Lofty, & O'Connell, 2004). This approach 
was advocated in Engel’s seminal work, who in an attempt to unify the three 
perspectives, namely biological, psychological, and social, proposed the 
biopsychosocial model (Engel, 1977). In Engel’s model, the individual is the focal 
point and therefore illness is viewed as a human experience with its inherent 
psychosocial as well as biological parameters (Figure 2.2). All three parameters are 
thought to interact to influence health. 
 
Figure 2.2. The biopsychosocial model 
It has been increasingly recognised that various factors may influence an individual’s 
HRQoL; these do not only include biomedical or clinical variables but also 
psychological and interpersonal variables (Ferrans, Zerwic, Wilbur, & Larson, 2005; 
Wilson & Cleary, 1995). Therefore, studying the collective effects of these variables 
can provide further insight about the HRQoL of people with ACHD.
Health
Biological
SocialPsychological
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2.6.3. Limitations of the studies reviewed and implications for future research 
There are number of methodological issues that are apparent in the research 
reviewed in the systematic review. One difficulty is that by definition the ACHD 
population is heterogeneous. This is exacerbated in some studies with a lack of 
distinction between diagnostic groups when examining differences between the 
sample and the comparison group. Furthermore, while some studies focused on a 
single diagnosis, the majority included various diagnoses. In general, the 
heterogeneity makes for large variability and difficulty in comparing studies. This 
heterogeneity coupled with the different nomenclature used in the studies makes it 
difficult to draw conclusions regarding HRQoL problems in specific diagnostic 
groups. While this limitation was addressed to some extent by more recent studies 
that focused on a single diagnostic group, there is a need for a more clear distinction 
between various diagnostic groups in future studies with mixed samples.  
The quality assessment of the reviewed studies indicated that lower quality was 
mainly due to poor reporting and insufficient sample sizes. Over half of the studies 
reviewed included a sample of less than 100 participants and it was not reported 
whether it was informed by power calculations. Studies were also characterised by 
poor reporting of methodology, including recruitment and statistical analysis. In 
addition, the vast majority of studies failed to define QoL and HRQoL. They also 
used various instruments to measure (HR)QoL. It has been argued that different 
conceptualizations and measures of (HR)QoL are likely to lead to diverse results 
(Testa & Nackley, 1994).  
The lack of longitudinal assessments was evident in the literature with only four 
studies assessing changes in HRQoL over time. Longitudinal studies are important 
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for establishing whether HRQoL changes over time and the factors that may 
influence such change. 
2.6.4. Limitations of the systematic review 
In addition to the limitations of the reviewed studies discussed in the previous 
section, the limitations of the systematic review need to be addressed. The review 
was limited to articles written in English and published in peer-reviewed journals. It 
is acknowledged that the use of translation services would have resulted in the 
inclusion of articles published in other languages; however, the funds for such 
services were not available at the time. The search strategy was broad and was 
conducted in a single step using the pre-determined terms. A staged search strategy 
of each facet (i.e. population, outcomes etc.) might have resulted in a more flexible 
and comprehensive search.  
As mentioned earlier, the systematic review attempted to provide some initial 
inferences on the impact of ACHD on HRQoL based on the magnitude of evidence. 
However, it should be noted that there were mixed findings across studies. An effort 
was made to identify possible reasons for the mixed findings, for example certain 
differences in methodologies, sample size, and patient characteristics; however, no 
systematic patterns were observed in these characteristics that could help explain 
why some studies reported poorer, better, or equal HRQoL in relation to the 
comparison group.   
It was not within the scope of the review to examine the relationship between 
psychosocial variables and HRQoL in ACHD. As discussed earlier, some of the 
variability in HRQoL may be explained by underlying psychosocial processes. These 
relationships remain largely unstudied in the ACHD population. However, research 
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interest in such associations is rapidly increasing and this literature is addressed in 
Chapter 3. 
2.7. Summary  
This systematic review is the first that attempted a synthesis of evidence regarding 
HRQoL in ACHD. The review also highlighted the limitations of previous research. 
These limitations are important in terms of implications for future research, as a 
growing number of studies are being published every year in this rapidly evolving 
field. Despite the mixed findings and methodological limitations evident in previous 
research, the magnitude of evidence indicated that people with ACHD face certain 
physical limitations compared to the general healthy population, and that some 
clinical factors that reflect disease complexity are associated with HRQoL. The role 
of psychosocial factors has begun to attract significant research interest with an 
increasing number of studies examining the relationship between these factors and 
HRQoL in ACHD. The next chapter will focus on psychosocial factors and their 
relationship with HRQoL guided by previous research in ACHD and the theoretical 
framework used in the present study.
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CHAPTER 3 – THE ROLE OF PSYCHOSOCIAL 
FACTORS IN RELATION TO HEALTH-RELATED 
QUALITY OF LIFE IN ADULT CONGENITAL 
HEART DISEASE 
3.1. Prologue 
The previous chapter described the current state of the literature regarding HRQoL in 
ACHD by presenting the findings of a systematic review. This indicated that people 
with ACHD experience impaired physical HRQoL, while their psychosocial and 
environmental/occupational HRQoL appeared to be similar to the general 
population. In addition, although some clinical factors were found to be associated 
with HRQoL they did not account for much of the variability in HRQoL. It is 
therefore possible that psychosocial factors may help explain some of the variation in 
HRQoL. This chapter describes the theory that was used to guide the selection of 
some of the psychosocial variables included in the present study. The role of 
psychosocial factors in relation to HRQoL in ACHD and other chronic illnesses 
across the lifespan is described by drawing evidence from both quantitative and 
qualitative studies. The chapter also addresses the literature with regards to 
longitudinal changes in psychosocial factors. 
3.2. Rationale for theoretical framework 
Theories in health psychology are typically concentrated in explaining behaviour by 
mapping the relationship between clinical, psychological, and social factors. 
Therefore, much of the focus has been the prediction of behaviour and the 
psychosocial processes through which behaviour change occurs. These theories 
provided the basis for many interventions aiming to alter unhealthy behaviours in 
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patients and healthy populations (Michie, Johnston, Francis, Hardeman & Eccles, 
2008). Some examples of such theories include the Health Belief Model, the Theory 
of Planned Behaviour, the Theory of Reasoned Action, the Social Cognitive Theory, 
the Transtheoretical Model, the Stress-Coping Model etc. (Michie, et al., 2005). 
These theories are not specifically focused on explaining HRQoL but rather consider 
it as an outcome which may be influenced by modifying cognitions, emotions, and 
behaviour. In fact, previous attempts to incorporate HRQoL in a theoretical model 
have been directed towards conceptualizing HRQoL rather than the processes which 
may influence HRQoL (Bakas et al., 2012; Taillefer, Dupuis, Roberge, & LeMay, 
2003). Examples include the conceptual model by Wilson and Cleary (1995) and its 
subsequent revision by Ferrans et al. (2005). Although this model helps 
conceptualize HRQoL, it lacks a description of how the relationship between various 
psychosocial factors may help explain HRQoL outcomes. 
The use of theory in studying the factors associated with HRQoL helps identify 
patients at risk for poor HRQoL and the psychosocial factors which are amenable to 
change and hence can be targeted in future interventions aiming to improve HRQoL. 
One model that has been used to study outcomes in already ill populations is the 
Self-Regulation Model (SRM) of health and illness proposed by Leventhal, Meyer, 
and Nerenz (1980), which was selected as the basis for the present study. There are 
several reasons that motivated the selection of this particular model. Firstly, it has 
been utilised more extensively in previous studies that examined HRQoL in cardiac 
populations as well as various other chronic illnesses (Hagger & Orbell, 2003). 
Secondly, the processes that underlie the model regarding the relationship between 
the variables are clearly defined. Thirdly, it describes psychosocial variables which 
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are amenable to change and can be therefore targeted in future interventions 
(McAndrew et al., 2008). Finally, it has been developed and validated in many 
chronic illnesses throughout the years, which resulted in the development of 
validated measures for its core components.  
Although the purpose of the study was not to test the validity of the assumptions 
underlying the SRM or an attempt to test the SRM, it was used to guide the selection 
of some of the psychosocial variables that were considered as likely to influence 
HRQoL in ACHD. This framework is described in the following section. 
3.3. The self-regulation model 
As mentioned earlier, the SRM of health and illness was proposed by Leventhal and 
colleagues (1980) and is part of the wider group of self-regulation theories. Self-
regulation broadly refers to efforts made by people to alter their own responses in 
relation to the achievement and maintenance of personal goals (Maes & Karoly, 
2005). In the context of health and illness, referral to self-regulation implies the 
capability of an individual to act in order to prevent unhealthy consequences or to 
restore one’s health and well-being when illness or health problems have already 
occurred (Purdie & McCrindle, 2002). 
According to the SRM, when people are faced with a symptom, an illness, or a threat 
to their health, they create mental representations (i.e. illness perceptions) in order to 
make sense of and manage their problem. Three basic assumptions underlie the 
model (Diefenbach & Leventhal, 1996): 
1) People are active problem-solvers that try to make sense of their condition 
and symptoms based on various sources of information. 
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2) The illness representation guides the choice of coping procedures and their 
evaluation in terms of their effectiveness to produce the desired outcomes. 
3) The illness representation is individualised and may not be in line with the 
medical reality.  
People form parallel cognitive and emotional representations that derive from 
internal (i.e. somatic cues or symptoms) or external (i.e. experience or doctor’s 
advice) stimuli. The cognitive and emotional representations lead to the choice of 
coping procedures to manage the health threat and emotional reactions respectively, 
which in turn are evaluated in relation to the expected outcomes (Leventhal, 
Diefenbach, & Leventhal, 1992). 
Leventhal, Leventhal, and Contrada (1998) defined coping procedures as “the 
cognitive and behavioural actions people take (or do not take) to enhance health and 
to prevent, treat (i.e. cure or control), and rehabilitate from illness” (p. 722). During 
evaluation, if the coping procedures do not produce the desired outcome, the illness 
representation may be re-defined (Figure 3.1). 
The SRM assumes that individual and social factors influence the process of illness 
representation. The history of prior illnesses stored in memory plays a significant 
role in the emotional and illness representation as well as the choice of coping 
procedures. According to Diefenbach and Leventhal (1996), these memories are 
automatically retrieved when a person forms a representation of their current 
experience. Moreover, a new ambiguous experience is interpreted based on the 
somatic self of an individual. Thus, people determine whether a symptom is novel or 
it is common part of the self. The authors also argue that people are continuously 
interacting with and are influenced by their social context and are active recipients of 
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social information. Hence, illness perceptions may be influenced by the medical 
encounter, family members as well as by social comparison (Leventhal et al., 1998). 
 
 
Figure 3.1. The self-regulation model [adapted from Hagger & Orbell (2003)] 
Illness perceptions have at least five attributes or dimensions (Leventhal et al., 
1998):  
1) Identity, which represents the disease label and its associated symptoms. 
2) Timeline, which defines whether the disease is acute, cyclic, or chronic.  
3) Alleged causes such as genes, infection, stress, and fate. 
4) Physical, social, and economic consequences (suppositional or real). 
5) Perceived controllability/curability, which is the extent to which the disease 
can be controlled and cured.  
Although these five dimensions are widely acknowledged as the cornerstone of how 
people perceive their illness, it has been argued that some may be more or less 
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relevant for specific group of patients and can therefore vary between illnesses 
(Heijmans & de Ridder, 1998). 
The SRM has been used to predict objective clinical outcomes as well as various 
illness adjustment outcomes including adherence to medication, and self-
management behaviours. However, the most common outcome used in previous 
studies across various conditions is HRQoL (Hagger & Orbell, 2003) which is also 
the focus of the present thesis. In this study, the cognitive representation being 
investigated are illness perceptions. The SRM can also integrate mood as part of the 
emotional representation. Although anxiety and depression can be important 
outcomes in their own right, their influence, and especially that of depression, on 
both clinical outcomes and HRQoL has been well supported by a wealth of studies in 
cardiac populations (e.g. Gaynes, Burns, Tweed, & Erickson, 2002; Hallas, Wray, 
Andreou, & Banner, 2011; Stafford, Berk, Reddy, & Jackson, 2007). The role of 
coping strategies will also be investigated within the SRM. Finally, the role of 
perceived social support will be examined, as the SRM can potentially integrate this 
well-established concept. Evidence regarding the role of these factors in HRQoL and 
changes in these factors over time will be discussed next. 
3.4. The role of illness perceptions in HRQoL 
Evidence suggests that illness perceptions may influence HRQoL directly or 
indirectly through coping. While some studies have provided support for the 
mediating role of coping, much of the research has indicated that illness perceptions 
have a direct association with outcomes (Hagger & Orbell, 2003).  
Illness perceptions have been studied in populations such as heart failure, coronary 
heart disease, myocardial infarction, cancer, arthritis, diabetes, asthma, HIV, and 
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epilepsy. Findings in myocardial infarction (French, Lewin, Watson, & Thompson, 
2005), coronary heart disease (Stafford, Berk, & Jackson, 2009) as well as other 
medical conditions (Petrie, Jago, & Devcich, 2007) have suggested that illness 
perceptions are significant predictors of HRQoL. A meta-analysis by Hagger and 
Orbell (2003) indicated that physical functioning, social functioning, and 
psychological well-being are strongly associated with having weaker perceptions of 
illness identity (i.e. fewer symptoms attributed to the illness) and weaker perceptions 
of illness consequences. Having a strong perception of control over one’s illness was 
also found to be associated with positive outcomes (Hagger & Orbell, 2003). 
In ACHD, very few studies have examined illness perceptions and their association 
to HRQoL. In a cross-sectional study of 99 people with ACHD, Riley and colleagues 
(2012) reported that strong perceptions about a negative illness impact (i.e. illness 
consequences) and perceptions of a cyclical illness timeline (i.e. illness 
unpredictability and experience of symptoms in cycles) was associated with poorer 
physical HRQoL. In addition, strong perceptions about a negative illness impact, 
strong perceptions of an emotional impact, and a cyclical illness timeline were 
associated with poorer psychosocial HRQoL. However, illness perceptions did not 
remain significant independent predictors of HRQoL when entered into a multiple 
regression model that included anxiety and depression. 
In a longitudinal study of 845 people with ACHD, Schoormans and colleagues 
(2014) measured illness perceptions at baseline and HRQoL two years later. They 
found that negative illness perceptions were predictive of poor physical and 
psychosocial HRQoL in the two-year follow-up, independent of age, gender, disease 
complexity, and functional status. Specifically, strong perceptions about negative 
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illness consequences and about a negative emotional impact of the illness predicted 
poor psychosocial HRQoL. Strong perceptions about negative illness consequences, 
a cyclical timeline, and weak perceptions about curability predicted poor physical 
HRQoL. Surprisingly, weak perceptions of a negative emotional impact predicted 
poor physical HRQoL. A weak perception of a coherent illness understanding also 
predicted impaired physical HRQoL. 
Other studies in ACHD have examined the relationship between one particular 
aspect of illness perceptions, namely sense of coherence, and HRQoL. In a cross-
sectional study of 546 people with ACHD, Müller et al. (2013b) found that a strong 
sense of coherence was associated with both physical and psychosocial HRQoL. 
Sense of coherence was associated with better HRQoL in both cross-sectional (Apers 
et al., 2013b; Wang, Hay, Clarke, & Menahem, 2014) and longitudinal studies 
(Apers et al., 2013c; Luyckx, Missotten, Goossens, & Moons, 2012) in adolescents 
with CHD. In the longitudinal study by Apers et al. (2013c), sense of coherence at 
baseline predicted increases in generic and disease-specific HRQoL over a period of 
9 months after accounting for demographic characteristics and disease complexity. 
Research on illness perceptions in ACHD and adolescent CHD has been limited to 
very few studies, which have suggested that illness perceptions were significant 
predictors of HRQoL in these populations. These studies have also suggested that 
illness perceptions may be better predictors of HRQoL than demographic 
characteristics and clinical status. The limited number of studies in ACHD on this 
topic highlights the need for more research to enable conclusions regarding these 
associations.  
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3.5. The role of coping in HRQoL 
In order to successfully adjust, people with ACHD will need to develop adequate 
coping strategies to help them manage the physical, cognitive, and psychosocial 
implications of living with ACHD and its treatment regimen. Coping can have two 
main functions, which are tackling the problem (i.e. problem-focused) and 
controlling the emotions (i.e. emotion-focused) (Folkman, Lazarus, Gruen, & 
DeLongis, 1986). For example, problem-focused coping may include efforts like 
planning and problem solving whereas emotion-focused coping may include 
avoidance and positive re-appraisal.  
Most research on coping in ACHD has been qualitative. Studies involving 
adolescents and adults with CHD indicated that they use coping strategies such as 
normalization (Berghammer et al., 2006; Claessens, et al., 2005; Lee & Kim, 2010; 
Shearer, Rempel, Norris, & Magill-Evans, 2013), denial or acceptance (Berghammer 
et al., 2006; Horner, Liberthson, & Jellinek, 2000; Overgaard, King, Christensen, 
Schrader, & Adamsen, 2013; Zahmacioglu, et al., 2011), and avoidance or approach 
(Birks, Sloper, Lewin, & Parsons, 2007; Chiang, Chen, & Chen, 2011; McMurray, et 
al., 2001; Tong et al., 1998). 
Denial, which is characterised by denying the reality of an event, has been reported 
as a way of coping with stressful experiences such as early operations in a qualitative 
study of adolescents with complex CHD (Zahmacioglu et al., 2011). However, 
another qualitative study with a mixed sample of adolescents with CHD found that 
denial was generally followed by a form of normalization, with adolescents reporting 
acceptance of their condition, an awareness of their limitations and adjustment of 
their activities or even avoidance of physically demanding situations (McMurray et 
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al., 2001). Normalization has also been reported in qualitative studies with people 
with ACHD (Berghammer et al., 2006; Claessens et al., 2005). Claessens et al. 
(2005) interviewed individuals with ToF, TGA, and SV and found that normalization 
was central for their successful adjustment to ACHD. Another qualitative study that 
included people with complex ACHD indicated that these individuals were accepting 
of their condition (Horner et al., 2000). Positive reframing is another coping strategy 
that has been reported in a previous qualitative study with people with complex 
ACHD (Overgaard et al., 2013). The development of such coping strategies as 
acceptance and normalization seemed to derive from the need for self-monitoring 
especially as people get older and recognise their role in managing their illness and 
treatment regimen (Chiang et al., 2011; Tong et al., 1998).  
A cross-sectional study reported lower use of active problem solving in people with 
ACHD (van Rijen et al., 2004). In this study, women appeared to engage more in 
avoidance coping and less in seeking social support than the norms. Men on the 
other hand used more social support and less venting of negative emotions than the 
norms. Reduced problem solving in people with ACHD has also been suggested by 
other authors (Enomoto et al., 2013). In another study by Eslami, Macassa, Sundin, 
Khankeh, and Soares (2014) people with ACHD engaged in more palliative reaction 
coping (attention diversion) than healthy controls. Evidence also suggests that the 
adoption of coping strategies is independent of disease complexity (Enomoto, et al., 
2013; Eslami et al., 2014; van Rijen et al., 2004). 
No studies have investigated the relationship between coping strategies and HRQoL 
in ACHD, yet the role of coping in other outcomes has been previously 
demonstrated. In a study of adolescents with CHD, task-oriented coping involving an 
CHAPTER 3 – THEORETICAL BACKGROUND 
113 
 
active approach to problem solving, explained 30% of the variance in resilience 
(Lee, Kim, & Choi, 2014). The authors concluded that active problem solving was a 
significant predictor of positive adaptation in adolescents with CHD. 
Research in other cardiac populations such as heart failure has suggested that denial, 
self-distraction, and self-blame coping strategies are predictive of poor HRQoL 
(Graven & Grant, 2013; Klein, Turvey, & Pies, 2007). Although small, the impact of 
coping strategies on HRQoL was evident in a number of chronic illnesses in a review 
by de Ridder and Schreurs (1996). Another review by the same authors that focused 
on psychological interventions targeting coping in chronic illnesses suggested coping 
to be effective in influencing positive HRQoL outcomes (de Ridder & Schreurs, 
2001). 
3.6. The role of mood in HRQoL 
In ACHD variable prevalence rates of clinically significant levels of anxiety and 
depression have been reported based on self-report measures and clinical interviews. 
Popelová, Slavík, & Skovránek (2001) reported that clinically significant depression 
was evident in 34% of the sample studied using Zung’s self-report questionnaire. 
Other studies that used the Beck Depression Inventory (BDI) indicated a 9-32% 
prevalence of moderate to severe depression (Bang et al., 2013; Kourkoveli, et al., 
2014; Kovacs, et al., 2009b). A study by Bromberg, Beasley, D’Angelo, Landzberg, 
& DeMaso (2003) reported that 27% of the sample exhibited clinical levels of 
depression using the Brief Symptom Inventory (BSI). Studies that used the Hospital 
Anxiety and Depression Scale (HADS) reported that 22-41% had at least moderate 
levels depression (Cohen et al., 2010; Eslami, Sundin, Macassa, Khankeh, & Soares, 
2013; Riley et al., 2012). Pike et al. (2012) used the Patient Health Questionnaire 
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depression module (PHQ-9) and found that moderate to severe depression was 
evident in 32% of the sample studied. Müller, Hess, & Hager (2012) reported a 
prevalence of 9% of depressive symptoms in people with ACHD using the Center 
for Epidemiologic Studies Depression scale (CES-D). When assessed by clinical 
interviews based on the Diagnostic and Statistical Manual of Mental Disorders 
(DSM) criteria, prevalence rates of depression ranged between 27% and 33% 
(Bromberg et al., 2003; Kovacs et al., 2009b). 
Studies that used the HADS self-report measure for anxiety indicated that moderate 
to severe anxiety levels were prevalent in 41-63% of the sample (Cohen et al., 2010; 
Eslami et al.; 2013; Riley et al., 2012). Kovacs et al. (2009b) used the State-Trait 
Anxiety Inventory-Trait version (STAI-T) and reported that 34% of the sample 
exhibited elevated anxiety. Assessments of anxiety by clinical interviews based on 
the DSM indicated prevalence between 9% and 26% (Bromberg et al., 2003; Kovacs 
et al., 2009b). 
Qualitative studies have also reported feelings of anxiety and depression in people 
with ACHD (Berghammer et al., 2006; Claessens et al., 2005; Horner et al., 2000). 
Berghammer et al (2006) found that people with ACHD felt more anxious during 
periods when their condition was more noticeable, for example when they felt sick or 
tired. They also found that people with ACHD were fearful about their future, that 
their health would worsen, and that they would experience a shortened life. Fear 
about the future has also been reported by Horner and colleagues (2000) who found 
that people with ACHD worried about sudden death or a progressive decline in their 
health and functioning. The authors also noted that during their young adulthood 
people with ACHD became increasingly focused on their physical symptoms which 
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caused symptoms of depression and anxiety and were worried about family planning. 
Cornett and Simms (2014) interviewed a sample of individuals with ACHD and 
found that they faced a number of emotional challenges, including depression and 
shame about their limitations, psychological trauma due to earlier operations, and 
fear about the future because of uncertainty. 
Studies that compared levels of anxiety and depression in people with ACHD and 
either healthy controls or normative data indicated mixed findings. Studies that used 
the HADS reported either higher (Eslami et al., 2013), lower (Cox, Lewis, Stuart, & 
Murphy, 2002), or equal (Cohen et al., 2010;  Loup, et al., 2009) levels of mood 
disorders in people with ACHD compared with norms or healthy controls. One study 
reported higher levels of psychological distress as measured by the Symptom 
Checklist-90-R (SCL-90-R) in people with ACHD compared with norms 
(Brandhagen, Feldt, & Williams, 1991). A study that used the CES-D found that 
people with ACHD had lower levels of depression than their healthy counterparts 
(Müller et al., 2012). Using the STAI, Müller, Hess, and Hager (2013a) indicated 
that people with ACHD had higher state anxiety levels but equal trait anxiety levels 
compared with healthy controls. Overall, the evidence suggests that disease 
complexity is not associated with anxiety and depression (Eslami et al., 2013; 
Kovacs et al., 2009b; Loup et al., 2009; Müller et al., 2012, Müller et al., 2013a; 
Popelová et al., 2001).  
An association between mood and HRQoL in ACHD has been suggested in a 
number of cross-sectional studies. In general, lower levels of anxiety, depression, 
and psychological distress have been found to be associated with better HRQoL 
(Chen et al., 2011; Pike et al., 2012; Riley et al., 2012). Riley and colleagues (2012) 
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studied the HRQoL of 99 people with ACHD and found that poor HRQoL in the 
physical and psychosocial domains was not associated with disease complexity but 
with higher anxiety and depression levels. 
Similar relationships have been reported in another study of a larger sample of 879 
adolescents and adults with CHD, in which both anxiety (Müller et al., 2013a) and 
depression (Müller et al., 2012) scores correlated to all domains of HRQoL. In the 
latter, stronger associations were observed between depression and the mental health 
sub-domain of HRQoL; hence higher levels of depression were associated with 
poorer mental health (Müller et al., 2012). Using regression analysis, Rietveld and 
colleagues (2002) found that lower scores of trait anxiety predicted better overall 
HRQoL.  
The association between higher levels of anxiety and depression and poor HRQoL 
has been reported in studies with various ACHD. In the study by Pike et al. (2012), 
poorer HRQoL was strongly predicted by higher depression levels in a sample of 54 
people with SV. Higher anxiety and depression levels were associated with poorer 
HRQoL in a study of 27 people with ASD (Cohen et al., 2010). Chen et al. (2011) 
studied the determinants of HRQoL in 289 people with various ACHD using 
regression analysis. The authors found that higher levels of psychological distress 
were predictive of poorer HRQoL in all domains including physical, psychological, 
social, and environmental after accounting for demographic characteristics and 
disease complexity. 
3.7. The role of the social environment in HRQoL 
It is believed that the social environment can enhance the people’s efforts to cope 
with their illness and the stress it may cause thus serving as a “buffer”. The presence 
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of social support may minimise the experience of stress in the first instance and 
influence the adoption of positive health behaviours (Heaney & Israel, 2008). 
It has been argued that social support consists of two types, namely structural and 
functional support (Lett et al., 2005). Structural support refers to size and frequency 
of contact with the patient’s network of people. Measures include number of people 
in a patient’s network and frequency of contact. Functional support refers to the 
nature of support. House (1981) categorised functional support based on the nature 
of supportive behaviours and includes: a) instrumental: provision of practical 
assistance b) emotional: provision of empathy, love, and caring c) informational: 
provision of advice and information that a person may use to solve problems and d) 
appraisal: provision of constructive feedback and affirmation. There is also a 
distinction between the actual received support and perceived support by the person 
who receives it (Lett et al., 2005). 
Social support however, might not always be beneficial. Shinn, Lehmann, and Wong 
(1984) argued that the impact of negative support, characterised by hostility, conflict 
or even incompatible support to an individual’s needs might be more prominent than 
the effects of positive social support. Other authors have characterised positive and 
negative social support as a “double-edged sword”, whereby there is an interaction 
between the two (Revenson, Schiaffino, Majerovitz, & Gibofsky, 1991).  
Evidence has suggested that people with ACHD received adequate amount of 
support from their environment. Knowles and colleagues (2012) reported no 
differences in support levels between people with ACHD and their siblings and Pike 
and colleagues (2012) reported that these individuals did not differ in perceived 
social support from norms. Another study suggested higher levels of social support 
CHAPTER 3 – THEORETICAL BACKGROUND 
118 
 
in people with ACHD compared with normative data (Rose et al., 2005). On the 
contrary, lower levels of instrumental, informative, problem-oriented, emotional, and 
total social support were reported in people with ACHD than norms in a study of 342 
patients (van Rijen et al., 2004). However, in the same study, fewer discrepancies 
between the preferred and received support were observed in people with ACHD 
rather than norms. A qualitative study by Cornett and Simms (2014) also found that 
people with ACHD received emotional support from their family but this was 
somehow complicated by their need to protect their family members from their own 
feelings and thoughts. Qualitative studies have also highlighted the challenges faced 
by people with ACHD regarding disclosure of their condition to their social 
environment (Berghammer et al., 2006; Claessens et al., 2005; Cornett & Simms, 
2014). These studies have found that although people with ACHD were comfortable 
disclosing their condition to close friends and family they tended to hide it from 
people outside their close circle. Non-disclosure in people with ACHD was 
prominent in situations where they would meet new people due to fear of being 
judged or rejected (Cornett & Simms, 2014).  
A number of studies have found an association between perceived social support and 
HRQoL in ACHD. In a cross-sectional study of 54 people with ACHD, higher levels 
of social support were found to be a significant independent predictor of better 
overall HRQoL after accounting for depression and functional status (Pike et al., 
2012). Rose and colleagues (2005) used structural equation modelling to study the 
determinants of HRQoL in 111 people with ACHD. The authors found that social 
support rather than clinical factors was a significant determinant of psychological 
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and social HRQoL. Therefore, a higher level of social support was strongly 
associated with better psychological and social HRQoL.  
Higher levels of social support were also associated with better HRQoL in all 
domains in the cross-sectional studies by Areias et al. (2013) and Wang et al. (2014) 
of mixed adolescent and young adult CHD cohorts. Other studies found that 
adolescents and adults with CHD who reported greater perceived social support, 
reported better HRQoL in all domains including physical, psychological, social, and 
environmental compared with those who reported poorer perceived social support 
(Coelho et al., 2013; Silva et al., 2011; Teixeira et al., 2011). Luyckx and colleagues 
(2014) conducted a longitudinal study of 429 adolescents (mean age: 15.75) to study 
the determinants of HRQoL using structural equation modelling analyses. They 
found that baseline parental support predicted relative improvements in HRQoL over 
a 9-month period. Although peer support did not predict longitudinal HRQoL, it was 
a significant predictor of HRQoL at both time points. These findings provide further 
support to the notion that higher levels of social support, and especially parental 
support, influence positive HRQoL outcomes in CHD. 
3.8. The dynamic process of self-regulation 
The SRM postulates that the self-regulation process is dynamic and thus influenced 
by changes in the illness experience, such as new symptoms or the introduction of a 
new treatment (Leventhal et al., 1998). There is currently a lack of longitudinal 
research in ACHD examining changes over time in the psychosocial factors 
described above. Similarly, research in other chronic illnesses is limited. This section 
describes the evidence from the wider chronic illness literature on longitudinal 
changes in illness perceptions, coping strategies, mood, and social support. 
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Regarding illness perceptions, a study in people recovering from myocardial 
infarction found that perceived controllability and curability decreased whereas 
illness identity and consequences remained stable over a period of twelve months 
(Petrie & Weinman, 1997). The authors argued that perceptions pertaining to the 
impact of cardiac disease remained stable over time because these are well-defined 
to the point that they become lay beliefs. On the other hand, perceptions about cure 
and control decreased because people’s initial perceptions of their myocardial 
infarction as an acute episode changed into a more chronic view of the illness (Petrie 
& Weinman, 1997). Another study in people with osteoarthritis found that those who 
experienced progression of disability reported decreased perceived controllability 
and coherence, a more negative illness identity, increased perceived consequences 
and a more negative emotional representation in the six-year follow-up compared 
with those who did not experience progression of disability (Bijsterbosch et al., 
2009). These findings suggest that changes in illness perceptions over time are 
associated with changes in illness progression as health deterioration can bring about 
new symptoms and physical limitations enhancing a more negative perception of the 
illness. Lawson et al. (2008) found that illness identity, consequences, and 
controllability remained stable over a period of two years in newly diagnosed people 
with diabetes. The authors also found that emotional representation decreased while 
illness coherence increased over the two-year follow-up. The authors argued that the 
overall stability in illness perceptions in their study may be because people 
developed their illness beliefs early in their illness experience and these were not 
challenged by changes in health and treatment. Taken together, the findings from the 
above studies suggest that illness perceptions change over the course of a chronic 
illness and these changes are associated with illness progression. 
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In addition to illness perceptions, long-term changes in coping may occur especially 
in the context of chronic illness (Lazarus, 1993). Limited research in cardiac 
populations has indicated that coping strategies in people with coronary heart disease 
(van Elderen, Maes, & Dusseldorp, 1999) and people recovering from myocardial 
infarction (Kristofferzon, Löfmark, & Carlsson, 2005) remained stable over a period 
of twelve months. Similarly, a review in stroke found that the coping strategies 
adopted by people remained stable over time (Donnellan, Hevey, Hickey, & O’Neill, 
2006). The observed stability of coping over time may reflect the adoption of 
habitual or automatic behaviours by people with chronic illnesses (de Ridder & 
Schreurs, 2001). On the other hand, a study in breast cancer has reported significant 
changes in coping six months after diagnosis, more specifically an increase in 
detachment and a decrease in seeking social support, spirituality, and wishful 
thinking (Danhauer, Crawford, Farmer, & Avis, 2009). These findings can 
potentially be explained by the nature and length of treatment as some people with 
cancer may need to undergo more frequent treatment such as chemotherapy and/or 
radiation therapy following diagnosis which may influence their coping process 
compared with people with cardiac disease or stroke.   
With regards to mood, there has been one study in ACHD that examined changes 
over time. van Rijen et al. (2005b) examined the development of psychopathology 
(including anxiety and depression) in 220 people with ACHD over a period of ten 
years. The analyses were based on categorization in trajectories of psychopathology 
and indicated that although the majority (80.9%) remained stable, 8.2% exhibited an 
increase and 10.9% exhibited a decrease in psychopathology over a period of ten 
years. Older adults (28-32) more often were free of emotional problems compared 
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with younger adults (20-27). The authors noted that emotional problems decreased 
over time despite the higher levels observed in young adulthood and concluded that 
people with ACHD recover from early emotional problems as they grow older. 
However, as the authors stated their analysis provided only a rough idea about 
psychopathology in people with ACHD over time and thus repeated measures 
analyses are required in future studies. 
Social support on the other hand has been generally viewed as a trait-like 
characteristic that remains stable over time (Hoyt & Stanton, 2012). Though, there 
has been evidence that social support may change over the course of a chronic illness 
depending on the illness and treatment demands. Research in cardiac disease has 
indicated that social support changes from the time of hospitalization to the early 
period of recovery from myocardial infarction. Specifically, up to 14.5% of people 
reported either reduced or increased support over a period of a month (Leifheit-
Limson et al., 2012). The authors argued that these changes in social support may be 
related to situational factors in the early period of myocardial infarction. Experiences 
like hospitalization and recovery following discharge from hospital may have altered 
people’s perceptions of social support as they can influence people’s support needs, 
availability, or quality of social support (Leifheit-Limson et al., 2012). In a five-
wave longitudinal study of people with rheumatoid arthritis, Strating, Suurmeijer, 
and van Schur (2006) found that satisfaction with emotional support remained stable 
from T1 to T4 but decreased over a period of eight years between T4 and T5. This 
change may also be related to the changing support needs of people with rheumatoid 
arthritis over the course of their illness (Strating et al., 2006). 
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The evidence above suggest that psychosocial factors including illness perceptions, 
coping strategies, mood, and social support can potentially change over the course of 
a chronic illness due to changes in health and treatment. The apparent lack of 
longitudinal research in ACHD point to the need for more longitudinal studies to 
examine how these psychosocial factors change over time. 
3.9. Summary 
This chapter highlighted the importance of various psychosocial variables in 
explaining variation in HRQoL in ACHD within the context of the SRM. The 
evidence reviewed in this chapter indicated that illness perceptions, coping, mood, 
and the social environment can significantly influence HRQoL. There are, however, 
limited studies that have examined the relative importance of these factors for 
HRQoL in ACHD and a lack of longitudinal research examining changes in these 
factors over time in ACHD. There is a need for further research in order to establish 
if and how these psychosocial variables impact on the HRQoL of people with ACHD 
and whether these factors change over time. The next chapter provides an overall 
summary of the literature and the rationale for the present thesis.
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CHAPTER 4 – SUMMARY OF THE LITERATURE, 
RATIONALE AND AIMS OF THE PRESENT THESIS 
4.1. Summary of the literature 
Chapter one highlighted the growing population of people with ACHD. It described 
CHD and its treatment and the long-term complications that affect people with 
ACHD. 
Chapter two described the impact of ACHD on HRQoL by presenting the findings of 
the systematic review of the literature. Despite the evident variability of the findings 
in the reviewed studies, strong evidence suggested that ACHD can have a significant 
impact on certain aspects of physical HRQoL. However, this impact did not appear 
to extend to psychosocial and other domains of HRQoL in most of the studies. In 
addition, clinical factors were found to have limited ability to explain variability in 
HRQoL. These findings suggest that it may be that psychosocial factors may help 
explain some of the variability not detected in the studies. 
Chapter three described the usefulness of the SRM in explaining and predicting 
variation in HRQoL in chronic illness. The chapter also reviewed the evidence in 
ACHD and other chronic illnesses regarding the impact of psychosocial variables on 
HRQoL and changes in these factors over time. 
4.2. Rationale for the present study 
There was a lack of agreement and clarity on the concept of HRQoL across the 
studies reviewed in Chapter 2. In addition, studies used one of the three types of 
measures (generic, disease-specific, or individual) to assess HRQoL. It has been 
increasingly recognised that the use of both generic and disease-specific measures 
CHAPTER 4 – SUMMARY OF LITERATURE, RATIONALE AND AIMS OF THESIS 
 
125 
 
may offer more insight into HRQoL of the population under study (Fletcher et al., 
1992). Generic measures offer the opportunity to compare HRQoL across various 
diagnostic groups and the general population, whereas disease-specific measures 
provide more detailed information regarding specific life domains that may be 
influenced by an illness. The present thesis utilises both generic and ACHD-specific 
instruments the measurement of HRQoL. 
The majority of the reviewed studies had small sample sizes and were not informed 
by power calculations. Insufficient sample sizes are generally limited in their ability 
to detect small effects and in some cases may lead to misinterpretations 
(Vandenbroucke et al., 2007). The present thesis addresses this limitation by 
including a large and adequately powered sample. 
One limitation of previous studies identified in the systematic review was the lack of 
clear distinction between various diagnostic groups that limits the ability to draw 
conclusions regarding the HRQoL in these groups. The review also identified a 
number of different clinical factors that were used across studies to examine their 
association with HRQoL. The present study includes four clearly defined diagnostic 
groups but also includes a wide range of clinical measures to study the impact of 
ACHD on HRQoL. 
In Chapter 3 it was evident that in ACHD very little research has investigated 
whether individual differences in HRQoL can be explained by psychosocial 
variables. A more comprehensive approach to studying the factors associated with 
HRQoL in ACHD is currently lacking. The present study attempts to address this 
gap in the literature by examining a broad range of factors that may potentially 
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influence HRQoL in ACHD, including demographic and clinical characteristics and 
psychosocial constructs drawn from the SRM and previous research. 
At present, there is also a lack of longitudinal research examining HRQoL in ACHD 
over time with only four studies reporting such findings (section 2.6.1.1, page 96). 
These studies had limitations in that they either focused on one diagnostic group or 
had small sample sizes. None of the studies included measures of both generic and 
disease-specific HRQoL. Furthermore, these studies used traditional methods of 
repeated measures analysis, which are prone to various statistical bias (see section 
5.6.8.4, page 165). The variation in follow-up years among participants was not 
controlled for in the analysis, thus the findings of these studies may have been a 
result of measurement bias. Furthermore, as evidenced in Chapter 3 (section 3.8, 
page 119) studies have yet to examine changes in psychosocial factors, including 
illness perceptions, coping strategies, mood, and social support in ACHD. The 
present thesis seeks to add to the literature by including a follow-up study to 
examine whether HRQoL and other psychosocial variables in ACHD change over 
time using a more appropriate statistical method, thereby eliminating some of the 
bias associated with traditional repeated measures analysis methods. 
Furthermore, most qualitative studies in congenital heart disease reviewed within 
Chapter 3 have focused on children and adolescents and very few on adults. 
However, with the rapidly increasing population of adults compared with younger 
people with ACHD (Tan, 2006), there is a need to study their experiences of living 
and adapting to ACHD over the life course. Previous qualitative studies in ACHD 
did not specifically focus on HRQoL and included predominantly younger adults 
with moderate and complex ACHD (i.e. ToF, TGA, SV). The thesis seeks to add to 
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the literature with the inclusion of a qualitative study and the adoption of a mixed 
methods approach. The qualitative study was designed to address aspects of the 
quantitative component of the thesis, thus enabling a more detailed understanding 
about HRQoL in ACHD. 
4.3. Aims and objectives 
The aims of the present thesis were defined as detailed below: 
 Aim 1a: To examine the impact of ACHD on HRQoL by comparing the 
HRQoL of people with ACHD with normative data from the general 
population. 
 Aim 1b: To examine differences in HRQoL between four diagnostic groups. 
 Aim 2: To investigate the factors associated with HRQoL in ACHD by using 
a set of demographic and clinical measures and psychosocial constructs. 
 Aim 3: To examine whether HRQoL and other psychosocial variables, 
including illness perceptions, coping strategies, mood, and social support, 
change over time and whether diagnostic group influences change. 
 Aim 4a: To explore the experiences of people on how ACHD had influenced 
their HRQoL in physical, social, occupational, and psychological domains 
over the years. 
 Aim 4b: To explore how people adjust to living with ACHD. 
4.4. Hypotheses 
The hypotheses formulated below were based on past literature outlined in Chapter 2 
and the theoretical framework of the present thesis described in Chapter 3. 
 People with ACHD will report significantly poorer HRQoL compared with 
the general population norm, predominantly in physical domains of HRQoL.  
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 Poorer HRQoL will be more pronounced in the SV group when compared 
with the general population and when compared with the Simple group. 
 Psychosocial variables including illness perceptions, coping strategies, mood, 
and social support will account for a significant amount of variance in 
HRQoL over and above that accounted for by demographic and clinical 
characteristics. 
No hypotheses were formulated for research questions #3 and #4 as these 
investigations were exploratory or of a qualitative nature. 
4.5. Using a mixed methods approach 
The present thesis uses a mixed methods approach by including a qualitative study. 
This approach has become an equally important research methodology to 
quantitative and qualitative approaches alone (Johnson, Onwuegbuzie, & Turner, 
2007). There have been several definitions of mixed methods research. Johnson et al. 
(2007) synthesized 19 different definitions and in turn, suggested the following 
definition: 
“Mixed methods research is the type of research in which a researcher or team of 
researchers combines elements of qualitative and quantitative research approaches 
(e.g., use of qualitative and quantitative viewpoints, data collection, analysis, 
inference techniques) for the broad purposes of breadth and depth of understanding 
and corroboration.” (p. 123) 
Therefore, the combination of both quantitative and qualitative methods can provide 
a deeper understanding of the phenomenon in question (Johnson et al., 2007). The 
application of mixed methods in health research is considered as a patient-centred 
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approach by some researchers (O'Cathain, Murphy, & Nicholl, 2007). Quantitative 
approaches usually include large samples and statistical analyses to investigate 
research questions. Although statistical approaches minimize researcher bias, they 
generally lack an in-depth understanding of a phenomenon, which qualitative 
approaches may offer (Ritchie & Lewis, 2003). For this reason, it is believed that 
mixed methods research may help “offset” each of the two methods’ weaknesses and 
bias (Bryman, 2006). Another benefit from using mixed methods is triangulation, 
which enables the researcher to compare the results and examine similarities and 
differences from the two approaches (Curry, Nembhard, & Bradley, 2009). 
 
There are several typologies of mixed methods designs, which generally depend on 
the timing of each method and whether one of the two methods (quantitative or 
qualitative) is predominant (Curry et al., 2013). The present study utilised a 
concurrent embedded design, whereby the quantitative approach was dominant, and 
the qualitative approach was supplemental or embedded within the quantitative study 
(Creswell & Plano Clark, 2011). The data collection for the qualitative study took 
place after the cross-sectional study but concurrently with the longitudinal study. The 
purpose of this mixed-methods approach was “complementarity”, defined by Greene 
et al. (1989) as using quantitative and qualitative methods to “measure overlapping 
but also different facets of a phenomenon, yielding an enriched, elaborated 
understanding of that phenomenon.” Therefore, the purpose of the qualitative study 
within this thesis was to enhance understanding and maximise the interpretation of 
the findings of the quantitative study (Onwuegbuzie & Leech, 2006).  
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4.6. Structure of subsequent chapters 
The analyses presented in Chapters 6 to 10 will address each of the aims described 
above. A discussion of the findings is included immediately after each set of 
analyses and a general discussion will integrate the findings and discuss the 
implications. The next chapter will describe the methodology of the quantitative 
component of the thesis. The methodological details of the qualitative study along 
with the analysis and findings are presented in its respective chapter (Chapter 10).  
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CHAPTER 5 – METHODOLOGY 
5.1. Prologue 
This chapter describes the methodology of the quantitative component of the thesis 
including the study design, recruitment strategy and procedures, the measures 
utilised, and the statistical analysis plan. 
5.2. Study design  
A cross-sectional design was used to answer research questions #1 and #2 presented 
in the previous chapter. Within-subjects repeated measures design was used to 
answer research question #3. Qualitative methods were used to answer research 
question #4 (described in Chapter 10).  
5.3. Ethical approval 
Full ethical approvals for both the cross-sectional and longitudinal studies were 
granted from the Joint UCL/UCLH Ethics Committee and NRES Committee London 
– Bentham in Ethics of Human Research (REC reference number: 08/H0715/105). 
Relevant approvals were also gained from the Research & Development (R&D) 
department at UCLH. 
5.4. Procedure 
5.4.1. Setting 
Both the cross-sectional and longitudinal studies were conducted at The Heart 
Hospital, part of the University College London Hospitals (UCLH) NHS Foundation 
Trust, that specialises in cardiac diagnosis and treatment.  
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5.4.2. Participants 
Between March 2009 and June 2011 all patients who had routine follow-up 
appointments at the Grown-Up Congenital Heart (GUCH) unit of The Heart 
Hospital, London were selected for the cross-sectional study. All participants of the 
cross-sectional study were subsequently invited for the longitudinal study. 
Participants were included in the study if they met the following inclusion criteria: 
 16 years of age and older 
 Diagnosed with either of the following: ToF, TGA, CoA, VSD, ASD,  PS, 
SAS, and SV physiology 
 Fluency in English to ensure the completion of questionnaires 
Participants were excluded if they met the following criteria: 
 Chromosomal conditions such as trisomy 21 (Down syndrome) and 22q11 
deletion (DiGeorge syndrome) 
 Severe learning difficulties/mental retardation as indicated in clinical notes  
 Diagnosis of patent foramen ovale (PFO) 
 Those with TGA who had arterial switch operation, as this treatment 
approach was adopted in the late 1980’s 
 Immediately prior to or post (6-months) a surgical intervention or pregnancy 
 Poor hearing or eyesight, as recorded in patients’ records 
 Previous stroke 
 Physically unable to attempt the exercise test (e.g. wheelchair-bound) 
5.4.3. Identification of eligible participants 
At the time of the present study, not many patients with ACHD were recorded into 
the newly established electronic record system at The Heart Hospital, London; 
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therefore, eligible participants were identified using two methods, which are 
described below. 
5.4.3.1. The paper records 
Eligible participants were identified in alphabetical order (surname, name) via 
hospital paper records, which documented all the active patients in the UCLH 
GUCH service. Once identified, a specialist nurse used the most recent clinical letter 
to assess eligibility against the inclusion/exclusion criteria. If the criteria were met, 
the participant’s name and contact details were added into an electronic spreadsheet. 
If the potential participant did not meet the criteria, they were excluded from the 
study and their details were entered into a separate electronic spreadsheet. 
Eligible participants were categorised into four equally sized diagnostic groups: 
Simple, ToF, TGA, and SV. People who had more than one diagnosis were 
categorised into one of the four diagnostic groups based on their more complex 
diagnosis. For example, a person with ASD and SV would have been categorised in 
the SV group. The final categorisations were based on the agreement between two 
consultant cardiologists, who were involved in the participants’ regular care and 
were familiar with their clinical history. The diagnostic groups are described in 
section 5.5.2 (page 137). The clinical details of these diagnostic groups have been 
described in the clinical background (section 1.4, page 24). 
The target maximum recruitment number was 90 participants from each of the four 
diagnostic groups (see section 5.6.1, page 154). All eligible participants with TGA 
and SV were invited to take part in the study; this was due to the small numbers of 
individuals with these diagnoses. For the Simple and ToF diagnoses, 90 participants 
were selected using a random number generator and were invited to take part in the 
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study. Whenever a negative response was received, another participant was 
randomly selected until the required number (n=  90) was achieved.  
5.4.3.2. The clinic lists 
The outpatients’ clinic lists were reviewed every month during the recruitment 
period, in order to identify eligible participants that were not recorded in the hospital 
paper records5. In addition to meeting the recruitment target, this method was 
followed in order to ensure that newly referred individuals were not missed. This 
method was therefore complementary to the method described above. Eligible 
participants with upcoming appointments were invited to take part in the study.   
5.4.4. Invitation 
5.4.4.1. Cross-sectional study 
Participants were invited for the study by post, which contained a formal invitation 
letter, an information sheet (see Appendix I) and an interest form, which participants 
were asked to complete and return in a freepost envelope. The information sheet 
included an explanation about the purpose of the study and the reason for which the 
participant was selected. Invited participants were informed about their role in the 
study, were explained about confidentiality issues, and their right to withdraw at any 
time. Finally, invited participants were provided with contact numbers in case they 
had any questions and comments about the study. If the participant had not 
responded within two weeks, a second invitation letter was sent with the same 
documents. If the participant had not responded after an additional two weeks, a 
telephone call was made.  
                                                          
5 These participants were typically patients that were newly referred to the UCLH GUCH clinic from 
other clinics around the UK; hence, no paper records of them were available at the time. 
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All the enrolled participants were assigned a unique study identification number (e.g. 
001, 002,…314). Appointment letters were sent to the participants for the same day 
of their upcoming outpatient appointment in order to minimise travelling burden and 
costs. 
5.4.4.2. Longitudinal study 
Participants were invited for the study by post, which contained a formal invitation 
letter, an information sheet (see Appendix J), and an interest form, which 
participants were asked to complete and return in a freepost envelope. Participants 
were informed that they were invited because they had participated in the cross-
sectional study and that there was no obligation for participating in the longitudinal 
study. Telephone reminders were carried out, when participants did not respond to a 
second postal invitation. Appointment letters were sent to interested participants for 
the same day of their upcoming outpatient appointment. Postal questionnaire packs 
were mailed to participants whose next appointment was after the study end date in 
order to maximise recruitment. 
5.4.5. Administration of questionnaires 
5.4.5.1. Cross-sectional study 
On the day of the assessment, participants were informed about the purpose of the 
study using the information sheet as a guide and were then asked to sign the consent 
form (see Appendix K). The latter indicated that the participant had enough time to 
consider their participation and that they agree to take part. Following the informed 
consent process, participants completed the questionnaires in a dedicated room at 
The Heart Hospital, London, with the researcher present available to answer 
potential questions. Participants received a £5 voucher to use for lunch. 
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Occasionally, participants had a long day of testing at the hospital; these participants 
were given the choice of completing the questionnaires at home. In these instances, 
participants were provided with a freepost envelope and telephone calls were 
conducted to answer possible questions and to ensure that the completed 
questionnaires were returned. 
5.4.5.2. Longitudinal study 
Follow-up administrations took place soon after the cross-sectional study was 
completed over a period of one year. For face-to-face administrations, the same 
informed consent process (see Appendix L) was followed as in the cross-sectional 
study (see previous section). For postal administrations, freepost envelopes were 
provided along with telephone numbers, on which participants could reach the 
researcher for any questions regarding the questionnaires. The same reminder 
protocol (described in section 5.4.5.1) was used for any participants who did not 
return the follow-up questionnaires. Participants did not receive a £5 voucher for 
lunch in the follow-up study. 
5.5. Measures 
The selection of measures was guided by the SRM and previous research. The study 
measures included demographic and clinical information as well as self-report 
questionnaires. Due to the large number of variables studied, where available, shorter 
versions of the questionnaires were used in order to minimise participant burden.  
5.5.1. Demographic characteristics 
Demographic data were collected during the cross-sectional study only using a self-
report form. Demographic details included: 
 Age 
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 Gender 
 Ethnicity 
 Marital status: married/in civil partnership, in relationship, single, 
divorced/separated, widowed 
 Educational level: Primary, secondary, tertiary, undergraduate degree, 
master’s degree, doctorate degree 
 Employment status: Employed, self-employed, seeking job, 
housewife/husband, student, retired, long-term sick leave, unable to work 
5.5.2. Clinical information 
A consultant cardiologist examined the participants’ paper and electronic hospital 
records (EPR, CDR) that included clinical reports, pre-assessment forms, and 
clinical testing reports and recorded detailed and comprehensive clinical information 
using a standard form during the cross-sectional study. Clinical information was also 
collected through electronic hospital records during the longitudinal study regarding 
further interventions, hospitalization days, and medication. The details of all clinical 
information obtained for the studies and the measurement details are presented in 
Table 5.1.  
Participants were categorised into four diagnostic groups. The “Simple” group 
included acyanotic people with ASD (treated surgically or percutaneously), VSD 
(treated surgically), PS, SAS, and CoA (treated both in childhood and adulthood and 
re-coarctations). People with CoA who had aortic valve replacement were excluded, 
as this condition does not meet the merit of a simple defect. The “ToF” group 
included people with a diagnosis of ToF, including those with pulmonary atresia, 
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Major Aortopulmonary Collaterals (MAPCAs6), and those who had pulmonary valve 
replacement. The “TGA” group included people with a diagnosis of TGA who had 
Mustard or Senning operations (i.e. atrial switch), including those with implantable 
cardioverter defibrillators and pacemakers. People who had arterial switch operation 
were not included as this treatment approach was adopted in the late 1980’s. Finally, 
the “SV” group included people with a single ventricle physiology, those who had 
the Fontan or TCPC operations, including those who are chronically cyanotic. 
Cyanosis information included the number of days that participants were cyanosed 
before they had undergone their first intervention that restored their saturation levels 
(i.e. duration of cyanosis). For chronically cyanosed participants this represented the 
days cyanosed up until the study participation date. 
Intervention history included the total number of cardiac-related interventions, 
including surgical operations and catheterization lab procedures since birth. 
Hospitalization days reflected the total number of days spend in hospital either for 
surgical/catheterization lab procedures or emergency hospitalizations since birth.  
The tests for current O2 saturation, VO2 max, and ventricular function data outlined 
in Table 5.1 were performed as part of the routine monitoring of ACHD for all study 
participants. The most recent pulse oximetry result was recorded to provide 
information about current O2 saturation.  
                                                          
6 Arteries that develop naturally in embryonic life to supply blood to the lungs when pulmonary 
circulation is underdeveloped. 
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Table 5.1. Clinical information obtained from hospital records 
Variable Group Measurement Details 
Disease characteristics 
        Diagnostic groups 
         
 
 
        Co-morbidities total 
        Arrhythmias 
        Cyanosis days (until study  
        participation date) 
 
1) Simple  
2) Tetralogy of Fallot 
3) Transposition of the great arteries 
4) Single ventricle  
Count 
Yes/No 
Count 
Intervention history 
        Interventions total (includes  
        cardiac-related surgical and  
        catheterisation lab procedures)* 
        Hospitalization days (since 
birth)* 
 
Count 
 
 
Count 
Current status 
        Medication total* 
        Current O2 saturation  
        Functional status (NYHA) 
 
 
        VO2 max 
        Left & right ventricular ejection  
        fraction 
 
Count 
% 
Groups: 
1) Class I 
2) Classes II, III, IV 
mL/(kg∙min) 
 
% 
 *Clinical variables for which information was collected at both cross-sectional and longitudinal studies. 
Details of a recent exercise test were recorded in order to collect information on 
exercise capacity as measured by maximal oxygen uptake (VO2 max). The gold 
standard in measuring VO2 max is thought to be cardiopulmonary exercise testing 
(CPEX), where the assessment is conducted via a mouthpiece/mask fitted while the 
individual is exercising on a bike. However, not all people with ACHD are required 
to undergo this test as part of their treatment and most are prescribed a standard test 
of exercise capacity based on the (modified) Bruce protocol performed on a 
treadmill. In these cases, although not directly measured, VO2 max may be predicted 
(calculated) using a formula that takes into account the duration of the test. In the 
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present study the standard formula7 proposed by Bruce, Kusumi, and Hosmer (1973) 
for cardiac populations was used for people that had undergone a (modified) Bruce 
protocol test instead of CPEX. The correlation between measured VO2 max and 
predicted (using the formula) is .93 for women and .87 for men with cardiac 
conditions (Bruce et al., 1973). For this reason, it was deemed a reliable way of 
obtaining comparable exercise capacity measurements for participants having 
different tests. 
Ventricular function was documented by recording left and right ventricular ejection 
fraction based on the results from the most recent MRI (where available) and ECHO 
tests. For people with SV ventricular function was based on the function of the 
“single ventricle”. 
5.5.3. Psychosocial variables 
Participants completed the same psychosocial measures in the cross-sectional and 
longitudinal studies. The psychosocial questionnaires are displayed in Appendix M. 
Participants were asked to respond to the questionnaires in relation to their ACHD. 
5.5.3.1. Primary outcome – health-related quality of life 
A disease-specific and a generic measure of HRQoL were utilised in this study. The 
generic measure was used to allow comparisons between people with ACHD and 
normative data. The disease-specific measure was used to study ACHD-specific 
HRQoL issues. Both measures were selected on the basis that together they address 
the multi-dimensionality of HRQoL (physical, occupational, psychological, 
interpersonal, and somatic sensation elements) highlighted in section 2.2.2 (page 47).  
                                                          
7 VO2 max= 2.327*time(min) + 9.48 (Bruce et al., 1973) 
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Generic HRQoL – Short-Form 36 Health Survey Version 1®8 
The SF-36v1® (Ware & Sherbourne, 1992) is the single most commonly used 
generic measure of HRQoL in healthy and ill populations. This measure was also 
identified in the systematic review (see Chapter 2) as the most frequently used 
generic HRQoL measure in ACHD. A benefit of the SF-36v1® is the use of norm-
based scores (NBS), which allows for easy comparison with general population norms 
and facilitates interpretability and guards against floor and ceiling effects. A study of a 
large general population sample indicated that the SF-36v1® appeared to measure 
HRQoL more accurately, compared with the WHOQOL-Bref which tended to 
measure more global QoL (Huang, Wu, & Frangakis, 2006). Furthermore, a review of 
common HRQoL measures in ischemic heart disease found that the SF-36v1® offered 
more reliable, valid, and sensitive assessment of HRQoL compared with the 
Nottingham Health Profile and SIP (Dempster & Donnelly, 2000). 
This 36-item instrument has eight subscales, which may be subsequently combined 
to form two components (Ware & Kosinski, 2001b). The subscales include physical 
functioning (10 items), role physical (role limitations due to physical health; 4 
items), bodily pain (2 items), general health (5 items), which form the physical 
component summary, and vitality (4 items), social functioning (2 items), role 
emotional (role limitations due to mental/emotional health; 3 items), and mental 
health (5 items), which form the mental component summary. The measure includes 
an additional item (health transition), which is not used in the subscale scoring and 
thus was not included in the present study. The definitions of the SF-36v1® subscales 
are presented in Table 5.2. 
                                                          
8 License was acquired for the use of SF-36v1©. The license agreement can be seen in Appendix N. 
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Table 5.2. Definition of the SF-36v1® subscales 
 Subscale Definition* 
Ph
ysi
cal
 co
mp
one
nt 
sum
ma
ry 
Physical functioning Performance of physical activities such as self-care, 
walking, and vigorous physical activities 
Role physical The degree to which physical status interferes with a 
person’s typical role activities 
Bodily pain Intensity, duration, and frequency of bodily pain and 
limitations in usual activities due to pain 
General health The beliefs and evaluations of a person’s overall 
health 
Me
nta
l co
mp
one
nt 
sum
ma
ry 
Vitality Feelings of energy; the absence of fatigue 
Role emotional The degree to which emotional status interferes with 
a person’s typical role activities 
Social functioning The degree to which a person develops and 
maintains social relationships 
Mental health A person’s emotional, cognitive and intellectual 
status 
*As defined by Saris-Baglama et al. (2010) in the QualityMetric Health Outcomes™ Scoring Software 4.0, User’s 
Guide. 
 
Participants are asked to rate their health status during the past 4 weeks. Response 
formats include 3- and 5-point Likert scales. The official software (QualityMetric 
Health Outcomes™ Scoring Software 4.0) was used for scoring the SF-36v1® 
subscales (Saris-Baglama et al., 2010). The eight subscales are linearly transformed 
into T-scores (i.e. NBS), with a mean of 50 and a standard deviation of 10. The 
software uses the 1998 general U.S. population norms. A NBS ranging between 0 and 
100 is obtained for each subscale, with higher scores representing better HRQoL. The 
scoring software also produces the aggregated physical and mental component 
summaries (Maruish & DeRosa, 2009).  
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The measure has good content, concurrent, criterion, and construct validity and good 
internal consistency (α≥ .78 for subscales) (McHorney, Ware, Lu, & Sherbourne, 
1994), which has been replicated in a significant amount of studies with different 
patient populations (Turner-Bowker, Bartley, & Ware, 2002). In addition to validity 
and reliability considerations, McHorney et al. (1994) noted ceiling (maximum scores) 
and floor (minimum scores) effects in the role physical and role emotional subscales as 
these represent the more coarse subscales in terms of response categories. However, 
empirical studies have shown that the SF-36 rarely misses significant differences in 
group level comparisons (Katz, Larson, Phillips, Fossel, & Liang, 1992) and reviews 
critically examining HRQoL measures in cardiac disease reported that, of all the 
generic HRQoL measures, the SF-36 appears to have fewer floor and ceiling effects 
and performs best (Thompson & Yu, 2003).  
Disease-specific HRQoL – Congenital Heart Disease-TNO/AZL Adult Quality of 
Life 
The CHD-TAAQOL is a disease-specific HRQoL measure for people with ACHD 
(Kamphuis et al., 2004). Its development is based on the pre-existing generic core 
measure, the TAAQOL by the Netherlands Organisation for Applied Scientific 
Research Academic Medical Centre. At the time of the present study, the CHD-
TAAQOL was the only available measure specifically designed to assess HRQoL in 
ACHD, thus the selection of a disease-specific instrument was limited to this 
measure. The 26-item scale has three subscales: symptoms (9 items), worries (10 
items), and impact cardiac surveillance (7 items). The definitions of the CHD-
TAAQOL subscales are presented in Table 5.3. 
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Table 5.3. Definition of the CHD-TAAQOL subscales 
Subscale Definition* 
Symptoms Specific cardiac symptoms (e.g. shortness of breath) 
weighted by emotional response to symptoms 
Worries ACHD-specific worries (e.g. having children) weighted by 
emotional response to worries 
Impact cardiac 
surveillance 
Cardiac surveillance weighted by emotional response to 
cardiac surveillance 
*As defined by Kamphuis et al. (2004). 
 
Each item consists of two questions. The first question refers to health and the 
second question refers to the emotional impact in case of a health status problem. 
Participants are asked about the frequency of specific problems during the last month 
except for the impact cardiac surveillance scale where participants are questioned 
about the last twelve months. For example:  
[Symptom frequency] “How often in the last month did you look pale?” 
[Emotional impact] “How much did that bother you?” 
The response format for problem frequency consists of a three-point Likert scale: 1= 
Never, 2= Occasionally, 3= Often. The response format for the impact cardiac 
surveillance scale is: 1= No, 2= Yes. The response format for emotional impact is: 1= 
Not at all, 2= A little, 3= Quite a lot, 4= Very much. One single score is given for 
each pair of items (functional item and the corresponding emotional item). For 
example, if a person indicates that the occurrence of a particular problem was often 
but was not causing any emotional impact, then a score of 4 is assigned. The 
subscale scores are then linearly transformed, ranging from 0 to 100, with higher 
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scores indicating better HRQoL. The scoring procedures were conducted based on 
the official algorithms provided by Kamphuis et al. (2004). 
The CHD-TAAQOL has good reliability (α=  .77 for symptoms, α= .78 for impact 
cardiac surveillance, α=  .82 for worries) and construct, convergent, and discriminant 
validity and appears to be free from floor and ceiling effects (Kamphuis et al., 2004).  
5.5.3.2. Psychosocial variables 
Illness perceptions – Brief Illness Perceptions Questionnaire 
The Brief Illness Perceptions Questionnaire (Brief IPQ; Broadbent, Petrie, Main, & 
Weinman, 2006) is the brief version of the original Illness Perceptions Questionnaire 
(IPQ; Weinman, Petrie, Moss-Morris, & Horne, 1996) and its subsequent revised 
version (IPQ-R; Moss-Morris, Weinman, Petrie, Horne, Cameron, & Buick, 2002). 
The original IPQ measure was developed to measure the five illness representations 
of the SRM and is therefore theoretically derived. The IPQ and its revised and brief 
versions are the most commonly used measures of illness perceptions in cardiac 
disease as well as other chronic illnesses (Broadbent, Wilkes, Koschwanez, 
Weinman, Norton, & Petrie, 2015; Hagger & Orbell, 2003). 
The Brief IPQ is a 9-item scale that provides rapid assessment of cognitive and 
emotional illness perceptions including consequences, timeline, controllability, 
curability, identity, concern, coherence, emotional representation and causal 
dimensions. Because of the congenital nature of ACHD, the causal dimension was 
not included in the present study. Definitions of the Brief IPQ subscales are 
presented in Table 5.4. 
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Table 5.4. Definition of the Brief IPQ subscales 
Subscale Definition* 
Consequences The expected effects of the illness 
Timeline How long the individual believes the illness will last 
Controllability The extent to which the individual believes that they can 
control the illness 
Curability The extent to which the individual believes that they can 
recover from the illness 
Identity The degree of experience of severe symptoms from the 
illness  
Concern The degree of concern about the illness 
Coherence The degree of understanding about the illness 
Emotional 
representation 
The extent to which the individual has negative reactions 
such as fear, anger, and distress from their illness 
*As defined by Weinman et al. (1996) and Broadbent et al. (2006). 
Each subscale is measured by a single item, which is rated using a continuous linear 
scale ranging from 0 to 10. Higher scores represent stronger perceptions in the 
subscale measured. 
The brief version was selected over the IPQ-R (>80 items) to minimise participant 
burden. It is considered an appropriate alternative to the fuller version when a large 
number of variables is studied as it has good concurrent validity with the IPQ-R 
(Broadbent et al., 2006). Furthermore, Leventhal and Nerenz (1985) have argued that 
since illness perceptions are now well-defined, single items are more suited to their 
assessment rather than multiple items assessing latent factors. The Brief IPQ is also 
recommended for use in longitudinal research to study changes in illness perceptions 
over time (Petrie et al., 2007). Compared with the original IPQ, the Brief IPQ covers 
a wider array of illness perceptions including illness coherence and emotional 
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representations which are not addressed in the original measure. The Brief IPQ has 
acceptable test-retest reliability (α=  .70 for consequences, α=  .67 for timeline, α=  
.63 for controllability, α=  .55 for curability, α=  .65 for identity, α=  .66 for concern, 
α=  .48 for coherence, α=  .65 for emotional representation) and good predictive 
validity in people recovering from myocardial infarction (Broadbent et al., 2006). 
The measure also has good discriminant validity, which is evidenced by its ability to 
distinguish between different illnesses (Broadbent et al., 2006). Data on floor and 
ceiling effects in the Brief IPQ are lacking but one study in low back pain indicates 
that ceiling effects are evident only in the timeline subscale (Løchting, Garratt, 
Storheim, Werner, & Grotle, 2013). More recently, a meta-analysis further 
demonstrated that the measure has good concurrent validity as the associations are 
consistent with theory and previous research, discriminant validity, predictive 
validity through longitudinal studies, and sensitivity to change through longitudinal 
studies and randomised controlled trials in various chronic illnesses including 
cardiovascular disease (Broadbent et al., 2015). 
Coping strategies – Brief COPE 
The Brief COPE was developed by Carver (1997) and it is an abbreviated version of 
the COPE Inventory (Carver, Scheier, & Weintraub, 1989). The Brief COPE 
assesses individuals’ coping styles and strategies. The measure considers coping as 
motivated action and is focused on the self-regulatory processes underlying people’s 
coping efforts. The COPE and Brief COPE measures are multidimensional and 
encompass a wide range of coping strategies. A study that compared the COPE with 
other well-established measures including the Ways of Coping Questionnaire (WCQ; 
Folkman & Lazarus, 1988) and the Coping Strategy Indicator (CSI; Amirkham, 
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1990) found that the COPE explained the most variance in psychosocial outcomes 
such as mood and QoL (Clark, Bormann, Cropanzano, & James, 1995). Furthermore, 
a large number of studies guided by the SRM have used the COPE measure to assess 
coping strategies in various chronic illnesses in the past (Hagger & Orbell, 2003) and 
more recently the Brief COPE has been the preferred method of assessing coping 
strategies in multiple studies in diabetes, HIV, chronic heart failure, and cancer 
(Bose, Bjorling, Elfstrom, Persson, & Saboonchi, 2015). For these reasons, the Brief 
COPE was also utilised in the present study. 
The instrument consists of 28 items, which measure 14 distinct coping reactions (2 
items each), from adaptive to problematic. The fourteen subscales and their 
definitions are presented in Table 5.5. 
Participants are asked to indicate the degree to which they usually use each strategy 
when they experience stress related to their condition. The response format consists 
of a four-point Likert scale: 0=  I don’t do this at all, 1=  I do this a little bit, 2=  I do 
this a moderate amount, 3=  I do this a lot. Mean scores for each subscale are 
obtained from the two items and they can range from 0 to 3, where higher scores 
indicate more use of the specific coping strategy. The author suggests that each 
subscale should be treated separately in the analysis. 
This brief measure was created in response to criticism that the full version was too 
burdensome for respondents in terms of length of time to complete the questionnaire 
and because of the redundancy of items (n=  60). Carver (1997) demonstrated the 
soundness of the internal structure of the Brief COPE through exploratory factor 
analysis on the item set to obtain factor loadings, which indicated that the measure’s 
factor structure was very similar to that of the full version.
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Table 5.5. Definition of the Brief COPE subscales 
Subscale Definition* 
Active coping Taking active steps to try to remove or circumvent 
the stressor or to ameliorate its effects 
Planning Thinking about how to cope with a stressor (thinking 
about steps and action plans) 
Positive reframing Construing the stressor in positive terms 
Acceptance Accepting the reality of a stressful situation 
Humour Using humour to reduce the stressor 
Religion Tendency to turn to religion in times of stress 
Using emotional support Getting moral support, sympathy, or understanding 
Using instrumental support Seeking advice, assistance, or information 
Self-distraction Engaging in activities that serve to distract the 
person from thinking about the stressor 
Denial Trying to push the reality of the stressor away 
Venting Venting whatever distress or upset one is 
experiencing 
Substance use Using alcohol or other drugs to reduce the stressor 
Behavioural disengagement Reducing one's effort to deal with the stressor or 
giving-up 
Self-blame Criticising oneself for responsibility in the situation 
Note. “Stressor” in the present study refers to stress relating to ACHD. 
*As defined by Carver et al. (1989) and Carver (1997). 
 
Considering that reliability is influenced by the number of items in a scale, the Brief 
COPE has minimally acceptable reliability with the values in each scale exceeding 
.50, and good construct validity (Carver, 1997). The theoretically-based 14-factor 
structure is also supported by a recent study of 606 adults through confirmatory 
factor analysis (Monzani, Steca, Greco, D’Addario, Cappelletti, & Pancani, 2015). 
The same study also reports good and excellent reliability across the 14 coping 
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dimensions and recommends the use of the Brief COPE as opposed to the full 
version and other lengthy coping instruments (e.g. WCQ) when a battery of 
measures is administered. Floor and ceiling effects in the Brief COPE have not been 
reported in the literature.   
Anxiety – Six-item Short-Form of Spielberger State-Trait Anxiety Inventory  
Anxiety was assessed using the STAI-6 developed by Marteau and Bekker (1992). 
This instrument is the abbreviated version of the 20-item state scale of the 
Spielberger State-Trait Anxiety Inventory (STAI) (Spielberger, Gorsuch, Lushene, 
Vagg, & Jacobs, 1983), which is the most frequently used measure of anxiety in 
cardiac populations (De Jong & Hall, 2006) and has also been used in ACHD 
(Müller et al., 2013a). The STAI-6 measures how a person feels at a given moment. 
It consists of six items, three indicating the absence of anxiety and three indicating 
the presence of anxiety. Participants are asked to give answers on statements on a 
four-point Likert scale using the following response format: 1=  Not at all, 2=  
Somewhat, 3=  Moderately, 4=  Very much. The three items indicating the absence of 
anxiety are reverse-scored. The mean score of the scale is obtained from the six 
items and can range between 1 and 4, where higher scores reflect higher anxiety 
levels.  
The short form was specifically designed for use in settings where time constraints 
or pragmatic considerations preclude the use of the full 20-item and it has been 
shown to be more acceptable by study participants compared with the full version 
(Marteau & Bekker, 1992). The STAI-6 has good reliability (α=  .82) and concurrent 
validity when applying the six item questionnaire and the full-form of the state 
anxiety scale to four study groups (n=261) (Marteau & Bekker, 1992). The STAI-6 
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was also found to be as sensitive as the full-form scale to different degrees of 
anxiety. More recent evidence supports the finding that the STAI-6 is a reliable and 
valid instrument (Court, Greenland, & Margrain, 2010; Tluczek, Henriques, & 
Brown, 2009). Data on floor and ceiling effects in the STAI-6 are generally lacking 
but a study in cancer patients indicated the absence of such effects (van den Bergh, 
Korfage, Borsboom, Steyerberg, & Essink-Bot, 2009). 
Depression – Center for Epidemiologic Studies Depression Scale 
Depression was assessed with the abbreviated version of the CES-D (CES-D 10) 
which was developed by Andersen, Malmgren, Carter, and Patrick (1994). The 
original 20-item scale was developed by Radloff (1977). There are several measures 
of depression which have been utilized within the cardiac and ACHD literature 
including the BDI, HADS, and CES-D, all of which have similarly good 
psychometric properties. However, CES-D has been shown to be cognitively simpler 
(assessed by length, readability, and linguistic problems) compared with the BDI and 
HADS (Shumway, Sentell, Unick, & Bamberg, 2004). Both the brief and full 
versions, have been applied in a range of health settings since their development and 
have also been used in research involving spinal cord injury, diabetes and 
cardiovascular disease. CES-D 10 measures depressive symptomatology and consists 
of 10 items, two of them worded in the positive direction.  
Participants rate how often each depressive symptom occurred during the past week. 
Responses are organised on a 4-point Likert scale: 0=  Rarely or none of the time 
(less than 1 day), 1=  Some or a little of the time (1-2 days), 2=  Occasionally or a 
moderate amount of the time (3-4 days), 3=  All of the time (5-7 days). The two 
positively worded items are reverse-scored. The summed score of the scale is 
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obtained from the 10 items and can range between 0 and 30, where higher scores 
indicate higher levels of depressive symptoms. There is considerable variation in the 
literature regarding a cut-off score to indicate clinical levels of depression. The cut-
off score of 10 suggested by Andersen and colleagues (1994) was used in the present 
study; a score of 0 to 10 was classified as “without depressive symptoms” and a 
score of more than 10 was classified as “with depressive symptoms”. At the cut-off 
point of 10, Boey (1999) found high sensitivity (.85) and specificity (.80), with a 
reduced misclassification rate at 17.5% compared with 23.5% when a cut-off point 
of 8 was used. In an outpatient sample of 1024 people with coronary heart disease 
the CES-D 10 had 76% sensitivity and 79% specificity compared with the 
Diagnostic Interview Schedule (McManus, Pipkin, & Whooley, 2005).  
The brief version was developed to minimise participant response burden in multi-
item surveys and research with physically ill populations as it takes just two minutes 
to complete. The CES-D 10 has acceptable convergent validity, internal consistency 
(α=  .78 to .79), test-retest reliability (α= .44) over a period of three years, and 
predictive accuracy when compared to the original 20-item measure (Boey, 1999). 
Test-retest reliability over a period of 22 days was found to be .59 by authors 
(Andersen et al., 1994). Studies in chronic illnesses have reported that the CES-D 10 
does not exhibit floor and ceiling effects (Amtmann et al., 2014; Miller, Anton, & 
Townson, 2008). 
Perceived social support – Multidimensional Scale of Perceived Social Support 
The Multidimensional Scale of Perceived Social Support (MSPSS) is a measure of 
subjective assessment of social support adequacy (Zimet, Dahlem, Zimet, & Farley, 
1988). The MSPSS was selected over traditional network measures in order to 
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determine perceived social support, as opposed to the quantity of social support 
available, which is often assessed by the size and density of the network. Other 
multidimensional measures of perceived social support like the Medical Outcomes 
Study Social Support Survey (MOS-SSS; Sherbourne & Stewart, 1991) and the 
Interpersonal Support Evaluation List (ISEL; Cohen & Hoberman, 1983) are lengthy 
and do not distinguish between various sources of support. The Perceived Social 
Support Scale (PSSS; Procidano & Heller, 1983) is an alternative measure that 
assesses perceived support from family and friends but it has limited response 
options (yes/no), is lengthy, and does not assess support from a significant other. 
Therefore, the MSPSS was selected because a) it assesses multiple aspects of 
perceived social support from three sources, b) it is brief and concise compared with 
other measures, and c) it has been used extensively in cardiac populations (Stafford 
et al., 2009) and more recently in ACHD (Pike et al., 2012). 
MSPSS assesses perceived social support from family, friends, and significant other 
using 12 items (4 items in each subscale). Support is assessed using a 5-point9 Likert 
scale using the following response format: 1=  Strongly disagree, 2=  Disagree, 3=  
Neither disagree nor agree, 4=  Agree, 5=  Strongly agree. The mean score is 
calculated for each subscale as well as a mean total score of perceived support and 
can range between 1 and 5. Higher scores indicate higher levels perceived social 
support. 
The instrument has construct validity, good internal consistency both at scale and 
subscale level (α≥ .85) across different populations, and good test-retest reliability 
                                                          
9 The revised version of the MSPSS utilises a 7-point scale. However, both scales were used by the 
authors of the measure (Zimet et al., 1990; Dahlem, Zimet, & Walker, 1991) and others (Cheng & 
Chan, 2004; Wongpakaran & Wongpakaran, 2012). 
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(.85) (Canty-Mitchell & Zimet, 2000; Zimet et al.,1988; Zimet, Powell, Farley, 
Werkman, & Berkoff, 1990). Ceiling effects have been observed in the MSPSS in 
some studies (Sawyer, Ayers, Young, Bradley, & Smith, 2012), while others did not 
find such effects (Zhou et al., 2015). 
5.6. Statistical analysis 
Statistical analysis was performed using IBM SPSS versions 20.0 and 21.0.  
5.6.1. A priori power analysis 
To estimate a statistically sufficient sample size for the cross-sectional study, G-
Power (Faul, Erdfelder, Lang, & Buchner, 2007) was used to calculate the required 
number of participants for each diagnostic group. Power calculations were based on 
a four-group, cross-sectional study utilising one-way ANOVA to detect significant 
group differences in HRQoL. A systematic review of a large number of studies has 
indicated that a 0.5 S.D. is the minimally important difference in HRQoL in chronic 
illnesses, irrespective of whether the instrument is generic or disease-specific 
(Norman, Sloan, Wyrwich, 2003). Therefore, an approximately medium effect size 
(Cohen, 1988) was adopted in the power calculations to detect differences in the 
generic and disease-specific HRQoL measures. Sample size calculations indicated 
that a total sample size of 360 participants should be sought, with 90 participants per 
diagnostic group. These calculations were based upon equal group sizes, 90% power 
to detect differences at the .05 significance level, and an effect size of f=  .20. The 
power calculations were based on high power (90%) to allow for possible loss of 
power ≤ 10%, in case the required sample size was not achieved. 
For the longitudinal study, literature was consulted for guidance on the appropriate 
sample size for measuring change over time using Hierarchical Linear Models 
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(HLM). At present, there is no gold standard for calculating the sample size required 
for HLM, because such calculations are mathematically complicated and require 
parameters unknown to the researcher prior to data collection (Hayes, 2006). 
Tabachnick and Fidell (2007), however, suggest that at least 60 participants are 
required for each level of the model. As the data was structured into two levels 
(section 5.6.8.4, page 165), a sample of minimum 120 participants was required for 
the study to have sufficient power. 
5.6.2. Data screening 
Data were screened to ensure that all variables fell within possible ranges. All values 
that were out of range were crosschecked using the raw questionnaire data and 
corrected where necessary. 
5.6.3. Missing value analysis  
The same approach to missing value analysis and imputation was performed for the 
cross-sectional and longitudinal data. Mean item replacement was undertaken when 
calculating scale scores for cases that had ≤ 50% of items missing before conducting 
scale imputation, as suggested by Graham (2009). This method and the subsequent 
scale imputation excluded the SF-36v1®, for which missing data estimations are 
conducted within the official scoring software (see section 5.6.3.1, page 156 for 
description). Missing value analysis was performed at scale level except for 
demographic and clinical variables. Little’s Missing Completely At Random 
(MCAR) test was conducted to check if differences existed between the missing 
values and the observed values (Little, 1988). An insignificant result (p>  .01) 
suggests that data are MCAR and that imputation is appropriate.  
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Traditional methods of imputation include mean imputation, last observation carried 
forward, hot-deck imputation, regression imputation, and multiple imputations 
among others. Given that there was less than 5% missing data in the dataset (see 
Appendix O & Appendix P), using almost any of the above methods would yield 
similar results (Tabachnick & Fidell, 2007). Missing data was imputed at scale or 
subscale level using Bayesian stochastic regression (using chained equations, 
Markov Chain Monte Carlo-MCMC). Data were not imputed for the 11 cases 
missing the whole questionnaire packs of the cross-sectional study and for cases that 
were missing the whole questionnaire pack of the longitudinal study. 
The imputation process was conducted in sets of variables (i.e. clinical, 
demographic, psychosocial questionnaires) due to logistical reasons (i.e. processing 
power and time). However, the predictive model for all imputations had the same 
predictors; specifically, all other variables within the dataset.  
5.6.3.1. Missing data on the SF-36v1® 
The SF-36v1® licence purchase is supplemented by a scoring software 
(QualityMetric Health Outcomes™ Scoring Software 4.0) (Saris-Baglama et al., 2010), 
which has built-in algorithms that deal with missing data prior to scoring the scales. 
The program offers two ways of estimating missing data:  
i) Half-scale rule, where missing values are estimated based on the available data for 
the scales that have at least half of the items completed. The average score of the 
completed items replaces the missing values and scales are rendered missing when 
more than half of the items are missing. In turn, the component summary scores are 
calculated only when there are available data (either actual or estimated) on all eight 
scales.  
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ii) Maximum data recovery, where missing values are estimated when at least one 
item in the scale is completed. A scale is rendered missing when all items in that 
scale are missing. The component summary scores are calculated when at least seven 
of the eight scales have completed data (either actual or estimated). One of the seven 
completed scales that are required is physical functioning for the physical component 
summary and mental health for the mental component summary, in order for these 
summaries to be calculated. 
For the present study, the official scoring software was used as per the scoring 
manual. The SF-36v1® data were exported into an excel spreadsheet and imported 
into the scoring software, according to the manual. In order to make best use of the 
data and owing to the low percentages of missing data, the maximum data recovery 
method was selected for missing data estimations. Scales that were still missing after 
the scoring process were recorded as such in order to avoid invalidating the 
software’s missing data estimations. After the appropriate missing data estimations 
and scoring procedures were completed using the software, the SF-36v1® dataset 
was imported back to the main imputed SPSS dataset. 
5.6.4. Outliers  
Outliers are defined as observations that “deviate so much from other observations 
as to arouse suspicions that it was generated by a different mechanism” (Hawkins, 
1980) and can be influential in statistical tests. Outliers were identified by graphical 
inspection and by standardised z scores greater than ±3.29 (Tabachnick & Fidell, 
2007). There is disagreement amongst researchers on whether outliers should be 
removed from the analysis. Provided they are not erroneous data entries, outliers 
may contain valuable information and can represent the inherent variability of the 
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variable in question (Orr, Sackett, & DuBois, 1991). In addition, removing cases that 
have random outlying scores would result in significant reduction of the sample size. 
Therefore, outliers were retained in order to maximise sample size and because it 
was felt that they would provide valuable information regarding the relationships 
studied. Multivariate outliers are discussed in section 5.6.8.3 (page 162).  
5.6.5. Normality 
Some multivariate statistical tests require that the data be normally distributed. 
Because multivariate normality is not easily tested without conducting multiple 
variable combinations (Tabachnick & Fidell, 2007), univariate normality was 
studied. Tabachnick and Fidell (2007) recommend that normality tests are based on 
the grouped data (in this case diagnostic group) when the analysis consists of group 
comparisons. Statistically, the Shapiro-Wilk test can be used to test whether 
skewness and kurtosis are statistically significant. A significant result indicates non-
normal distribution. However, in large samples (n˃ 200) the impact of skewness and 
kurtosis deviations diminishes making this test over-sensitive to violations of 
normality (Field, 2013). In the present study the distribution of the variables was also 
examined visually by exploring the data visually using Q-Q plots and histograms for 
skewness and kurtosis.  
Floor and ceiling effects in the measures were also assessed. A floor effect occurs 
when a large proportion of people score at the lowest possible score, whereas a 
ceiling effect occurs when a large proportion of people score at the highest possible 
score. These effects may make it difficult to distinguish between groups and reduce 
measure responsiveness in longitudinal studies examining change (Fayers & 
Manchin, 2009). More specifically, a questionnaire may be unable to detect further 
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deterioration in a group of people if a high proportion of them scored at the scale 
minimum or further improvement if a high proportion scored at the scale maximum. 
In the present study, the distribution of the variables and the proportion of people 
scoring at the scale minimum/maximum were examined in order to assess floor and 
ceiling effects. When the median values were the same as the minimum or maximum 
values of a scale and a proportion of >25% of people scored at the scale minimum or 
maximum then floor and ceiling effects were considered substantial (McHorney et 
al., 1994). When ceiling and floor effects are present, data may be transformed but 
transformations may result in problems regarding interpretation of the data (Osborne, 
2002). 
A majority of the analyses presented in this thesis consisted of regressions, where 
normal distribution refers to the residuals rather than the variables. Section 5.6.8.3 
(page 162) describes the method used for exploring the distribution of the residuals 
in the regression-based analyses. 
Both parametric and non-parametric analyses were initially conducted where 
necessary; however, parametric analyses were presented when both approaches 
yielded similar results. This approach was followed because non-parametric tests 
may sometimes lead to loss of power for near-normal data (Pallant, 2013). 
5.6.6. Internal reliability of scales and subscales 
To assess the internal reliability of the measures, Cronbach’s α was calculated and 
reported for scales or subscales containing three or more items. Because Cronbach’s 
α is sensitive to the number of items in a scale, the inter-item correlation was also 
calculated and reported for two-item scales or subscales (Pallant, 2013). Cronbach’s 
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α of >.70 (Pallant, 2013) and inter-item correlations between .20 and .50 are 
generally considered optimal (Clark & Watson, 1995). 
5.6.7. Preliminary analyses  
For all preliminary and main analyses, the level of statistical significance was set at 
p<  .01 in order to minimise family-wise error due to multiple testing. 
Means and standard deviations for continuous variables and frequencies with 
percentages for categorical variables were presented. One-way ANOVAs were used 
to examine differences in continuous demographic and clinical characteristics and 
questionnaire data between the four diagnostic groups. Chi-square (χ2) tests were 
employed to test associations between categorical demographic/clinical variables and 
the four diagnostic groups. One-way ANOVAs and chi-square tests were also 
employed to examine differences in continuous demographic and clinical 
characteristics and questionnaire data between responders and non-responders in the 
longitudinal study. The Fisher’s exact probability test was reported where cell counts 
were lower than five. Cramer’s V (φc) (.10=  small, .30=  medium, .50=  large) and 
eta squared (ɳ2) (.01=  small, .06=  medium, .14=  large) were reported for χ2 tests and 
one-way ANOVAs respectively.  
5.6.8. Main analyses 
5.6.8.1. Research question #1a: HRQoL comparisons in people with ACHD with 
normative data from the general population 
The use of T-scores (NBS) in the SF-36v1® enables direct comparisons between the 
participants’ mean scores and the population average. The use of US population 
norms in the present study may pose some limitations as these are not culture-
specific. However, there are several reasons that informed the decision to use US 
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normative data. Firstly, there are currently no official UK norms recommended by 
the licensing company (QualityMetric Incorporated, personal communication, April 
5, 2013). Secondly, published UK normative data from four studies are either 
outdated (pre-1996), geographically restricted, age-restricted, and overall non-
representative of the UK population resulting in substantial differences between 
them (Bowling, Bond, Jenkinson, & Lamping, 1999). Thirdly, the SF-36v1® 
licensing company encourages researchers to use the official scoring software which 
at present only uses US population norms. Fourthly, US norms have been used as a 
point of comparison in other international studies in ACHD (e.g. Bruto et al., 2007). 
In light of the above limitations the present study used the official scoring software, 
which utilises more recent healthy population norms albeit from a different country, 
a wide age range, and a more representative sample of a healthy population.  
A cut-off point of ≥ 1 standard deviation was selected to assess the percentage of 
participants scoring below or above the general population mean, based on the 
authors’ recommendation (Ware & Kosinski, 2001a). To test whether the mean 
generic physical and psychosocial HRQoL (SF-36v1®) scores of the total sample as 
well as each of the diagnostic groups differ statistically from the norm mean, one-
sample t-tests were employed. An alternative way of analysis is to conduct 
comparisons with age- and gender-matched controls or normative data. However, the 
SF-36v1® was not administered to matched controls, owing to time limitations and 
lack of resources. In addition, age- and gender- normative data are currently only 
available for the latest instrument version (i.e. SF-36v2®) (QualityMetric 
Incorporated, personal communication, April 5, 2013). Furthermore, since the 
question was how much of a normal life people with ACHD lead, no comparisons 
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with other chronic illnesses were made. Effect sizes for mean differences were 
calculated using Cohen’s d (.20=  small, .50=  medium, .80=  large) (Cohen, 1988) 
along with 99% Confidence Intervals (CI). 
5.6.8.2. Research question #1b: HRQoL comparisons between four diagnostic 
groups 
To examine differences between the four diagnostic groups in physical, 
psychosocial, and disease-specific HRQoL, and due to the slightly unequal sample 
sizes in the four diagnostic groups, one-way ANOVA with Gabriel (for equal 
variances) or Games-Howell (for unequal variances) post-hoc tests were employed, 
based on 99% CI. The Welch test was implemented where necessary (for unequal 
variances). Effect sizes for the proportion of variance explained were calculated 
using ɳ2 (.01=  small, .06=  medium, .14=  large). 
5.6.8.3. Research question #2: factors associated with HRQoL in ACHD 
In order to examine the demographic, clinical, and psychosocial factors associated 
with HRQoL hierarchical multiple regressions were performed. Outcome variables 
included generic physical HRQoL (physical component summary and its subscales), 
generic psychosocial (mental component summary and its subscales) and all three 
scales of the disease-specific (CHD-TAAQOL) measure. Categorical predictor 
variables with more than two groups were dummy coded where appropriate. 
Bivariate linear regressions were employed first, in order to reduce the number of 
predictor variables entered into the regressions and therefore preserve power (Field, 
2013). The general rules regarding adequate sample size in multiple regression are 
n≥ 50+8m (m=  number of independent variables) when testing a model and n≥ 
104+m for testing individual predictors (Tabachnick & Fidell, 2007). Both equations 
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were calculated for each regression and the highest n required was taken as a general 
guideline. All regression models had sufficient sample size as a result of using the 
bivariate regressions to reduce the number of predictor variables.  
The entry method was used instead of stepwise as the latter does not necessarily 
produce the best model if there are redundant predictors, but rather produces a 
statistical model which may be biased (Harrell, 2001; Tabachnick & Fidell, 2007). 
Demographic and clinical factors were entered into the first blocks followed by 
psychosocial variables. Mood variables were entered in the last block as these were 
found to be highly correlated with HRQoL outcomes in previous research. The order 
of entry of the predictors in the regressions is displayed in Figure 5.1. NYHA 
functional status was not included in the hierarchical multiple regressions because it 
covered clinical function measured by other clinical variables in the models.  
 
Figure 5.1. Order of entry of predictor variables in hierarchical multiple regressions  
In order to assess whether the assumptions for regression analyses were met, 
evaluations were conducted for singularity, multicollinearity, independence of errors, 
outliers, normality, linearity, and homoscedasticity. 
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Singularity: To avoid singularity, either the subscale scores or the total scale scores 
were entered in the regressions. Specifically, for the perceived social support 
measure (MSPSS) the family, friends, and significant other support subscales were 
entered into the regressions, omitting the total scale score. 
Multicollinearity: Prior to the regression analysis, correlations between the 
independent variables were investigated in order to check for strong correlations (≥ 
.80). This would indicate correlations that could potentially be problematic for the 
regression analysis. Collinearity diagnostics were also examined including Variance 
Inflation Factor (VIF), tolerance statistic, variance proportions, and eigenvalues. VIF 
indicates strong linear relationships between the independent variables and a general 
rule is that values ≥ 4 are indicative of possible problems, while values ≥ 10 are a 
definite cause of concern (Belsley, Kuh, & Welsch, 1980). Acceptable tolerance 
values were set at ≥ 0.20 with lower values indicating a problem (Field, 2013).  
Independence of errors: The Durbin-Watson test was employed to test for 
independence of errors in the regressions. It tests whether there are correlations 
between adjacent residuals. Generally, a value close to 2 indicates no correlation and 
values less than 1 or greater than 3 may be problematic (Field, 2013). 
Outliers: In the regressions, multivariate outliers were examined in detail and their 
influence on the overall model was assessed using Cook’s distance (values ˃ 1 were 
deemed problematic). In addition, leverage values greater than twice the average 
were deemed problematic. For the hierarchical linear models it was not appropriate 
to check for multivariate outliers given the independent variables were time, 
diagnostic group, and Diagnostic Group x Time which were categorical. 
CHAPTER 5 – METHODOLOGY 
165 
 
Normality, linearity, homoscedasticity: Frequency histograms and normal probability 
plots were examined to determine the distribution of the residuals. Scatter plots of 
standardized predicted scores against standardized residuals were examined to check 
for unusual patterns. The above assumptions are met provided that: the residuals are 
normally distributed about the predicted dependent variable scores, the residuals 
have a straight-line relationship with predicted dependent variable scores, and the 
residuals variance about predicted dependent variable scores is the same for all 
predicted scores (Tabachnick & Fidell, 2007). Non-linearity of the relationship 
between the independent variables and the dependent variable may lead to biased 
estimates of the true population values and heteroscedasticity may lead to type I 
errors (Osborne & Waters, 2002). 
5.6.8.4. Research question #3: Changes over time in clinical, HRQoL, and other 
psychosocial factors 
Hierarchical Linear Models (HLM) were used to examine changes over time in 
clinical, HRQoL, and psychosocial factors10. HLM are complex statistical models 
used to analyse variance in continuous outcome variables when the predictor 
variables have hierarchical structure. HLM involve both fixed and random effects 
(West, Welch, & Galecki, 2007).  
HLM is a statistical analysis that has had an increasing use in health psychology 
research in recent years. HLM may be used to study complex relationships by 
including a number of covariates. The HLM method has a number of advantages 
over traditional methods such as repeated measures ANOVA [see Quené & van den 
Bergh (2004) or West (2009) for a more detailed description].  
                                                          
10 Mixed within-between ANOVAs were used where HLM analyses did not converge. 
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In the present study, HLM was used over repeated measures ANOVA for two main 
reasons. Firstly, HLM account for the hierarchical structure of data evident in 
longitudinal designs where assessments at different time points are “nested” within 
individuals and are correlated (Figure 5.2). Traditional methods assume that the 
observations and residuals are independent. This may result in inflated standard 
errors of the regression coefficients. HLM allow specification of the within-
individual error covariance structure that is most appropriate for the data. This is 
important because in longitudinal designs the assessment waves may be unequally 
spaced (Shek & Ma, 2011). Various covariance structures may be assessed by 
comparing the information criteria of each model, the commonest being -2 log 
likelihood. Lower -2 log likelihood values indicate better model fit.  
 
Figure 5.2. Hierarchical structure of data in the present study 
Secondly, HLM are quite robust against missing data (West et al., 2007). Traditional 
methods exclude cases when they have missing data from an administration point. 
With HLM, the data from completed assessments are still used in the analysis even if 
an individual did not complete both time points thus preserving statistical power. 
Before conducting HLM, the Intra-Class Correlation (ICC) was calculated in order to 
confirm the hierarchical structure of the data. The ICC estimates the amount of 
variance in the outcome explained by the grouping structure (Hox, 2002). High 
values suggest that the assumption of independence of errors is violated and that 
errors are correlated, hence the hierarchical structure is supported (Tabachnick & 
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Fidell, 2007). The ICC values confirmed the hierarchical structure of the data in this 
study. 
HLM was used to examine changes in clinical and psychosocial factors over time 
and across diagnostic groups. Diagnostic group, time (entered as a categorical 
variable), and the interaction Diagnostic Group x Time were entered as fixed effects 
into the model and “Participant ID” was entered as a random effect. Due to the 
variability in the timing of the longitudinal assessments, differences were tested 
between the diagnostic groups to establish whether there was a need for it to be 
adjusted during HLM. 
The selected method of estimation was the restricted maximum likelihood (REML) 
method. As opposed to maximum likelihood (ML), REML provides unbiased 
estimates of covariance parameters by considering the loss of degrees of freedom in 
the estimation of fixed effects (West et al., 2007). A “step-up” approach to modelling 
was adopted, whereby models were built from simple to more complex (West et al., 
2007). The following steps were followed: 1. Unconditional or “null” model, 2. 
Added the fixed effect of time, 3. Added a repeated statement where the covariance 
structure for the residuals was defined (diagonal), 4. Added the fixed effect of 
control variables (follow-up years), 5. Added the fixed effect of the predictor of 
interest (diagnostic group) as well as the Diagnostic Group x Time interaction. The 
diagonal covariance structure for the residuals appeared to be the most appropriate 
for the data, which achieved convergence. It assumes a heterogeneous variance at 
each time point and an independent covariance between measurement times.  
At each modelling step, the model fit may be evaluated using the information criteria 
(e.g. -2 restricted log likelihood). When the REML estimation method is used, 
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significance tests may be conducted when comparing models that share the same 
fixed effects and only differ in random effects (Snijders & Bosker, 2012). For this 
reason, significance tests were not appropriate in the present study. However, smaller 
values in the information criteria generally suggest a better model fit.  
A significant Diagnostic Group x Time interaction was interpreted as an indication 
that changes were different by diagnostic group. In order to examine significant 
mean differences pairwise comparisons were requested from SPSS using Sidak’s 
adjustment for multiple comparisons. Standardized adjusted effect sizes for 
significant mean differences were calculated using Cohen’s d (.20=  small, .50=  
medium, .80=  large) (Cohen, 1988).  
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CHAPTER 6 – SAMPLE CHARACTERISTICS 
6.1. Prologue 
This chapter presents the baseline characteristics of the sample. It begins with a 
description of participation rates in the cross-sectional study using a flow diagram 
and continues with a description of missing value analysis. Examination of data 
assumptions is presented before the description of participant demographic, clinical, 
and psychosocial characteristics along with differences between the four diagnostic 
groups. The final section includes a discussion of the sample characteristics with 
comparisons to other available literature.  
6.2. Participation rates 
Current estimations indicate that approximately 5000 people are followed-up by 
specialist cardiologists at The Heart Hospital, London. However, not all 5000 were 
active (and therefore recorded in paper records) at the time of the study (see section 
5.4.3, page 132). A total of 1199 active patients were identified as potential 
participants and were assessed for eligibility for the present study (Figure 6.1). One 
hundred and twenty-three (10.3%) were excluded based on the inclusion/exclusion 
criteria. All eligible participants with TGA and SV diagnoses were invited to take 
part in the study due to the limited number of people with these diagnoses, while a 
random sample of eligible participants with ToF and Simple diagnoses were selected 
for invitation (n=  236 and n=  197 respectively). Out of those invited, 273 declined 
(38.6%) and 81 (11.4%) did not respond to the invitation and telephone calls. Out of 
the 354 (50%) participants who agreed to take part, twenty-nine (11.3%) withdrew 
from the study without providing a reason and 11 (3.1%) participants did not 
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complete the psychosocial questionnaire pack. The final sample used for the main 
analyses consisted of 303 participants. Demographic and clinical information was 
reported for all participants with available data in those variables (n=  314; response 
rate: 44%).  
Due to ethical reasons in relation to accessing the patient records of individuals who 
did not consent, examining differences in key demographic and clinical 
characteristics between participants and non-participants was not possible, except for 
diagnostic group. Chi-square analysis indicated an association between diagnostic 
group and response to the invitation to participate in the study, χ2(3)=  19.29, p<  
.001; φc=  .17. The TGA group was more likely and the Simple group less likely to 
respond and complete the study.  
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Figure 6.1. Flow diagram of participation rates for the cross-sectional study 
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6.3. Missing value analysis 
Missing value analysis was performed at scale level except for demographic and 
clinical variables and is presented in Appendix O. In demographic and clinical 
characteristics, 61 (1.2%) items were missing out of 5024. In the psychosocial 
questionnaires 52 (0.4%) values were missing out of 12120 values. Little’s MCAR 
test was conducted to check if differences existed between the missing values and 
the observed values (Little, 1988). The result was p=  .219, suggesting that data were 
MCAR and that imputation is appropriate. Imputation was not performed for the 
eleven participants who did not complete the psychosocial questionnaires but for 
which clinical and demographic characteristics were available. 
6.4. Data assumptions 
6.4.1. Scale reliability 
All scales and subscales of the psychosocial questionnaires used in the study showed 
satisfactory internal reliability based on Cronbach’s α scores and/or inter-item 
correlations (Table 6.1) and were thus retained for the analyses. 
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Table 6.1. Internal reliability of scales/subscales used in the cross-sectional 
study 
Scales & Subscales No. of Items  Cronbach α/ Inter-Item 
Correlations§ 
SF-36   
    Physical functioning 10 .91 
    Role physical 4 .88 
    Bodily pain 2 .88/ .82 
    General health 5 .80 
    Vitality 4 .87 
    Social functioning 2 .68/ .51 
    Role emotional 3 .85 
    Mental health 5 .82 
CHD-TAAQOL   
    Symptoms 9 .84 
    Worries 10 .82 
    Impact cardiac surveillance 7  .74 
Brief COPE   
    Planning 2 .69/ .53 
    Active coping 2 .70/ .53 
    Positive reframing 2 .73/ .57 
    Acceptance 2 .63/ .46 
    Humour 2 .90/ .81 
    Religion 2 .90/ .81 
    Seeking emotional support 2 .78/ .64 
    Seeking instrumental support 2 .82/ .69 
    Self-distraction 2 .58/ .41 
    Denial 2 .50/ .35 
    Venting 2 .62/ .45 
    Substance use 2 .93/ .87 
    Behavioural disengagement 2 .64/ .48 
    Self-blame 2 .62/ .48 
STAI-6 6 .81 
CES-D 10 10 .85 
MSPSS   
    Family support 4 .88 
    Friends support 4 .93 
    Special person support 4 .95 
§Inter-item correlations are also reported for scales and subscales consisting of two items. 
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6.4.2. Normality 
Normality was tested statistically using the Shapiro-Wilk test and visually by 
examining Q-Q plots and histograms for skewness and kurtosis. The Shapiro-Wilk 
test was significant (p<  .001) for most variables. However, as described in section 
5.6.5 (page 158) the test may be over-sensitive to violations of normality in large 
samples. Visual exploration of plots indicated a more normal distribution in some 
variables than the Shapiro-Wilk test suggested. 
Due to the non-normality in some of the variables, floor and ceiling effects were 
examined by considering the median value of a scale and calculating the proportion 
of participants with the lowest or highest possible score in all measures. When the 
median values were the same as the minimum or maximum values of a scale and a 
proportion of >25% scored at the scale minimum or maximum then floor/ceiling 
effects were considered substantial (McHorney et al., 1994). Ceiling effects were 
observed in the role physical and role emotional subscales of the SF-36. Ceiling 
effects were observed only in the timeline subscales of the Brief IPQ. Floor effects 
were observed in the religion, denial, substance use, behavioural disengagement and 
self-blame subscales of the Brief COPE. No ceiling/floor effects were observed in 
the disease-specific HRQoL, anxiety, depression, and MSPSS measures.  
Data were not transformed because preliminary transformations in some variables 
using square root and logarithmic base 10 failed to improve non-normality. In 
addition, transformations may result in problems regarding interpretation of the data 
(Osborne, 2002). It has also been argued that with large sample sizes the sampling 
distributions of means are normally distributed irrespective of univariate 
distributions according to the central limit theorem (Tabachnick & Fidell, 2007).  
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6.5. Demographic characteristics of the sample 
The demographic characteristics of the total sample and each diagnostic group are 
displayed in Table 6.2.  
Due to the small number of participant within some variables’ categories, these were 
merged for some demographic variables. For ethnicity, all other groups other than 
“British” were categorised as “other”.  For marital status, the groups “married/civil 
partnership” and “in a relationship” were merged together and the groups 
“divorced”, “separated”, and “widowed” were merged into single. For educational 
level, the groups “primary education”, “secondary education”, “tertiary education” 
were merged into school level and the groups “undergraduate degree”, “master’s 
degree”, and “doctorate degree” were merged into university level. For employment 
status, the groups “employed” and “self-employed” were merged together and the 
groups “student”, “seeking job”, “housewife/husband”, “retired”, “unable to work”, 
and “long-term sick leave” were merged into unemployed. 
Mean age was 33.2 (S.D. 10.7) years (range: 19-76) with 177 (56.4%) males and 137 
(43.6%) females in the sample. Approximately half were married or in a relationship 
(50.6%). A total of 66.9% completed school level education, while 33.1% completed 
a higher degree. The majority were employed (70.4%), while 29.6% were 
unemployed.  
There were age differences between diagnostic groups (p<  .001). Games-Howell 
post-hoc comparisons indicated that the Simple group was older than the TGA (mean 
difference= 5.49, p=  .007, 99% CI [0.22, 10.77]; d=  .51) and SV (mean difference= 
8.62, p<  .001, 99% CI [3.05, 14.18]; d=  .76). The ToF group was older than the SV 
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(mean difference= 6.18, p=  .001, 99% CI [1.32, 11.03]). No other differences were 
observed between the diagnostic groups in demographic characteristics. 
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Table 6.2. Demographic characteristics of the sample by diagnostic group 
Demographic Variable Total Sample 
n= 314 
Simple 
n= 84 
ToF 
n= 81 
TGA 
n= 81 
SV 
n= 68 
Test Statistic Sig. Effect Size 
Age (mean, S.D., range) 33.2 (10.7) 
18-76 
37.1 (13.7) 
19-76 
34.6 (11) 
19-66 
31.6 (6.5) 
19-50 
28.4 (7.6) 
18-58 
f(3,167.07)=  
10.29§ 
<.001 ɳ2=  .09 
Gender (n, %)      χ2(3)=  10.22 .017 φc=  .18 
    Male 177 (56.4) 37 (44) 43 (53.1) 52 (64.2) 45 (66.2)    
    Female 137 (43.6) 47 (56) 38 (46.9) 29 (35.8) 23 (33.8)    
Ethnicity* (n, %)         
    British 266 (84.7) 68 (81) 72 (88.9) 72 (88.9) 54 (79.4) χ2(3)=  4.58 .206 φc=  .12 
    Other 48 (11.3) 16 (19) 9 (11.1) 9 (11.1) 14 (20.6)    
Marital status* (n, %)      χ2(3)=  1.98 .576 φc=  .08 
    Married/relationship 159 (50.6) 45 (53.6) 44 (54.3) 36 (44.4) 34 (50)    
    Single 155 (49.4) 39 (46.4) 37 (45.7) 45 (55.6) 34 (50)    
Educational level* (n, %)      χ2(3)=  3.28 .351 φc=  .10 
    School level 210 (66.9) 53 (63.1) 55 (67.9) 60 (74.1)  42 (61.8)    
    University level 104 (33.1) 31 (36.9) 26 (32.1) 21 (25.9) 26 (38.2)    
Employment status* (n, %)      χ2(3)=  2.49 .478 φc=  .09 
    Employed 221 (70.4) 57 (67.9) 59  (72.8) 61 (75.3) 44 (64.7)    
    Unemployed 93 (29.6) 27 (32.1) 22 (27.2) 20 (24.7) 24 (35.3)    
* Variables where categories were merged, § Welch Anova, φc: .10=  small, .30=  medium, .50=  large. ɳ2: .01=  small, .06=  medium, .14=  large.   
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6.6. Clinical characteristics of the sample 
Details of the primary diagnosis by diagnostic group are presented in Table 6.3 and 
the remaining clinical characteristics are presented in Table 6.4. 
Table 6.3. Primary diagnosis of the participants by diagnostic group 
Diagnosis Total Sample 
n= 314 (n, %) 
Simple 
n= 84 
ToF 
n= 81 
TGA 
n= 81 
SV 
n= 68 
Transposition of the great 
arteries 
83 (26.4) 0 0 81 2 
Tetralogy of Fallot 81 (25.8) 0 81 0 0 
Coarctation of the aorta 39 (12.4) 39 0 0 0 
Ventricular septal defect 9 (2.9) 9 0 0 0 
Secundum atrial septal 
defect 
6 (1.9) 6 0 0 0 
Atrial septal defect 18 (5.7) 18 0 0 0 
Pulmonary valve stenosis 10 (3.2) 10 0 0 0 
Sub-aortic stenosis 2 (0.6) 2 0 0 0 
Tricuspid atresia 23 (7.3) 0 0 0 23 
Double inlet left ventricle 14 (4.5) 0 0 0 14 
Pulmonary atresia/intact 
ventricular septum 
11 (3.5) 0 0 0 11 
Pulmonary atresia/ 
ventricular septal defect 
5 (1.6) 0 0 0 5 
Double outlet right 
ventricle 
5 (1.6) 0 0 0 5 
Hypoplastic right ventricle 3 (1) 0 0 0 3 
Isomerism 3 (1) 0 0 0 3 
Hypoplastic left ventricle 1 (0.3) 0 0 0 1 
Mitral atresia 1 (0.3) 0 0 0 1 
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Table 6.4. Clinical characteristics of the sample by diagnostic group 
Clinical Variable Total Sample  
n= 314 
Simple 
n= 84 
ToF 
n= 81 
TGA 
n= 81  
SV 
n= 68 
Test Statistic Sig. Effect 
Size 
Disease characteristics         
    Co-morbidities no. (mean, S.D., range) 1 (1.1) 
0-6 
0.8 (1) 
0-4 
0.9 (1) 
0-4 
1.1 (1.2) 
0-5 
1.2 (1.1) 
0-6 
f(3,310)=  1.40 .243 ɳ2=  .01 
    Arrhythmias (n, %)      χ2(3)=  32.98 <.001 φc=  .32 
        Yes 83 (26.4) 7 15 34 27    
        No 231 (73.6) 77 66 47 41    
    Cyanosis days (mean, S.D.) 1317.4 (2712) 9.5 (87.3) 1510.6 (2251.9) 592.8 (1593.7) 3566 (4160.1) f(3,125.61)=  31.75§ <.001 ɳ2=  .23 
Intervention history (mean, S.D.)         
    Interventions no. 2.4 (1.4) 1.5 (.8) 2.4 (1.2) 2.6 (1.3) 3.2 (1.7) f(3,160.86)=  33.17§ <.001 ɳ2=  .20 
    Hospitalization days  40.9 (52.9) 17 (16.7) 46.5 (33.5) 35.4 (24.8) 70.2 (94.9) f(3,152.99)=  26.72§ <.001 ɳ2=  .13 
Current status         
    Medication no. (mean, S.D.) 1 (1.3) 0.8 (1.3) 0.5 (1.1) 1.1 (1.4) 1.5 (1.2) f(3,310)=  8.05 <.001 ɳ2=  .08 
    Current O2 saturation (mean, S.D.) 95.9 (4.7) 98.2 (1.7) 97.3 (1.4) 96.2 (2.3) 91.1 (7.6) f(3,157.73)=  28§ <.001 ɳ2=  .32 
    NYHA class (n, %)      χ2(3)=  6.14 .105 φc=  .14 
        Class I 275 (87.6) 79 70 71 55    
        Class II, III, IV 39 (12.4) 5 11 10 13    
    VO2 Max (mean, S.D.) 28 (8.2) 30.3 (8) 27.2 (8.2) 27.2 (8.3) 27 (7.8) f(3,310)=  3.12 .026 ɳ2=  .03 
    Right ventricular function (mean, S.D.) 57.4 (8.7) 63.4 (5.1) 55.8 (8.9) 54.3 (7.6) 55.6 (9.5) f(3,161.22)=  36.76§ <.001 ɳ2=  .18 
    Left ventricular function (mean, S.D.) 60.9 (8.6) 64.7 (6.9) 59.9 (7.5) 62.8 (8.1) 55 (9.2) f(3,310)=  21.50 <.001 ɳ2=  .17 
§Welch ANOVA. 
φc: .10=  small, .30=  medium, .50=  large. ɳ2: .01=  small, .06=  medium, .14=  large.  
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6.6.1. Disease characteristics 
There were no differences in the number of co-morbidities (p>  .01) between 
diagnostic groups. A total of 24.6% of the sample experienced arrhythmias. Chi-
square analysis indicated an association between diagnostic group and arrhythmias 
(p<  .001). The TGA and SV were more likely to experience arrhythmias whereas the 
Simple group were less likely to.  
There were differences in cyanosis days (p<  .001) between diagnostic groups 
(Figure 6.2). The SV group experienced longer duration of cyanosis than the ToF 
(mean difference= 2055.41, p=  .002, 99% CI [256.61, 3854.21]), TGA (mean 
difference= 2973.20, p<  .001, 99% CI [1257.07, 4689.33]), and Simple (mean 
difference= 3556.49, p<  .001, 99% CI [1924.65, 5188.33]). The ToF and TGA 
groups experienced longer duration of cyanosis than the Simple group (mean 
difference= 1501.08, p<  .001, 99% CI [696.37, 2305.79] & mean difference= 
583.29, p=  .008, 99% CI [13.43, 1153.16] respectively).  
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Figure 6.2. Mean number of cyanosis days by diagnostic group 
6.6.2. Intervention history 
There were differences in the number of interventions that patients had undergone 
(p<  .001) between diagnostic groups (Figure 6.3). The SV group had undergone 
more interventions than the ToF (mean difference= 0.78, p=  .009, 99% CI [0.01, 
1.55]) and Simple (mean difference= 1.72, p<  .001, 99% CI [1.02, 2.43]). In 
addition, the ToF and TGA groups had undergone more interventions than the 
Simple group (mean difference= 0.94, p<  .001, 99% CI [0.43, 1.45] & mean 
difference= 1.18, p<  .001, 99% CI [0.65, 1.71] respectively).  
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Figure 6.3. Mean number of interventions by diagnostic group 
There were also differences in hospitalization days (p<  .001) between diagnostic 
groups (Figure 6.4). The ToF, TGA, and SV groups each had more hospitalization 
days than the Simple group (mean difference= 29.50, p<  .001, 99% CI [16.30, 
42.69], mean difference= 18.40, p<  .001, 99% CI [7.93, 28.86] & mean difference= 
53.11, p<  .001, 99% CI [15.49, 90.73] respectively). 
 
Figure 6.4. Mean number of hospitalization days by diagnostic group 
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6.6.3. Current status 
There were differences in the number of medications people were taking (p<  .001) 
between diagnostic groups (Figure 6.5). The SV group was taking more medications 
than the ToF (mean difference= 0.98, p<  .001, 99% CI [0.33, 1.64]) and Simple 
(mean difference= 0.69, p=  .005, 99% CI [0.04, 1.34]).  
 
Figure 6.5. Mean number of medication by diagnostic group 
There were differences in current O2 saturation (p<  .001) between diagnostic groups 
(Figure 6.6). The Simple group had significantly higher saturation levels than the 
ToF (mean difference= 0.92, p=  .002, 99% CI [0.14, 1.70]), TGA (mean difference= 
1.93, p<  .001, 99% CI [0.93, 2.93]), and SV (mean difference= 7.06, p<  .001, 99% 
CI [4.05, 10.08]). The ToF group had higher saturation levels than the TGA (mean 
difference= 1.01, p=  .006, 99% CI [0.06, 1.97]) and the SV (mean difference= 6.14, 
p<  .001, 99% CI [3.14, 9.14]). The TGA group had higher saturation levels than the 
SV (mean difference= 5.13, p<  .001, 99% CI [2.07, 8.19]). 
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Figure 6.6. Mean O2 saturation by diagnostic group 
NYHA functional classes II, III, and IV were merged due to the small number of 
individuals in these groups. The majority were classified at NYHA functional class I, 
while 39% were at II, III, and IV. There was no association between functional status 
as measured by the NYHA classification and diagnostic group (p>  .01). No 
significant effect of diagnostic group on the degree of exercise capacity as measured 
by VO2 max was observed (p>  .01). 
There were differences in both right and left ventricular function (p<  .001) between 
diagnostic groups (Figure 6.7 and Figure 6.8). The Simple group had better right 
ventricular function than the ToF (mean difference= 7.59, p<  .001, 99% CI [3.98, 
11.20]), TGA (mean difference= 9.11, p<  .001, 99% CI [5.89, 12.33]), and SV 
(mean difference= 7.78, p<  .001, 99% CI [3.69, 11.87]). In addition, the Simple 
group had better left ventricular function than the ToF (mean difference= 4.86, p=  
.001, 99% CI [0.96, 8.76]) and SV (mean difference= 9.78, p<  .001, 99% CI [5.70, 
13.86]) groups. The ToF and TGA groups had better left ventricular function than 
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the SV group (mean difference= 4.92, p=  .001, 99% CI [0.81, 9.04] & mean 
difference= 7.87, p<  .001, 99% CI [3.76, 11.99] respectively). 
 
Figure 6.7. Mean right ventricular function by diagnostic group 
 
Figure 6.8. Mean left ventricular function by diagnostic group 
6.7. Psychosocial predictor variables 
6.7.1. Illness perceptions 
The mean scores and results from group comparisons on illness perceptions are 
reported in Table 6.5.  
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Table 6.5. Mean scores and group comparisons on illness perceptions 
§Welch ANOVA. ɳ2: .01=  small, .06=  medium, .14=  large. 
Scale 0 – 10, higher score = stronger perceptions.  
Illness Perceptions  Mean (S.D.) Model Parameters 
f df Sig. ɳ2 
Consequences   4.39§ 162.59 .005 .05 
 Simple 2.95 (2.78)   
 
 
 ToF 3.05 (2.50)   
 
 
 TGA 2.94 (2.37)   
 
 
 SV 4.44 (2.98)   
 
 
 Total 3.30 (2.71)   
 
 
Timeline   4.17§ 154.63 .007 .05 
 Simple 8.60 (2.82)   
 
 
 ToF 9.34 (2.04)   
 
 
 TGA 9.73 (1.03)   
 
 
 SV 9.58 (1.64)   
 
 
 Total 9.29 (2.06)   
 
 
Controllability   0.80§ 163.13 .496 .01 
 Simple 4.99 (3.34)     
 ToF 5.62 (2.70)     
 TGA 5.46 (2.58)     
 SV 5.08 (3.11)     
 Total 5.30 (2.94)     
Curability   7.02§ 164.03 <.001 .06 
 Simple 6.29 (3.43)     
 ToF 8.27 (2.23)     
 TGA 7.12 (2.79)     
 SV 7.27 (2.53)     
 Total 7.22 (2.88)     
Identity   6.89 299 <.001 .06 
 Simple 2.39 (2.42)     
 ToF 2.35 (2.23)     
 TGA 2.50 (2.01)     
 SV 3.85 (2.45)     
 Total 2.73 (2.34)     
Concern   0.94 299 .423 .01 
 Simple 3.96 (2.91)     
 ToF 4.36 (2.81)     
 TGA 3.83 (2.66)     
 SV 4.50 (2.88)     
 Total 4.15 (2.82)     
Coherence   1.62 299 .186 .02 
 Simple 6.59 (2.65)     
 ToF 6.21 (2.32)     
 TGA 6.31 (2.40)     
 SV 5.68 (2.70)     
 Total 6.22 (2.52)     
Emotional representation   2.69§ 162.76 .048 .03 
 Simple 3.13 (3.22)     
 ToF 3.55 (3.01)     
 TGA 3.09 (2.69)     
 SV 4.45 (3.37)     
 Total 3.51 (3.10)     
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ANOVA indicated a significant effect of diagnostic group on illness consequences 
(p<  .01), timeline (p<  .01), curability (p<  .001), and identity (p<  .001). Post-hoc 
analysis indicated that the SV group reported stronger perception of negative 
consequences as a result of their ACHD than those with TGA (mean difference= 
1.50, p=  .007, 99% CI [0.06, 2.95]) (Figure 6.9). The TGA group reported stronger 
beliefs about illness chronicity than the Simple group (mean difference= 1.13, p=  
.005, 99% CI [0.07, 2.19]). The ToF group reported a stronger belief about treatment 
effectiveness than the Simple (mean difference= 1.98, p<  .001, 99% CI [0.57, 3.39]). 
The SV group attributed more severe symptoms to their condition than all the other 
groups (Simple: mean difference= 1.46, p=  .001, 99% CI [0.27, 2.65], ToF: mean 
difference= 1.50, p=  .001, 99% CI [0.29, 2.71], TGA: mean difference=1.35, p=  
.003, 99% CI [0.14, 2.56]).  
 All scales 0 – 10, higher scores = 1 severe illness consequences, 2 illness is chronic, 3 treatment extremely helpful, 
4many severe symptoms 
Figure 6.9. Mean scores in illness perceptions by diagnostic group  
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6.7.2. Coping strategies 
Table 6.6 presents the mean scores and results from group comparisons on coping 
strategies. 
Table 6.6. Mean scores and group comparisons on coping strategies 
Coping Strategies  Mean (S.D.) Model Parameters 
f df Sig. ɳ2 
Planning   3.55 299 .015 .03 
 Simple 1.45 (0.92)   
 
 
 ToF 1.47 (0.80)   
 
 
 TGA 1.13 (0.87)   
 
 
 SV 1.58 (0.90)   
 
 
 Total 1.40 (0.88)   
 
 
Active coping   2.03 299 .109 .02 
 Simple 1.63 (0.87)   
 
 
 ToF 1.80 (0.80)   
 
 
 TGA 1.47 (0.83)   
 
 
 SV 1.70 (0.85)   
 
 
 Total 1.65 (0.84)   
 
 
Positive reframing   0.59 299 .625 .01 
 Simple 1.58 (0.98)     
 ToF 1.51 (0.91)     
 TGA 1.42 (0.92)     
 SV 1.40 (0.90)     
 Total 1.48 (0.93)     
Acceptance   2.38 299 .070 .02 
 Simple 2.24 (0.76)     
 ToF 2.32 (0.73)     
 TGA 2.13 (0.89)     
 SV 2.46 (0.70)     
 Total 2.28 (0.78)     
Humour   1.38 299 .251 .01 
 Simple 1.21 (1.05)     
 ToF 1.27 (1.16)     
 TGA 1.13 (1.13)     
 SV 1.49 (1.04)     
 Total 1.27 (1.10)     
Religion   1.97* 160.08 .121 .01 
 Simple 0.52 (0.83)   
 
 
 ToF 0.60 (1.01)   
 
 
 TGA 0.33 (0.64)   
 
 
 SV 0.58 (0.95)   
 
 
 Total 0.51 (0.87)   
 
 
Emotional support   1.52 299 .211 .01 
 Simple 1.18 (0.85)   
 
 
 ToF 1.35 (0.93)   
 
 
 TGA 1.06 (0.93)   
 
 
 SV 1.30 (1.00)   
 
 
 Total 1.22 (0.92)   
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Table 6.6 Continued 
* Welch ANOVA. ɳ2: .01=  small, .06=  medium, .14=  large. 
Scale 0 – 3, higher score = greater use of coping strategy.  
 
Coping Strategies  Mean (S.D.) Model Parameters 
f df Sig. ɳ2 
Instrumental support   0.94 299 .420 .01 
 Simple 1.00 (0.87)     
 ToF 1.24 (0.91)     
 TGA 1.11 (0.90)     
 SV 1.13 (0.94)     
 Total 1.11 (0.90)     
Self-distraction   4.20 299 .006 .04 
 Simple 1.41 (0.91)     
 ToF 1.28 (0.85)     
 TGA 1.06 (0.89)     
 SV 1.53 (0.72)     
 Total 1.31 (0.86)     
Denial   0.14 299 .935 .00 
 Simple 0.19 (0.42)     
 ToF 0.17 (0.40)     
 TGA 0.17 (0.47)     
 SV 0.21 (0.46)     
 Total 0.18 (0.44)     
Venting   2.73 299 .044 .03 
 Simple 0.74 (0.65)     
 ToF 0.75 (0.81)     
 TGA 0.59 (0.71)     
 SV 0.94 (0.75)     
 Total 0.75 (0.74)     
Substance use   1.89* 160.31 .133 .02 
 Simple 0.29 (0.60)     
 ToF 0.18 (0.40)     
 TGA 0.13 (0.39)     
 SV 0.29 (0.59)     
 Total 0.22 (0.51)     
Behavioural disengagement   1.22* 160.41 .304 .01 
 Simple 0.26 (0.55)     
 ToF 0.16 (0.44)     
 TGA 0.19 (0.38)     
 SV 0.31 (0.59)     
 Total 0.23 (0.50)     
Self-blame   0.79 299 .503 .01 
 Simple 0.55 (0.66)   
 
 
 ToF 0.40 (0.63)   
 
 
 TGA 0.47 (0.65)   
 
 
 SV 0.52 (0.73)   
 
 
 Total 0.49 (0.66)   
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ANOVAs showed no differences in the use of coping strategies between the 
diagnostic groups (p>  .01) except for self-distraction (p<  .01) (Figure 6.10). The SV 
group used more self-distraction than the TGA group (mean difference= 0.47, p=  
.006, 99% [0.02, 0.92]). 
  Scale 0 – 4, higher score = greater use of self-distraction 
Figure 6.10. Mean scores in self-distraction by diagnostic group 
6.7.3. Social support 
Table 6.7 presents the mean scores and group comparisons on social support. 
ANOVAs did not indicate statistically significant differences between the diagnostic 
groups (p>  .01).  
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Table 6.7. Mean scores and group comparisons on social support 
* Welch ANOVA. ɳ2: .01=  small, .06=  medium, .14=  large.  
Scale 1 – 5, higher score = greater support 
 
6.7.4. Mood 
Mean scores for anxiety are displayed in Table 6.8 and the percentage of the sample 
with depressive symptoms is displayed in Table 6.9. ANOVA and chi-square 
analysis did not suggest statistically significant differences between the diagnostic 
groups in anxiety levels and depressive symptoms (p>  .01). 
Table 6.8. Mean scores and group comparisons on anxiety levels 
ɳ2: .01=  small, .06=  medium, .14=  large. 
Scale score 1 – 4, higher score = higher anxiety levels.  
 
 
Social Support  Mean (S.D.) Model Parameters 
f df Sig. ɳ2 
Family support   1.68* 163.12 .174 .01 
 Simple 4.17 (0.93)   
 
 
 ToF 4.35 (0.69)   
 
 
 TGA 4.19 (0.71)   
 
 
 SV 4.07 (0.83)   
 
 
 Total 4.20 (0.80)   
 
 
Friends support   1.02 299 .382 .01 
 Simple 4.12 (0.88)   
 
 
 ToF 4.01 (0.83)   
 
 
 TGA 4.01 (0.81)   
 
 
 SV 3.86 (1.02)   
 
 
 Total 4.01 (0.88)   
 
 
Significant other support   2.63* 161.29 .052 .03 
 Simple 4.32 (0.87)   
 
 
 ToF 4.43 (0.83)   
 
 
 TGA 4.17 (1.10)   
 
 
 SV 3.98 (1.11)   
 
 
 Total 4.24 (0.99)   
 
 
 Mean (S.D.) Model Parameters 
f df Sig. ɳ2 
Anxiety   1.62 299 .163 .02 
 Simple 1.68 (0.61)    
 
 
 ToF 1.62 (0.56)   
 
 
 TGA 1.60 (0.51)   
 
 
 SV 1.80 (0.60)   
 
 
 Total 1.67 (0.57)   
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Table 6.9. Percentages of people with depressive symptoms and group 
comparisons  
Depression 
n (%) 
Total  Simple ToF TGA SV Model Parameters 
      χ2 df Sig. φc 
No depressive 
symptoms 
238 
(78.5) 
59  
(72) 
63 
(81.8) 
68 
(87.2) 
48 
(72.7) 
7.38 3 .061 .16 
With depressive 
symptoms 
65 
(21.5) 
23  
(28) 
14 
(18.2) 
10 
(12.8) 
18 
(27.3) 
 
  
 
φc: .10=  small, .30=  medium, .50=  large.  
 
6.8. Discussion 
The following discussion focuses on comparisons between the current sample and 
other studies in ACHD.  
6.8.1. Participation rates  
Due to lack of reports regarding participation rates in previous studies, comparisons 
can only be made to one study. The participation rate in the current study was 44% 
compared with 59% in a previous study (Lane, Lip, & Millane, 2002). The lower 
participation rate might have been due to practical reasons. The administration of 
questionnaires was conducted in person and participants were asked to arrive at the 
hospital prior to their outpatient appointment, whereas in the study by Lane et al. 
(2002) questionnaires were sent by post.  
The TGA group was more likely and the Simple group less likely to respond and 
complete the study. It is possible that individuals in the Simple group did not 
perceive themselves as having problems with their HRQoL and therefore had no 
interest in participating in the study. Because invited participants were not required 
to give a reason for not participating, this assumption and the reason for the 
participation rates for the Simple and TGA groups could not be explored further. 
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6.8.2. Demographic characteristics 
This study was similar to other ACHD studies regarding the demographic 
characteristics of the sample. The higher percentage of male (56.4%) compared to 
female participants was also evident in the systematic review of 31 studies (average: 
56.3% male) (Fteropoulli, Stygall, Cullen, Deanfield, & Newman, 2013). Prevalence 
rates of ACHD are typically higher for females than in males (Marelli, Mackie, 
Ionescu-Ittu, Rahme, & Pilote, 2007). Simpler diagnoses, including ASD and PS, are 
generally more common in females than males, while ToF and TGA are more 
common in males (Mulder, 2012; Perloff, 1991). The larger (combined) proportion 
of people in the ToF and TGA groups over people in the Simple group is likely to be 
the explanation for the higher percentage of males in the present study. 
The proportion of people who were married or in a relationship was 50.6%. This is at 
the higher end but is consistent with previous studies, where the proportion of 
married participants ranged between 30% and 55% (Chen et al., 2011; Lane et al., 
2002; Moons et al., 2006; Rose et al., 2005; Simko & McGinnis, 2003).  
Previous reports regarding the percentage of people with ACHD completing 
university level education varied between 25-70% (Kamphuis et al., 2002c; Simko & 
McGinnis, 2003; Zomer et al., 2012b). The percentage in the present study was 
33.1%, therefore within the reported range. This percentage was only slightly lower 
than the percentage of people who have a graduate degree (38%) in the UK in 2013 
(Office for National Statistics, 2013). The proportion of employed participants in the 
study (70.4%) was within the range of 35-79% reported in the literature (Chen et al., 
2011; Jefferies et al., 2004; Lane et al., 2002). This percentage was slightly lower 
than the employment rate (73%) in the UK in 2014 (Office for National Statistics, 
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2014). These findings potentially have implications regarding the provision of career 
advice to people with ACHD (Crossland, Jackson, Lyall, Burn, & O’Sullivan, 2005).   
6.8.3. Clinical characteristics 
As anticipated, there were differences between the four diagnostic groups. There was 
increased morbidity in the SV group in the form of chronic cyanosis, number of 
interventions, hospitalization days, and medication, and ventricular function 
compared with the ToF, TGA, and Simple groups. It was difficult to compare the 
current sample with previous studies in clinical characteristics due to the variability 
in diagnostic groups and the limited reports of participants’ clinical characteristics in 
previous studies.  
Comparisons can be made regarding the exclusion criteria. The current study 
excluded individuals with chromosomal conditions and/or severe learning difficulties 
or mental retardation, and history of stroke because the self-report measures required 
normal intellectual abilities and people who were able to complete the questionnaires 
unassisted. Similar exclusion criteria have been used in previous studies (Callus, et 
al., 2014; Chen et al., 2011; Irtel et al., 2005; Kamphuis et al., 2002b; Loup et al., 
2009; Moons, et al., 2006; Moons et al., 2009; Saliba et al., 2001; Simko & 
McGinnis, 2005).  
6.8.4. Illness perceptions 
Only two studies have examined illness perceptions in ACHD, both of which have 
used the revised version of the IPQ to measure illness perceptions as opposed to the 
brief IPQ used in the present study. Therefore, the differences between the two 
measures limited direct comparisons between this and previous studies. 
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Overall, the low mean scores in the consequences, emotional representation, and 
concern subscales suggest that people believe that their condition has a relatively 
small impact on their lives. Similar findings have been reported by Schoormans et al. 
(2014). The findings of the present study also indicate that people do not believe that 
their condition causes many severe symptoms (identity subscale). Data from 
previous studies were not directly comparable to the present study. Riley et al. 
(2012) reported a mean of four symptoms experienced by people with ACHD in 
their study, the most common being palpitations, breathlessness, and fatigue. 
Although the findings of the present study may reflect the absence of severe 
symptoms in the sample, it is also possible that the treatment regimen helps 
ameliorate some of these symptoms. In fact, mean scores in the curability subscale 
were high, suggesting that people believe that they benefit from their treatment 
regimen. Mean scores in the controllability subscale were in the scale average, 
indicating neither strong nor weak beliefs regarding personal control. These findings 
are consistent with the findings reported by Riley et al. (2012) and Schoormans et al. 
(2014). 
High mean scores in the timeline subscale suggest that people acknowledge the 
chronicity of their condition. Similar findings were reported in the study by Riley et 
al. (2012). This finding is not surprising considering the congenital nature of ACHD. 
The mean scores in the illness coherence subscale suggest that individuals in the 
present study have average understanding of their condition. Schoormans et al. 
(2014) reported higher levels, whereas Riley et al. (2012) reported similar levels of 
illness coherence compared with the present study. A possible explanation for the 
higher coherence level in the study by Schoormans et al. is their inclusion of a large 
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proportion (60%) of people with simple defects, which may be easier to understand 
as opposed to more complex defects. 
The comparisons between the four diagnostic groups on illness perceptions indicated 
that the SV group perceived their condition and its impact more negatively than the 
other groups, as also reported by Schoormans et al. (2014). Negative illness 
perceptions in the SV group may be valid reflections of their poorer physical status. 
However, some negative perceptions in the Simple group warrant attention. These 
individuals reported weaker perceptions of illness chronicity than those with TGA 
and weaker perceptions of curability than those with ToF. One possible explanation 
for why people in the Simple group do not recognise the chronicity of their condition 
to the same degree as people with TGA is the nature of their condition, which is less 
complex and has fewer consequences. In addition, people in the Simple group are 
more likely to be medically managed as opposed to those with ToF who usually have 
reparative surgery early in their lives; hence, their weaker perceptions of treatment 
benefit. 
6.8.5. Coping strategies 
Participants in the present study engaged moderately in certain coping strategies, 
including acceptance and active coping, and to a lesser degree in others, including 
positive reframing, planning, self-distraction, humour, emotional support, 
instrumental support, denial, venting, and religion. In addition, mean scores in 
behavioural disengagement, substance use, and self-blame suggest minimal 
engagement in these coping strategies.  
Similar findings have been reported in previous studies in ACHD that used the 
Utrecht Coping List and reported that the most used coping strategy is active 
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problem solving, while the least used is expression of emotions (Eslami et al., 2013; 
van Rijen et al., 2004). The findings of the present study are consistent with previous 
qualitative reports of normalization coping in people with ACHD (Berghammer et 
al., 2006; Claessens et al., 2005). Normalization includes a process of accepting and 
adjusting to one’s limitations. This appears to be the case for participants in the 
present study who accept their condition and take active steps to cope with it. 
It is important to note that participants engaged less in what is generally considered 
maladaptive coping, including self-distraction, denial, venting of negative emotions, 
behavioural disengagement, substance use, and self-blame. Such coping strategies 
have been commonly reported in qualitative studies of adolescents with CHD. 
Zahmacioglu et al. (2011), using qualitative interviews, found that denial is used by 
adolescents to cope with stressful interventions but is shortly followed by more 
active approaches. Similar findings have been reported by McMurray et al. (2001). It 
appears that as people get older they accept their condition and begin to adjust their 
lives based on their limitations (Chiang et al., 2011).  
Comparisons between the four diagnostic groups did not reveal differences in the use 
of coping strategies with the exception of self-distraction. The findings indicated that 
the SV group uses self-distraction more than the TGA group. Previous studies 
showed that the adoption of coping strategies was independent of disease complexity 
(Enomoto et al., 2013; Eslami et al., 2014; van Rijen et al., 2004). It is likely that 
people with SV use more self-distraction than those with TGA because they 
experience greater emotional burden from their condition. Self-distraction may serve 
as an adaptive rather than maladaptive coping strategy, because it helps people with 
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SV to ameliorate stress associated with their condition (Tuncay, Musabak, Gok, & 
Kutlu, 2008). 
6.8.6. Social support 
The mean scores in perceived social support ranged between “agree” and “strongly 
agree”, suggesting that participants perceive high levels of support from family, 
friends, and their significant others. Similar high levels of social support have been 
reported in a study by Pike et al. (2012) who used the same measure (MSPSS).  
There were no differences between the four diagnostic groups in levels of perceived 
social support. No previous studies have examined levels of perceived social support 
across different diagnostic groups. However, high levels of social support have been 
reported in studies that included people with SV (Pike et al., 2012), ToF (Knowles et 
al., 2012), and studies with mixed samples (Rose et al., 2005). 
6.8.7. Mood 
Responses in anxiety ranged from “not at all” to “somewhat”, suggesting that 
participants in this study experience low levels of anxiety. Similar levels of anxiety 
have been reported by Müller et al. (2013a) who also used the STAI. Previous 
studies that applied cut-off points to categorise people on the degree of anxiety and 
indicated that up to 63% of people with ACHD may experience elevated anxiety 
levels (Cohen et al., 2010; Eslami et al., 2013; Riley et al., 2012). 
A total of 21.5% of the total sample exhibited depressive symptoms. Variable 
prevalence rates up to 41% have been reported in previous studies using self-report 
measures (Bang et al., 2013; Cohen et al., 2010; Eslami et al., 2013; Kourkoveli, et 
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al., 2014; Kovacs, et al., 2009b; Bromberg et al., 2003; Müller et al., 2012; Pike et 
al., 2012; Popelová et al., 2001; Riley et al., 2012). 
No differences were observed between the four diagnostic groups in anxiety levels 
and the presence of depressive symptoms. Previous studies in ACHD failed to find 
any association between disease complexity and mood (Eslami et al., 2013; Kovacs 
et al., 2009b; Loup et al., 2009; Müller et al., 2012, Müller et al., 2013a; Popelová et 
al., 2001).  
6.9. Summary  
This chapter described the demographic, clinical, and psychosocial characteristics of 
the study sample. Overall, the findings suggest that the present sample of people 
with ACHD is comparable to previous studies in the literature. The next chapter will 
address the first aim of the study by describing the HRQoL of people with ACHD 
and differences between the four diagnostic groups.
CHAPTER 7 – IMPACT OF ACHD ON HRQOL 
200 
 
CHAPTER 7 – IMPACT OF ADULT CONGENITAL 
HEART DISEASE ON HEALTH-RELATED 
QUALITY OF LIFE 
7.1. Prologue 
The previous chapter presented a description of the sample characteristics. The 
current chapter describes the analyses from the cross-sectional study to examine the 
impact of ACHD on HRQoL by comparing the HRQoL of people with ACHD with 
normative data from the general population and to examine differences in HRQoL 
between four diagnostic groups. It was hypothesized that people with ACHD will 
report significantly poorer HRQoL compared with the general population norm, 
predominantly in physical domains of HRQoL and that there will be differences in 
HRQoL between the diagnostic groups, predominantly between the Simple and SV 
groups (section 4.4, page 127). The following sections present the results of the t-test 
and ANOVA analyses and discussion of the findings. 
7.2. HRQoL comparisons between people with ACHD and general population 
norms 
Comparisons between people with ACHD and normative data were conducted for 
generic HRQoL (SF-36v1®). 
7.2.1. Physical HRQoL 
The distribution of participants’ scores in the physical component summary and its 
subscales are presented in the form of percentage of people that scored within the 
norm mean (0), 1 S.D. below (< -1), and 1 S.D. above (> 1) the norm mean. 
In the total sample, the majority (range: 60.4- 88.1%) scored within the average 
range in the physical component summary and all of the subscales, followed by those 
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who scored below the norm mean (range: 11.9- 32.7%) (Figure 7.1). A smaller 
number (range: 0- 10.6%) scored above the norm mean. This excludes the bodily 
pain subscale, in which more people scored above the norm mean (49.5%) than 
within the average (36%) or below the nom mean (14.5%). None scored above the 
norm mean in the physical functioning and role physical subscales. 
 Note. -1= 1 S.D. or more below the norm mean, 0= within the norm mean, 1= 1 S.D. or more above the 
norm mean 
Figure 7.1. Distribution of physical HRQoL scores for total sample 
The same pattern of results was observed within each of the diagnostic groups, with 
two exceptions (Figure 7.2). Firstly, in the ToF group, more people scored above 
(18.2%) than below the norm mean (7.8%) in the physical component summary. 
Secondly, in the SV group, slightly more people scored within the average (42.4%) 
than above the norm mean (39.4%) in the bodily pain subscale.  
More people scored below the norm mean in general health than any other physical 
HRQoL subscale. On the other hand, more people scored above the norm mean in 
bodily pain than any other subscale. This pattern was evident in the total sample and 
across all diagnostic groups.   
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Note. -1= 1 S.D. or more below the norm mean, 0= within the norm mean, 1= 1 S.D. or more above the norm mean 
Figure 7.2. Distribution of physical HRQoL scores for each diagnostic group 
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The standardised mean scores of the total sample and diagnostic groups for physical 
HRQoL compared with the norm mean and results from t-tests are presented in 
Table 7.1. 
Table 7.1. T-tests: physical HRQoL comparisons with norms 
 
Note. Norm mean 50 (10). Positive and negative t values indicate better and poorer HRQoL respectively. 
Cohen’s d: .20= small, .50= medium, .80= large. 
 
  
Scale/Subscale  Mean 
(S.D.) 
T-test Sig. 99% CI  
of the 
Difference 
d 
Physical component 
summary 
     
 Total 50.9 (9.4) t(301)=  1.74 .083 -0.46, 2.34 .09 
 Simple 51.5 (10) t(81)=  1.38 .170 -1.38, 4.42 .15 
 ToF 52.8 (8.7) t(76)=  2.84 .006 0.20, 5.44 .30 
 TGA 51 (7.5) t(76)=  1.18 .241 -1.25, 3.27 .11 
 SV 47.9 (10.8) t(65)=  -1.56 .123 -5.59, 1.45 .20 
Physical functioning      
 Total 49.8 (8.9) t(302)=  -0.35 .728 -1.50, 1.15 .02 
 Simple 50.9 (9.2) t(81)=  0.88 .381 -1.79, 3.57 .09 
 ToF 51.4 (7.2) t(76)=  1.70 .094 -0.78, 3.57 .16 
 TGA 50.5 (7.5) t(77)=  0.62 .538 -1.73, 2.78 .06 
 SV 45.8 (10.6) t(65)=  -3.20 .002 -7.65, -0.71 .41 
Role physical      
 Total 50.5 (9.7) t(301)=  0.94 .346 -0.92, 1.97 .05 
 Simple 50.4 (9.9) t(81)=  0.34 .733 -2.52, 3.27 .04 
 ToF 52.2 (8.5) t(76)=  2.28 .025 -0.35, 4.75 .24 
 TGA 51.3 (8.4) t(76)=  1.33 .187 -1.26, 3.82 .14 
 SV 47.9 (11.6) t(65)=  -1.48 .144 -5.92, 1.68 .20 
Bodily pain    
 
  
 Total 54.5 (10.4) t(302)=  7.46 <.001 2.91, 6.00 .44 
 Simple 52.7 (11.8) t(81)=  2.07 .042 -0.74, 6.16 .25 
 ToF 56.7 (8.7) t(76)=  6.79 <.001 4.12, 9.37 .72 
 TGA 55.4 (10) t(77)=  4.80 <.001 2.44, 8.39 .54 
 SV 52.8 (10.3) t(65)=  2.22 .030 -0.55, 6.20 .28 
General health    
 
  
 Total 45.1 (10.6) t(302)=  -8.08 <.001 -6.47, -3.33 .48 
 Simple 46 (11.5) t(81)=  -3.15 .002 -7.33, -0.65 .37 
 ToF 46.8 (9.8) t(76)=  -2.83 .006 -6.14, -0.21 .33 
 TGA 44.7 (9) t(77)=  -5.24 <.001 -7.99, -2.64 .56 
 SV 42.4 (11.5) t(65)=  -5.32 <.001 -11.32, -3.78 .71 
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In the physical component summary, people with ToF reported significantly better 
HRQoL than the norm (p<  .01) (Figure 7.3). 
Scale 0 – 100, higher score= better HRQoL. 
Norm mean= 50. Star indicates significant difference between the group and the norm. 
Figure 7.3. Comparisons with norm in physical component summary  
In the physical functioning subscale, the SV group reported poorer HRQoL than the 
norm (p<  .01) (Figure 7.4).  
 Scale 0 – 100, higher score= better HRQoL. 
Norm mean= 50. Star indicates significant difference between the group and the norm. 
Figure 7.4. Comparisons with norm in physical functioning 
No differences were observed between the total sample and diagnostic groups and 
the norm in the role physical subscale. In the bodily pain subscale, the total sample 
0
5
10
15
20
25
30
35
40
45
50
55
60
Total Sample Simple ToF TGA SV
Me
an 
sco
res
 in
 ph
ysi
cal
fun
ctio
nin
g
0
5
10
15
20
25
30
35
40
45
50
55
60
Total Sample Simple ToF TGA SV
Me
an 
sco
res
 in
 ph
ysi
cal
com
po
nen
t 
sum
ma
ry
CHAPTER 7 – IMPACT OF ACHD ON HRQOL 
205 
 
and ToF and TGA groups reported better HRQoL than the norm (p<  .001) (Figure 
7.5).  
 Scale 0 – 100, higher score= better HRQoL. 
Norm mean= 50. Star indicates significant difference between the group and the norm. 
Figure 7.5. Comparisons with norm in bodily pain 
In the general health subscale, the total sample and all diagnostic groups reported 
poorer HRQoL than the norm (p<  .01) (Figure 7.6). 
 Scale 0 – 100, higher score= better HRQoL. 
Norm mean= 50. Star indicates significant difference between the group and the norm. 
Figure 7.6. Comparisons with norm in general health 
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7.2.2. Psychosocial HRQoL 
In the total sample, the majority (range: 60.8- 82.5%) scored within the average in 
the mental component summary and all of the subscales, followed by those who 
scored below the norm mean (range: 17.5- 22.4%) (Figure 7.7). A smaller number 
(range: 0- 6.9%) scored above the norm mean. However, in the vitality subscale, 
slightly more people scored above the norm mean (20.1%) than below the nom mean 
(19.1%). None scored above the norm mean in the social functioning and role 
emotional subscales. 
 
Note. -1= 1 S.D. or more below the norm mean, 0= within the norm mean, 1= 1 S.D. or more above the 
norm mean 
Figure 7.7. Distribution of psychosocial HRQoL scores for total sample 
The same pattern of results was observed within each of the diagnostic groups, with 
the exception of ToF and TGA groups (Figure 7.8). In these groups, more people 
scored above (ToF: 26%, TGA: 24.4%) than below the norm mean (ToF: 10.4%, 
TGA: 12.8%) in the vitality subscale.  
More people scored below the norm mean in mental health than any other 
psychosocial HRQoL subscale. This pattern was evident in the total sample and in 
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the ToF, TGA, and SV groups. In the Simple group, more people scored below the 
norm in vitality than any other subscale. On the other hand, more people scored 
above the norm mean in vitality than any other subscale. This pattern was evident in 
the total sample and across all diagnostic groups.   
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Note. -1= 1 S.D. or more below the norm mean, 0= within the norm mean, 1= 1 S.D. or more above the norm mean 
Figure 7.8. Distribution of psychosocial HRQoL scores for each diagnostic group 
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The standardised mean scores of the total sample and diagnostic groups for 
psychosocial HRQoL compared with the norm mean and results from t-tests are 
presented in Table 7.2. 
Table 7.2. T-tests: psychosocial HRQoL comparisons with norms 
 
Note. Norm mean 50 (10). Positive and negative t values indicate better and poorer HRQoL respectively. 
Cohen’s d: .20= small, .50= medium, .80= large. 
 
Scale/Subscale  Mean 
(S.D.) 
T-test Sig. 99% CI  
of the 
Difference 
d 
Mental component summary   
 
  
 Total 48.2 (10.9) t(301)=  -2.95 .003 -3.47, -0.22 .17 
 Simple 45.9 (12) t(81)=  -3.06 .003 -7.57, -0.56 .37 
 ToF 50 (9.4) t(76)=  -0.00 .997 -2.83, 2.82 .00 
 TGA 50.4 (9.1) t(76)=  0.38 .703 -2.33, 3.12 .04 
 SV 46.1 (12.2) t(65)=  -2.56 .013 -7.84, 0.14 .35 
Vitality       
 Total 50.8 (10.6) t(302)=  1.36 .176 -.075, 2.40 .08 
 Simple 47.8 (11.1) t(81)=  -1.82 .073 -5.44, 1.00 .21 
 ToF 53.6 (9.1) t(76)=  3.43 .001 0.82, 6.32 .38 
 TGA 53 (9.6) t(77)=  2.72 .008 0.08, 5.85 .31 
 SV 48.9 (11.5) t(65)=  -0.80 .429 -4.88, 2.63 .10 
Social functioning      
 Total 48.7 (10.5) t(302)=  -2.13 .034 -2.84, 0.28  .13 
 Simple 48.4 (10.6) t(81)=  -1.37 .175 -4.68, 1.48 .16 
 ToF 51.4 (8.4) t(76)=  1.48 .142 -1.11, 3.97 .15 
 TGA 50 (8.9) t(77)=  -0.03 .976 -2.68, 2.62 .00 
 SV 44.5 (12.9) t(65)=  -3.47 .001 -9.75, -1.30 .48 
Role emotional    
 
  
 Total 49.2 (11) t(301)=  -1.21 .227 -2.40, 0.87 .08 
 Simple 47.4 (12.6) t(81)=  -1.89 .062 -6.28, 1.03 .23 
 ToF 50.3 (9.9) t(76)=  0.25 .806 -2.70, 3.26 .03 
 TGA 51.5 (8.9) t(76)=  1.49 .139 -1.16, 4.18 .16 
 SV 47.7 (11.8) t(65)=  -1.60 .114 -6.16, 1.52 .21 
Mental health       
 Total 47.9 (10.7) t(302)=  -3.41 .001 -3.69, -0.50 .20 
 Simple 46.9 (11.2) t(81)=  -2.53 .014 -6.40, 0.14 .29 
 ToF 49.7 (9.6) t(76)=  -0.28 .778 -3.20, 2.58 .03 
 TGA 49.2 (10) t(77)=  -0.69 .495 -3.78, 2.22 .08 
 SV 45.6 (11.6) t(65)=  -3.12 .003 -8.22, -0.67 .41 
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In the mental component summary, the total sample and Simple group reported 
poorer HRQoL than the norm (p<  .01) (Figure 7.9). 
 
Scale 0 – 100, higher score= better HRQoL. 
Norm mean= 50. Star indicates significant difference between the group and the norm. 
Figure 7.9. Comparisons with norm in mental component summary 
In the vitality subscale, the ToF and TGA groups reported better HRQoL than the 
norm (p<  .01) (Figure 7.10). 
 
Scale 0 – 100, higher score= better HRQoL. 
Norm mean= 50. Star indicates significant difference between the group and the norm. 
Figure 7.10. Comparisons with norm in vitality 
In social functioning, the SV group reported poorer HRQoL than the norm (p<  .01) 
(Figure 7.11). 
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 Scale 0 – 100, higher score= better HRQoL. 
Norm mean= 50. Star indicates significant difference between the group and the norm. 
Figure 7.11. Comparisons with norm in social functioning 
No differences were observed between the total sample and diagnostic groups and 
the norm in the role emotional subscale. In the mental health subscale, the total 
sample and SV group reported poorer HRQoL than the norm (p<  .01) (Figure 7.12). 
 
Scale 0 – 100, higher score= better HRQoL. 
Norm mean= 50. Star indicates significant difference between the group and the norm. 
Figure 7.12. Comparisons with norm in mental health  
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7.3. HRQoL comparisons between diagnostic groups 
Comparisons between the four diagnostic groups were conducted for the generic 
(physical and psychosocial) and disease-specific HRQoL. 
7.3.1. Generic physical HRQoL 
Results from the comparisons between the diagnostic groups for generic physical 
HRQoL are presented in Table 7.3. 
Table 7.3. ANOVA: group comparisons in generic physical HRQoL 
Scale/Subscale  
 
 Mean (S.D.) Model Parameters 
 f df Sig. ɳ2 
Physical component 
summary 
  2.93* 161.15 .035 .03 
 Simple 51.5 (10)     
 ToF 52.8 (8.7)     
 TGA 51 (7.5)     
 SV 47.9 (10.8)     
Physical 
functioning 
  4.60* 161.06 .004 .06 
 Simple 50.9 (9.2)   
 
 
 ToF 51.4 (7.2)   
 
 
 TGA 50.5 (7.5)   
 
 
 SV 45.8 (10.6)   
 
 
Role physical   2.20* 161.10 .091 .03 
 Simple 50.4 (9.9)     
 ToF 52.2 (8.5)     
 TGA 51.3 (8.4)     
 SV 47.9 (11.6)     
Bodily pain   3.01* 163.63 .032 .03 
 Simple 52.7 (11.8)     
 ToF 56.7 (8.7)     
 TGA 55.4 (10)     
 SV 52.8 (10.3)     
General health   2.16* 162.54 .095 .02 
 Simple 46 (11.5)     
 ToF 46.8 (9.8)     
 TGA 44.7 (9)     
 SV 42.4 (11.5)     
*Welch ANOVA. 
Note. ɳ2: .01=  small, .06=  medium, .14=  large.  
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There was no significant effect of diagnostic group on the physical component 
summary and the following subscales: role physical, bodily pain, general health (p>  
.01). There was a significant effect of diagnostic group on physical functioning (p<  
.01). Post-hoc comparisons indicated that the SV reported poorer physical 
functioning than the ToF group (mean difference= -5.58, p=  .003, 99% CI [-10.50, -
0.66]; d=  .63) (see Figure 7.4, page 204).  
7.3.2. Generic psychosocial HRQoL 
The comparisons between the diagnostic groups for generic psychosocial HRQoL 
are presented in Table 7.4.  
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Table 7.4. ANOVA: group comparisons in generic psychosocial HRQoL 
Scale/Subscale  
 
 Mean (S.D.) Model Parameters 
 f df Sig. ɳ2 
Mental component 
summary 
  3.76* 161.55 .012 .04 
 Simple 45.9 (12)     
 ToF 50 (9.4)     
 TGA 50.4 (9.1)     
 SV 46.1 (12.2)     
Vitality   6.07 299 .001 .06 
 Simple 47.8 (11.1)   
 
 
 ToF 53.6 (9.1)   
 
 
 TGA 53 (9.6)   
 
 
 SV 48.9 (11.5)   
 
 
Social functioning   4.99* 160.68 .002 .06 
 Simple 48.4 (10.6)   
 
 
 ToF 51.4 (8.4)   
 
 
 TGA 50 (8.9)   
 
 
 SV 44.5 (12.9)   
 
 
Role emotional   2.72* 161.90 .046 .03 
 Simple 47.4 (12.6)     
 ToF 50.3 (9.9)     
 TGA 51.5 (8.9)     
 SV 47.7 (11.8)     
Mental health   2.47 299 .062 .02 
 Simple 46.9 (11.2)     
 ToF 49.7 (9.6)     
 TGA 49.2 (10)     
 SV 45.6 (11.6)     
*Welch ANOVA. 
Note. ɳ2: .01=  small, .06=  medium, .14=  large.  
 
There was no significant effect of diagnostic group on the mental component 
summary and the following subscales: role emotional, mental health (p>  .01). There 
was a significant effect of diagnostic group on vitality, and social functioning (p<  
.01). Post-hoc analysis indicated that the Simple group reported less vitality than the 
ToF (mean difference= -5.79, p=  .003, 99% CI [-10.99, -0.58]; d=  .57) (see Figure 
7.10, page 210). The SV group reported poorer social functioning than the ToF 
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(mean difference= -6.96, p=  .002, 99% CI [-12.88, -1.03]; d=  .65) group (see Figure 
7.11, page 211).  
7.3.3. Disease-specific HRQoL 
Results from the comparisons between the diagnostic groups for disease-specific 
HRQoL are presented in Table 7.5. 
Table 7.5. ANOVA: group comparisons in disease-specific HRQoL 
Subscale  
 
 Mean (S.D.) Model Parameters 
 f df Sig. ɳ2 
Symptoms   4.02 299 .008 .04 
 Simple 87.41 (14.22)   
 
 
 ToF 87.96 (12.28)   
 
 
 TGA 87.70 (13.04)   
 
 
 SV 80.92 (16.63)   
 
 
Impact cardiac 
surveillance 
  5.04 299 .002 .05 
 Simple 87.96 (10.49)  
 
  
 ToF 87.38 (9.36)  
 
  
 TGA 84.88 (10.04)  
 
  
 SV 81.97 (11.36)  
 
  
Worries   4.03 299 .008 .04 
 Simple 82.10 (14)   
 
 
 ToF 84.69 (13.60)   
 
 
 TGA 84.17 (15.32)   
 
 
 SV 76.79 (17.14)   
 
 
Note. ɳ2: .01=  small, .06=  medium, .14=  large.  
 
There was a significant effect of diagnostic group on all subscales, including 
symptoms, impact cardiac surveillance, and worries (p<  .01). Post-hoc comparisons 
did not reveal statistically significant differences between the diagnostic groups in 
the symptoms and worries subscales. In the impact cardiac surveillance subscale, the 
SV group reported greater impact and therefore poorer HRQoL than the Simple 
(mean difference= -5.99, p= .003, 99% CI [-11.38, -0.60]; d=  .55) (Figure 7.13). 
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 Scale 0 – 100, higher score= better HRQoL. 
Figure 7.13. Mean scores in impact cardiac surveillance by diagnostic group 
7.4. Discussion 
This chapter presented the analyses conducted to examine the impact of ACHD on 
HRQoL and to investigate differences in HRQoL between four diagnostic groups. It 
was postulated that people with ACHD would report significantly poorer HRQoL 
compared with the general population norm, predominantly in physical HRQoL. In 
addition, it was hypothesized that impairments in HRQoL would be predominant in 
the SV group who would report poorer HRQoL compared with the general 
population. Differences between diagnostic groups were expected to be prominent 
between the SV and Simple group, with the SV reporting poorer HRQoL. The next 
sections will discuss the findings of the present study in relation to previous 
literature and provide explanations for what these findings might mean.  
7.4.1. Comparisons with general population norms in generic HRQoL 
 
7.4.1.1. Physical HRQoL  
The study showed that there were no differences between the total sample or the 
diagnostic groups and the general population norms in the physical component 
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summary of the SF-36. This finding supports those observed in a previous study that 
used the physical component summary in a mixed ACHD sample (Müller et al., 
2013b). In another study however, Müller et al. (2014) found poorer HRQoL in the 
physical component summary in a mixed sample. This discrepancy may be attributed 
to the inclusion of a larger proportion of complex ACHD in their recent study, as this 
group (i.e. SV) tended towards lower scores in the physical component summary 
compared with the general population in the present study. A closer examination of 
the differences between the current sample (total and diagnostic groups) and the 
general population in the subscales that comprise the summary scale provides a more 
detailed account of HRQoL in various diagnostic groups.  
The lack of impairment in most physical subscales of HRQoL across the total sample 
and diagnostic groups can help explain the normal physical component summary 
score. With the exception of poorer general health in the total sample and diagnostic 
groups and poorer physical functioning in the SV group, physical HRQoL in this 
sample was comparable and sometimes better than the general population in role 
limitations due to physical problems and bodily pain respectively.  
General health was perceived to be poorer than the general population, irrespective 
of diagnostic group. There was some variability in the general health scores but a 
large proportion (30-40%) in each diagnostic group reported poorer general health, 
especially in the SV group. In accordance with these results, previous studies in 
ACHD have found poor general health in mixed samples (e.g. Enomoto et al., 2013; 
Hager & Hess, 2005; Jefferies et al, 2004; Riley et al., 2012). These findings suggest 
that people with ACHD seem to acknowledge that their general health is 
compromised due to their condition, hence their general health perception appears to 
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hold true. This may be the result of long-term management of ACHD. These 
individuals attend follow-up appointments in a specialist clinic and experience repeat 
interventions and long-term medication uptake, which may act as a continuous 
reminder that their health is compromised. 
Despite poor general health, the total sample and the Simple, ToF, and TGA groups 
reported normal physical functioning, with only the SV group reporting poorer 
physical functioning than the general population. A small number of people with 
Simple, ToF, and TGA (<10%) also scored below the norm in this subscale but there 
was a larger proportion of lower scores in people with SV (>20%). These results 
differ from the majority of previous studies in ACHD that have found poorer 
physical functioning in mixed samples. However, very few of these studies have 
distinguished between diagnostic groups. Bruto et al. (2007) found poorer physical 
functioning in a mixed sample, yet when comparing the various diagnostic groups 
with norms, poorer physical functioning was only evident in the most complex. 
Consistent with the present study, previous studies that included a single diagnostic 
group reported normal physical functioning in Simple (Buys et al., 2013; Hanninen 
et al., 2011; Kahya Eren et al., 2013; Kamphuis et al., 2002a) and poorer physical 
functioning in SV samples (Idorn et al., 2013; Pike et al., 2012; van den Bosch et al., 
2004; Winter et al., 2008). The findings of studies in ToF and TGA samples have 
been less consistent; while some studies reported no differences between people with 
ToF/TGA and the general population (e.g. Loup et al., 2009; Opić et al., 2013), 
others found poorer physical functioning in these individuals (e.g. Irtel et al., 2005; 
Hickey et al., 2012). The small sample sizes in some of these studies make it difficult 
to draw conclusions regarding the ToF and TGA groups.  
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The finding of lack of role limitations due to physical problems in the total sample 
and all diagnostic groups supports the findings of previous studies (Fteropoulli et al., 
2013). Although not statistically significant, there was a tendency for lower scores in 
the SV group compared with the norms, which may help explain the small number 
studies in the systematic review that have found greater role limitations due to 
physical problems in people with SV than the general population (e.g. Hickey et al., 
2012; Idorn et al., 2013; Pike et al., 2012; Winter et al., 2008). The findings of the 
present study suggest that people with ACHD are able to carry on with fulfilling 
their usual role activities without feeling that their condition interferes with them. It 
is likely that by accepting their limitations they are able to adjust to ACHD by either 
engaging in less physically demanding activities or even avoiding such activities 
altogether (Claessens et al., 2005). 
It is also important to highlight that the total sample and especially the ToF and TGA 
groups experienced less bodily pain, whilst the Simple and SV groups had pain 
levels comparable with the general population. The majority of previous studies have 
found normal pain levels in people with ACHD, which may be explained by the 
inclusion of either a large proportion of people from the Simple and SV groups in 
mixed sample studies (e.g. Kamphuis et al., 2002b; Müller et al., 2011) or the 
inclusion of exclusively either of these two groups in others (e.g. Angeli et al., 2012; 
Buys et al., 2013; Hanninen et al., 2011; van den Bosch et al, 2004). Similar to the 
present study, a smaller number of studies also reported less pain in mixed (e.g. 
Bruto et al., 2007; Mokhles et al., 2011) and ToF (Hickey et al., 2012; Knowles et 
al., 2012) samples. One possible explanation for the normal or better scores in bodily 
pain may be that people with ACHD experience symptom relief following 
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interventions (Mokhles et al., 2011). This notion was further supported by Lane et al. 
(2002), who found that people with inoperable ACHD experienced greater pain than 
those who had surgery. Another plausible explanation is that the lifelong nature of 
ACHD may have resulted in a higher pain threshold, hence a different point of 
reference for judging bodily pain in people with ACHD than the general population. 
Taken together, the findings regarding physical HRQoL indicate that people with 
ACHD as a whole experience good HRQoL. Examining each of the diagnostic 
groups in comparison to normative data demonstrated that physical limitations are 
prominent in the SV group. One implication of these findings is that it is potentially 
more informative to distinguish between diagnostic groups in order to establish what 
is causing the effect in studies with mixed samples.  
7.4.1.2. Psychosocial HRQoL  
The study showed differences in the mental component summary scores of the SF-36 
with the total sample reporting poorer HRQoL compared with the norm. All three 
previous studies that used the mental component summary reported HRQoL 
comparable to the general population (Enomoto et al., 2013; Müller et al., 2013b; 
Müller et al., 2014). It is difficult to explain this discrepancy but it might be related 
to cultural differences as the abovementioned studies have been conducted in 
Japanese and German samples. Although the low scores evident in the present study 
can be mainly attributed to the Simple and SV groups. The SV group tended towards 
lower scores in the mental component summary but this did not reach statistical 
significance. The Simple group did, however, score significantly lower in the mental 
component summary compared with the general population. This finding 
corroborates those of a recent study with exclusively people with CoA (Buys, Budts, 
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Delecluse, Vanhees, 2013). The authors found that people with CoA experienced 
significant impairment in psychosocial domains of their HRQoL and argued that 
CoA may not be as simple as it was considered to be in the past. In the present study 
a large proportion (46%) of people comprising the Simple group had a CoA 
diagnosis. This rather surprising finding has important implications about the 
expected impact of ACHD on the HRQoL of people in the Simple group. This group 
is structurally simpler compared with the other diagnostic groups in the study and 
despite possible long-term complications, they are generally expected to be free from 
disease burden, evident from the minimal impact on their physical HRQoL (see 
section 7.4.1.1, page 216). However, the Simple group consisted of people that still 
require health monitoring at a specialist clinic as opposed to those who are 
physically well, free from long-term complications, and more likely to have been 
discharged and followed-up by their local general practitioners. Another possible 
explanation may be related to expectations. Being told that their condition is 
“simple” in nature, that their long-term prognosis is excellent, and that they are 
expected to live “normal” lives may lead to unrealistic expectations (Warnes, 2005). 
People in the Simple group may expect that their functioning levels will get back to 
their normal standards after what they may consider curative surgery, especially if 
they had operations during adulthood (Lane et al., 2002). If people’s expectations are 
not fulfilled and they still experience minor limitations, this may result in greater 
emotional impact.  
The findings in the specific subscales that comprise the mental component summary 
indicated poorer mental health in the total sample and SV group and poorer social 
functioning in the SV group compared with the general population. Participants had 
CHAPTER 7 – IMPACT OF ACHD ON HRQOL 
222 
 
comparable and sometimes better HRQoL than the general population in the 
subscales of role limitations due to emotional problems and vitality respectively.  
The finding of poorer mental health in the total sample compared with the general 
population suggests significant emotional impact of ACHD in these individuals. This 
finding is contrary to the majority of studies identified in the systematic review 
(Fteropoulli et al., 2013) and can be attributed to the lower scores of the Simple and 
SV groups, which would have negatively influenced the mental health score of the 
total sample. Indeed, the scores of the ToF and TGA groups in this subscale were not 
different from the norms, whereas the scores of the SV group were significantly 
lower (and near significant for the Simple group). Furthermore, more than 30% of 
those with SV and 20-25% of those in the Simple group scored lower than the norm, 
while less than 20% of those with ToF and TGA scored lower than the norm. A 
detailed examination of the sample composition in previous studies revealed that 
normal mental health was mostly evident in samples that consisted of either people 
with ToF (e.g. Daliento et al., 2005), TGA (e.g. Müller et al. 2013c) or a large 
proportion of these diagnostic groups (e.g. Bruto et al., 2007; Loup et al., 2009). 
Some studies that have found normal mental health in samples with SV as opposed 
to the present study were small in sample size (n<  60), which might have resulted in 
lack of power to detect an effect. Two previous studies that included people with SV 
shared the findings of the present study regarding impaired mental health in this 
diagnostic group (e.g. Angeli et al., 2012; van den Bosch et al., 2004). These 
findings suggest that increased survival into adulthood in people with SV brings 
about emotional challenges that warrant attention. This was expected as people with 
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SV represent the most complex group which can pose significant physical and 
emotional burden.  
In addition to poorer mental health, people with SV also reported poorer social 
functioning, while all other diagnostic groups and the total sample were comparable 
to the general population. More than 30% of those with SV scored lower than the 
norm in this subscale, while a smaller proportion did so in all other diagnostic 
groups. The majority of the studies in the systematic review reported normal social 
functioning in mixed ACHD samples, which is in agreement with the present study. 
However, the present study contradicts the findings of previous studies in SV 
samples, which have found normal social functioning (e.g. Angeli et al., 2012; Idorn 
et al., 2013; Pike et al., 2012; van den Bosch et al., 2004). This discrepancy may be 
attributed to rather smaller samples included in previous studies compared with the 
current study, which might have resulted in their lack of power to detect an effect.  
Despite some limitations in the Simple and SV groups, participants did not differ 
significantly from the general population in role limitations due to emotional 
problems irrespective of diagnostic group. This finding is in line with other studies 
as evidenced in the systematic review (Fteropoulli et al., 2013). This finding 
complements the finding of lack of role limitations due to physical problems (section 
7.4.1.1, page 216) and suggests that irrespective of whether people experience 
significant emotional burden from their condition their usual role activities remain 
unaffected. As mentioned earlier, this may be indicative of successful adaptation to 
ACHD and in this case its emotional burden. Some authors have suggested that 
people with ACHD develop a strong sense of coherence, which is characterised by a 
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feeling of understanding, manageability, and meaningfulness that helps them find 
meaning in their experiences and adapt to their condition (Moons et al., 2006). 
This study also showed that the sample experienced similar and in the case of ToF 
and TGA better HRQoL in vitality compared with the general population. A large 
proportion of people with ToF and TGA (> 20%) reported greater vitality than the 
norm as opposed to the smaller proportion (< 15%) who reported lower vitality. The 
majority of previous studies reported normal vitality levels (e.g. Gratz et al., 2009), 
while a smaller number studies reported lower vitality levels (e.g. Müller et al., 
2011) in people with ACHD compared with the general population. Only one recent 
study of people with TGA who had arterial switch (as opposed to atrial switch as in 
the current TGA sample) reported greater vitality in these individuals than the 
general population (Ruys et al., 2013). Although these findings are not directly 
comparable to the present study both studies suggest that people with TGA, 
regardless of the type of operation, have excellent outcomes in this particular 
domain. An explanation for the normal or high vitality levels may be that vitality 
was rated based on the degree of functioning, as people with ACHD may not engage 
in the same energy demanding activities as average healthy individuals generally do. 
If this is the case it is possible that people with ACHD have successfully adjusted to 
their limitations by engaging in less energy demanding activities more suited to their 
capabilities (Claessens et al., 2005). In this study, however, it was not possible to 
establish whether the higher than average vitality levels in people with ToF and TGA 
and their generally high ratings in most HRQoL subscales are due to them adjusting 
their expectations and activities to their capacity. 
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Overall, the findings regarding psychosocial HRQoL indicate that people may 
experience significant emotional burden as a result of living with ACHD, 
particularly people in the SV and Simple groups. On the other hand, people in the 
ToF and TGA groups appear to have normal psychosocial HRQoL. These findings 
raise interesting questions regarding patient expectations and the degree of 
adjustment of expectations based on people’s capacity. 
7.4.2. Comparisons between diagnostic groups in HRQoL 
The impact of ACHD on HRQoL was explored further with comparisons between 
the four diagnostic groups on generic and disease-specific HRQoL. 
7.4.2.1. Generic HRQoL 
Comparisons between the diagnostic groups in physical HRQoL did not show 
differences in the physical component summary and the subscales of role limitations 
due to physical problems, bodily pain, and general health. There were, however, 
differences in physical functioning with the SV group experiencing poorer HRQoL 
than the ToF in this subscale. This finding is in line with previous research which 
has found impaired physical functioning in people with SV compared with other 
groups (e.g. Gratz et al., 2009). This was not surprising as people with SV 
experienced significant physical burden, including arrhythmias, long-term cyanosis, 
repeat interventions, multiple medication, and compromised ventricular function 
compared with the other diagnostic groups (see section 6.6, page 178). The multiple 
long-term complications associated with SV may lead to reduced physical 
functioning including an impact on walking, running, and other daily activities as 
evidenced in the comparisons with the general population (section 7.4.1.1, page 
216). Notably, the SV group differed from the ToF but not the Simple group as 
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originally hypothesized. Generally, the ToF group appeared to have good HRQoL 
with a tendency towards higher scores than the other groups in physical domains, 
including physical functioning. 
Further comparisons between the diagnostic groups in psychosocial HRQoL did not 
indicate differences in the mental component summary and the subscales of role 
limitations due to emotional problems and mental health. The SV group did report 
poorer social functioning compared with the ToF group. The physical manifestation 
of SV in the form of symptoms, repeat interventions and hospitalizations may hinder 
people’s ability to participate in social activities and increase the likelihood of social 
isolation (McMurray et al., 2001). Similar to the group comparisons in physical 
functioning, the SV group differed from the ToF but not the Simple group as 
originally hypothesized. This can also be attributed to the tendency of the ToF group 
towards higher scores than the other diagnostic groups in psychosocial domains, 
including social functioning. 
The generally good HRQoL in people with ToF was also evident in relation to 
vitality, where they reported better HRQoL compared with those with a Simple 
condition. This finding corroborates the findings of Ternestedt et al. (2001), who 
also found greater vitality in people with ToF than those with ASD. The authors 
proposed that people with ToF are generally more purposeful and less willing to 
compromise compared to those with ASD but did not provide detailed explanation 
for this assumption. It is difficult to establish the specific pathways that lead to the 
overall good HRQoL (including high vitality levels) evident in people with ToF 
compared with other diagnostic groups. To speculate, there may be a difference in 
their standards of what constitutes good HRQoL in this particular and other domains. 
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People in the Simple group may generally expect their vitality levels to be similar to 
healthy individuals, whereas those with ToF may have adjusted their expectations to 
their capacity. Further studies with more focus on the expectations of various 
diagnostic groups are therefore suggested.  
7.4.2.2. Disease-specific HRQoL 
Disease-specific HRQoL measures are believed to be more sensitive to subtle 
differences between people with various diagnoses. In the present study, however, 
the ACHD-specific measure failed for the most part to distinguish between the four 
diagnostic groups. A significant effect was observed for all three subscales, however, 
significant group differences were only observed in the impact of cardiac 
surveillance but not in symptoms and worries.  
The study showed that people with SV experienced greater impact of cardiac 
surveillance compared with those in the Simple group. In the original CHD-
TAAQOL validation study, Kamphuis and colleagues (2004) examined differences 
between two groups (mild and complex) and found poorer HRQoL in the complex 
group compared with the mild group on all three scales. The difference in findings 
with the current study may be attributed to differences in the composition of the 
samples. In the Kamphuis et al. study the mild group consisted of people not 
requiring treatment and specialist follow-up while the complex group consisted of all 
others who had undergone operations and were followed-up in a specialist clinic. In 
the current study the sample consisted of four diagnostic groups varied in structural 
complexity and were all followed-up in a specialist clinic. Thus, it may be that the 
CHD-TAAQOL is able to discriminate between relatively healthy and ill patients but 
not across the entire spectrum of ACHD complexity.  
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The findings of the present study suggest that people with SV find cardiac 
surveillance more burdening than those in the Simple group. The subscale of impact 
cardiac surveillance measures the impact (frequency weighted by emotional impact) 
of diagnostic tests and hospitalizations. It may be expected that the SV group would 
report greater impact of cardiac surveillance as due to the nature and complexity of 
this diagnostic group people need regular monitoring with blood, MRI, ECHO, ECG, 
and exercise testing annually or biannually. In addition, they are generally more 
likely to be hospitalized due to complications compared with the other diagnostic 
groups (see section 1.8, page 40 & section 6.6, page 178). Regardless of the 
frequency, cardiac surveillance may have a greater impact on people with SV due to 
its specific purpose. Generally, cardiac testing in these individuals is not only 
performed to ensure their continuous functioning but to also identify and manage 
long-term complications in a timely manner (Warnes et al., 2008).  
This finding was supportive of the findings from group comparisons on generic 
HRQoL in that both identified HRQoL impairment in people with SV. The disease-
specific measure, however, showed differences between the SV and the Simple 
group as it was originally hypothesized, whereas the generic measure showed 
differences between the SV and the ToF group. This may indicate that the CHD-
TAAQOL has good discriminant validity in the impact of cardiac surveillance but 
not in the symptoms and worries scales where there was lack of group differences. 
Considering the observed group differences in the physical functioning subscale of 
the SF-36, it may be expected that diagnostic groups would differ in the symptoms 
scale of the CHD-TAAQOL. Validation of the measure was beyond the scope of the 
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study and it may be informative if future studies used the CHD-TAAQOL to validate 
further its use in people with ACHD.  
7.5. Summary  
The present study is one of the largest studies that examined HRQoL in people with 
ACHD and differences in HRQoL between four diagnostic groups. Overall, there 
were few differences between the total sample and the general population. The 
impact of ACHD on HRQoL was not predominant in physical HRQoL domains as 
hypothesized, rather some differences were observed between people with ACHD 
and the general population in both physical and psychosocial HRQoL domains. The 
comparisons between each diagnostic group and the general population further 
indicated that physical and psychosocial HRQoL impairments were as hypothesized 
predominant in the SV group. Notably, people in the Simple group also reported 
some impairment in psychosocial HRQoL. On the other hand, those with ToF and 
TGA generally reported good or excellent HRQoL in most domains compared with 
the general population. Comparisons between the diagnostic groups on generic and 
disease-specific HRQoL supported the above findings regarding HRQoL impairment 
in the SV group and the overall good HRQoL in the ToF group. Differences between 
diagnostic groups were mostly evident between the SV and ToF group, with the 
latter reporting poorer HRQoL. The categorisation of people with ACHD into four 
diagnostic groups helped identify specific HRQoL issues for each group and built on 
previous studies with ill-defined samples. The findings highlight the importance of 
distinguishing between diagnostic groups against generalising across the whole 
ACHD population. 
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As discussed in Chapter 3 underlying psychosocial processes may also help explain 
some of the evident variation in HRQoL. The next chapter presents the findings of 
regression analyses conducted to study the demographic, clinical, and psychosocial 
factors associated with HRQoL.
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CHAPTER 8 – FACTORS ASSOCIATED WITH 
HEALTH-RELATED QUALITY OF LIFE IN ADULT 
CONGENITAL HEART DISEASE 
8.1. Prologue 
The previous chapter described the impact of ACHD on HRQoL and found an 
impact on both physical and psychosocial HRQoL domains. The SV group reported 
poorer physical and psychosocial HRQoL compared with the general population and 
other diagnostic groups. However, the Simple group also experienced some 
impairment in psychosocial HRQoL compared with the general population. Some of 
the evident variation in HRQoL can be further explained by psychosocial factors. At 
present, limited research has examined the role of psychosocial factors in the 
HRQoL of people with ACHD. This chapter investigates the factors associated with 
HRQoL in ACHD, this includes comprehensive demographic and clinical measures 
along with psychosocial constructs drawn from the SRM and previous research using 
hierarchical multiple regressions. It was hypothesized that psychosocial factors, 
including illness perceptions, coping strategies, mood, and social support will 
account for a significant amount of variance in HRQoL over and above that 
accounted for by demographic and clinical characteristics. 
8.2. Factors associated with HRQoL in ACHD 
Before multivariate analyses were performed correlations between the predictors 
were examined for multicollinearity (see Appendix Q). As none of the relationships 
exceeded .80, multicollinearity was not considered to be of concern. 
Bivariate regressions were conducted to examine the relationships between the 
predictor variables and HRQoL outcomes, which included generic physical HRQoL 
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(physical component summary and the subscales of physical functioning, role 
physical, bodily pain, general health of the SF-36), generic psychosocial HRQoL 
(mental component summary and the subscales of vitality, social functioning, role 
emotional, mental health of the SF-36), and disease-specific HRQoL (symptoms, 
impact of cardiac surveillance, worries of the CHD-TAAQOL) (see Appendix R). 
Some consistent and statistically significant associations were observed.  
Of all of the demographic factors employment status exhibited the most consistent 
associations with both physical and psychosocial HRQoL. No consistent associations 
were observed between demographic factors and disease-specific HRQoL. Clinical 
factors that were consistently associated with physical HRQoL included number of 
co-morbidities, number of medication, and current O2 saturation. No consistent 
associations were observed between clinical factors and psychosocial HRQoL. 
Clinical factors that were consistently associated with disease-specific HRQoL 
included being in the ToF group (vs Simple), number of co-morbidities, and current 
O2 saturation. Illness perceptions except for illness coherence and curability were 
consistently associated with physical, psychosocial, and disease-specific HRQoL. Of 
all the coping strategies, venting, behavioural disengagement, and self-blame 
exhibited consistent associations with physical, psychosocial, and disease-specific 
HRQoL. None of the social support variables were associated with physical HRQoL, 
whilst only friend support was consistently associated with psychosocial HRQoL. 
No consistent associations were observed between social support and disease-
specific HRQoL. Both anxiety and the presence of depressive symptoms were 
consistently associated with physical, psychosocial, and disease-specific HRQoL.  
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Only significant predictors from the bivariate regressions were entered into the 
hierarchical multiple regression models. This resulted in a sufficient subject to 
predictor variable ratio as discussed in section 5.6.8.3 (page 162). The order in which 
the predictor variables were entered into the hierarchical multiple regressions and a 
detailed description of the method used is presented in Figure 5.1 (page 163). The 
results of the hierarchical multiple regressions are reported in the next sections for 
generic (physical and psychosocial of the SF-36) and disease-specific (CHD-
TAAQOL) HRQoL. The final model of each regression is presented and the full 
hierarchical multiple regressions that include all the steps are displayed in Appendix 
S. A table with a summary of the significant predictors is presented at the end of the 
results section (page 251). 
8.2.1. Factors associated with generic physical HRQoL  
The final model for physical component summary is displayed in Table 8.1. 
Demographic variables, including education level, employment status, and age were 
entered in Step 1 and explained 7.9% of the variance in physical component 
summary. The addition of diagnostic group, cyanosis days, and number of co-
morbidities in Step 2 explained an additional 11.6% of the variance in the physical 
component summary. Hospitalization days, entered in Step 3 did not explain 
additional variance in the outcome. Current O2 saturation, number of medication, and 
VO2 max, were entered in Step 4 and explained a further 3.3% of the variance. 
Illness perceptions were entered in Step 5 and explained an additional 27.5% of the 
variance. Neither coping strategies entered in Step 6, nor mood entered in Step 7 
explained any additional variance. The final model was significant, f(22,278)=  
13.48; p<  .001 and explained 47.8% of the variance in physical component 
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summary. Illness identity was the only unique predictor in this final model indicating 
that a perception of more severe symptoms due to ACHD was associated with poorer 
physical HRQoL. 
Table 8.1. Final regression model for physical component summary (n= 301) 
Predictor Variables β sr2  
Education level .066 .061  
Employment status .045 .041  
Age -.010 -.008  
ToF .099 .074  
TGA .020 .015  
SV .114 .069  
Cyanosis days -.066 -.046  
Co-morbidities no. -.032 -.023  
Hospitalization days -.069 -.058  
Current O2 saturation .075 .049  
Medication no. .006 .004  
VO2 max .015 .013  
Brief IPQ consequences -.126 -.076  
Brief IPQ controllability .038 .035  
Brief IPQ identity -.517** -.332  
Brief IPQ concern -.057 -.040  
Brief IPQ emotional representation .081 .047  
Brief COPE religion -.064 -.060  
Brief COPE venting .042 .035  
Brief COPE behavioural 
disengagement 
-.010 -.008  
STAI-6 anxiety -.037 -.030  
CES-D 10 depression -.003 -.003  
Step R2  Adjusted R2 ΔR2  
Step 1 .079 .069 .079** 
Step 2 .195 .172 .116** 
Step 3 .202 .178 .008 
Step 4 .235 .203 .033* 
Step 5 .510 .481 .275** 
Step 6 .515 .481 .005 
Step 7 .516 .478 .001 
Note. Educational level: 0=  school, 1=  university, employment status: 0=  unemployed, 1=  employed, 
ToF, TGA, SV: dummy-coded- reference group was Simple, CES-D 10: 0=  no depressive symptoms, 
1=  with depressive symptoms. 
*p<  .01, **p<  .001 
 
Analyses were also conducted for the subscales comprising the physical component 
summary including physical functioning, role physical, bodily pain, and general 
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health. A fuller description of the hierarchical multiple regressions including all the 
steps is displayed in Appendix S. 
8.2.1.1. Physical functioning  
The final model for the physical functioning subscale is displayed in Table 8.2. The 
final model was significant, f(26,275)=  17.08; p<  .001 and explained 58.1% of the 
total variance in the physical functioning subscale. The unique predictors in the final 
model were illness identity, consequences, and emotional representation. Perceptions 
of more severe symptoms and consequences due to ACHD and a perception of less 
emotional impact were associated with poorer physical functioning.  
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Table 8.2. Final regression model for physical functioning (n= 302) 
Predictor Variables β sr2  
Gender -.096 -.081  
Employment status .083 .074  
ToF .010 .007  
TGA -.037 -.026  
SV -.013 -.008  
Cyanosis days .016 .011  
Co-morbidities no. -.116 -.078  
Arrhythmias .056 .041  
Intervention no. .019 .015  
Hospitalization days -.066 -.053  
Current O2 saturation .132 .084  
Medication no. -.014 -.010  
VO2 max .038 .031  
LVEF .018 .015  
Brief IPQ consequences -.216* -.130  
Brief IPQ identity -.381** -.246  
Brief IPQ concern -.096 -.066  
Brief IPQ emotional representation .172* .098  
Brief COPE religion -.049 -.045  
Brief COPE denial -.102 -.093  
Brief COPE venting .102 .082  
Brief COPE substance use -.099 -.089  
Brief COPE behavioural 
disengagement 
-.020 -.015  
Brief COPE self-blame -.004 -.003  
STAI-6 anxiety -.103 -.082  
CES-D 10 depression -.064 -.047  
Step R2  Adjusted R2 ΔR2  
Step 1 .099 .093 .099** 
Step 2 .273 .253 .174** 
Step 3 .283 .258 .009 
Step 4 .346 .314 .064** 
Step 5 .573 .546 .227** 
Step 6 .605 .571 .032* 
Step 7 .618 .581 .012 
Note. Gender: 0=  male, 1=  female, employment status: 0=  unemployed, 1=  employed, ToF, TGA, SV: 
dummy-coded- reference group was Simple, arrhythmias: 0=  no arrhythmias, 1=  arrhythmias, CES-D 
10: 0=  no depressive symptoms, 1=  with depressive symptoms. 
*p<  .01, **p<  .001 
 
8.2.1.2. Role physical  
The final model for the role physical subscale is displayed in Table 8.3. The final 
model was significant, f(14,286)=  13.52; p<  .001 and explained 36.9% of the total 
variance in the role physical sub-domain. The unique predictors in the final model 
were employment status, illness identity, and presence of depressive symptoms. 
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Being unemployed, a perception of more severe symptoms due to ACHD and the 
presence of depressive symptoms were associated with greater role limitations due to 
physical problems. 
Table 8.3. Final regression model for role physical (n= 301) 
Predictor Variables β sr2  
Employment status .140* .130  
Cyanosis days -.113 -.086  
Co-morbidities no. .048 .044  
Current O2 saturation .001 .001  
Brief IPQ consequences -.176 -.108  
Brief IPQ controllability .009 .009  
Brief IPQ identity -.304** -.201  
Brief IPQ concern .027 .020  
Brief IPQ emotional representation .089 .052  
Brief COPE venting -.022 -.018  
Brief COPE behavioural 
disengagement 
.001 .000  
Brief COPE self-blame -.013 -.011  
STAI-6 anxiety -.058 -.046  
CES-D 10 depression -.249** -.190  
Step R2  Adjusted R2 ΔR2  
Step 1 .085 .082 .085** 
Step 2 .140 .131 .055** 
Step 3 .148 .137 .009 
Step 4 .342 .322 .194** 
Step 5 .351 .324 .009 
Step 6 .398 .369 .047** 
Note. Employment status: 0=  unemployed, 1=  employed, CES-D 10: 0=  no depressive symptoms, 1=  
with depressive symptoms. 
*p<  .01, **p<  .001 
 
8.2.1.3. Bodily pain 
The final model for the bodily pain subscale is presented in Table 8.4. The final 
model was significant, f(15,287)=  10.99; p<  .001 and explained 33.2% of the total 
variance in the bodily pain sub-domain. The only unique predictor in the final model 
was illness identity, indicating that a perception of more severe symptoms due to 
ACHD was associated with greater bodily pain. 
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Table 8.4. Final regression model for bodily pain (n= 303) 
Predictor Variables β sr2  
Co-morbidities no. -.019 -.015  
Current O2 saturation -.045 -.041  
Medication no. .048 .038  
Brief IPQ consequences .006 .004  
Brief IPQ controllability .067 .063  
Brief IPQ identity -.455** -.300  
Brief IPQ concern -.061 -.043  
Brief IPQ emotional representation .040 .024  
Brief COPE religion -.090 -.088  
Brief COPE denial -.110 -.102  
Brief COPE venting -.038 -.031  
Brief COPE behavioural 
disengagement 
.003 .002  
Brief COPE self-blame .030 .025  
STAI-6 anxiety -.138 -.110  
CES-D 10 depression -.077 -.059  
Step R2  Adjusted 
R2 
ΔR2  
Step 1 .032 .029 .032* 
Step 2 .051 .041 .019 
Step 3 .317 .299 .266** 
Step 4 .344 .314 .027 
Step 5 .365 .332 .021* 
Note. CES-D 10: 0=  no depressive symptoms, 1=  with depressive symptoms. 
*p<  .01, **p<  .001 
 
8.2.1.4. General health 
The final model for the general health subscale is displayed in Table 8.5. The final 
model was significant, f(21,281)=  12.73; p<  .001 and explained 44.9% of the total 
variance in the general health sub-domain. The unique predictors in this final model 
were illness identity and presence of depressive symptoms. A perception of more 
severe symptoms due to ACHD and presence of depressive symptoms were 
associated with poorer general health. 
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Table 8.5. Final regression model for general health (n= 303) 
Predictor Variables β sr2  
Education level .112 .106  
Employment status .017 .016  
Co-morbidities no. .004 .003  
Intervention no. .004 .003  
Hospitalization days -.036 -.030  
Current O2 saturation -.001 -.001  
Medication no. -.095 -.073  
VO2 max .017 .015  
RVEF .073 .065  
Brief IPQ consequences -.049 -.030  
Brief IPQ controllability .075 .068  
Brief IPQ curability .111 .101  
Brief IPQ identity -.313** -.202  
Brief IPQ concern -.105 -.073  
Brief IPQ emotional representation -.093 -.054  
Brief COPE venting .020 .016  
Brief COPE substance use -.038 -.035  
Brief COPE behavioural 
disengagement 
-.002 -.001  
Brief COPE self-blame .005 .004  
STAI-6 anxiety .037 .029  
CES-D 10 depression -.186* -.140  
Step R2  Adjusted R2 ΔR2  
Step 1 .071 .064 .071** 
Step 2 .125 .116 .054** 
Step 3 .133 .118 .008 
Step 4 .191 .167 .059** 
Step 5 .465 .437 .273** 
Step 6 .468 .432 .003 
Step 7 .488 .449 .020* 
Note. Educational level: 0=  school, 1=  university, employment status: 0=  unemployed, 1=  employed, 
CES-D 10: 0=  no depressive symptoms, 1=  with depressive symptoms. 
*p<  .01, **p<  .001 
 
8.2.2. Factors associated with generic psychosocial HRQoL  
The final model for the mental component summary is displayed in Table 8.6. 
Demographic variables were entered in Step 1, explaining 9.5% of the variance in 
mental component summary. Illness perceptions were entered in Step 2 and 
explained an additional 25% of the variance. Coping strategies, entered in Step 3, 
explained a further 12% of the variance. Social support, entered in Step 4, did not 
explain additional variance. Mood was entered in Step 5 and explained an additional 
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13.3% of the variance. The final model was significant, f(20,281)=  21.54; p<  .001 
and explained 57.7% of the variance in the mental component summary. The unique 
predictors in the final model were age, self-blame, anxiety, and presence of 
depressive symptoms. Younger age, greater use of self-blame as a coping strategy, 
greater anxiety, and the presence of depressive symptoms were associated with 
poorer psychosocial HRQoL. 
Table 8.6. Final regression model for mental component summary (n= 302) 
Predictor Variables β sr2  
Age .164** .151  
Employment status .074 .068  
Brief IPQ consequences -.040 -.024  
Brief IPQ controllability -.008 -.007  
Brief IPQ curability .034 .031  
Brief IPQ identity -.036 -.024  
Brief IPQ concern -.036 -.026  
Brief IPQ emotional representation -.065 -.038  
Brief COPE positive reframing .070 .060  
Brief COPE acceptance .044 .038  
Brief COPE self-distraction -.059 -.050  
Brief COPE denial -.027 -.024  
Brief COPE venting -.019 -.015  
Brief COPE substance use .000 .000  
Brief COPE behavioural 
disengagement 
.029 .023  
Brief COPE self-blame -.172** -.142  
MSPSS friends support .056 .050  
MSPSS significant other support -.006 -.005  
STAI-6 anxiety -.131* -.099  
CES-D 10 depression -.421** -.319  
Step R2 Adjusted R2 ΔR2  
Step 1 .095 .089 .095** 
Step 2 .345 .327 .249** 
Step 3 .465 .435 .121** 
Step 4 .472 .438 .006 
Step 5 .605 .577 .134** 
Note. Employment status: 0=  unemployed, 1=  employed, CES-D 10: 0=  no depressive symptoms, 1=  
with depressive symptoms. 
*p<  .01, **p<  .001 
 
Analyses were conducted for the subscales comprising the mental component 
summary including vitality, social functioning, role emotional, and mental health. A 
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fuller description of the hierarchical multiple regressions including all the steps is 
displayed in Appendix S. 
8.2.2.1. Vitality 
The final model for the vitality subscale is displayed in Table 8.7. The final model 
was significant, f(23,279)=  18.91; p<  .001 and explained 57.7% of the total variance 
in the vitality sub-domain. The unique predictors were diagnostic group, illness 
identity and present of depressive symptoms. Being in the ToF, TGA, and SV vs. 
being in the Simple group was associated with greater vitality. In addition, a 
perception of more severe symptoms due to ACHD and the presence of depressive 
symptoms were associated with less vitality.  
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Table 8.7. Final regression model for vitality (n= 303) 
Predictor Variables β sr2  
Employment status .079 .071  
Gender -.036 -.032  
ToF .175** .135  
TGA .147* .114  
SV .157* .102  
Co-morbidities no. -.003 -.002  
Current O2 saturation .030 .023  
Medication no. .022 .017  
Brief IPQ consequences -.078 -.047  
Brief IPQ controllability .046 .042  
Brief IPQ curability .012 .011  
Brief IPQ identity -.376** -.245  
Brief IPQ concern -.009 -.006  
Brief IPQ emotional representation .008 .005  
Brief COPE acceptance .091 .082  
Brief COPE self-distraction -.062 -.051  
Brief COPE denial -.047 -.042  
Brief COPE venting .018 .014  
Brief COPE substance use .005 .004  
Brief COPE behavioural 
disengagement 
.026 .021  
Brief COPE self-blame -.099 -.082  
STAI-6 anxiety -.076 -.057  
CES-D 10 depression -.302** -.226  
Step R2 Adjusted R2 ΔR2  
Step 1 .095 .089 .095** 
Step 2 .177 .160 .082** 
Step 3 .201 .179 .024 
Step 4 .491 .466 .290** 
Step 5 .544 .510 .053** 
Step 6 .609 .577 .065** 
Note. Gender: 0=  male, 1=  female, employment status: 0=  unemployed, 1=  employed, ToF, TGA, SV: 
dummy-coded- reference group was Simple, CES-D 10: 0=  no depressive symptoms, 1=  with 
depressive symptoms. 
*p<  .01, **p<  .001 
 
8.2.2.2. Social functioning 
The final model for the social functioning subscale is displayed in Table 8.8. The 
final model was significant, f(22,280)=  12.67; p<  .001 and explained 45.9% of the 
total variance in the social functioning sub-domain. The unique predictors in this 
final model were illness identity, consequences, and presence of depressive 
symptoms. Perceptions of more severe symptoms and consequences due to ACHD 
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and the presence of depressive symptoms were associated with poorer social 
functioning. 
Table 8.8. Final regression model for social functioning (n= 303) 
Predictor Variables β sr2  
Employment status .055 .051  
ToF .116 .091  
TGA .022 .017  
SV .002 .001  
Co-morbidities no. .015 .011  
Hospitalization days -.030 -.025  
Current O2 saturation .048 .037  
Medication no. .070 .052  
Brief IPQ consequences -.224* -.134  
Brief IPQ controllability -.012 -.011  
Brief IPQ identity -.242** -.159  
Brief IPQ concern -.049 -.034  
Brief IPQ emotional representation .006 .003  
Brief COPE self-distraction -.030 -.026  
Brief COPE denial -.030 -.027  
Brief COPE venting .017 .013  
Brief COPE substance use -.014 -.013  
Brief COPE behavioural 
disengagement 
.012 .009  
Brief COPE self-blame .019 .016  
MSPSS friends support .034 .031  
STAI-6 anxiety -.119 -.093  
CES-D 10 depression -.249** -.187  
Step R2 Adjusted 
R2 
ΔR2  
Step 1 .065 .062 .065** 
Step 2 .138 .124 .073** 
Step 3 .142 .124 .004 
Step 4 .162 .139 .020 
Step 5 .430 .405 .269** 
Step 6 .439 .401 .009 
Step 7 .442 .403 .004 
Step 8 .499 .459 .056** 
Note. Employment status: 0=  unemployed, 1=  employed, ToF, TGA, SV: dummy-coded- reference 
group was Simple, CES-D 10: 0=  no depressive symptoms, 1=  with depressive symptoms. 
*p<  .01, **p<  .001 
 
8.2.2.3. Role emotional 
The final model for the role emotional subscale is displayed in Table 8.9. The final 
model was significant, f(16,285)=  12.88; p<  .001 and explained 38.7% of the total 
variance in the role emotional sub-domain. The unique predictors in the final model 
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were self-blame and presence of depressive symptoms. Greater use of self-blame as 
a coping strategy and the presence of depressive symptoms were associated with 
greater role limitations due to emotional problems. 
Table 8.9. Final regression model for role emotional (n= 302) 
Predictor Variables β sr2  
Employment status .087 .081  
Brief IPQ consequences -.085 -.051  
Brief IPQ controllability .004 .003  
Brief IPQ identity -.014 -.010  
Brief IPQ concern .007 .005  
Brief IPQ emotional representation -.011 -.006  
Brief COPE positive reframing .033 .029  
Brief COPE acceptance .030 .027  
Brief COPE self-distraction -.052 -.045  
Brief COPE venting -.021 -.017  
Brief COPE substance use -.013 -.012  
Brief COPE behavioural 
disengagement 
.025 .020  
Brief COPE self-blame -.146* -.123  
MSPSS friends support .080 .075  
STAI-6 anxiety -.098 -.076  
CES-D 10 depression -.384** -.291  
Step R2 Adjusted R2 ΔR2  
Step 1 .063 .060 .063** 
Step 2 .218 .202 .155** 
Step 3 .301 .270 .084** 
Step 4 .312 .278 .010 
Step 5 .420 .387 .108** 
Note. Employment status: 0=  unemployed, 1=  employed, CES-D 10: 0=  no depressive symptoms, 1=  
with depressive symptoms. 
*p<  .01, **p<  .001 
 
8.2.2.4. Mental health 
The final model for the mental health subscale is displayed in Table 8.10. The final 
model was significant, f(20,282)=  20.04; p<  .001 and explained 55.8% of the total 
variance in the mental health sub-domain. The unique predictors in this final model 
were age, self-blame, anxiety, and presence of depressive symptoms. Younger age, 
greater use of self-blame as a coping strategy, greater anxiety, and presence of 
depressive symptoms were associated with poorer mental health. 
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Table 8.10. Final regression model for mental health (n= 303) 
Predictor Variables β sr2  
Age .186** .172  
Employment status .082 .076  
Brief IPQ consequences -.019 -.011  
Brief IPQ controllability .020 .018  
Brief IPQ identity -.050 -.033  
Brief IPQ concern -.076 -.054  
Brief IPQ emotional representation -.070 -.041  
Brief COPE positive reframing .047 .040  
Brief COPE acceptance .024 .021  
Brief COPE self-distraction .001 .001  
Brief COPE denial -.075 -.067  
Brief COPE venting -.015 -.012  
Brief COPE substance use .021 .019  
Brief COPE behavioural 
disengagement 
-.004 -.004  
Brief COPE self-blame -.156* -.129  
MSPSS friends support .039 .033  
MSPSS family support -.018 -.014  
MSPSS significant other support -.019 -.016  
STAI-6 anxiety -.192** -.148  
CES-D 10 depression -.356** -.270  
Step R2 Adjusted R2 ΔR2  
Step 1 .096 .090 .096** 
Step 2 .351 .336 .255** 
Step 3 .463 .435 .112** 
Step 4 .467 .433 .004 
Step 5 .587 .558 .120** 
Note. Employment status: 0=  unemployed, 1=  employed, CES-D 10: 0=  no depressive symptoms, 1=  
with depressive symptoms. 
*p<  .01, **p<  .001 
 
8.2.3. Factors associated with disease-specific HRQoL (CHD-TAAQOL) 
8.2.3.1. Symptoms 
The final model for symptoms is displayed in Table 8.11. Demographic variables 
were entered in Step 1, explaining 9.4% of the variance in symptoms. Addition of 
diagnostic group, cyanosis days, number of co-morbidities, and arrhythmias in Step 
2 explained an additional 11.3% of the variance in the outcome. Hospitalization 
days, entered in Step 3, did not explain additional variance. Current O2 saturation, 
number of medication, VO2 max, and LVEF were entered in Step 4 and explained a 
CHAPTER 8 – FACTORS ASSOCIATED WITH HRQOL IN ACHD 
246 
 
further 7.1% of the variance. Illness perceptions were entered in Step 5 and 
explained an additional 30.3% of the variance. Coping strategies, entered in Step 6, 
did not explain additional variance. Mood, entered in Step 7, explained an additional 
4.1% of the variance in symptoms. The final model was significant, f(26,275)=  
18.29; p<  .001 and explained 59.9% of the total variance in symptoms. The unique 
predictors in the final model were illness identity and presence of depressive 
symptoms. A perception of more severe symptoms due to ACHD and the presence 
of depressive symptoms were associated with greater symptom impact. 
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Table 8.11. Final regression model for symptoms (n= 302) 
Predictor Variables β sr2  
Gender -.051 -.043  
Employment status .075 .067  
ToF -.010 -.007  
TGA -.022 -.016  
SV -.012 -.007  
Cyanosis days .042 .030  
Co-morbidities no. -.047 -.032  
Arrhythmias .031 .023  
Hospitalization days .042 .035  
Current O2 saturation .096 .062  
Medication no. -.007 -.005  
VO2 max .078 .066  
LVEF .038 .033  
Brief IPQ consequences -.060 -.035  
Brief IPQ controllability -.018 -.017  
Brief IPQ identity -.431** -.279  
Brief IPQ concern -.107 -.074  
Brief IPQ emotional representation .001 .001  
Brief COPE self-distraction -.015 -.013  
Brief COPE denial -.039 -.035  
Brief COPE venting .038 .030  
Brief COPE substance use -.008 -.007  
Brief COPE behavioural 
disengagement 
.013 .010  
Brief COPE self-blame -.029 -.024  
STAI-6 anxiety -.097 -.075  
CES-D 10 depression -.215** -.160  
Step R2 Adjusted R2 ΔR2  
Step 1 .094 .088 .094** 
Step 2 .207 .185 .113** 
Step 3 .207 .182 .000 
Step 4 .278 .246 .071** 
Step 5 .581 .555 .303** 
Step 6 .593 .558 .011 
Step 7 .634 .599 .041** 
Note. Gender: 0=  male, 1=  female, employment status: 0=  unemployed, 1=  employed, ToF, TGA, SV: 
dummy-coded- reference group was Simple, arrhythmias: 0=  no arrhythmias, 1=  arrhythmias, CES-D 
10: 0=  no depressive symptoms, 1=  with depressive symptoms. 
*p<  .01, **p<  .001 
 
8.2.3.2. Impact of cardiac surveillance 
The final model for impact of cardiac surveillance is displayed in Table 8.12. 
Diagnostic group, number of co-morbidities, and arrhythmias were entered in Step 1, 
explaining 12.6% of the variance in impact of cardiac surveillance. Addition of 
number of interventions in Step 2 and current O2 saturation, number of medication, 
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and VO2 max in Step 3 did not explain any additional variance. Illness perceptions 
were entered in Step 4 and explained further 16.8% of the variance in the outcome. 
Coping strategies, entered in Step 5, did not explain additional variance. Mood, 
entered in Step 6, did not explain additional variance. The final model was 
significant, f(19,283)=  8.57; p<  .001 and explained 32.3% of the total variance in 
impact of cardiac surveillance. The unique predictors in the final model were 
planning and anxiety. Greater use of planning as a coping strategy and greater 
anxiety were associated with greater impact of cardiac surveillance. 
Table 8.12. Final regression model for impact cardiac surveillance (n= 303) 
Predictor Variables  β sr2  
ToF .016 .012  
TGA -.079 -.057  
SV -.034 -.021  
Co-morbidities no. .014 .010  
Arrhythmias -.141 -.105  
Intervention no. -.070 -.056  
Current O2 saturation .037 .028  
Medication no. -.029 -.021  
VO2 max .011 .010  
Brief IPQ consequences -.011 -.006  
Brief IPQ identity -.142 -.093  
Brief IPQ concern -.135 -.093  
Brief IPQ emotional representation -.132 -.077  
Brief COPE planning -.138* -.130  
Brief COPE venting .019 .016  
Brief COPE substance use .003 .002  
Brief COPE behavioural 
disengagement 
-.088 -.074  
STAI-6 anxiety -.159* -.127  
CES-D 10 depression -.005 -.004  
Step R2 Adjusted R2 ΔR2  
Step 1 .126 .111 .126** 
Step 2 .129 .112 .003 
Step 3 .154 .128 .024 
Step 4 .322 .292 .168** 
Step 5 .347 .309 .025 
Step 6 .365 .323 .018 
Note. ToF, TGA, SV: dummy-coded- reference group was Simple, arrhythmias: 0=  no arrhythmias, 1=  
arrhythmias, CES-D 10: 0=  no depressive symptoms, 1=  with depressive symptoms. 
*p<  .01, **p<  .001 
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8.2.3.3. Worries 
The final model for worries is displayed in Table 8.13. Only age was entered in Step 
1, explaining 2.3% of the variance in worries. The addition of the diagnostic group 
and number of co-morbidities in Step 2 explained an additional 8.1% of the variance. 
Current O2 saturation, entered in in Step 3, did not explain additional variance in the 
outcome. Illness perceptions were entered in Step 4 and explained an additional 
32.1% of the variance. Coping strategies, entered in Step 5, explained a further 4.3% 
of the variance in worries. Social support, entered in Step 6, did not explain 
additional variance. Mood was entered in Step 7 and significantly explained an 
additional 3.7% of the variance. The final model was significant, f(22,280)=  13.97; 
p<  .001 and explained 48.6% of the total variance in worries. The unique predictors 
in this final step were age, illness consequences, and presence of depressive 
symptoms. Younger age, a perception of more consequences due to ACHD, and the 
presence of depressive symptoms were associated with greater worries. 
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Table 8.13. Final regression model for worries (n= 303) 
Predictor Variables β sr2  
Age .218** .183  
ToF .061 .048  
TGA .048 .036  
SV .060 .038  
Co-morbidities no. -.014 -.012  
Current O2 saturation .049 .037  
Brief IPQ consequences -.179* -.109  
Brief IPQ controllability -.023 -.021  
Brief IPQ curability .067 .060  
Brief IPQ identity -.137 -.089  
Brief IPQ concern -.146 -.103  
Brief IPQ emotional representation -.106 -.061  
Brief COPE planning -.117 -.103  
Brief COPE self-distraction -.024 -.020  
Brief COPE venting .090 .071  
Brief COPE substance use -.066 -.060  
Brief COPE behavioural 
disengagement 
.084 .069  
Self-blame -.126 -.103  
MSPSS friend support .047 .040  
MSPSS family support .021 .018  
STAI-6 anxiety -.061 -.047  
CES-D 10 depression -.224** -.168  
Step R2 Adjusted R2 ΔR2  
Step 1 .023 .020 .023* 
Step 2 .104 .089 .081** 
Step 3 .116 .098 .012 
Step 4 .437 .414 .321** 
Step 5 .480 .447 .043* 
Step 6 .487 .450 .006 
Step 7 .523 .486 .037** 
Note. ToF, TGA, SV: dummy-coded- reference group was Simple, CES-D 10: 0=  no depressive 
symptoms, 1=  with depressive symptoms. 
*p<  .01, **p<  .001 
 
 
8.2.4. Summary of factors associated with HRQoL from hierarchical multiple 
regressions 
Table 8.14 presents a summary of the factors associated with generic (physical & 
psychosocial) and disease-specific HRQoL in the final models. 
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Table 8.14. Summary of the factors associated with generic (physical & psychosocial) and disease-specific HRQoL from hierarchical 
multiple regressions 
 Generic Physical HRQoL (Physical 
Component Summary and Subscales)  
Generic Psychosocial HRQoL (Mental 
Component Summary and Subscales) 
Disease-specific HRQoL 
 
Ph
ysi
cal
 
com
pon
ent
 
sum
ma
ry 
Ph
ysi
cal
 
fun
ctio
nin
g 
Ro
le 
ph
ysi
cal
 
Bo
dil
y p
ain
 
Ge
ner
al 
hea
lth
 
Me
nta
l 
com
pon
ent
 
sum
ma
ry 
Vit
ali
ty 
So
cia
l 
fun
ctio
nin
g 
Ro
le 
em
oti
on
al  
Me
nta
l 
hea
lth
 
Sym
pto
ms
 
Im
pac
t of
 
car
dia
c 
sur
vei
lla
nce
 
Wo
rri
es 
Employment status   ▲           
Age      ▲    ▲   ▲ 
TOF       ▲       
TGA       ▲       
SV       ▲       
Brief IPQ consequences  ▼      ▼     ▼ 
Brief IPQ identity ▼ ▼ ▼ ▼ ▼  ▼ ▼   ▼   
Brief IPQ emotional 
representation 
 ▲            
Brief COPE self-blame      ▼   ▼ ▼    
Brief COPE planning            ▼  
STAI anxiety      ▼    ▼  ▼  
CES-D 10 depression   ▼  ▼ ▼ ▼ ▼ ▼ ▼ ▼  ▼ 
▲Significant positive relationship, ▼Significant negative relationship 
Note. Employment status: 0= unemployed, 1= employed, ToF, TGA, SV: dummy-coded- reference group was Simple, CES-D 10: 0=  no depressive symptoms, 1=  with depressive symptoms. 
HRQoL scale 0 – 100, higher scores= better HRQoL.
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8.3. Examining the assumptions of hierarchical multiple regression analyses 
Across all regression models VIF values were below 4 and tolerance values were 
greater than 0.20 indicating that there was no multicollinearity issues in the 
hierarchical multiple regressions. Multivariate outliers can be found in Appendix T. 
Cook’s distance indicated that these multivariate outliers did not influence the results 
of the hierarchical multiple regressions and were therefore retained in the analyses. 
The Durbin-Watson values for all regressions were within the acceptable limit of 2, 
indicating that the assumption of independence of errors was met. Examination of 
the plots indicated that the assumption of normality of residuals was met for most 
regressions. Some deviation from normality was observed in role emotional. The 
assumptions of linearity and homoscedasticity were met for most of the analyses. 
There appeared to be an unequal spread of values above or below the zero line for 
physical functioning, role physical, bodily pain, social functioning, and role 
emotional sub-domains of the SF-36v1®. Although these patterns were observed in 
the data, they were not sufficiently pronounced as to be a cause for concern. This 
may weaken the analyses, but it does not invalidate them (Tabachnick & Fidell, 
2007). 
8.4. Discussion 
This chapter presented the analyses conducted to investigate the demographic, 
clinical, and psychosocial factors associated with both generic and disease-specific 
HRQoL in ACHD. It was hypothesized that psychosocial factors, including illness 
perceptions, coping strategies, mood, and social support would account for a 
significant amount of variance in HRQoL, over and above that accounted for by 
demographic and clinical characteristics. Some, but not all, of these psychosocial 
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factors explained more variance and were significantly associated with HRQoL and 
over and above demographic and clinical factors as predicted. 
8.4.1. Factors associated with generic physical HRQoL 
8.4.1.1. Demographic factors 
Demographic factors explained only a small proportion of the variance in physical 
HRQoL, including the physical component summary and the subscales of physical 
functioning, role physical, and general health (6-9%). Of note, employment status 
was found to predict the subscale of role limitations due to physical problems in the 
final model but not the physical component summary score which encompasses this 
subscale. This finding is in agreement with a study of 676 people with ACHD by 
Vigl et al. (2011) who did not find an association between unemployment and the 
physical component summary. Employment status was a consistent predictor of the 
physical component summary and the subscales of physical functioning and general 
health; however, this association was supplanted when clinical variables were 
entered into the models. This suggests that this relationship may be related to disease 
complexity as unemployment has been previously found to be associated with more 
complex ACHD (Kamphuis et al., 2002c). 
Employment status was, however, associated with the subscale of role physical in the 
final model, suggesting that unemployed individuals experienced greater role 
limitations due to physical problems compared with employed individuals. It is 
likely that people with ACHD are unemployed because they experience more 
physical problems and greater role limitations which prevent them from gaining and 
maintaining employment. However, the cross-sectional nature of this study limits the 
ability to establish the direction of this relationship. 
CHAPTER 8 – FACTORS ASSOCIATED WITH HRQOL IN ACHD 
254 
 
8.4.1.2. Clinical factors 
Diagnostic group, cyanosis days, and co-morbidities number together and current O2 
saturation, exercise capacity, medication number, and ventricular function together 
explained some of the variance (3-17% and 3-6% respectively) in the physical 
component summary and all of the subscales. However, clinical factors were not 
found to predict physical HRQoL and were supplanted by illness perceptions. This 
finding is in agreement with a longitudinal study of 845 people with ACHD by 
Schoormans et al. (2014), who found that disease complexity was not associated 
with the physical component summary of the SF-36 in a model that included illness 
perceptions. It appears that the effects of clinical factors are encompassed in the 
relationship between illness perceptions and physical HRQoL. Psychosocial factors, 
including illness perceptions explained more of the variance in physical HRQoL and 
were significant unique predictors of physical HRQoL over and above clinical 
factors, which is in agreement with previous studies in ACHD (Chen et al., 2011; 
Pike et al., 2012; Riley et al., 2012; Schoormans et al., 2014).  
8.4.1.3. Psychosocial factors 
After accounting for demographic and clinical characteristics, illness perceptions 
consistently explained the largest proportion of variance (19-28%) in the physical 
component summary and all of the subscales. Negative illness perceptions, 
specifically perceiving more severe symptoms related to ACHD was associated with 
poorer physical HRQoL in the physical component summary and all physical 
subscales of HRQoL, including poorer physical functioning, greater role limitations 
due to physical problems, greater bodily pain, and poorer general health. Two 
previous studies in ACHD used the IPQ-R as opposed to the Brief IPQ used in the 
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present study but did not examine the relationship between illness identity and 
physical HRQoL (Riley et al., 2012; Schoormans et al., 2014). The findings support 
previous studies in other chronic conditions, in both a meta-analysis and systematic 
review (Hagger & Orbell, 2003; Petrie et al., 2007), including studies in coronary 
artery disease (Stafford et al., 2009) and myocardial infarction (Weinman et al., 
1996). Hagger and Orbell (2003) found strong relationships between illness identity 
and physical and role functioning over and above clinical factors across a range of 
long-term conditions. The results of the current study also corroborate those of 
Scharloo et al. (1998), who found that the largest proportion of variance in SF-36 
outcomes was explained by illness identity in people with rheumatoid arthritis, 
chronic obstructive pulmonary disease, and psoriasis. Taken together, these findings 
suggest the importance of subjective perceptions of symptoms over and above 
clinical factors for physical HRQoL across chronic conditions, including people with 
ACHD. As mentioned earlier, illness perceptions are likely to mediate the 
relationship between clinical factors and physical HRQoL as their effect became 
insignificant after the inclusion of illness perceptions in the models. 
Other illness perceptions measured in the Brief IPQ, including illness coherence, 
controllability, and curability, were not found to be associated with the physical 
component summary confirming the findings of Riley et al. (2012) and Schoormans 
et al. (2014). Schoormans et al. (2014) found that illness controllability and 
coherence were not predictive of the physical component summary in a longitudinal 
study of 845 people with ACHD. This is likely attributed to the congenital nature of 
ACHD as recent data in coronary heart disease suggests that illness coherence and 
controllability are associated with HRQoL but only in people who experience an 
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unexpected medical event rather than outpatients (Foxwell, Morley, & Frizelle, 
2013). The authors argued that an unexpected rather than a familiar situation would 
require people to have an increased illness understanding and sense of control in 
order to successfully adapt.  
This study did not corroborate some the findings of Schoormans et al. (2014) who 
reported that perceiving the illness to have more serious consequences and less 
emotional consequences at baseline were predictive of poorer physical HRQoL in 
the physical component summary in the two-year follow-up. This is possibly due to 
the inclusion of the illness identity subscale in the present study, which shared some 
variance with these illness perceptions and was the strongest predictor of physical 
HRQoL. Illness consequences and emotional representation were, however, 
associated with the subscale of physical functioning, which is encompassed in the 
physical component summary. Firstly, perceiving the illness to have more serious 
consequences was associated with poorer physical functioning, a finding that is 
consistent with previous studies in coronary heart disease (e.g. Stafford et al., 2009) 
and myocardial infarction (Alsén, Brink, Persson, Brändström, & Karlson, 2010; 
French et al., 2005). Secondly, surprisingly a perception of fewer emotional 
consequences as a result of ACHD was associated with poorer instead of better 
physical functioning. Results from bivariate analyses showed an inverse rather than a 
positive relationship between the two variables. This association was limited to only 
physical functioning and no other domains. For these reasons it was assumed that 
this may be a spurious finding possibly the result of suppression effects, whereby the 
change in the nature of the association is due to the inclusion of other variables 
controlled for in the model (Tu, Gunnell, & Gilthorpe, 2008). More research will 
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likely help determine the nature of the relationship between illness emotional 
representation and physical HRQoL. 
In addition to illness perceptions, anxiety and the presence of depressive symptoms 
also explained a small proportion of the variance in some domains of physical 
HRQoL, including role limitations due to physical problems (5%) and general health 
(2%) but not the physical component summary.  
Contrasting the present findings regarding the physical component summary, a 
smaller study of 99 people with ACHD found that higher depression levels 
(measured with the HADS) were associated with poorer HRQoL in the physical 
component summary (Riley et al., 2012). Other studies in ACHD that utilised 
different measures of HRQoL (WHOQOL-Bref) and depression also found a 
significant association between depression and overall physical HRQoL (Chen et al., 
2011; Rose et al., 2005). These conflicting findings may be a result of 
methodological differences but also reflect the findings observed in the wider cardiac 
literature, where depression has been more consistently associated with psychosocial 
as opposed to physical HRQoL (Stafford et al., 2007) (see section 8.4.2.3, page 260). 
The findings in relation to the subscales, however, indicated that people with 
depressive symptoms reported more role limitations due to physical problems and 
poorer general health compared with those with no depressive symptoms, two 
subscales that are encompassed in the physical component summary. It may be that 
depressive symptoms have a greater role in relation to certain domains of physical 
HRQoL than other, which may be masked when solely examining aggregated scales, 
also evidenced by research in pulmonary hypertension and diabetes (Ali et al., 2010; 
Vanhoof et al., 2014). A possible explanation for these findings may be that 
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depression “amplifies” the effects of a medical condition like ACHD on physical 
HRQoL (Gaynes et al., 2002). Nearly a quarter of participants in this study had 
depressive symptoms and all participants irrespective of diagnostic group reported 
diminished general health (see section 7.4.1.1, page 216). These findings further 
highlight the importance of assessing depressive symptoms in people with ACHD as 
these symptoms can pose additional physical burden even on those that are clinically 
stable (Stafford et al., 2007). 
8.4.2. Factors associated with generic psychosocial HRQoL 
8.4.2.1. Demographic factors 
Demographic factors explained the same small proportion of variance in 
psychosocial HRQoL, including the mental component summary and the subscales 
of vitality, social functioning, role emotional, and mental health (6-9%), as they did 
in physical HRQoL. Age was found to be associated with the mental component 
summary and the subscale of mental health in the final models. In particular, 
younger individuals experienced poorer overall psychosocial HRQoL and poorer 
mental health compared with older ones. Previous research has reported variable 
findings regarding the association between age and psychosocial HRQoL in ACHD. 
The findings of the present study are in agreement with the longitudinal study by 
Schoormans et al. (2014), where older age was a significant unique predictor of 
better scores on the mental component summary of the SF-36 at the two-year follow-
up. Silva et al. (2011) also found that younger individuals reported poorer 
psychological HRQoL (as measured by the WHOQOL-Bref) than older individuals 
with ACHD. However, other studies in ACHD have not observed a relationship 
between people’s age and their psychosocial HRQoL (Hickey et al., 2012; Kahya 
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Eren et al., 2013; Loup et al., 2009; van Rijen et al. 2005a) possibly due to the 
exclusion of people with SV. This group was younger than the other diagnostic 
groups included in the present study (see section 6.5, page 175) and were found to 
experience diminished psychosocial HRQoL (see section 7.4.1.2, page 220). A 
possible explanation for the association between age and psychosocial HRQoL is 
that people adapt to living with ACHD and cope better as they age (Bruto et al., 
2007). The findings may have implications for the assessment of people’s 
psychological needs throughout their lives, especially with the growing number of 
individuals with SV surviving well into adulthood resulting in an older population 
(DoH, 2006).  
8.4.2.2. Clinical factors 
Clinical factors were not part of the multivariate analysis for the mental component 
summary and the subscales of role emotional and mental health as they were not 
associated with these outcomes in the bivariate analyses. Diagnostic group and co-
morbidities number did, however, explain a small proportion of the variance (7-8%) 
in the subscales of vitality and social functioning. Overall, clinical factors were 
found to be poor predictors of psychosocial HRQoL, in a model that included 
psychosocial factors as these explained more variance in psychosocial HRQoL. This 
finding is consistent with previous studies in ACHD (Chen et al., 2011; Riley et al., 
2012; Rose et al., 2005). 
Diagnostic group was only found to be associated with vitality in the final model. 
Being in the ToF, TGA, and SV groups as opposed to the Simple (reference group) 
was associated with greater vitality. This finding, in part, gives further support to the 
differences between the diagnostic groups found in earlier analyses (section 7.4.1.1, 
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page 216), whereby people in the Simple group had significantly lower vitality levels 
than other groups and especially people with ToF. Ternestedt et al. (2001) also 
reported greater vitality in people with ToF compared with ASD when the converse 
may be expected. In Chapter 7, it was speculated that people in different diagnostic 
groups may have differing expectations about their vitality. People in the Simple 
group may expect their functioning to be similar to healthy individuals, while the 
other diagnostic groups may have adjusted their expectations according to their 
capacity. This is an area worthy of investigation in future studies. 
8.4.2.3. Psychosocial factors 
After accounting for demographic and clinical characteristics, illness perceptions 
consistently explained the largest proportion of variance (16-29%) in psychosocial 
HRQoL, including the mental component summary and all of the subscales. 
However, illness perceptions were not found to be associated with the mental 
component summary in the final model. Schoormans et al. (2014) found that the 
mental component summary was only predicted by negative emotional 
representation. In the present study, emotional representation was associated with the 
mental component summary before being superseded by mood in the final model. 
This can be attributed to the similarity between constructs or the effects of emotional 
representation may have been encompassed in the relationship between mood and 
psychosocial HRQoL. Riley et al. (2012) also failed to find an association between 
illness perceptions and the mental component summary in a model that included 
anxiety and depression.  
The findings in relation to the subscales, however, indicated that perceiving more 
severe symptoms due to ACHD was associated with less vitality and poorer social 
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functioning. A perception of more severe consequences as a result of ACHD was 
also associated with poorer social functioning. These findings support the earlier 
findings in relation to physical HRQoL and further suggest that negative perceptions 
about their symptoms and the consequences of ACHD can potentially be detrimental 
for only certain domains of people’s psychosocial HRQoL. These findings are also 
in agreement with a meta-analysis of studies across long-term conditions, which 
found that illness identity and consequences were negatively associated with social 
functioning and vitality (Hagger & Orbell, 2003). Such negative perceptions may be 
accurate in people with SV, who reported poorer social functioning compared with 
the general population (section 7.4.1.2, page 220). However, in people in the Simple 
group, where there was variation in vitality (section 6.7.1, page 185), negative 
perceptions about symptoms may not represent their actual clinical state, leading to 
misconceptions about the condition and its impact (Schoormans et al., 2014). 
In addition to illness perceptions, coping explained 5-12% of the variance in 
psychosocial HRQoL, including the mental component summary and the subscales 
of vitality, role limitations due to emotional problems, and mental health. Only the 
use of self-blame was associated with poorer psychosocial HRQoL in the mental 
component summary as well as greater role limitations due to emotional problems 
and poorer mental health in the final models. This finding supports previous studies 
in people with heart failure (Graven et al., 2014; Klein et al., 2007), cancer (Shapiro, 
McCue, Heyman, Dey, & Haller, 2010), and across other chronic conditions 
(Bombardier, D'Amico, & Jordan, 1990). Bombardier et al. (1990) found that the use 
of self-blame was associated with poorer psychosocial HRQoL after controlling for 
disease complexity in a sample of 101 individuals with various chronic conditions. It 
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is believed that long-term use of maladaptive coping strategies, such as self-blame, 
can be problematic as they aggravate negative emotions and distract people from 
actively improving their situation (Carver, 1989). This has important implications for 
people with ACHD. Because of the congenital nature of their illness, these 
individuals have more time to accept the reality of their condition and take steps 
towards improving and sustaining their HRQoL. However, such efforts can be 
impaired when they blame themselves or are being overly critical of themselves 
(Klein et al., 2007). It may therefore be beneficial to identify and address 
maladaptive self-blame in people with ACHD in order to help them cope 
successfully. 
Conversely, the lack of a relationship between a majority of the coping strategies and 
particularly adaptive coping (planning, active coping, emotional support, and 
instrumental support) and psychosocial HRQoL in both bivariate and multivariate 
analyses is in line with previous studies in heart failure (Klein et al., 2007), end-stage 
renal disease and congestive heart failure (Kristofferzon, Lindqvist, & Nilsson, 
2011), and asthma and chronic obstructive pulmonary disease (Hesselink et al., 
2004). This appears to be a common occurrence in the chronic illnesses literature and 
has been attributed to their incurable nature, as the adoption of emotion-focused 
coping may be more effective in ameliorating the emotional impact and therefore 
maintaining psychosocial HRQoL (Petrie & Reynolds, 2007). However, people with 
ACHD in present study reported using predominantly adaptive coping strategies, 
including acceptance and active coping (section 6.7.2, page 188). It is also possible 
that the lack of an association between these coping strategies and psychosocial 
HRQoL is due to the operationalization of coping in this study. Previous studies in 
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other populations that have shared similar findings have concluded that generic 
coping checklists may be problematic if coping is successful or when people use 
habitual coping behaviours which they may not be able to identify (Steed, Newman, 
& Hardman, 1999). Some authors have argued in favour of disease-specific coping 
measures (Hagger & Orbell, 2003), which are not currently available in ACHD. 
More research on this topic needs to be undertaken before the association between 
coping and psychosocial HRQoL is more clearly understood. 
Mood, including anxiety and depressive symptoms also explained a proportion of the 
variance (6-13%) in the mental component summary and all of the subscales. The 
presence of depressive symptoms was associated with poorer HRQoL in the mental 
component summary and all of the subscales, including lower vitality, poorer social 
functioning, more role limitations due to emotional problems, and poorer mental 
health in the final models. Higher anxiety levels were only associated with poorer 
HRQoL in the mental component summary and poorer mental health. These findings 
confirm previous studies in ACHD (Chen et al., 2011; Müller et al., 2012; Müller et 
al., 2013a; Riley et al., 2012). Chen et al. (2011) found that after accounting for 
demographic and clinical variables, psychological distress (anxiety, depression) was 
the strongest predictor of both psychological and social HRQoL as measured by the 
WHOQOL-Bref. These findings have also been replicated across various ACHD 
samples including people with SV (Pike et al., 2012) and people with ASD (Cohen 
et al., 2010). The present study extends these findings by demonstrating that mood 
can potentially influence all aspects of psychosocial HRQoL including vitality, 
social functioning, role limitations, and mental health. The present and previous 
studies in ACHD are also in agreement with the wider cardiac literature, in which 
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mood disorders are considered amongst the strongest predictors of poor psychosocial 
HRQoL (Ruo et al., 2003). These findings coupled with the considerable incidence 
of depressive symptoms in 22% of the sample in this study, may help explain the 
impairment in psychosocial HRQoL observed across the total sample in Chapter 7 
(section 7.4.1.2, page 220). It may also help explain the impaired psychosocial 
HRQoL in the SV and Simple groups, which had the highest proportion of people 
with depressive symptomatology (27% and 28% respectively). 
A possible explanation for this relationship is that depressive symptomatology poses 
an additional burden on people with ACHD, making them more vulnerable to 
experiencing poorer psychosocial HRQoL and limitations in their social activities 
and their social role, while also encouraging a more negative perception in these 
outcomes (Stafford et al., 2007). Alternatively, for some subscales it could be an 
issue with definition. According to the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV), depressive symptoms include reduced energy levels and 
decreased interest in activities (American Psychiatric Association, 2000). Assuming 
the CESD-10’s validity as a measure of symptoms relating to clinical depression, it 
may reflect the vitality, impaired social functioning, and mental health aspects of 
HRQoL, posing possible overlap between the concepts. Therefore, it would not be 
surprising that the presence of depressive symptomatology was associated with 
poorer HRQoL in these subscales. However, the measure did not tackle these 
concepts directly and depressive symptomatology was also associated with certain 
aspects of physical HRQoL. Overall, these findings highlight the importance of 
measuring and addressing anxiety and depressive symptoms in people with ACHD, 
as these can potentially be detrimental for their HRQoL.  
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It is important to note that social support did not explain significant variance and was 
not associated with either the mental component summary or any of the subscales in 
the multivariate analyses. This finding suggests that despite the high social support 
levels experienced by people in the present study (section 6.7.3, page 190), other 
factors are more important in explaining variation in psychosocial HRQoL. In 
contrast to these findings, Pike et al. (2012) found that social support was a 
significant unique predictor of overall HRQoL rather than the mental component 
summary and its subscales in a smaller sample of people with SV, after accounting 
for the effects of depression and functional status. Rose et al. (2005) also found that 
social support was a significant determinant of psychological and social HRQoL as 
measured by the WHOQOL-Bref in people with ACHD. Both these studies did not 
account for other confounding variables including illness perceptions, which were 
found to be amongst the strongest predictors of psychosocial HRQoL in the present 
study. 
There are several possible explanations for the lack of a relationship between social 
support and psychosocial HRQoL. Firstly, this lack of relationship may be partially 
explained by the lack of variability in social support. It may also be that social 
support had an indirect impact on HRQoL through other factors included in the 
multivariate analyses. Recent studies in other populations found that depression may 
serve as a mediator between social support and psychosocial HRQoL (Wicke et al., 
2014). Evidence also suggests that in addition to a direct effect on HRQoL, social 
support may have an indirect effect by serving as a “buffer” to reduce the emotional 
impact associated with an illness (Cohen & Wills, 1985). While testing the 
abovementioned assumptions was beyond the scope of the present study, their 
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examination in future studies may provide important insight into the relationship 
between social support and HRQoL in ACHD. 
8.4.3. Factors associated with disease-specific HRQoL 
8.4.3.1. Demographic factors 
Demographic factors explained a small proportion of the variance in the symptoms 
(9%) and worries (2%) scales of the CHD-TAAQOL. Age remained a significant 
unique predictor of the worries subscale in the final model. Younger people reported 
greater ACHD-specific worries as opposed to older individuals. This finding is 
consistent with the findings in generic psychosocial HRQoL, as discussed in section 
8.4.2.1 (page 258). Schoormans et al. (2014) also found that younger age was a 
significant predictor of greater worries (also measured using the CHD-TAAQOL) at 
the two year follow-up. Inspection of the items within the worries subscale provides 
further insight into this finding. It may be expected that as people with ACHD age 
they worry less about educational attainment, employment opportunities, and being 
able to have children, all of which may be important issues for younger people. The 
finding may therefore be an artefact of the type of worries specified within the scale 
rather than worries in general. A broader measure or inclusion of older age specific 
items may have made the measure more relevant to this population. This finding 
does however have important implications for the provision of information for 
younger adults, especially during key periods such as their transition from child to 
adult care (Sable et al., 2011).  
8.4.3.2. Clinical factors 
Diagnostic group, co-morbidities, cyanosis days, and presence of arrhythmias 
together explained a proportion of variance in all subscales of the disease-specific 
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HRQoL including symptoms, impact of cardiac surveillance, and worries (8-13%). 
Current O2 saturation, medication number, exercise capacity, and ventricular 
function together also explained significant variance but only in symptoms (7%). 
However, none of the clinical variables were associated with disease-specific 
HRQoL in the final models and became insignificant after the inclusion of illness 
perceptions. This is consistent with the findings for physical and psychosocial 
HRQoL, whereby clinical variables were found to be poor unique predictors of 
HRQoL when psychosocial factors are accounted for (see section 8.4.1.2, page 254 
and section 8.4.2.2, page 259) and may signify that illness perceptions mediate the 
relationship between clinical factors and disease-specific HRQoL. 
8.4.3.3. Psychosocial factors 
After adjusting for demographic and clinical characteristics, illness perceptions 
explained a substantial amount of variance (17-32%) in all three subscales of the 
CHD-TAAQOL. Perceiving ACHD to have more serious consequences was 
associated with greater worries, a finding that is in agreement with the longitudinal 
study by Schoormans et al. (2014). Furthermore, a perception of more severe 
symptoms due to ACHD was found to be associated with greater symptom impact. It 
may be argued that this relationship is an artefact of overlapping definitions, yet their 
distinction is subtle but important. The symptoms subscale of the CHD-TAAQOL 
measures the frequency of symptoms, but weighted by their emotional impact on the 
person. Whilst the illness identity subscale of the Brief IPQ quantifies the degree to 
which people experience symptoms attributable to ACHD and is a cognitive rather 
than emotional evaluation. Although it may not be possible to draw clear conclusions 
regarding this particular association, the strong relationships between illness identity 
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and all other physical and psychosocial HRQoL domains discussed in sections 
8.4.1.3 (page 254) and 8.4.2.3 (page 260), provide further support for its importance 
in both generic and disease-specific HRQoL.  
Coping explained 4% of the variance but only in the worries scale. The findings 
indicated that greater use of planning as a coping strategy was found to be associated 
with greater impact of cardiac surveillance in the final model. Planning is a problem-
focused coping strategy, which involves the formation of plans towards dealing with 
a problem and it is thought to be one of the most important coping strategies in 
chronic illness that facilitates adjustment (Felton et al., 1984). Owing to the cross-
sectional design of the study it is difficult to draw conclusions on causality for this 
particular association. It may be expected that people who reported greater impact of 
cardiac surveillance would need to engage in more planning in order to 
accommodate cardiac testing and hospital appointments. 
Anxiety and depressive symptoms also explained some variance (4%) in symptoms 
and worries. The findings indicated that individuals with depressive symptoms 
reported greater symptom impact and greater worries than those with no depressive 
symptoms, whilst higher levels of anxiety were associated with greater impact of 
cardiac surveillance. The findings are consistent with those in relation to generic 
HRQoL, further supporting the wider notion that anxiety and depression can 
potentially be detrimental for HRQoL in cardiac populations (Ruo et al., 2003). Ruo 
et al. (2003) also found that depressive symptoms were associated with greater 
symptom burden in people with coronary artery disease and this has been attributed 
to the additional functional limitations people with depression suffer from (Stafford 
et al., 2007). Individuals with depressive symptoms in the present study were also 
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found to experience greater worries in relation to their education, employment, their 
ability to have children, and independent living. The finding that higher levels of 
anxiety were associated with greater impact of cardiac surveillance was not 
surprising; the impact of cardiac surveillance subscale assesses the frequency of 
cardiac surveillance but weighted by its emotional impact on the person, hence it is 
not independent of mood. In addition, anxiety was measured in its state form, where 
participants were asked about their feelings at the particular time of the assessment 
and these assessments generally took place in the hospital. It is likely that the 
hospital environment itself might have been a confounding factor as it may be 
connected to negative experiences, such as previous hospitalizations and may also be 
a reminder that their health is not ideal. However, it is difficult to determine the 
direction of the relationship between anxiety and the impact of cardiac surveillance 
based on cross-sectional data. It is also likely that greater impact of cardiac 
surveillance might have resulted in higher levels of anxiety in patients. 
8.5. Summary  
This chapter presented the results of hierarchical multiple regressions conducted to 
examine the factors associated with HRQoL in people with ACHD. Overall, the 
findings indicated that psychosocial factors and specifically illness perceptions 
significantly explained a large proportion of variance in HRQoL after adjusting for 
demographic, clinical, and other psychosocial factors. Coping and mood 
significantly explained a smaller proportion of variance in HRQoL but 
predominantly in psychosocial domains. Psychosocial factors, including illness 
perceptions and specifically illness identity and consequences, the use of self-blame 
as a coping strategy, and mood were found to be strong unique predictors of 
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HRQoL. The findings provided further support to the wealth of literature in other 
chronic populations, which highlighted the importance of psychosocial factors for 
understanding the factors associated with people’s HRQoL. The limitations of the 
cross-sectional study and the theoretical, clinical, and research implications of the 
findings will be addressed in the general discussion in Chapter 11. 
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CHAPTER 9 – LONGITUDINAL CHANGES IN 
HEALTH-RELATED QUALITY OF LIFE AND 
PSYCHOSOCIAL FUNCTIONING 
9.1. Prologue 
The previous chapters described and discussed the findings of the cross-sectional 
study. Chapter 2 (section 2.6.1.1, page 96) highlighted that very few studies have 
examined changes in HRQoL over time in people with ACHD. In addition, no 
studies have examined changes in psychosocial functioning over time in ACHD, 
including the perceptions people hold about their condition, the coping strategies 
they utilise, their perceptions of social support, and their mood (section 3.8, page 
119). The longitudinal study in this thesis was designed to address both these issues. 
This chapter describes the analyses conducted using hierarchical linear models to 
examine changes in psychosocial factors and HRQoL over time and concludes with a 
discussion of the findings.  
9.2. Response rate and sample attrition 
Figure 9.1 displays the flow diagram for the participant recruitment process.  
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Figure 9.1. Flow diagram of the participant recruitment process for the longitudinal 
study 
 
A total of 314 prospective participants, all in the initial cross-sectional study were 
invited to participate in the follow-up study. Of the 238 (75.8%) who consented to 
take part, one (0.4%) participant withdrew and 49 (20.6%) failed to return the postal 
questionnaire packs. The final sample for the longitudinal study consisted of 188 
participants, resulting in a 60% response rate. 
9.3. Missing value analysis 
Missing value analysis was performed at scale level and is presented in Appendix P. 
A total of 14 (0.2%) values were missing of 7520. Little’s MCAR suggested that the 
data were MCAR (p=  .283) and that imputation is appropriate. Imputation was not 
performed for participants who did not complete the follow-up assessments as 
Invited (n= 314) 
Simple n=  84 
ToF n=  81 
TGA n=  81 
SV n=  68 
Total non-participants (n=76) 
Declined n=  36 
Non respondents n=  33 
Deceased n=  7 
 
Positive response (n= 238) 
Simple n=  66 
ToF n=  69 
TGA n=  60 
SV n=  43 
Completed assessments (n= 188) 
Simple n= 46 
ToF n= 56 
TGA n= 50 
SV n= 36 
Withdrawn (n=  1) 
Questionnaires not returned (n=  49) 
CHAPTER 9 – CHANGES IN HRQOL AND PSYCHOSOCIAL FUNCTIONING 
273 
 
hierarchical linear models still use all available data without deleting cases that have 
completed only one of the assessments. 
9.4. Scale reliability 
All scales and subscales of the questionnaires demonstrated satisfactory internal 
reliability based on Cronbach’s α scores and/or inter-item correlations (Table 9.1). 
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Table 9.1. Internal reliability of scales/subscales at follow-up 
Scales & Subscales No. of Items  Cronbach α/ Inter-Item 
Correlations§ 
SF-36   
    Physical functioning 10 .93 
    Role physical 4 .93 
    Bodily pain 2 .80/ .68 
    General health 5 .86 
    Vitality 4 .87 
    Social functioning 2 .85/ .75 
    Role emotional 3 .80 
    Mental health 5 .84 
CHD-TAAQOL   
    Symptoms 9 .82 
    Worries 10 .85 
    Impact cardiac surveillance 7  .77 
Brief COPE   
    Planning 2 .72/ .56 
    Active coping 2 .84/ .72 
    Positive reframing 2 .76/ .62 
    Acceptance 2 .64/ .47 
    Humour 2 .91/ .84 
    Religion 2 .94/ .88 
    Seeking emotional support 2 .83/ .70 
    Seeking instrumental support 2 .84/ .72 
    Self-distraction 2 .62/ .45 
    Denial 2 .81/ .68 
    Venting 2 .64/ .48 
    Substance use 2 .96/ .93 
    Behavioural disengagement 2 .47/ .38 
    Self-blame 2 .57/ .42 
STAI-6 6 .84 
CES-D 10 10 .82 
MSPSS   
    Family support 4 .95 
    Friends support 4 .94 
    Special person support 4 .97 
§Inter-item correlations are also reported for scales and subscales consisting of two items. 
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9.5. Differences between responders and non-responders 
There were no significant differences in demographic and clinical characteristics 
between people who completed the follow-up assessment and those that did not 
(Table 9.2). 
Table 9.2. Comparisons between responders and non-responders in 
demographic and clinical characteristics 
 
Characteristic Responders 
(n= 188) 
Non-
Responders 
(n= 126) 
Test Statistic Sig. 
Age (mean, S.D.) 34 (11.5) 31.9 (9.3) f(1,312)=  2.94 .088 
Gender (n, %)   χ2(1)=  0.48 .490 
    Male 103 (58.2) 74 (41.8)   
    Female 85 (62) 52 (38)   
Marital status (n, %)   χ2(1)=  2.04 .154 
    Married 89 (56) 70 (44)   
    Single 99 (63.9) 56 (36.1)   
Educational level (n, %)   χ2(1)=  1.97 .161 
    School 120 (57.1) 90 (42.9)   
    University 68 (65.4) 36 (34.6)   
Employment status (n, %)   χ2(1)=  1.39 .238 
    Employed 137 (62) 84 (38)   
    Unemployed 51 (54.8) 42 (45.2)   
Diagnostic group (n, %)   χ2(3)=  5.28 .152 
    Simple 46 (54.8) 38 (45.2)   
    ToF 56 (69.1) 25 (30.9)   
    TGA 50 (61.7) 31 (38.3)   
    SV 36 (52.9) 32 (47.1)   
Co-morbidities no. (mean, 
S.D.) 
1 (1.09) .92 (1.09) f(1,312)=  0.40 .526 
Cyanosis days (mean, S.D.) 1311.16 
(2819.48) 
1326.73 
(2554.28) 
f(1,312)=  0.00 .960 
Interventions no. (mean, S.D.) 2.35 (1.36) 2.4 (1.44) f(1,312)=  0.11 .738 
Medication no. (mean, S.D.) 0.97 (1.32) 0.94 (1.27) f(1,312)=  0.05 .833 
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There were also no significant differences on any of the psychosocial measures 
between people who completed the follow-up assessment and those that did not, 
except for depression (Table 9.3). The chi-square test was significant (χ2(1)=  8.10, 
p<  .004, φc=  .16) suggesting a significant relationship between depressive symptoms 
and completion of the follow-up assessment. Individuals with depressive symptoms 
were more likely to have not completed the follow-up assessment. The effect size 
was however small. 
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Table 9.3. Comparisons between responders and non-responders in 
psychosocial measures 
 
Variable (mean, S.D.) Responders  
 
Non-
responders 
Test Statistic Sig. 
Physical component summary 50.7 (9.3) 51.3 (9.6) f(1,300)=  0.27 .601 
Physical functioning 50.2 (8.5) 49.3 (9.5) f(1,301)=  0.77 .380 
Role physical 50.5 (9.4) 50.5 (10.3) f(1,300)=  0.00 .981 
Bodily pain 53.8 (10.7) 55.6 (9.9) f(1,301)=  2.15 .143 
General health 45.3 (10.5) 44.8 (10.7) f(1,301)=  0.21 .649 
Mental component summary 48.7 (47.3) 47.3 (11.3) f(1,300)=  1.21 .272 
Vitality 51 (10.5) 50.5 (10.8) f(1,301)=  0.15 .700 
Social functioning 48.9 (10.6) 48.4 (10.3) f(1,301)=  0.21 .647 
Role emotional 49.5 (10.8) 48.9 (11.3) f(1,300)=  0.19 .668 
Mental health 48.7 (10.4) 46.6 (11.1) f(1,301)=  2.91 .089 
Symptoms 85.9 (14.6) 86.7 (13.7) f(1,301)=  0.20 .659 
Worries 82.4 (15.7) 81.7 (14.4) f(1,301)=  0.16 .686 
Impact cardiac surveillance 85.6 (10.4) 85.8 (10.8) f(1,301)=  0.02 .884 
Brief IPQ consequences 3.2 (2.7) 3.4 (2.8) f(1,301)=  0.24 .625 
Brief IPQ timeline 9.3 (2.1) 9.3 (2) f(1,301)=  0.03 .865 
Brief IPQ controllability 5.4 (2.8) 5.1 (3.2) f(1,301)=  0.64 .424 
Brief IPQ curability 7.4 (2.7) 6.9 (3.2) f(1,301)=  2.05 .153 
Brief IPQ identity 2.8 (2.4) 2.6 (2.3) f(1,301)=  0.30 .582 
Brief IPQ concern 4.2 (2.7) 4.1 (3) f(1,301)=  0.05 .822 
Brief IPQ coherence 6.4 (2.4) 5.9 (2.7) f(1,301)=  2.99 .085 
Brief IPQ emotional representation 3.3 (2.9) 3.8 (3.4) f(1,301)=  2.07 .151 
Brief COPE planning 1.5 (0.8) 1.3 (0.9) f(1,301)=  4.86 .028 
Brief COPE active coping 1.7 (0.8) 1.5 (0.9) f(1,301)=  6.23 .013 
Brief COPE positive reframing 1.5 (0.9) 1.4 (0.9) f(1,301)=  1.42 .234 
Brief COPE acceptance 2.3 (0.7) 2.2 (0.8) f(1,301)=  2.00 .159 
Brief COPE humour 1.3 (1.1) 1.3 (1.1) f(1,301)=  0.03 .870 
Brief COPE religion 0.5 (0.9) 0.6 (0.9) f(1,301)=  1.31 .254 
Brief COPE emotional support 1.2 (0.9) 1.2 (1) f(1,301)=  0.06 .800 
Brief COPE instrumental support 1.2 (0.9) 1 (0.9) f(1,301)=  2.35 .126 
Brief COPE self-distraction 1.3 (0.8) 1.3 (0.9) f(1,301)=  0.00 .980 
Brief COPE denial 0.2 (0.4) 0.2 (0.4) f(1,301)=  0.33 .565 
Brief COPE venting 0.7 (0.7) 0.8 (0.8) f(1,301)=  0.42 .519 
Brief COPE substance use 0.2 (0.4) 0.3 (0.6) f(1,301)=  0.84 .359 
Brief COPE behavioural 
disengagement 
0.2 (0.5) 0.3 (0.6) f(1,301)=  0.93 .336 
Brief COPE self-blame 0.5 (0.7) 0.5 (0.7) f(1,301)=  0.03 .865 
MSPSS family support 4.2 (0.7) 4.2 (0.9) f(1,301)=  0.00 .969 
MSPSS friend support 4 (0.8) 4 (0.9) f(1,301)=  0.11 .742 
MSPSS significant other support 4.3 (0.9) 4.2 (1.1) f(1,301)=  1.13 .288 
Anxiety 1.6 (0.6) 1.7 (0.6) f(1,301)=  1.92 .167 
Depression (n, %)   χ2(1)=  8.10 .004 
    No depressive symptoms 156 (65.5) 82 (34.5)   
    With depressive symptoms 30 (46.2) 35 (53.8)   
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9.6. Changes over time in clinical and psychosocial factors 
The mean follow-up was 3.3 years (S.D.=  0.68, range: 1.7-4.5). The analysis 
indicated that the interval between baseline and follow-up assessments was 
significantly different between diagnostic groups [f (3,184)=  3.37, p=  .020]; hence, 
follow-up years was included as a covariate (fixed effect) in the HLMs or mixed 
within-between ANOVAs.  
F-test results are presented for the analyses conducted to determine the effect of 
time, diagnostic group, and Diagnostic Group x Time interaction. The main effects 
of diagnostic group are presented but are not interpreted as these analyses replicate 
those discussed in Chapter 7. The main effects of time are reported for each 
outcome, however their interpretation is not recommended when interaction effects 
are significant (Pallant, 2013). Therefore, the main effects of time were interpreted 
only when interaction effects were not significant. A significant time effect was 
interpreted as an indication of significant change over time. A significant Diagnostic 
Group x Time interaction was interpreted as an indication that changes over time 
were different by diagnostic group. Where within-between ANOVAs were 
conducted this is indicated with the results in the associated tables. Effect sizes 
(Cohen’s d) are reported where differences between diagnostic groups are 
significant. Statistical tests for which results were significant (p<  .01) are presented 
in bold. 
9.6.1. Changes over time in clinical factors  
Table 9.4 presents the results of the mixed within-between ANOVAs. There were no 
statistically significant interaction effects between diagnostic group and time or main 
effects for time on clinical factors, indicating no change over time and across 
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diagnostic groups. See Appendix U for a graphical representation of clinical factors 
over time. 
 Table 9.4. Adjusted means (S.D.) and effects for clinical factors (n= 188) 
Clinical Factors Baseline 
(Mean, S.D.) 
 
Follow-up 
(Mean, S.D.) 
 
Effect of 
Time  
Effect of 
Diagnostic 
Group 
Effect of 
Diagnostic 
Group x 
Time 
Intervention no.*   f(1,183)= 
1.59, p=  .208 
f(3,183)= 
10.54, p<  .001 
f(3,183)= 
3.35, p=  .020 
 Simple 1.46 (1.28) 1.67 (1.73)    
 ToF 2.43 (1.27) 2.58 (1.73)    
 TGA 2.76 (1.27) 3.12 (1.73)    
 SV 2.81 (1.27) 3.52 (1.72)    
 Total 2.36 (1.28) 2.72 (1.74)    
Hospitalization 
days* 
  f(1,183)= 
3.00, p=  .085 
f(3,183)= 
15.42, p<  .001 
f(3,183)= 
1.99, p=  .118 
 Simple 18.59 (28.70) 19.80 (29.69)    
 ToF 48.78 (28.59) 49.22 (29.57)    
 TGA 36.09 (28.58) 37.06 (29.56)    
 SV 58.07 (28.57) 60.76 (29.54)    
 Total 40.38 (28.81) 41.71 (29.79)    
Medication no.*   f(1,183)= 
0.54, p=  .464 
f(3,183)= 3.85, 
p=  .011 
f(3,183)= 
0.43, p=  .733 
 Simple 0.88 (1.29)  1.48 (2.27)    
 ToF 0.57 (1.29) 1.39 (2.25)    
 TGA 0.99 (1.29) 1.62 (2.26)    
 SV 1.67 (1.28) 2.61 (2.25)    
 Total 1.03 (1.29) 1.78 (2.28)    
*Based on mixed within-between ANOVA analyses.  
9.6.2. Changes over time in HRQoL  
Table 9.5 presents the results of the HLM for generic physical HRQoL, including the 
physical component summary and all of the subscales. There were no statistically 
significant interaction effects between diagnostic group and time or main effects for 
time on physical HRQoL, indicating no change over time and across diagnostic 
groups. Figure 9.2 presents a graphical representation of the physical component 
summary over time. Figures 9.3 to 9.6 present a graphical representation of the 
physical subscales over time. 
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Table 9.5. HLM: Adjusted means (S.D.) and effects for generic physical HRQoL 
(n= 188) 
HRQoL 
Subscale 
Baseline 
(Mean, S.D.) 
 
Follow-up 
(Mean, S.D.) 
 
Effect of 
Time 
Effect of 
Diagnostic 
Group 
Effect of 
Diagnostic 
Group x Time 
Physical 
component 
summary 
  f(1,181.61)= 
0.46, p=  .499 
f(3,183.19)= 
3.71, p=  .013 
f(3,181.61)= 
1.18, p=  .319 
 
Simple 52.85 (9.12) 53.44 (9.87)    
 
ToF 51.82 (9.13) 49.79 (9.79)    
 
TGA 50.35 (9.09) 50.80 (9.83)    
 
SV 47.13 (9.13) 46.49 (9.77)    
 
Total 50.54 (9.18) 50.13 (9.90)    
Physical 
functioning 
  f(1,183.84)= 
3.57, p=  .060 
f(3,183.66)= 
5.77, p<  .001 
f(3,183.87)= 
1.28, p=  .283 
 Simple 52.70 (8.26) 52.40 (9.93)    
 ToF 51.25 (8.28) 48.33 (9.89)    
 TGA 50.22 (8.25) 49.78 (9.89)    
 SV 45.42 (8.27) 44.66 (9.89)    
 Total 49.90 (8.32) 48.79 (10)    
Role physical   f(1,183.79)= 
0.11, p=  .739 
f(3,183.49)= 
3.20, p=  .025 
f(3,183.81)= 
0.32, p=  .810 
 Simple 51.94 (9.35) 52.75 (9.90)    
 ToF 51.36 (9.35) 51.49 (9.87)    
 TGA 50.55 (9.33) 51.61 (9.86)    
 SV 47.58 (9.35) 46.60 (9.87)    
 Total 50.36 (9.42) 50.61 (9.97)    
Bodily pain   f(1,182.81)= 
0.02, p=  .899 
f(3,183.34)= 
1.14, p=  .336 
f(3,182.88)= 
1.95, p=  .124 
 Simple 52.49 (10.60) 55.21 (10.53)    
 ToF 56.04 (10.60) 53.79 (10.46)    
 TGA 54.16 (10.58) 53.40 (10.49)    
 SV 51.37 (10.60) 51.26 (10.49)    
 Total 53.51 (10.68) 53.42 (10.60)    
General health   f(1,183.47)= 
0.21, p=  .647 
f(3,183.45)= 
4.12, p=  .007 
f(3,183.50)= 
0.39, p=  .757 
 Simple 48.16 (10.34) 48.37 (11.56)    
 ToF 45.91 (10.36) 46.19 (11.52)    
 TGA 44.93 (10.31) 44.87 (11.52)    
 SV 41.52 (10.35) 39.85 (11.51)    
 Total 45.13 (10.42) 44.82 (11.63)    
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Figure 9.2. Graphical representation of the physical component summary over time 
 
 
Figure 9.3. Graphical representation of the physical functioning subscale over time 
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Figure 9.4. Graphical representation of the role physical subscale over time 
 
 
Figure 9.5. Graphical representation of the bodily pain subscale over time 
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Figure 9.6. Graphical representation of the general health subscale over time 
 
Table 9.6 presents the results of the HLM for generic psychosocial HRQoL, 
including the mental component summary and all of the subscales. There were no 
statistically significant interaction effects between diagnostic group and time or main 
effects for time on psychosocial HRQoL, indicating no change over time and across 
diagnostic groups. Figure 9.7 presents a graphical representation of the mental 
component summary over time. Figures 9.8 to 9.11 present a graphical 
representation of the psychosocial subscales over time. 
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Table 9.6. HLM: Adjusted means (S.D.) and effects for generic psychosocial 
HRQoL (n= 188) 
HRQoL 
Subscale 
Baseline 
(Mean, S.D.) 
 
Follow-up 
(Mean, S.D.) 
 
Effect of 
Time 
Effect of 
Diagnostic 
Group 
Effect of 
Diagnostic 
Group x 
Time 
Mental 
component 
summary 
  f(1,182.11)= 
0.07, p=  .793 
f(3,182.99)= 
3.60, p=  .015 
f(3,182.09)= 
0.90, p=  .442 
 
Simple 46.72 (10.54) 48.27 (10.55)    
 
ToF 50.80 (10.54) 51.23 (10.49)    
 
TGA 50.36 (10.52) 48.62 (10.51)    
 
SV 45.40 (10.54) 44.34 (10.63)    
 
Total 48.32 (10.62) 48.12 (10.61)    
Vitality   f(1,182.30)= 
0.05, p=  .820 
f(3,183.52)= 
3.50, p=  .017 
f(3,182.29)= 
2.39, p=  .071 
 Simple 48.14 (10.19) 51.04 (10.93)    
 ToF 54.23 (10.20) 52.18 (10.86)    
 TGA 52.71 (10.16) 51.38 (10.89)    
 SV 47.25 (9.11) 47.05 (10.99)    
 Total 50.58 (10.27) 50.41 (10.98)    
Social 
functioning 
  f(1,183.08)= 
0.13, p=  .717 
f(3,183.42)= 
4.28, p=  .006 
f(3,183.14)= 
0.06, p=  .980 
 Simple 49.51 (10.44) 49.23 (11.16)    
 ToF 51.20 (10.45) 50.64 (11.10)    
 TGA 49.70 (10.42) 49.06 (11.13)    
 SV 43.82 (10.45) 44.13 (11.13)    
 Total 48.56 (10.53) 48.26 (11.23)    
Role emotional   f(1,182.81)= 
0.70, p=  .406 
f(3,182.69)= 
2.54, p=  .058 
f(3,182.88)= 
2.09, p=  .103 
 Simple 49.17 (10.88) 50.87 (10.74)    
 ToF 49.59 (10.87) 51.04 (10.70)    
 TGA 51.05 (10.86) 48.27 (10.71)    
 SV 47.34 (10.87) 43.83 (10.71)    
 Total 49.29 (10.97) 48.50 (10.80)    
Mental health   f(1,181.49)= 
0.01, p=  .931 
f(3,182.76)= 
3.01, p=  .032 
f(3,181.47)= 
0.42, p=  .741 
 Simple 47.35 (10.28) 48.42 (10.51)    
 ToF 51.32 (10.28) 50.33 (10.44)    
 TGA 49.61 (10.26) 49.38 (10.47)    
 SV 44.87 (10.28) 45.27 (10.57)    
 Total 48.29 (10.35) 48.35 (10.56)    
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Figure 9.7. Graphical representation of the mental component summary over time 
 
 
Figure 9.8. Graphical representation of the vitality subscale over time 
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Figure 9.9. Graphical representation of the social functioning subscale over time 
 
 
Figure 9.10. Graphical representation of the role emotional subscale over time 
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Figure 9.11. Graphical representation of the mental health subscale over time 
 
Table 9.7 presents the results of the HLM for disease-specific HRQoL. There were 
no statistically significant interaction effects between diagnostic group and time or 
main effects for time on disease-specific HRQoL, indicating no change over time 
and across diagnostic groups. Figures 9.12 to 9.14 present a graphical representation 
of disease-specific HRQoL over time. 
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Table 9.7. HLM: Adjusted means (S.D.) effects for disease-specific HRQoL (n= 
188) 
HRQoL 
Subscale 
Baseline 
(Mean, S.D.) 
 
Follow-up 
(Mean, S.D.) 
 
Effect of Time Effect of 
Diagnostic 
Group 
Effect of 
Diagnostic 
Group x Time 
Symptoms   f(1,182.53)= 
0.20, p=  .655 
f(3,183.40)= 
3.93, p=  .010 
f(3,182.53)= 
1.21, p=  .308 
 
Simple 88.77 (14.30) 88.43 (13.35)    
 
ToF 87.72 (14.34) 85.42 (13.30)    
 
TGA 86.95 (14.26) 86.34 (13.29)    
 
SV 78.41 (14.33) 80.30 (13.30)    
 
Total 85.46 (14.43) 85.12 (13.41)    
Impact cardiac 
surveillance 
  f(1,183.11)= 
2.54, p=  .113 
f(3,182.75)= 
14.81, p<  .001 
f(3,183.13)= 
1.22, p=  .304 
 
Simple 89.30 (10.06) 91.96 (9.59)    
 
ToF 86.90 (10.05) 89.46 (9.56)    
 
TGA 84.78 (10.04) 86.71 (9.55)    
 
SV 80.29 (10.04) 78.63 (9.56)    
 
Total 85.32 (10.13) 86.69 (9.65)    
Worries   f(1,183.14)= 
0.13, p=  .718 
f(3,183.42)= 
5.41, p=  .001 
f(3,183.16)= 
0.03, p=  .993 
 Simple 83.55 (15.33) 83.02 (15.69)    
 ToF 85.91 (15.36) 85.64 (15.63)    
 TGA 83.39 (15.29) 83.49 (15.63)    
 SV 74.24 (15.36) 73.63 (15.63)    
 Total 81.77 (15.45) 81.44 (15.77)    
 
 
Figure 9.12. Graphical representation of symptoms over time 
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Figure 9.13. Graphical representation of worries over time 
 
 
Figure 9.14. Graphical representation of impact of cardiac surveillance over time 
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Table 9.8 presents the results of the HLM for illness perceptions. There were no 
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concern, and emotional representation, indicating no change over time and across 
diagnostic groups. See Appendix V for a graphical representation of these results. 
Table 9.8. HLM: Adjusted means (S.D.) and effects for illness perceptions (n= 
188) 
Illness 
Perceptions 
Baseline 
(Mean, 
S.D.) 
 
Follow-up 
(Mean, 
S.D.) 
 
Effect of Time Effect of 
Diagnostic 
Group 
Effect of 
Diagnostic 
Group x 
Time 
Consequences   f(1,183.20)= 
0.01, p=  .920 
f(3,183.36)= 
10.02, p<  .001 
f(3,183.22)= 
1.22, p=  .305 
 
Simple 2.54 (2.56) 1.99 (2.62)    
 
ToF 2.91 (2.56) 3.04 (2.61)    
 
TGA 3.04 (2.55) 3.06 (2.61)    
 
SV 4.84 (2.56) 5.18 (2.61)    
 
Total 3.34 (2.58) 3.32 (2.63)    
Timeline   f(1,182.32)= 
0.21, p=  .645 
f(3,182.50)= 
5.04, p=  .002 
f(3,182.34)= 
1.87, p=  .137 
 Simple 8.38 (2.05) 8.37 (2.30)    
 ToF 9.40 (2.05) 8.67 (2.29)    
 TGA 9.71 (2.04) 9.71 (2.29)    
 SV 9.70 (2.05) 10 (2.29)    
 Total 9.30 (2.06) 9.24 (2.32)    
Controllability  
 
 
 
f(1,182.17)= 
2.66, p=  .104 
f(3,181.87)= 
1.81, p=  .147 
f(3,182.20)= 
5.00, p= .002 
 Simple 4.84 (2.79) 6.04 (3.11)    
 ToF 6 (2.78) 4.91 (3.10)    
 TGA 5.48 (2.79) 5.04 (3.10)    
 SV 5.04 (2.78) 3.71 (3.10)    
 Total 5.34 (2.81) 4.93 (3.13)    
Curability   f(1,183.69)= 
0.04, p=  .833 
f(3,183.21)= 
0.82, p=  .483 
f(3,183.72)= 
4.45, p= .005 
 Simple 6.62 (2.64) 7.94 (2.83)    
 ToF 8.15 (2.64) 7.43 (2.82)    
 TGA 7.26 (2.64) 7.60 (2.82)    
 SV 7.46 (2.64) 6.71 (2.82)    
 Total 7.37 (2.66) 7.42 (2.85)    
Identity   f(1,183.37)= 
2.23, p=  .138 
f(3,183.36)= 
8.69, p<  .001 
f(3,183.39)= 
2.05, p=  .109 
 Simple 2.33 (2.27) 2.03 (2.46)    
 ToF 2.24 (2.28) 2.88 (2.45)    
 TGA 2.75 (2.27) 2.83 (2.45)    
 SV 4.20 (2.28) 4.70 (2.45)    
 Total 2.88 (2.29) 3.11 (2.47)    
Concern  
 
 f(1,181.89)= 
0.54, p=  .464 
f(3,182.09)= 
2.12, p=  .100 
f(3,181.91)= 
0.77, p=  .511 
 Simple 3.95 (2.73) 3.46 (2.96)    
 ToF 4.10 (2.73) 3.78 (2.95)    
 TGA 4.05 (2.72) 3.93 (2.95)    
 SV 4.84 (2.73) 5.20 (2.95)    
 Total 4.24 (2.75) 4.09 (2.98)    
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Table 9.8 Continued 
Illness 
Perceptions 
Baseline 
(Mean, 
S.D.) 
 
Follow-up 
(Mean, 
S.D.) 
 
Effect of 
Time 
Effect of 
Diagnostic 
Group 
Effect of 
Diagnostic 
Group x 
Time 
Coherence   f(1,182.41)= 
55.07, p< 
.001 
f(3,182.80)= 
0.83, p=  .479 
f(3,182.43)= 
0.03, p=  .994 
 
Simple 6.75 (2.42) 7.93 (2.27)    
 
ToF 6.36 (2.42) 7.45 (2.26)    
 
TGA 6.39 (2.42) 7.46 (2.26)    
 
SV 6.05 (2.42) 7.19 (2.26)    
 
Total 6.39 (2.44) 7.51 (2.28)    
Emotional 
representation 
  f(1,181.41)= 
0.71, p=  .400 
f(3,182.80)= 
0.83, p=  .479 
f(3,182.43)= 
0.03, p=  .994 
 
Simple 2.77 (2.86) 2.07 (3.04)    
 
ToF 3.14 (2.87) 2.90 (3.03)    
 
TGA 3.14 (2.86) 3.20 (3.03)    
 
SV 4.58 (2.87) 4.80 (3.03)    
 
Total 3.41 (2.89) 3.24 (3.06)    
 
The interaction effects for diagnostic group and time were significant for 
controllability and curability. Pairwise comparisons indicated that the change in 
illness controllability was different for the SV group than for the Simple group; the 
SV group exhibited a significant reduction in perceptions about illness controllability 
over time compared with the Simple group which exhibited a significant increase in 
illness controllability (mean difference= -2.34, p=  .005, 99% CI [-4.53, -0.15]; d=  
.78) (Figure 9.2). Pairwise comparisons for interactions effects on curability did not 
reach statistical significance. However, there was an increase in perceptions of 
curability within the Simple group over time (mean difference= -1.32, p=  .005, 99% 
CI [-2.54, -0.10]; d=  .44) (Figure 9.3). 
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 Note. Star indicates significant interaction effect between diagnostic group (Simple vs. SV) and time  
Figure 9.15. Graphical representation of change over time in illness controllability 
 Note. Star indicates significant main effect for time in the Simple group 
Figure 9.16. Graphical representation of change over time in illness curability 
There was a significant effect for time on the illness coherence subscale, with a 
significant increase in scores over time for the whole sample and all diagnostic 
groups (mean difference= -1.12, p<  .001, 99% CI [-1.51, -0.73]; d=  .48) (Figure 
9.4). 
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 Note. Star indicates significant main effect for time in the total sample and all diagnostic groups 
Figure 9.17. Graphical representation of change over time in illness coherence 
9.6.4. Changes over time in coping  
Table 9.9 presents the HLM for each of the coping strategies. There were no 
statistically significant interaction effects between diagnostic group and time or main 
effects for time on any of the coping strategies, indicating no change over time and 
across diagnostic groups. See Appendix W for a graphical representation of coping 
over time. 
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Table 9.9. HLM: Adjusted means (S.D.) and effects for coping strategies (n= 
188) 
Coping 
Strategies 
Baseline 
(Mean, 
S.D.) 
 
Follow-up 
(Mean, 
S.D.) 
Effect of Time Effect of 
Diagnostic 
Group 
Effect of 
Diagnostic 
Group x 
Time 
Planning   f(1,183.62)= 
0.85, p=  .358 
f(3,183.32)= 
3.00, p=  .032 
f(3,183.64)= 
1.03, p=  .381 
 
Simple 1.42 (0.85) 1.19 (0.90)    
 
ToF 1.55 (0.85) 1.42 (0.90)    
 
TGA 1.30 (0.85) 1.37 (0.90)    
 
SV 1.73 (0.85) 1.76 (0.89)    
 
Total 1.50 (0.85) 1.44 (0.90)    
Active coping   f(1,183.75)= 
0.84, p=  .359 
f(3,183.35)= 
5.47, p=  .001 
f(3,183.78)= 
0.30, p=  .827 
 Simple 1.53 (0.80) 1.45 (0.92)    
 ToF 1.93 (0.80) 1.82 (0.92)    
 TGA 1.57 (0.80) 1.44 (0.92)    
 SV 1.94 (0.80) 2 (0.92)    
 Total 1.74 (0.80) 1.68 (0.93)    
Positive 
reframing 
  
 
f(1,183.14)= 
0.38, p=  .540 
f(3,183.14)= 
1.62, p=  .186 
f(3,183.16)= 
3.25, p=  .023 
 Simple 1.53 (0.95) 1.23 (0.94)    
 ToF 1.65 (0.94) 1.83 (0.94)    
 TGA 1.53 (0.95) 1.53 (0.94)    
 SV 1.37 (0.95) 1.67 (0.94)    
 Total 1.52 (0.95) 1.56 (0.95)    
Acceptance  
 
 f(1,183.76)= 
0.25, p=  .621 
f(3,183.32)= 
3.34, p=  .021 
f(3,183.78)= 
0.79, p=  .503 
 Simple 2.20 (0.73) 2.08 (0.73)    
 ToF 2.41 (0.73) 2.43 (0.73)    
 TGA 2.25 (0.73) 2.39 (0.74)    
 SV 2.48 (0.73) 2.57 (0.73)    
 Total 2.33 (0.74) 2.37 (0.74)    
Humour   f(1,182.65)= 
0.56, p=  .454 
f(3,182.72)= 
0.80, p=  .497 
f(3,182.68)= 
1.17, p=  .323 
 Simple 1.28 (1.09) 1.12 (1.13)    
 ToF 1.19 (1.09) 1.28 (1.12)    
 TGA 1.18 (1.08) 1.41 (1.12)    
 SV 1.47 (1.09) 1.54 (1.12)    
 Total 1.28 (1.09) 1.34 (1.14)    
Religion   f(1,182.65)= 
0.03, p=  .875 
f(3,183.24)= 
0.40, p=  .753 
f(3,182.66)= 
1.00, p=  .393 
 
Simple 0.47 (0.85) 0.55 (0.85)    
 
ToF 0.56 (0.85) 0.48 (0.85)    
 
TGA 0.40 (0.85) 0.36 (0.85)    
 
SV 0.37 (0.85) 0.44 (0.85)    
 
Total 0.45 (0.86) 0.46 (0.86)    
Emotional 
support 
  f(1,182.28)= 
0.00, p=  .962 
f(3,182.27)= 
1.48, p=  .221 
f(3,182.31)= 
1.05, p=  .372 
 Simple 1.12 (0.91) 0.97 (0.98)    
 ToF 1.38 (0.91) 1.31 (0.97)    
 TGA 1.11 (0.91) 1.26 (0.97)    
 SV 1.31 (0.91) 1.39 (0.97)    
 Total 1.23 (0.91) 1.23 (0.99)    
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Table 9.9 Continued 
Coping 
Strategies 
Baseline 
(Mean, 
S.D.) 
 
Follow-up 
(Mean, 
S.D.) 
 
Effect of Time Effect of 
Diagnostic 
Group 
Effect of 
Diagnostic 
Group x 
Time 
Instrumental 
support 
  f(1,182.84)= 
0.62, p=  .433 
f(3,182.75)= 
1.43, p=  .237 
f(3,182.87)= 
2.08, p=  .105 
 Simple 1.05 (0.92) 0.84 (0.92)    
 ToF 1.26 (0.92) 1.17 (0.92)    
 TGA 1.25 (0.92) 1.07 (0.92)    
 SV 1.13 (0.92) 1.39 (0.92)    
 Total 1.17 (0.93) 1.12 (0.93)    
Self-distraction   f(1,182.38)= 
0.23, p=  .634 
f(3,182.11)= 
4.23, p=  .006 
f(3,182.41)= 
1.64, p=  .182 
 Simple 1.37 (0.80) 1.16 (0.88)    
 ToF 1.24 (0.80) 1.13 (0.88)    
 TGA 1.09 (0.80) 1.28 (0.88)    
 SV 1.67 (0.80) 1.67 (0.88)    
 Total 1.34 (0.80) 1.31 (0.89)    
Denial   
 
f(1,183.85)= 
0.53, p=  .469 
f(3,183.52)= 
1.71, p=  .166 
f(3,183.88)= 
1.94, p=  .124 
 Simple 0.20 (0.45) 0.05 (0.47)    
 ToF 0.15 (0.45) 0.15 (0.47)    
 TGA 0.22 (0.45) 0.14 (0.47)    
 SV 0.25 (0.45) 0.36 (0.47)    
 Total 0.20 (0.45) 0.17 (0.47)    
Venting  
 
 f(1,182.44)= 
0.42, p=  .516 
f(3,182.14)= 
4.49, p=  .005 
f(3,182.47)= 
0.70, p=  .554 
 Simple 0.67 (0.68) 0.72 (0.69)    
 ToF 0.74 (0.68) 0.63 (0.69)    
 TGA 0.59 (0.68) 0.47 (0.69)    
 SV 0.96 (0.68) 1 (0.68)    
 Total 0.74 (0.68) 0.70 (0.69)    
Substance use   f(1,182.60)= 
0.10, p=  .751 
f(3,182.11)= 
0.97, p=  .406 
f(3,182.63)= 
0.98, p=  .403 
 
Simple 0.29 (0.44) 0.19 (0.48)    
 
ToF 0.16 (0.45) 0.11 (0.48)    
 
TGA 0.18 (0.45) 0.16 (0.48)    
 
SV 0.19 (0.44) 0.30 (0.48)    
 
Total 0.21 (0.45) 0.19 (0.48)    
Behavioural 
disengagement 
  f(1,183.78)= 
0.07, p=  .786 
f(3,183.46)= 
2.13, p=  .097 
f(3,183.80)= 
1.24, p=  .298 
 
Simple 0.20 (0.45) 0.16 (0.47)    
 
ToF 0.10 (0.45) 0.15 (0.46)    
 
TGA 0.26 (0.45) 0.14 (0.47)    
 
SV 0.30 (0.45) 0.36 (0.46)    
 
Total 0.21 (0.45) 0.20 (0.47)    
Self-blame   f(1,182.16)= 
1.99, p=  .160 
f(3,181.80)= 
1.34, p=  .264 
f(3,182.19)= 
0.68, p=  .565 
 Simple 0.55 (0.66) 0.38 (0.61)    
 ToF 0.36 (0.66) 0.36 (0.61)    
 TGA 0.55 (0.67) 0.40 (0.61)    
 SV 0.57 (0.66) 0.57 (0.62)    
 Total 0.51 (0.67) 0.43 (0.62)    
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9.6.5. Changes over time in social support  
Table 9.10 presents the HLM for social support. There were no statistically 
significant interaction effects between diagnostic group and time or main effects for 
time on levels of social support, indicating no change over time and across 
diagnostic groups. See Appendix X for a graphical representation of social support 
over time. 
Table 9.10. HLM: Adjusted means (S.D.) and effects for social support (n= 188) 
Social Support Baseline 
(Mean, 
S.D.) 
 
Follow-up 
(Mean, 
S.D.) 
 
Effect of Time Effect of 
Diagnostic 
Group 
Effect of 
Diagnostic 
Group x 
Time 
Family support   
 
f(1,184.03)= 
2.79, p=  .096 
f(3,184.18)= 
2.32, p=  .077 
f(3,184.06)= 
1.34, p=  .262 
 
Simple 4.05 (0.74) 3.73 (1.04)    
 
ToF 4.37 (0.73) 4.21 (1.04)    
 
TGA 4.22 (0.74) 4.18 (1.04)    
 
SV 4.12 (0.74) 4.18 (1.04)    
 
Total 4.19 (0.74) 4.08 (1.06)    
Friends support  
 
 f(1,183.51)= 
3.19, p=  .076 
f(3,183.23)= 
0.62, p=  .602 
f(3,183.54)= 
0.74, p=  .531 
 Simple 4.16 (0.85) 3.93 (0.98)    
 ToF 4 (0.85) 3.79 (0.98)    
 TGA 4.06 (0.85) 3.98 (0.98)    
 SV 3.85 (0.85) 3.87 (0.98)    
 Total 4.02 (0.85) 3.89 (0.99)    
Significant 
other support 
 
 
 f(1,183.61)= 
1.69, p=  .195 
f(3,183.28= 
0.88, p=  .454 
f(3,183.64)= 
0.13, p=  .940 
 Simple 4.27 (0.91) 4.08 (1.14)    
 ToF 4.45 (0.91) 4.30 (1.14)    
 TGA 4.20 (0.90) 4.13 (1.13)    
 SV 4.16 (0.91) 4.11 (1.13)    
 Total 4.27 (0.91) 4.16 (1.15)    
 
9.6.6. Changes over time in mood  
Table 9.11 presents the HLM for anxiety and depression. There was a significant 
time effect on levels of anxiety, with anxiety increasing over time in the whole 
sample (mean difference= -0.12, p= .007, 99% CI [-0.23, -0.01]; d=  .21) (Figure 
9.5). There were no statistically significant interaction effects between diagnostic 
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group and time or main effects for time on levels of depression, indicating no change 
over time and across diagnostic groups. See Appendix Y for a graphical 
representation of depression over time. 
Table 9.11. HLM: Adjusted means (S.D.) and effects for mood (n= 188) 
Mood Baseline 
(Mean, 
S.D.) 
 
Follow-up 
(Mean, 
S.D.) 
 
Effect of 
Time 
Effect of 
Diagnostic 
Group 
Effect of 
Diagnostic 
Group x 
Time 
Anxiety  
 
 f(1,183.63)= 
7.41, p= .007 
f(3,183.32)= 
2.72, p=  .046 
f(3,183.66)= 
0.12, p=  .951 
 
Simple 1.61 (0.56) 1.74 (0.62)    
 
ToF 1.60 (0.55) 1.68 (0.62)    
 
TGA 1.55 (0.55) 1.68 (0.62)    
 
SV 1.84 (0.55) 1.97 (0.62)    
 
Total 1.65 (0.56) 1.77 (0.63)    
Depression*   
 
f(1,183.30)= 
4.30, p=  .039 
f(3,183.37)= 
3.71, p=  .013 
f(3,183.33)= 
1.29, p=  .280 
 Simple 7.46 (4.95) 7.42 (5.26)    
 ToF 5.57 (4.95) 5.80 (5.25)    
 TGA 6 (4.94) 7.04 (5.24)    
 SV 8.17 (4.96) 9.69 (5.24)    
 Total 6.83 (4.99) 7.49 (5.29)    
*HLM analysis was conducted on the continuous scale due to convergence issues. 
 
Note. Star indicates significant main effect for time in the total sample 
Figure 9.18. Graphical representation of change over time in anxiety 
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9.7. Discussion 
9.7.1. Changes over time in clinical factors 
No changes were observed over time in the clinical factors measured, including the 
number of interventions, number of days spent in hospital, and number of 
medication. These findings suggest that this sample of people with ACHD was 
clinically stable over the assessment period. This would have been expected as 
participants in the longitudinal study were not specifically assessed following a 
major clinical event, including changes in the treatment regimen, further 
interventions, or hospitalizations, especially as disease progression and reoperation 
timing varies even between people with the same diagnosis (Warnes et al., 2008). In 
addition, the length of follow-up may have been too short to allow for significant 
disease progression to take place. This enables any changes in HRQoL to be assessed 
against a background of clinical stability. 
9.7.2. Changes over time in HRQoL 
Overall, no changes in generic or disease-specific HRQoL were observed suggesting 
stability in HRQoL in this population over the time period of the follow-up. Three 
previous longitudinal studies in ACHD have also reported minimal changes in 
HRQoL. A small study in one diagnostic group examined changes in HRQoL as 
measured by the SF-36 over nine years in 35 individuals with TGA who had 
undergone a Mustard operation (Ebenroth & Hurwitz, 2007). They found no changes 
in HRQoL domains with the exception of a decrease in vitality. In the present study 
vitality scores in the TGA group were lower at follow-up but this did not reach 
statistical significance. Skoglund et al. (2014) examined changes in HRQoL over 
three years in 103 individuals with previous RVOTO surgery (see page 29), a sample 
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that primarily consisted of people with ToF. With the exception of a decrease in 
general health, no changes in HRQoL were observed. In the present study the ToF 
group exhibited slightly better general health at follow-up, which was not 
statistically significant. Skoglund et al. (2014) did use the EQ-VAS and EQ-5D, 
rather than the SF-36 as in this study. van Rijen and colleagues (2005a) followed-up 
243 individuals with ACHD over 10 years using the Heart Patients Psychological 
Questionnaire. They found increased negative emotions and decreased social 
inhibition (feeling unpleasant among other people) over time. These findings are not 
directly comparable to the present study.  
The above studies examined HRQoL at a different stage to the current study. They 
assessed participants between their 20s to middle adulthood (30s) whereas the 
present study examined participants on average from mid to late 30s. The challenges 
transitioning from young to middle adulthood are likely to be different to those in the 
older group in the present study. In addition, the follow-up in the studies differed 
markedly from the present study. Ebenroth & Hurwitz (2007) and van Rijen et al. 
(2005a) had an interval of almost 10 years between the assessments with a variation 
in follow-up years among participants, not controlled for in the analysis as opposed 
to the present study. It is thus unclear whether the minimal changes in HRQoL 
reported in previous studies were true changes or a result of measurement 
limitations. 
It is possible that the relatively short interval between the two time points did not 
allow significant changes to take place in HRQoL. This stability of the SF-36 over 
moderate time periods has also been demonstrated in other chronic yet clinically 
stable populations. A study of a clinically stable sample of people with systemic 
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lupus erythematosus from Canada, U.S., and the UK indicated that the SF-36 
physical and mental component summary scores remained stable over 4 years 
(Panopalis et al., 2005). The authors argued that stability in HRQoL was due to the 
long-term nature of the condition, which allowed people to adapt and therefore 
maintain their HRQoL. Considering that the responsiveness of the SF-36 has been 
demonstrated in the literature (Garratt, Ruta, Abdalla, & Russell, 1994), the findings 
of the present study more likely suggest that no true change has taken place in 
HRQoL over the assessment period. This is further supported by the lack of changes 
in the disease-specific CHD-TAAQOL, which is believed to be more responsive to 
changes in HRQoL over time (Garratt et al., 1994). 
Some authors argue that measuring HRQoL longitudinally is particularly challenging 
as a response shift may take place in the interval between the assessment points. 
Therefore it could be argued that the lack of change in HRQoL was a result of 
redefinition of the concept of HRQoL and/or change in people’s internal standards 
and values (Schwartz & Sprangers, 1999). However, considering the relatively short 
follow up time period and the clinical stability observed in the current sample it is 
unlikely that substantial response shift effects have taken place in the study (Ahmed, 
Sawatzky, Levesque, Ehrmann-Feldman, & Schwartz, 2014).     
9.7.3. Changes over time in psychosocial factors 
The SRM postulates a dynamic nature of illness perceptions, whereby changes in the 
illness experience, such as change in illness manifestation (e.g. new symptoms) or 
the introduction of a new treatment can result in people reformulating their initial 
perceptions of their illness (Leventhal et al., 1998). The findings indicated that the 
whole sample experienced an increase in illness coherence, which suggests that 
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people with ACHD increased their illness understanding over the period of the 
follow-up. Increase in illness coherence has also been reported in people with 
diabetes over a period of 2 years post-diagnosis (Lawson et al., 2008). Bijsterbosch 
et al. (2009) also found an increase in illness coherence in people with chronic 
osteoarthritis over a period of 6 years, which was greater in people who did not 
experience progression of disability than those who did. The lifelong management of 
people with ACHD in a specialist clinic and the continual provision of information 
from healthcare professionals during outpatient appointments may have enhanced 
people’s understanding of their condition. Specifically, individuals attending the 
GUCH outpatient clinic at The Heart Hospital, London typically meet with specialist 
nurses prior to seeing their consultant, where they are reminded about the nature of 
their condition, implications for their functioning, their treatment regimen, and 
potential future complications. However, without quantifying the amount and nature 
of the information given to or sought by these individuals, it is not possible to 
attribute these improvements directly to these consultations. Although the present 
sample remained clinically stable over the assessment period, the change in illness 
coherence may be related to other factors not measured in the study.  
Some changes in illness perceptions were also observed in certain diagnostic groups. 
People in the Simple group showed an increase in perceptions of illness curability 
over time. This group also had an increase in perceptions of illness controllability 
compared with those in the SV group who reported a decline over the assessment 
period. This finding suggests that people with SV felt less in control compared with 
people in the Simple group who felt more in control of their condition and 
experienced the benefits of their treatment over the period of the follow-up. Limited 
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longitudinal research in other chronic populations, including people with 
osteoarthritis and myocardial infarction, used the IPQ-R and has also showed that 
perceptions about personal control decrease over time (Bijsterbosch et al., 2009; 
Petrie & Weinman, 1997; Sheldrick, Tarrier, Berry, & Kincey, 2006). Bijsterbosch et 
al. (2009) found that people with osteoarthritis who experienced progression of 
disability reported decreased perceptions of control in the two-year follow-up 
compared with people who did not experience progression of disability. Foster et al. 
(2008) also found that increase in perceptions of personal control was associated 
with good clinical outcome in people with low back pain. 
The sample in the current study was clinically stable as measured by clinical events 
such as further interventions, hospitalization, and medication. In light of the clinical 
stability it is possible that some items of the Brief IPQ do not offer reliable 
measurement of illness perceptions over time. There are limited studies that have 
reported findings on the psychometric properties of the Brief IPQ. These studies 
reported satisfactory test-retest reliability over a short period of time (1-3 weeks) in 
most dimensions of the Brief IPQ, yet test-retest agreement in illness controllability 
and coherence was low (de Raaij, Schröder, Maissan, Pool, & Wittink, 2012; 
Hallegraef, van der Schans, Krijnen, & de Greef, 2013; Løchting et al., 2013). The 
Brief IPQ and especially the items measuring illness controllability and coherence 
may be further evaluated in future studies in ACHD to establish their test-retest 
reliability. 
Perceptions about the symptoms and consequences experienced as a result of ACHD 
remained unchanged over the time of the follow-up. Petrie and Weinman (1997) also 
reported stability in these illness perceptions in people with myocardiac infarction 
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over time. They argued that the initial perceptions of the impact of cardiac disease 
are readily available to people, because they are well defined to the degree that they 
become lay beliefs. The beliefs people hold about the impact of ACHD appear to be 
similarly stable over time, which may be explained by the similarity of some 
symptoms and consequences between congenital and acquired cardiac disease.  
It is evident that the pattern of change in illness perceptions is similar to other 
chronic conditions. It should be noted, however, that other chronic conditions that 
have their onset during adulthood (e.g. myocardial infarction) may have different 
trajectories in relation to illness perceptions. Initially, myocardial infarction may be 
perceived in acute terms and with passing time people may form more chronic 
illness perceptions attached to other associated cardiac conditions such as 
hypertension (Petrie & Weinman, 1997). On the other hand, ACHD is congenital and 
therefore trajectories of illness perceptions may follow a different pattern. Future 
studies with multiple assessments may provide further insight on trajectories of 
change in the illness perceptions of people with ACHD.  
There were increased levels of anxiety over the assessment period, yet the effect size 
was rather small and the overall level of anxiety was low. The reason for this 
increase is unclear but it may be attributable to situational factors as state anxiety is 
naturally transitory (Marteau & Bekker, 1992). Notably, participants did not alter 
their use of their coping strategies over the assessment period or perceived a change 
in their social support. This implies that for people with ACHD family, friends, and 
significant others provided the same levels of support over the period of the follow-
up. These findings may have important implications for identifying and addressing 
persistent engagement in maladaptive coping strategies, including self-blame which 
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was found to be significantly associated with HRQoL in the cross-sectional study 
(section 8.4.2.3, page 260).  
9.8. Summary  
This chapter examined changes in HRQoL and other psychosocial factors over time. 
The results indicated that clinical factors, HRQoL, and a majority of the 
psychosocial factors remained stable over time. Over the assessment period there 
was an increase in illness coherence and anxiety across the whole sample, increase in 
perceptions of curability within the Simple group and increase in perceptions of 
illness controllability in the Simple group compared with the SV group. These 
findings suggest an overall stability in the HRQoL and psychosocial functioning of 
people with ACHD. The limitations of the longitudinal study and the implications of 
the findings will be addressed in the general discussion in Chapter 11. 
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CHAPTER 10 – THE EXPERIENCES OF PEOPLE 
WITH ACHD: A QUALITATIVE STUDY 
10.1. Prologue  
The previous chapters described the quantitative component of the thesis. Chapters 7 
and 8 described the results of the cross-sectional study examining the impact of 
ACHD on HRQoL and the demographic, clinical, and psychosocial factors 
associated with HRQoL in people with ACHD. Chapter 9 described the findings 
from the longitudinal study examining changes in HRQoL and psychosocial 
functioning over time. Chapter 4 highlighted that very few qualitative studies 
focused on adults with ACHD (Berghammer et al., 2006; Claessens et al., 2005; 
Cornett & Simms, 2014; Horner et al., 2000; Overgaard et al., 2013). These studies 
were not focused on HRQoL and included predominantly younger adults with more 
complex conditions. Living with and adapting to a chronic and progressive condition 
like ACHD is a complex experience and can benefit from in-depth exploration. The 
overall purpose of the qualitative study was to further explore the experiences of 
people with ACHD in relation to their HRQoL and how people adjust to living with 
the condition. The rationale and purpose of this mixed methods approach was 
discussed in Chapter 4 (section 4.5, page 128). 
The present study aims to: 
 Aim 4a: Explore the experiences of people on how ACHD had influenced 
their HRQoL in physical, social, occupational, and psychological domains 
over the years. 
 Aim 4b: Explore how people adjust to living with ACHD.  
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10.2. Methodology 
10.2.1. Ethical approval 
Ethical approval was granted by the Joint UCL/UCLH Ethics Committee and NRES 
Committee London – Bentham in Ethics of Human Research (REC reference 
number: 08/H0715/105). 
10.2.2. Design 
This study utilised semi-structured interviews with participants who completed both 
the cross-sectional and longitudinal study. Individual interviews were selected over 
focus groups because the purpose of the study was to gain in-depth accounts of the 
participants’ experiences.  
10.2.3. Participants and consent 
Participants who had completed the quantitative studies were eligible for 
participation in this study. A purposive sampling approach was followed to recruit 
participants from all four diagnostic groups and to make sure that gender was 
adequately represented.  
After the completion of the quantitative longitudinal assessments, participants were 
informed about the qualitative study in person and their interest was recorded. 
Interested participants received a formal invitation letter and an information sheet 
(Appendix Z). Interviews were arranged for a time convenient to the participants. 
Written consent was obtained before the interview (Appendix AA). Participants were 
reminded the interviews were to be audio-recorded, confidential, and that the 
transcripts would not include personally identifiable information.   
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10.2.4. Location of the interviews and safety protocol 
Participants were offered a choice of location either at home, at the hospital or 
university at a time convenient for them and all participants indicated their 
preference of conducting the interview at the hospital. Interviews were conducted in 
designated quiet rooms at The Heart Hospital, London. It was ensured that all rooms 
were supplied with telephones and that the researcher could easily contact the 
research team in case of safety concerns. It was also ensured that members of the 
clinical team at The Heart Hospital, London were aware of the time and location of 
the interview. 
10.2.5. Topic guide 
The interview schedule (Figure 10.1) was developed by the researcher in 
collaboration with the supervisory team. The interview schedule was designed to 
cover topics relating to the impact of ACHD, the ways people cope with living with 
ACHD, priorities, future expectations, and social support. The process of developing 
the schedule began with establishing the subjects to be covered by reviewing the 
relevant literature (e.g. Berghammer et al., 2006; Claessens et al., 2005) and further 
issues raised by participants in informal conversations during the quantitative 
studies. The subjects were discussed with the supervisory team, in terms of how they 
group together into broad topic areas, how questions may be phrased, prompts, and 
subject coverage. Two independent researchers with extensive experience in 
qualitative research then reviewed the interview schedule and made 
recommendations with regards to how it will work in practice, wording, and length. 
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The semi-structured approach allowed for key topics of interest to be explored, while 
also permitting flexibility in the order those questions were asked. This approach 
also allowed for new themes to emerge (Ritchie & Lewis, 2003). 
All interviews were conducted and transcribed verbatim by the researcher. Brief 
notes were taken after each interview summarizing the researcher’s reflections, 
impressions about the interview, the general attitude of the participant, moments of 
discomfort or emotional charge, and emergent themes. These notes were taken into 
consideration during the analysis. A detailed reflective account can be found in 
Appendix BB. 
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Introduction: Purpose of study, confidentiality, consent, demographic information 
Example questions (to be used as a general guideline): 
General 
1. How is it to live with congenital heart disease? 
Impact of ACHD 
2. How is ACHD influencing or not influencing your life? 
Prompts: impact on current physical health, symptoms, physical limitations, health changes over 
the years. 
3. How much does your condition affect your social life? 
Prompts: social activities, disclosure, changes over the years. 
4. How much does/did your condition affect/ed your working life? 
Prompts: disclosure, adjustments at work, changes over the years. 
5. How does it feel living with congenital heart disease? 
Prompts: ways your condition affects you emotionally, emotions experienced, changes over the 
years. 
Coping 
6. How would you deal with problems arising from your health? 
Prompts: coping with symptoms, physical limitations, social limitations, and work limitations. 
7. How would you deal with negative emotions arising from your condition? 
Prompts: steps or approach taken to cope with negative emotions. 
Future expectations 
8. What are your future expectations regarding your quality of life? 
Prompts: extend of health influencing quality of life. 
Social support 
9. Who is your main source of support? 
10. How would you describe the current function of your support system? 
11. What sort of support do you mainly need? 
Domain importance 
12. What does having a good quality of life mean to you? 
13. Which area(s) of your life are most important to you at the moment and why? 
14. What do you think you can do to make your quality of life better? 
Closing: Additional comments, participant impressions, thanking, confidentiality.  
Figure 10.1. Interview schedule for the qualitative study  
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10.2.6. Sample size 
The approach to sample size in quantitative research, where larger numbers are 
generally more desirable, is not applicable to qualitative research, where the sample 
size reflects the depth and richness of information that describes a phenomenon 
(O'Reilly & Parker, 2013). Data saturation was defined as the emergence of no new 
themes relating to the “pre-established conceptual categories” or study research 
question and it was ensured by setting an initial recruitment target and estimating 
how many further interviews would be needed before no new themes emerged, and 
applying a ‘stopping criterion’ of the number of consecutive interviews that elicited 
no new themes or ideas (Francis et al., 2010). The present study aimed to include an 
initial sample of 10 participants, with a “stopping criterion” of two consecutive 
interviews that did not elicit any new themes before recruitment ended, ensuring an 
equal number of female and male participants and at least two participants from each 
diagnostic group. 
10.2.7. Data analysis 
The systematic guide to Framework Analysis (FA) suggested by Ritchie and Lewis 
(2003) was used to analyse the data. Framework analysis is a type of thematic 
analysis that allows the development of a thematic framework, consisting of main 
themes and related sub-themes (Ritchie & Spencer, 1994). This method was selected 
because it involves distinct steps and analysis may take a theme-based, case-based 
approach or a combination of the two (Ward, Furber, Tierney, & Swallow, 2013). 
Alternative approaches to data analysis were reviewed and compared. Grounded 
theory (Glaser & Strauss, 2009) is concerned with generating theory for a particular 
phenomenon and generally requires larger sample sizes to reach data saturation and 
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is therefore more time consuming (O'Reilly & Parker, 2013). Since the purpose of 
the present study was not to generate theory, grounded theory was deemed 
inappropriate. Interpretative Phenomenological Analysis (IPA) was not selected 
because it focuses both on an individual’s unique experiences and on patterns of 
meaning across participants (Smith, Flowers, & Larkin, 2009). The current study 
was not concerned with the experience of individuals per se but the experiences 
across the sample. IPA also generally requires a small homogeneous sample (3-6), 
which within the purpose of the present study was not deemed appropriate for 
exploring the range of participants’ experiences (Smith et al., 2009). The present 
study was informed by previous literature and the quantitative component of the 
thesis and it has been argued that IPA may not be appropriate within pre-existing 
theoretical frameworks (Brocki & Wearden, 2006). Moreover, there is no 
consistency in the methodology used for IPA or a detailed procedure for conducting 
data analysis. Thematic analysis is a method of identifying, analysing, and reporting 
patterns (themes) within data (Braun & Clarke, 2006). This method was considered 
an appropriate alternative to FA. However, FA was selected rather than thematic 
analysis for three main reasons:  
1) FA is considered as an explicit and straightforward approach to thematic analysis, 
which allows flexibility and provides a transparent path of the analytical procedures 
with the use of charted data summaries (Ward et al., 2013). This method was deemed 
more appropriate as it would enable the experienced supervisory team to oversee the 
analysis using an audit trail and would facilitate the discussion of ideas using charted 
summaries within the team. 
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2) FA allows for the combination of case-based and theme-based approaches to 
thematic analysis; this would facilitate the identifications of patterns both across 
different groups of cases and within a single case and allow for comparisons to be 
made (Ritchie & Lewis, 2003). 
3) FA is shaped by existing ideas and can address specific questions. However, it 
enables a combination of inductive and deductive approaches; this was significant 
for the present study, which had specific issues to explore but also allowed new 
themes to emerge.  
The analysis involved a number of stages and was conducted using paper-based 
methods and the computer software NVivo, version 10 for Windows by QSR 
International. Specifically, analysis involved the following stages: 
1. Familiarisation: According to Spencer, Ritchie, and O’ Connor (2003), the 
purpose of this stage is to “gain an overview of the data and become thoroughly 
familiar with the data” (p. 221). Familiarisation with the data was achieved by 
listening to the audiotapes, reading the interview transcripts, and studying field notes 
made following each interview. The familiarisation process was facilitated by the 
researcher’s involvement in all stages of the research, including conducting and 
transcribing the interviews. During this step, recurring themes were identified and 
recorded in a spreadsheet. Generally, it is not necessary to review all the material but 
rather a selection of the data set (Srivastava & Thompson, 2009); however, because 
of the small number of interviews conducted for the present study, it was decided 
that all data should be included at this stage. This ensured that no data were 
overlooked and that less frequent themes were detected.   
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2. Developing a conceptual framework: During this stage the recurrent themes 
identified in the previous stage along with the topics introduced through the 
interview schedule are used to form a conceptual framework or “index” (Spencer et 
al., 2003). Recurrent themes were grouped under broader main themes to form an 
overall framework. The development of the framework was conducted using paper-
based methods, where post-it notes were used to record the recurrent themes. This 
method facilitated the sorting and re-sorting of sub-themes under the main themes. 
The domains explored during the interviews were taken into consideration when 
developing the conceptual framework. However, a flexible approach was 
maintained, whereby new emerging themes were also recorded and integrated into 
the framework. A worked example from this analysis stage is presented in Appendix 
CC. Ritchie and Spencer (1994) highlight that this framework is tentative and 
refinement is possible during further stages.  
3. Indexing the data: At this point, the interview transcripts were uploaded into 
NVivo. During this analysis stage, the conceptual framework developed in the 
previous stage was applied systematically to all of the interviews. Interview 
transcripts were re-read and sections of the data were indexed to corresponding 
themes. Emerging interconnections between themes were noted for subsequent 
associative analyses. At this stage, a refinement of the initial conceptual framework 
is common. For example, themes may be added, removed, merged, or subdivided in 
order to describe the data in a more suitable way (Ritchie, Spencer, & O' Connor, 
2003). In the present study further immersion in the data resulted in the refinement, 
combination, and development of themes and sub-themes. It became apparent that 
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some sub-themes belonged to multiple main themes. Hence, the framework was 
developed to represent the data more accurately (see example in Appendix DD).  
4. Sorting, charting, and summarising the data by theme: During this step, the 
themes are sorted so that those with similar content are located together (Ritchie et 
al., 2003). This involved the creation of case by theme charts, with summaries of 
what was said by each participant using the framework matrix function in NVivo. 
Charts retained the “feel” of participants’ experiences by using exact quotations, 
where possible (Gale, Heath, Cameron, Rashid, & Redwood, 2013). In addition, 
references to illustrative quotations were noted within charts (see example in 
Appendix EE). 
5. Mapping and interpretation: The final step of the analysis involves a close 
examination of the themes and sub-themes, whereby differences in the representation 
of a phenomenon are identified, patterns are detected, associations are mapped, and 
explanations are explored (Gale et al., 2013) (see example in Appendix EE).  
10.2.7.1. Rigor and Trustworthiness 
The following actions were taken to ensure rigor and trustworthiness: 
1. An audit trail of the data analysis process was recorded with descriptions and 
explanations of decisions about conceptualization, combination, and 
omission of themes, the development of the initial framework, and the 
framework refinement. This was used to discuss the process of data analysis 
with the supervisory team. 
2. Reflective accounts were recorded at the end of each interview, which 
included the researcher’s feelings and impressions about the interview, the 
CHAPTER 10 – THE EXPERIENCES OF PEOPLE WITH ACHD 
315 
 
general attitude of the participant, and emotionally charged or uncomfortable 
moments. These accounts were taken into consideration during data analysis. 
A detailed reflective account can be found in Appendix BB. 
3. External validation of 25% (n=  3) of the interviews was conducted by an 
independent examiner who coded the transcripts without prior knowledge of 
the conceptual framework. Differences in coding were discussed until an 
agreement was achieved (see section 10.3.2, page 316). 
4. A “thick description” approach was adopted for the presentation of the 
findings. Descriptive interpretations were accompanied by excerpts from the 
participants’ transcripts, which allow the reader to verify the validity of the 
interpretations and potentially to consider their “transferability” to other 
contexts (Ritchie & Lewis, 2003). 
10.3. Results 
10.3.1. Sample characteristics 
Seventy-eight participants were eligible to take part in the study and were 
approached by the researcher between January 2013 and January 2014. Twenty-four 
participants agreed to take part in the study. Twelve could not attend an interview 
prior to the completion of the study due to other commitments. A total of 12 semi-
structured interviews were therefore conducted. This is considered an appropriate 
sample size for mixed methods studies (Francis et al., 2010). Importantly, at this 
point no new themes were emerging, hence data saturation was achieved. Interviews 
lasted between 30 minutes and 1 hour 42 minute, allowing participants to elaborate 
on their experiences as much as they wished. Basic demographic and clinical 
characteristics of the participants are presented in Table 10.1. Pseudonyms were 
assigned to each participant to protect their identity. 
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Table 10.1. Characteristics of participants interviewed 
Participant 
Pseudonym 
Age Gender Diagnostic 
Group 
Marital 
Status 
Employment 
Status 
Anastasia 45 Female TGA Married Unemployed 
Maria 25 Female SV In a 
relationship 
Employed 
Doreen 37 Female SV Married Unemployed 
Chloe 36 Female TGA Married Employed 
Janis 35 Female SV Married Employed 
Sophia 27 Female Simple In a 
relationship 
Employed 
Ron 54 Male TGA Married Employed 
Phil 37 Male ToF Married Employed 
Robert 40 Male TGA Married Employed 
Leo 32 Male SV Single Unemployed 
Jim 36 Male ToF Married Employed 
Peter 39 Male Simple In a 
relationship 
Employed 
 
10.3.2. External validation of coding 
The coding by the independent researcher was compared to the coding conducted by 
the current researcher and no major inconsistencies were observed. The only 
discrepancies were the codes “impact of treatment” and “information from 
healthcare professionals” assigned by the independent researcher. After a discussion 
it was agreed that “impact of treatment” had been captured in the original conceptual 
framework as “physical and social consequences” and “information from healthcare 
professionals” had been captured in the original framework as either “seeking social 
support” or “receipt of social support”. 
10.3.3. Themes 
A thematic map was developed during the final stage of the analysis (Figure 10.2). 
Three overarching processes were identified within the data; the first reflected the 
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narratives regarding the impact of living with ACHD on people’s HRQoL and the 
second reflected the narratives regarding the processes through which people coped 
with ACHD. Embedded into these two processes was the overarching theme of 
change over time which reflected the narratives about the impact of changes in 
health and treatment over the illness trajectory. 
Four main themes were identified within the coping process: 1) priorities and goals, 
2) acceptance and adjustment, 3) gaining perspective, and 4) social influence. Four 
main themes were identified within the impact of ACHD: 1) physical and social 
consequences, 2) occupational consequences, 3) illness disclosure, and 4) 
psychological consequences. Within some of these themes, sub-themes were 
identified (Figure 10.3).  
Change over time was an over-arching theme that reflected the dynamic facet of 
living with ACHD and ran through many of the participants’ narratives. People 
appeared to be in a dynamic state, where periods of health deterioration and change 
in the treatment regimen influenced both their experiences about their HRQoL and 
the ways they coped with ACHD. These changes in health over time made the 
physical, social, occupational, and emotional consequences of ACHD more salient 
for some participants and challenged their coping efforts, specifically their attempts 
to accept and re-adjust and gain perspective. This dynamic facet of living and coping 
with ACHD was also evident during major changes across people’s adult lives, 
including establishing, maintaining, and leaving employment and family planning. 
Adjustment was therefore not an endpoint but an ongoing process across the illness 
trajectory. The overarching theme of change over time was inherent in the processes 
of coping and the impact of ACHD on HRQoL and not independent of the themes 
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and sub-themes identified in Figure 10.3. Therefore, it is described in terms of the 
impact of changes in health and treatment within the relevant themes or sub-themes, 
which are presented in the following sections. Illustrative quotes are provided along 
with the themes and sub-themes to support the interpretations. 
CHAPTER 10 – THE EXPERIENCES OF PEOPLE WITH ACHD 
319 
 
 
 
 
 
 
Figure 10.2. Thematic map of the three overarching processes and the eight main themes within these processes  
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Theme 1: Priorities and goals  
Theme 2: Acceptance and adjustment 
Theme 3: Gaining perspective 
Sub-theme: Social comparisons 
Sub-theme: Positivity 
Theme 4: Social influence  
Sub-theme: Receipt of social support 
Sub-theme: Seeking social support 
Theme 5: Physical and social consequences of ACHD 
Theme 6: Occupational consequences of ACHD 
Theme 7: Illness disclosure 
Theme 8: Psychological consequences of ACHD 
Sub-theme: Negative emotions 
Sub-theme: Family planning  
Sub-theme: Expectations and uncertainty 
Figure 10.3. The final themes and sub-themes identified during framework analysis 
10.3.3.1. Priorities and goals 
Most participants talked about their health being a priority to maintaining their QoL, 
in terms of “being able” to do the things they wanted to do within their limitations 
and without being “inhibited” by their heart condition. Health and physical ability 
was a recurrent theme across many of the interviews, followed by having a job that 
provided financial stability, “being happy”, and maintaining social relationships. 
“Just your health. It’s got to be your health comes first. And then just enjoying your 
family, enjoying your social life, and again work. You got to enjoy, to me, if you don’t 
enjoy work don’t do it.” – Ron, 54, TGA  
“Being healthy. Being able to sort of go out do whatever you want sort of thing. Not 
being worried about sort of money stuff. Just yeah just sort of have the freedom to do 
whatever you want without any sort of restrictions.” – Phil, 37, ToF  
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Some individuals, for whom health issues appeared to be less of a concern, talked 
about prioritising their work and personal lives and keeping a “balance” between the 
two. One person, who prioritised his personal life, appreciated that health may 
become the focal point when it deteriorates.  
“…I’ve diverted far more personal time towards my relationship rather than friends 
and other areas of my life […] It [health] isn’t an issue ‘till it becomes an issue. You 
don’t think about it until it goes wrong. You take it for granted until then and then 
when it does have an impact then everything has to be built around it.” – Peter, 39, 
Simple  
Most participants felt unsure about whether they could improve or control their QoL. 
Some felt that at times, their health was “in control” of them rather than the 
opposite.  
“I feel like the only control I have is making sure that…my body is as good as it can 
be. So I do keep walking and I do keep my weight off. The other parts of my life, I have 
total control over as much as my heart condition lets me, if you like.” – Janis, 35, SV  
These perceptions were accompanied by descriptions of how they prioritised and 
directed more attention and efforts towards their health, by engaging in healthy 
lifestyle behaviours, including controlling their eating habits and exercising. Some 
participants emphasized that keeping healthy was important to them because they 
wished to “be there” for their families. 
 “But I think right now it’s probably a physical point of view because I wanna be there 
for my family, I wanna be there for my son, I wanna be able to do things with him.” – 
Jim, 36, ToF  
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“I’m putting a lot of input into my health at the moment. I mentioned before that over 
in the last three years I’ve lost a lot of weight and I got to the point where I thought 
that logically a smaller body mass means your heart has to work less hard. So I did 
lose three stone and made myself better that way.” – Janis, 35, SV  
10.3.3.2. Acceptance and adjustment 
Across many of the interviews there was an underlying narrative that participants 
had accepted their condition and achieved some normalcy in their lives, being able to 
carry on with “day-to-day living” despite limitations resulting from ACHD. They 
talked about how they have “always lived with it” and “got used to not feeling 
100%” and how they had accepted their condition as being part of their lives and 
their identity (“who they are”).  
“Accept it. It’s there, that’s the way it is. It isn’t going to change so it’s no use 
getting upset over it. I suppose that’s how I emotionally deal with it I just say “Well 
it’s not gonna change so.”” – Leo, 32, SV  
“…you can make a big deal out of it if you want to or you just accept it as being 
there and you deal with it if issues come up. And I think that’s what I’ve tried to do 
with my life…” – Jim, 36, ToF  
They described how they “get on” with their condition and their lives by “knowing 
their limits” and being “realistic” about what they were able to do. Participants 
described that they found ways to cope with their limitations by “planning” ahead, 
“pacing” themselves when they did something physically demanding, and 
“avoiding” situations, which may be challenging for them.  
“I know my limits if you know what I mean. I don’t run around, I can’t play football 
or I don’t go to the gym or anything like that but yeah I get by. If there’s something I 
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feel I can’t do, I just won’t do it like just, I’ll just sit out  of something […] there are 
certain things you sort of limit yourself, you know what yourself you can do” – Ron, 
54, TGA 
“I just focus on what I need to do at that right moment in time, just take a step back 
and just think about it a little bit further whether I can do or not  […] just focusing 
on certain house chores I would do, but I will do it and I’ll have a rest afterwards so 
I just pace myself to do it…” – Robert, 40, TGA  
“There’s always gonna be limits. That’s just parts of living with a heart condition. 
And it’s just finding ways of them not being a problem. So we don’t go to India for 
holiday. We go somewhere closer. That’s, to me that’s just common sense.” – Janis, 
35, SV  
“I probably just think of strategies around it, sort of saying, just find a way of not 
having to face a particular issue if it was going to be a problem for me. I guess if 
you take going to a holiday of altitude, rather than sort of pushing on through it and 
seeing how I go, I would just not really go on that holiday, cause it might be a 
problem and I don’t wanna get into a problem situation.” – Peter, 39, Simple  
Participants also characterised their treatment regimen, including follow-up 
appointments and diagnostic tests as “routine” and “second nature”. Those who had 
interventions during adulthood also talked about how these had helped them get 
“back to normality”. 
“So used to them [hospital visits] now, it’s no problem at all. You’re sort of used to 
the people, what, the various things that you have to do. Sort of, it’s like a routine, 
you just get used to it.” – Phil, 37, ToF   
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Most people talked about how they had learned to successfully manage their 
limitations and integrate their treatment regimen into their lives. Some described 
how they attempted to adjust to changes in their health and treatment regimen. A 
younger person, who was experiencing recent health deterioration, talked about how 
she thought of her condition as a “barrier” to achieving a previous state of 
functioning. She described her experience of how she struggled with the limitations 
caused by her health changing and the process of gradually accepting and re-
adjusting her plan to work around her limitations.  
“I’m always striving to get back to that point where I could part-time work, be at 
Uni, and be physically active. That’s what I aspire to be able to do again and I find 
it hard that I can’t […] So I’m trying to come to terms with the fact that there are 
certain jobs I can’t do, there are certain things that I’m not gonna be able to do but 
that’s not the end of the world. I’m just gonna have to change my plan. I struggle a 
bit with a change of my plan…” – Maria, 25, SV  
Similarly, another person described the process of adjusting to a recent change in her 
treatment regimen and specifically the introduction of Warfarin medication and the 
installation of a pacemaker as part of her daily life. 
“About three weeks ago I had a pacemaker fitted so I’m kind of being a bit careful 
with that. So just kind of sort of getting used to things […] When I first started my 
Warfarin I was like “Oh, be careful of what I eat”. I was just like stop. They tailor it 
to you, you do whatever you like, if it’s different one week then it’s different. Don’t 
try and make it the numbers. They’ll make the medication match what you’re doing 
and it took me about two months to actually get that kind of balance. But I’m still 
kind of like thinking about what I’m drinking […] “I’ve got a pacemaker, does that 
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mean I can’t drive? Or I can drive? Do I not drive? Do I tell them?” That sort of 
thing so yeah it’s the admin bit.” – Chloe, 36, TGA  
10.3.3.3. Gaining perspective 
Participants described how they often tried to find meaning in their experiences of 
living with ACHD and gain perspective. One individual described her experience of 
putting things into perspective despite the significant impact that her heart condition 
had on her life. 
“There are times when it [heart condition] feels like the only thing in my life and it’s 
really overwhelming and I can’t deal with it. But if I’m looking from the outside […] 
if my heart was fine then I would have a sickly perfect life. So I suppose, in some 
ways you can’t have everything. And I’ve got nice things. So there, that’s a bit sickly 
[laughs] but it’s true.” – Janis, 35, SV  
Social comparisons 
Some people engaged in “downward” comparisons, describing how their situation 
could have been “worse” and that comparing themselves with other people had 
helped them gain perspective and adjust to their condition.  
“I’ve met up with people who have heart conditions as well and they were born with 
it, it affects them differently because it’s a lot worse so. It depends on severity but I 
just think that you need to kind of realise what you’ve got and understand what 
you’ve got and just try to have the best life you can.” – Jim, 36, ToF  
“I just feel like I can still get around and I know there’s worse people off than me 
that got the same condition as me so I’m just happy and glad that I can do what I 
can do basically.” – Ron, 54, TGA  
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Others engaged in “upward” comparisons, describing how they gained perspective 
by comparing themselves with people who coped really well despite being in a more 
difficult situation than them. 
“I met a man, when I went in for my pacemaker and he’d had, he was on like his 
14th pacemaker or something. He had his 1st when he was 6 months. And I spoke to 
him and he was the cheeriest person ever and I was like ”Wow, you’ve been through 
loads”. Me I only had one lead, that’s not really anything, is it? It’s like I’m gonna 
have to put things into perspective […] And I’m like “Oh ok. So this isn’t the big 
cloud.”” – Chloe, 36, TGA  
Positivity 
Gaining perspective was also linked to feelings of luck and gratefulness. Some 
people believed that they were in a fortunate position and appreciated that they were 
“lucky” to be alive and to have reached this far in their lives having being born with 
congenital heart disease. Some female patients felt lucky and “privileged” to have 
got married and to have had families of their own.  
“…I do feel very lucky […] I think time-wise from when I was born I was very lucky 
that I was, quite at the early days of babies being cured with this condition […] I 
suppose just emotionally, just that the fact that, yeah, the realisation that I am here 
and that I was a lucky one.” – Anastasia, 45, TGA 
Others described how they tried to reframe their situation in more positive terms by 
“adjusting negative motions into positive ones” or how they generally tried to keep a 
positive outlook.  
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“…in everyday life I’m really positive about it. Tried my best, well I do, I make the 
best out of my situation as much as I can, I’m trying to think outside the box.” – 
Maria, 25, SV  
Positive outlook and seeing the positive aspects of their situation helped some people 
cope with their treatment demands, for example operations and the need to attend 
regular outpatient appointments. 
“Well I think I’m quite a positive person... I always had a positive outlook so I don’t 
know, but I imagine it probably just helps you make better recovery and more 
speedy, cause you’re like “Oh it’ll be fine, it’ll be fine”” – Sophia, 27, Simple 
I’m a bit of a positive person really [chuckles]. I don’t like to really dwell on 
negative sides... I sort of twist it to make it more enjoyable, having to come down to 
London to visit the hospital every once a year or every couple, twice a year. I sort 
of, I don’t mind it a great deal… It’s a good excuse to, to venture down London and 
shop and see the sights and go round the clubs and that sort of things. So I try and 
treat it as positively as I can. – Leo, 32, SV 
For some participants, who experienced a change in their health, maintaining a 
positive outlook and reframing the negative into positive was difficult due to 
uncertainty about the future. They talked about how they had actively sought 
counselling in order to cope with uncertainty, which subsequently had helped them 
achieve a positive outlook, see the big picture, and appreciate other aspects of their 
life.  
10.3.3.4. Social influence 
Although social support was intended as a pre-determined topic to be tackled during 
the interviews, the role of people’s social environment was a recurrent and 
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unprompted theme in all of the participants’ narratives that was often linked to other 
themes pertaining to the coping process. All participants identified their social 
environment, including their partner, family, and friends, as a beneficial resource 
that helped them cope with their changing condition and its treatment (seeking social 
support). The nature of social support was further elaborated under the sub-theme of 
receipt of social support. 
Receipt of social support 
All participants talked about having a supportive environment, which helped them 
cope with their condition. They also described how they were receiving the right 
type and amount of support they needed. Those who were married or in a 
relationship talked about how their partner provided them with both instrumental and 
emotional support. They referred to their partner as being “always there” and 
willing to talk about anything that worried them about their condition. Some 
mentioned that the experiences they had shared with their partner had brought them 
closer together, to the point where their support was “unsaid”. Others commented 
on how their partner was “practical”, while some people used the terms 
“confidence-building” and “encouraging”. 
“…emotional support and physical support and that he’ll just do stuff so he knows I 
don’t have to do it. And that’s real support. Just get on and do stuff and it’s, and I 
don’t have to say to him “I’m tired”. He will say “You look tired” or “I’m gonna 
take our son out so you can have rest”. So I don’t have to go to him all the time and 
say “I really need some time out”. He’ll just get on and do it. And I think that 
support is just unsaid but brilliant. And that helps me.” – Doreen, 37, SV  
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“…he’ll be suggesting like sort of to go out and encourage me to go out and ask me 
how it was like at work, and encourage me to go back to work. But equally if I can’t 
do stuff he took, he worked from home the week after I had my pacemaker put in. So 
he was sort of preparing the food, more going out and taking the take-aways.” – 
Chloe, 36, TGA  
Some commented on how their partner helps them maintain a positive outlook. 
“I think he’s [husband] the positive to my negative. So it works quite well cause 
actually he’ll say, you know “It was a positive appointment. You know, they said 
this, and this, and this and to me that is really positive”…I suppose he balances me 
out.” – Janis, 35, SV  
Most people also talked about how their parents and especially their mother were 
concerned about them and provided them with emotional and practical support when 
they needed it. They commented on how their parents had been there throughout 
their lives and how they were “still involved” in their healthcare. A few individuals 
described their mother as “fussy” but mentioned that they preferred that approach 
and that they “understood” their concern. 
“I know it worries them [parents] and they’re always “Oh how did you get on today 
at the hospital?” So they’re always concerned about, or want to know what’s going 
on during the day and how I’m feeling at the end of the day.” – Robert, 40, TGA  
“Well I think my mum is quite, she had always been quite involved anyway, but 
she’s like, she’s not like more overly involved in with me than she is with my sister 
[…] my mum does worry about us but I think that was probably something she had 
anyway without, maybe the medical things have made it more pronounced than it 
would have been, I don’t know, but yeah, I guess I’d rather have somebody who was 
too fussy than not fussy enough I think.” – Sophia, 27, Simple  
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“…my mum’s approach is just been built up over the years. She needs to constantly 
check and, so that’s built upon the years because of the worrying and that but she 
tries to tame it back a bit now.” – Leo, 32, SV  
Many people described how their friends were understanding and accommodating of 
their physical limitations by adjusting the group activities based on the individual’s 
abilities. They felt able to talk to their friends and be emotionally supported.  
“…they [friends] accept it and they do things to me, really, you know “And myself 
are gonna do this. Will you be able to do that?” and I’ll say “Yeah”. If I say no 
they’d go “Oh we’re not gonna do that, we’ll do something else.”” – Ron, 54, TGA  
One person, whose friends also lived with other chronic conditions, commented on 
how they all supported and “kept an eye out” for each other. 
“I’ve got other friends who’ve got conditions where they can’t go out at times 
because they feel unwell so they understand when I don’t feel, when I say “Well I’m 
not coming out, I can’t go cause I’m feeling”. They will all be understanding cause 
they’re all on the same boat at times […] they all are relatively sympathetic.” – Leo, 
32, SV  
Seeking social support 
The availability of social support encouraged people to seek help when needed. 
Many of them commented on seeking support from their environment as a way of 
coping with their condition. Some also talked about contacting their healthcare 
professionals first in order to obtain information and reassurance about their 
condition and treatment.  
“I phone the nurses first. So usually I sit down and I’m like “Right. Is this different, 
is this normal?” And then if I’m worried I’m like “Well I must be worried about 
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something” […] You know, there is always somebody at the end of the phone during 
the week […] very factual but they are quite good at sorting out how you feeling and 
sort of just calming you down.” – Chloe, 36, TGA  
Others described how they turned to friends and family for emotional support. 
“…my family and I are really close and I’ve got lots of really good friends […] I 
think usually if you have something you worry about, you can usually talk about it 
with somebody so, and then find an answer through talking.” – Sophia, 27, Simple  
“I just cope, I don’t know how. Well, I talk a lot with my wife about vivid things 
related to my health or and well I always talk about things like that yeah. I’ll let my 
emotions come out to my wife more than anybody else I suppose.” – Robert, 40, 
TGA  
Although all participants acknowledged that having support was very important to 
them, some pointed out that they sometimes prevented themselves from seeking 
support from their family because they did not want them to “worry”. 
“I’m probably less willing to let mum know about any problems now because she 
worries and I suppose as I got older I’ve appreciated what that worry means so. But 
she is always there to pick up the pieces.” – Anastasia, 45, TGA  
“You hide things, you hide your feelings as much and sometimes from your partner, 
you know, you don’t want them to worry. You’re worrying but, you know. I guess 
there is two ways you can deal with that. Sharing it helps you but sometimes 
actually “Do I want her to worry as much as I’m worrying about it?”” – Jim, 36, 
ToF   
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10.3.3.5. Physical and social consequences of ACHD 
Most participants described their general health as “good”, “pretty good”, “quite 
good”, or “alright”. Some mentioned that their health was “not too bad” or “fairly 
good” stating weight issues and fitness levels as the main reasons for dissatisfaction. 
“Fairly good I think. I’d like to be fitter…I’d like to lose some weight and be fitter 
which I think it would probably be general mid-forties mom thing.” – Anastasia, 45, 
TGA 
Most people described a range of symptoms associated with their condition. The 
most common symptoms were shortness of breath when exerting themselves, an 
overall feeling of tiredness, headaches, light-headedness, and dizziness. One person 
characterised her condition as “my heart poorly”.  
“I noticed when I try to do a lot of running or something like that, I do find I get out of 
breath really quickly.” – Jim, 36, ToF 
Some people cited “feeling hearty” and having a “racing heart” which resulted in 
hospitalization. One person described a recent occasion when she had to be taken 
into hospital because of an acute arrhythmic episode. 
“When I had my suspected TIA I was literally, I was just walking down the street….I 
had really bad double vision, like literally somebody had taken my eyes and stuck 
inside razors….And they phoned me an ambulance” – Chloe, 36, TGA 
Some participants described how their symptoms had progressed through the years 
and had made them realise that their health “becomes a big deal” as they aged.  
“I suppose really it’s been in the last 10 years that things have started to, obviously 
I’m getting older, and my heart’s getting older and things have started to happen 
perhaps that weren’t really thought about before then.” – Janis, 35, SV 
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The experience of symptoms, particularly tiredness, shortness of breath, and 
arrhythmias were consistently linked with physical limitations. The majority of 
participants described being physically limited by their condition in the type and 
amount of activities they could do and their engagement in sports and activities such 
as swimming and running.  
“I get short of breath, I can’t run too far. I’ve done my exercise last year on the 
running machine. So I can’t run too far. I like to do a little bit of swimming if I go out 
with my family….I’ll do a couple of whips or a couple of them swimming and that 
would be enough for me then but I find that…I get out of breath easier.” – Ron, 54, 
TGA 
Some people compared themselves to their peers and described that since their 
childhood, they “struggle to keep up with others” due to their limited exercise 
capacity. 
“It’s been hard all my life cause I was watching children who were physically able to 
and I wasn’t […] I’ve caught up in my own time I should say so. On the physical way I 
could never compete with anybody anyway I mean my brothers’ been, are always 
physical and they wanted to do a lot of things… I wasn’t able to do what they could do. 
I still can’t now, you know. Growing up with, still growing up with it, I think there’s 
“Oh I can’t do that”” – Robert, 40, TGA 
A few people mentioned that there was variation in what they could do day-to-day 
depending on their health and how ill they were feeling. A few people indicated that 
the weather could have a “massive effect” on their ability to do things.  
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“…my health just dips and peaks and I find that difficult because one day I’ll be able to 
do something, the next I won’t so….So one day I’ll be able to do something, I’ll be able 
to walk the dog, the next day I won’t be able to walk the dog.” – Maria, 25, SV 
“Some days I don’t feel like I’ve done everything I’ve wanted to do. But I think is also 
cause things just takes so long to do but also cause I know I don’t want to run around 
like a lunatic cause I’m tired as well…I feel it more definitely, those limitations in the 
winter when it’s just harder to do stuff.” – Doreen, 37, SV 
It appeared that for some people the degree to which symptoms and physical 
limitations had influenced their lives was linked to the experience of health decline 
which resulted in a significant impact on their lives. 
“I’m noticing exercising, walking, going up the stairs gets me a lot way out of 
breath. Now that could well be the effect of my, my valve is leaking more now.” – 
Jim, 36, ToF 
Most people described that their physical limitations had, at times, interfered with 
their social activities. They described occasions when they felt “exhausted” and “not 
physically able” to go out, or occasions when they had to leave a social gathering 
because they were having “a particularly bad day”. There were some people, who 
talked about being unable to engage in social sporting activities that they enjoyed, 
for example mountaineering, climbing, and swimming.  
“I used to really enjoy climbing, swimming, I can’t really do them anymore. I think 
socially it’s changed a lot. It’s been a lot less active my social life.” – Maria, 25, SV  
The treatment regimen and particularly medication appeared to influence people’s 
social lives as they needed to regulate their alcohol consumption and their eating 
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habits. One person said that taking Warfarin had “ruined [his] drinking sessions”. 
Some talked about their condition and treatment interfering with holiday planning. 
“I want to go to Italy […] and just having all my admin in order. Whereas before I 
didn’t have any pills and I didn’t have a pacemaker and stuff like that. So that’s all 
kind of new for me and I was like “Ok. So don’t forget of what I eat. When do I get my 
blood tests before I go?”” – Chloe, 36, TGA  
Others reported that their condition had not influenced their social life and their 
activities. However, these persons described their hobbies and activities as “light” 
and not physically demanding.  
“I haven’t noticed it to affect my ability to tap dance so I’m still as bad or as good 
as I was before […] I mean playing the violin isn’t that, quite so athletic, I suppose” 
– Sophia, 27, Simple  
10.3.3.6. Occupational consequences of ACHD 
There was a common narrative across some people who were in employment at the 
time or who were employed in the past, that their condition influenced their work 
life. They talked about reducing their working hours because they were “tiring” 
themselves and it was “extremely difficult” to remain in full-time employment.  
“I’ve reduced my hours purely as well as on that basis as well as being the area of 
work where I was working was becoming more. So it was no way I could do that full-
on anyway. Cause the warehouse where I was in, was, some of the products were 
removed and other products within our warehouse which were too physical, 
manhandling things so it was. I’d be doing that for a 9-hour day, as early as late, as 
early as late, so too much for me to be honest.” – Robert, 40, TGA  
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These people also described having to adjust the nature of work that they were 
doing, for example reducing manual or more physically demanding work because of 
their condition and symptoms. One person described her experience of how she 
needed to adjust her work responsibilities because of a sudden health deterioration. 
“…when I was going they were saying my heart rate was quite low with my heart 
monitor stuff. They were like “Have you passed out?” And because I work in a 
laboratory that’s not great. So there was a period of time when they were like “Oh, you 
don’t go in the lab”. So then I was just sitting on my desk, “Oh yeah this is fun”, just 
doing sort of menial desk-based stuff. Not actually the job that, part of my job, but not 
the job that I wanted to do.” – Chloe, 36, TGA 
Some female participants who were employed in the past talked about their decision 
to retire after having their baby because they felt it was too difficult to “manage” 
motherhood and working.  
“…then six months down the line I put her [baby] into nursery and went back to work 
part-time and I think actually I should have given myself more time. So as the years 
went on I think that sort of built up ‘till in the end I just thought “I can’t, can’t do this 
anymore, I need a proper break” in terms of a year, or years rather than just months, 
you know. So I suppose in that way my heart condition yes, did affect the decision but 
indirectly really.” – Anastasia, 45, TGA 
Some people also described that their condition limited their choice of work in that 
they needed to find a “flexible” job that would be accommodating to their condition 
and their limitations.  
“I probably, in today’s world, they wouldn’t accommodate someone like me that has to 
have medical appointments and go sick. I tend to get flues and colds probably a bit 
CHAPTER 10 – THE EXPERIENCES OF PEOPLE WITH ACHD 
337 
 
quicker than anyone else […] so I just went into jobs that I could do easy which is 
driving.” – Ron, 54, TGA  
Another younger individual, who was starting her first job after finishing university, 
described her job responsibilities and how these were adapted for her condition and 
treatment demands. 
“It’s [job] part time, it’s twenty hours a week and I can choose my hours, which is 
really handy, because obviously with hospital appointments and some days I’m not 
very well and things like that. It’ll just be going in and doing group activities, like 
quizzes, bingo, little bit of sort of exercise that oldies can do. So nothing [chuckles]  
strenuous, sitting on a chair, which is my kind of exercise and I can do that.” – 
Maria, 25, SV 
Some people mentioned that their condition did not influence their working life and 
that the only occasion that it did interfere with their work was when they had to 
attend their outpatient appointments. 
“The only time it [condition] affects it [working life], it’s when I have to take time to 
come to hospital for appointments. Obviously that’s not very often so minimal 
impact I would say.” – Phil, 37, ToF 
10.3.3.7. Disclosure of illness 
There was an underlying narrative across all interviews that disclosure of their 
condition to close friends had not been an issue. Participants highlighted the 
importance of disclosure as opposed to leaving people to “guess” why they could 
not do a particular task. Others mentioned that their thoracotomy scar was evidence 
that they had undergone some sort of surgery and therefore could not hide it from 
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their social circle. One person emphasized the safety aspects of disclosure especially 
in emergency situations, where people would need to know. 
“I’ve always been really honest. It’s like “This is me”. And, you know, I think it’s 
really important, you know, it’s not fair on them, to go out with people and them not 
know […] it’s not fair to put them in a position where something might happen to me.” 
– Janis, 35, SV  
One person acknowledged that disclosing his condition had become easier in 
adulthood because adults were more interested and understanding. 
“It’s a lot easier to tell people as you, when you’re older. People understand more, 
wanna listen more. I think it’s difficult when you’re younger. You know, you’re 
walking around with scars on your body […] when you get older you’re more 
mature, you’re more concerned and stuff like that. So it’s just easier to disclose it. 
It’s nothing, there’s nothing there that I need to hide and I don’t feel that I need to 
hide it.” – Jim, 36, ToF 
A few people found it “hard” to disclose their condition to new friends or 
acquaintances. A younger person described that she had difficulty in finding a 
“balance” of when or how to disclose her condition and engaged in cost-benefit 
decisions about disclosure. She described some social situations, where she 
“struggled” and worried about how other people would perceive her.  
“When you first meet people, obviously, I don’t wanna be like “Oh by the way I’ve got 
a heart condition”. That’s not appropriate. At the same time when they’re like “Ok, 
let’s just go walk to this place” and there’s a big hill, and I think “Oh I can’t walk 
there I need to get a taxi, or a lift”. And then I’d start think “Oh but they’re just gonna 
think I’m lazy. I don’t want people to think I’m lazy”. Or when I have to sit down, if 
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there’s music on, cause I can’t and they’re like “Oh no, come on, come on dance” and 
I can’t dance but I don’t want them to just think I’m boring.” – Maria, 25, SV  
The majority of participants described their experience of disclosing their condition 
to their employer as “fine” owing to the fact that they had to fill in forms or undergo 
medical tests. Most of them appreciated that they had to be “honest” and “open” 
with their employers. They also referred to the importance of disclosing changes in 
their health that could potentially affect their work. 
“…when I know that things are possibly gonna get worse then you tell them that “I’m 
gonna have to go for a lot more tests and it’s gonna involve obviously having days off. 
And there’s a possibility at some point where I’d need to have quite a bit of time off if I 
have an operation.”” – Jim, 36, ToF  
Some people mentioned that they were unsure that they would secure the job after 
disclosing their condition due to fear of discrimination. 
“I’m not sure I’ve disclosed it as much as I should have, like on reflection and in all 
honesty. I’ve told them of my heart condition, I told them I need, I will have a lot of 
hospital appointments, but I’ve said that I don’t think it will affect the job, which I’m 
not sure is entirely truthful. But I think if you go in there and lay it all down, I don’t 
know. I wouldn’t give me a job.” – Maria, 25, SV  
Another individual wanted her condition to be “private” and was particularly careful 
not to get herself into situations where she experienced symptoms, especially 
shortness of breath, in front of other people. She described her experience of not 
disclosing her condition to her work colleagues until she actually had to.  
“I remember at my old job, old, old job we went skiing. And I didn’t say anything 
cause like I know what is skiing and I didn’t think it would be that bad but basically 
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it was a nightmare when I went to a height-like ski up the hill. And I was like 
“Actually dudes I can’t, I can’t do this”. And they said “Oh well why didn’t you say 
anything?” I was like “Well, cause it’s not what I actually need to talk about it.”” – 
Doreen, 37, SV 
10.3.3.8. Psychological consequences of ACHD 
Negative emotions 
Many people talked about how their physical limitations affected them emotionally. 
They mentioned that not being able to do what they wanted, made them feel “down” 
and “frustrated”. Many expressed a wish that they could do more and “achieve” 
what they wanted regarding their family role, social participation, and work.  
“So you feel a bit, the thing that you can’t join in as much sort of thing. You feel a 
bit down with that side of thing. You can’t run around so much with your 
grandchildren. And my kids as they were growing up as well. […] I can honestly say 
I’ve never been depressed over my heart condition. I’ve been a bit, like sometimes 
when you can’t join in on certain activities, you’re a bit “Oh I wish I could do that, I 
wish I could do this.”” – Ron, 54, TGA  
“…you’re out with friends and you, just it’s time to go home because you’re 
absolutely shattered, everyone else will be moving on somewhere else, it’s “I can’t, 
I need to go home, I'm really tired”. And so it can be frustrating when you’re 
enjoying yourself out and you just feel too tired and you go home so. Emotionally it 
can be frustrating any time.” – Leo, 32, SV  
One person, who did not experience significant physical limitations except for 
extreme sporting activities, felt “resentment” when he was unable to engage in these 
activities.  
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“I think if you are physically limited and unable to take part in sporting activities 
and social activities, things that you want to […] there’s always a bit of resentment 
that you are unable to do what other people take for granted” – Peter, 39, Simple  
Some individuals, who were experiencing a change in their health, described feeling 
“depressed” at times and worried.  
“I think where I’ve had an issue in the last couple of months...where I had all the 
problems with, possibly with the heart getting worse […] it’d become a bit too much 
for me around November time and I’d been depressed and a bit down. But things 
are better now. And that’s probably the only time I’ve ever let health issues affect 
me.” – Jim, 36, ToF  
Some described that being told by healthcare professionals that “they are not fine” 
had made them more “aware” of their condition and hence more anxious and 
“obsessive” with their heart and symptoms.  
“When you’re fine, it’s fine. When you’re not fine or people tell you you’re not fine 
it’s kind of a bit all-consuming. It’s like everything you worry about. Every time you 
wake up you’re like “Oh is it that?” Every time that you can feel pain it’s like “Oh 
do I need to go to the hospital?” Whereas before I felt a bit of a fool going for 
check-ups and they were “Oh yeah you’re all fine”. […] I was sitting there like 
wearing my heart rate monitor last year for days, plotting the graphs, seeing how 
fast it was.” – Chloe, 36, TGA  
For one person, this increased heart-related anxiety had made her more hesitant 
about engaging in activities that could potentially cause further symptoms; this led to 
loss of confidence in her ability to engage in activities that required physical effort.  
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“So slightly nervous about pushing myself physically in case that [atrial flutter] 
happens because when it does happen I’m just sort of completely floored, obviously 
if I end up in hospital so […] the atrial flutter did knock my confidence a lot as far 
as pushing myself physically. So I sort of try to overcome that now as well really and 
get going again before it’s too late.” – Anastasia, 45, TGA 
Some participants who did not generally experience significant physical burden from 
their heart condition reported that they were not particularly worried about it. One 
person talked about not noticing the “heart stuff” because of other more serious co-
morbid conditions. 
“I don’t really notice it […] I think just because I was so used to having a lot of 
things, when I was a child, I don’t really. This is kind of like an extra thing that I 
don’t really, it doesn’t really bother me, that much.” – Sophia, 27, Simple  
Some others talked about previous interventions and how these were “rough”, 
“stressful”, and “dramatic”. One person refused to talk about his latest heart 
operation because it made him feel “uncomfortable”. Another individual felt that the 
emotional impact of her heart operation was more apparent compared with other 
operations, which were unrelated to her heart. 
“…when I had the heart surgery, that was, it was more, it felt more traumatic than 
the other operations I’d had. But I don’t know if that was because I was older and I 
could understand the risks a bit more, or if it is because it was the heart so it was a 
bit more I don’t know feels more serious, I don’t know […] I think when I went 
home I was so relieved I was like, I did cry a lot when I got home.” – Sophia, 27, 
Simple  
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Family planning 
Female participants talked about emotional issues surrounding pregnancy and family 
planning. Those who did not have children, talked about how a future pregnancy 
might be “overwhelming” and that it is something they were concerned about. Those 
that did have children talked about the “emotional” impact of being advised that 
they could not have (any more) children. One person, who went on to adopt her son, 
described how she needed more clear and timely information from healthcare 
professionals regarding her capacity to withstand the challenges of pregnancy. 
“I really wish I understand and I understood more clearly that I couldn’t have 
children, a lot earlier, earlier stage of my life...rather than when I was already in my 
thirties. Cause I think I would have done things [cries] slightly differently […] just 
felt like “Ok I’m 34 now and I’m now been told I can’t, it just wouldn’t be good to 
have kids”. I should have been 24.” – Doreen, 37, SV  
Another person felt some “pressure” as she was advised to have her children before 
the age of 30. Although she went on to have two children, she described that her 
experience was emotional. 
“Probably later when I wanted children that was a bit of an emotional thing I 
suppose that hang over me. That I was, I think when I was 18, I was told “Yes you 
will be able to have children but you must get on and do it before you get 30”. So 
that was always this sort of, a bit of a pressure I suppose.” – Anastasia, 45, TGA  
Expectations and uncertainty 
Uncertainty was a common narrative across many interviews and was closely linked 
to expectations about the future. The majority of people acknowledged that health 
deterioration was inevitable in the future saying that “it will get worse before it gets 
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better”, that “the only way is down” and that they would probably need to have 
further interventions.  
“Eventually I will start to get symptoms, eventually I will need to have some kind of 
procedure.” – Peter, 39, Simple 
Others felt unsure about the course of their condition indicating that “it’s a bit of an 
unknown”. 
“I don’t know. No, I really don’t know and I don’t think I’ve ever been given an 
answer by the doctors on that either.” – Anastasia, 45, TGA 
For some, health deterioration was already their reality and faced long-term 
complications and changes in their treatment regimen. In these individuals the 
emotional consequences of living with ACHD (described in the previous sub-theme) 
were enhanced by a feeling of uncertainty about the future and their ability to follow-
through on future plans. Uncertainty was heightened by health care professionals not 
being able to give them “definitive answers”. One person mentioned that she had to 
seek professional help because of how this uncertainty had affected her emotionally. 
“...we are at an age where people before us didn’t survive. So we are the test group 
of people. So nobody can give you any answers. So that does take a lot of coming to 
terms with really […] Psychologically, I have had periods, especially over the last 
few years, where it has really affected me and I’ve been offered stress [therapy] […] 
just purely, you don’t know what’s gonna happen so it’s not like you can ever, you 
don’t ever have a real plan “This is gonna happen and then you gonna get to this 
stage and this is gonna happen”. So psychologically you have to come to terms with 
the fact that actually you just have to live in the here and now, you can’t think too 
much about what’s gonna happen because actually nobody knows.” – Janis, 35, SV   
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Furthermore, the possibility of future interventions was described by some people as 
“always in the back of [their] mind”. They felt “worried” and often wondered about 
future interventions; feelings which appeared to be mostly prominent around the 
time of their follow-up appointments. In addition to their follow-up appointments 
being a reminder of possible interventions, people talked about the “uncertainty” 
about the timing of an upcoming intervention.  
“I guess you’ve always got it there, at the back of your mind that you’ve had a 
problem and that something could happen in the future. It’s always there, you know. 
I’ve always sort of come in back to the hospital every couple of years or whenever it 
is. I know they’ve mentioned that I’m gonna have to have another procedure at some 
point later on so. Obviously a bit worried about it” – Phil, 37, ToF  
“I guess it’s more the anticipation of what might happen in the future as you get 
older and the fact that you probably will need an operation at some point and what 
that means for your quality of life […] rather than any impact now.” – Peter, 39, 
Simple  
“I’d like to get a good, if the valve’s leaking more, do we, are talking about 
operation in the next year or two years. I’d rather kind of get it firmed up, because it 
does play in the mind.” – Jim, 36, ToF  
10.4. Discussion 
The aim of the present study was to explore the experiences of people with ACHD 
and to gain a deeper understanding of how they adjust to living with their condition. 
There were three overarching processes identified across the narratives; the impact 
of ACHD, the coping process, and change over time. People with ACHD appeared to 
have developed effective ways of coping with their condition and its treatment. 
Coping with ACHD appeared to be a result of interplay of factors including setting 
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goals and priorities, acceptance and adjustment, gaining perspective, and social 
influences. These factors influenced the degree to which people experienced an 
impact on their HRQoL as a result of ACHD. There was a range of consequences as 
a result of living with ACHD, including, physical, social, occupational, and 
psychological, as well as issues relating to disclosure (Figure 10.2, page 319). As 
mentioned earlier, the process of change over time was embedded in the participants’ 
narratives, which suggested the dynamic aspect of living with ACHD and its 
progressive nature. Changes in health and treatment over time influenced people’s 
HRQoL experiences and their coping efforts. They described a number of symptoms 
and limitations caused by their health deteriorating and by the introduction of new 
treatment regimens, which had an evident impact on their lives. Such changes in the 
illness trajectory over time appeared to initiate a new cycle of adjustment to different 
limitations and treatment routines that needed to be accepted and incorporated into 
their lives. During these periods people also experienced increased uncertainty and 
negative emotions and tried to gain perspective and find meaning in these new 
experiences. In addition, the life situation appeared to be significant for how people 
experienced the consequences of ACHD and how they coped with them. For 
example life events such as finding work, retirement, and starting a family brought 
new insights on the nature of what it is like to live with and adjust to ACHD. The 
impact of change over time is addressed further within the themes, which will now 
be discussed in relation to previous research. Synthesis of the findings of this study 
in relation to the quantitative studies described in the previous chapters and the 
general implications for theory, research and clinical practice will be addressed in 
Chapter 11. 
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10.4.1. Priorities and goals 
Most people placed significant importance on health and physical ability along with 
financial stability, happiness, and maintaining social relationships. These findings 
provide further support to the assumption that HRQoL is a multidimensional concept 
that may contain physical, occupational, psychological, interpersonal, and somatic 
sensation aspects (Schipper et al., 1996).  
On the whole people prioritised their health above any other domain of their life. 
Although a few people tended to place more importance on their personal and work 
lives. Most people expressed doubt about the degree of control they have over their 
QoL more broadly and especially their health. Lack of control in people with ACHD 
has also been reported in a study of 12 individuals with moderate and complex 
ACHD by Claessens et al. (2005), who reported that people felt they were being 
controlled and “dominated” by their condition. In the present study people described 
how they took active steps in an attempt to maintain their health, including eating 
healthy and exercising. This finding suggests that despite feeling that their illness is 
uncontrollable, people still strive to gain control over certain aspects of their health. 
Rönning et al. (2008) found that receiving information about their condition and 
support resources helped people feel more in control of their ACHD. This approach 
to patient education may therefore be useful in enhancing people’s sense of control. 
10.4.2. Acceptance and adjustment 
The narratives of many participants revolved around achieving normalcy in their 
lives by accepting their condition and integrating it into their personal identity and 
their lives. People acknowledged their condition, were aware of their limitations, and 
attempted to adjust their lives based on their abilities. Deatrick and colleagues (1999) 
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have argued that this is a process of normalization, which occurs early in people’s 
lives and is key to the way families cope with a chronically ill child. They identified 
several elements of normalization evident within families with chronically ill 
children: a) acknowledging of the impairment, b) defining life as normal, c) 
minimising the social consequences of the illness, d) engaging in behaviour that are 
consistent with normality, e) incorporating a treatment regimen consistent with 
normality. The family of chronically ill children attempt to form their own normality 
by integrating the child’s illness and treatment into their daily lives. Multiple 
qualitative studies with children and adolescents with CHD have found 
normalization to be integral in adjusting to their condition (Andresen, Andersen, 
Lindberg, Døhlen, & Fosse, 2014; Chiang et al., 2011; Gantt, 2002; Horner et al., 
2000; Kools, Gilliss, & Tong, 1999; Shearer et al., 2013; Tong et al., 1998; 
Zahmacioglu et al., 2011).  
The findings of present study suggest that this process of normalisation and 
specifically acceptance and adjustment is part of people’s coping attempts 
throughout their life course and not just in childhood. This notion has been supported 
in previous qualitative studies of people with ACHD (Berghammer et al., 2006; 
Claessens et al., 2005). Acceptance of the presence of an underlying health problem 
and the limitations associated with it was the first step towards achieving normality 
for individuals in the present study. These people defined normality based on their 
capabilities and had knowledge about what they were able to do. For example, by 
planning ahead, pacing themselves, and avoiding social activities that were beyond 
their limitations. In addition, they constructed their normality to include their 
treatment regimen. 
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The degree to which people adjusted to living with ACHD was largely influenced by 
the stability of their health. Those that had experienced changes in their health and 
treatment over time often struggled to incorporate these into their lives. This 
dynamic nature of adjustment has also been identified in previous studies in ACHD 
(Claessens et al., 2005; Gantt, 2002) and other chronic illnesses (Deatrick et al., 
1999). Claessens et al. (2005) found that illness progression and the impact of 
ACHD influenced people’s attempts to achieve normalcy. Gantt (2002) conducted 
interviews with mother-daughter dyads, which included people with ACHD and 
found evidence that adjustment was influenced by worsening in symptoms, further 
surgeries, and hospitalizations. These events made normalization a difficult goal to 
achieve (Gantt, 2002). The findings of the present study indicated that experience of 
health changes resulted in people trying to readjust to the increasing demands of 
their condition and treatment. This is an important finding because as people with 
ACHD move through life, they are progressively faced with inevitable long-term 
complications and changes to their treatment. Some authors suggest that, although 
the course of ACHD may not be predictable for many individuals, providing timely 
information about possible changes may help people accept them as part of their life 
and aid better adjustment when they do occur in the future (Moons et al., 2001). 
10.4.3. Gaining perspective 
People’s coping efforts also consisted of trying to find meaning in their experiences 
of living with ACHD and gain perspective over their condition. Claessens et al. 
(2005) also found that people’s efforts to adjust with ACHD involved “putting things 
in perspective”. In the present study people with ACHD attempted to gain 
CHAPTER 10 – THE EXPERIENCES OF PEOPLE WITH ACHD 
350 
 
perspective by comparing themselves to other people in similar situations, 
appreciating their survival and achievements, and maintaining a positive attitude. 
Participants engaged in both upwards and downwards social comparisons with other 
patients. Upwards comparisons were mainly associated with attempts to cope with a 
new treatment regimen, where individuals compared themselves to people who 
managed to adjust successfully. Downwards comparisons were associated with 
participants’ need to adjust to their condition and health changes by comparing 
themselves with other people in “worse” situations. Previous studies have found that 
during adolescence people compared themselves and their functioning with healthy 
individuals, which enhanced a feeling of being different (Berghammer et al., 2006; 
Claessens et al., 2005). This study extends the findings of previous studies by 
demonstrating that people with ACHD also engage in positive social comparisons 
during their adult lives. For example, an individual who had her first pacemaker 
fitted at the time of the interview, described how comparing herself with another 
person who had multiple pacemaker fittings throughout the years, made her gain 
perspective and subsequently minimised the emotional burden of this change in her 
treatment regimen. The findings in relation to the benefits of social comparisons 
support the findings of a recent review on chronic illnesses which reported that 
comparisons made by individuals with others who were coping better as opposed to 
coping poorly and with others who were experiencing a more severe illness as 
opposed to less severe were beneficial for their adjustment (Arigo, Suls, & Smyth, 
2014). The findings of the present study are important in light of evidence 
suggesting that people with ACHD need mentorship programmes in order to better 
cope with their condition (Pagé, Kovacs, Irvine, 2012). 
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Participants also felt “lucky” and “privileged” to have survived and to have 
achieved their life plans, such as having a family. This stemmed from the recognition 
of the treatment advances in ACHD during the period of their birth and that patients 
before that did not have the same chances of survival. This phenomenon was 
expressed as “beating the odds” in a study by Horner et al. (2000). Thinking in these 
terms helped participants in the present study gain perspective over their condition 
and realise that they had achieved their goals despite being born with a life-
threatening condition. Adopting a positive outlook and reframing negative emotions 
and situations were key processes that helped people cope with their condition, 
enabling them to view the illness and treatment disruptions including operations and 
regular follow-up appointments, as manageable and generally in more positive terms. 
This made people shift focus from the negative aspects of living with ACHD to more 
positive life experiences such as their social life, family, and work and therefore gain 
perspective. Similar positive attitudes have been reported in children and adolescents 
(Birks et al., 2007; Tong et al., 1998) as well as in young people with ACHD 
(Overgaard et al., 2013). Positive reframing is a cognitive coping strategy where a 
person appraises a difficult situation more positively and is believed to encourage 
positive affect (Folkman & Moskowitz, 2000). Studies in chronic illnesses have also 
demonstrated that positive reframing may buffer against the stress associated with a 
chronic condition and contribute towards gaining perspective and finding meaning 
(Folkman & Moskowitz, 2000). Moreover, a study in congestive heart failure found 
that people who coped through seeing their illness in a positive light experienced 
higher levels of meaning (Park, Malone, Suresh, Bliss, & Rosen, 2008). In the 
present study, individuals who experienced changes in their health and were facing 
the possibility of further interventions, gaining perspective through positive 
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reframing was more difficult due to uncertainty and it involved a more active 
approach like seeking psychological counselling. This was helping them place their 
heart condition within the bigger picture and appreciate other positive aspects of 
their lives. These findings provide further support to studies indicating the efficacy 
of providing psychological support for people with ACHD particularly during 
periods of health decline and introduction of changes in their treatment regimen as it 
may help people cope more effectively with their condition and the uncertainty (see 
section 10.4.8, page, 359) associated with illness progression (Rönning et al., 2008). 
10.4.4. Social influence 
All participants in the study highlighted the importance of having a supportive 
environment that helped them cope with the demands of their condition and 
treatment regimen. They expressed high levels of support from their friends and 
family. These findings are in line with quantitative studies that have reported equal 
to or higher levels of support in people with ACHD compared with the general 
population (Knowles et al., 2012; Pike et al., 2012). People also described how they 
receive the right type and amount of support they need, thus indicating no 
inconsistencies between their preferred and received support. This finding has been 
reported in a previous quantitative study, which indicated that people with ACHD 
reported fewer inconsistencies between their preferred and received support 
compared with healthy individuals (van Rijen et al., 2004). Congruence between 
preferred support and received support has been highlighted in the literature as 
potentially important for people’s well-being (Thoits, 1995). 
Partners provided practical support by sharing everyday responsibilities that 
required physical effort, whilst friends were accommodating by engaging in 
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activities suited to the individual’s limitations, minimising in this way the physical 
and social consequences of ACHD. These findings have important implications 
about helping people with ACHD build and maintain supportive social relationships, 
considering that children and adolescents with CHD may experience impaired social 
functioning, including engagement in social activities and establishing social 
relationships (e.g. McMurray et al., 2001).  
People also described how they received emotional support from their family and 
friends. It has been suggested that social support can enhance people’s efforts to 
cope with the stress associated with their illness, thus aiding as a “buffer” (Heaney & 
Israel, 2008). People in the present study sought to reduce the emotional burden of 
living with ACHD through sharing their worries and negative emotions and seeking 
reassurance from their family and friends. It is important to note that most people 
also reported seeking and receiving information and reassurance about their 
condition and treatment from their healthcare professionals and more specifically 
nurse specialists. This is reassuring given that research in the U.S. (Kools et al., 
2002) found that people with ACHD felt that they lacked support from nurses, who 
did not have adequate experience and sensitivity towards their challenges. Notably, 
this study was conducted in the U.S. where such problems in the care and provision 
of information to people with ACHD have been found (Webb, 2010). Promoting 
supportive relationships between people with ACHD and clinical staff, where the 
former feel comfortable seeking information and communicating their needs, may 
aid their efforts to adjust to their condition (Cornett & Simms, 2014).  
For some people, parental involvement in their healthcare and in ensuring their well-
being had been ongoing since their childhood. There were few reports of parental 
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over-protection in this study, which is a common theme across qualitative studies 
with children with CHD but also in people with ACHD (Claessens et al., 2005; 
Kools et al., 2002). Some authors have argued that parental over-protection may 
hinder independence in children with CHD and the development of social skills later 
in adulthood (McMurray et al., 2001; Tong et al., 1998). Research also highlighted 
that gaining autonomy from parents might take longer in people with ACHD as 
opposed to healthy individuals (Overgaard et al., 2013). In the present study it was 
evident that individuals managed to gain their autonomy, even those who were 
experiencing some parental over-protection. They also expressed an understanding 
and even a preference towards parental involvement because for them, it was 
indicative of genuine concern.  
Most importantly, parental over-protection did not appear to have an impact on the 
people’s social functioning. One explanation may be older age, as most were well 
into their thirties and therefore had years of establishing social relationships outside 
of the family environment. A previous longitudinal study suggested that social 
inhibition in people with ACHD diminishes over time resulting in them feeling more 
secure in social situations (van Rijen et al., 2005a). This finding coupled with the 
findings of the present study suggest that as people get older they manage to gain 
their independence, develop their social skills, and maintain their social functioning 
without feeling restricted by parental over-protection.  
It is important to note that a few individuals reported that they were, at times, 
hesitant about reaching out to close people because they did not want to worry them. 
Similar findings have been reported in another qualitative study with people with 
ACHD (Cornett & Simms, 2014), which found that people’s help-seeking behaviour 
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was complicated by them wishing to “protect” their family members. The authors 
argued that not seeking support may hinder the positive effects of the social 
environment on people’s coping efforts. Encouraging people with ACHD to 
effectively communicate their needs may help them receive the support that is most 
suited to their needs but may also help them adjust to their condition.  
10.4.5. Physical and social consequences of ACHD 
Participants perceived their health to be generally good, yet the physical 
manifestation of ACHD was evident in most people. Severe symptoms such as 
arrhythmias and cyanosis were cited by some people. For most people the experience 
of symptoms resulted in some physical and social limitations, including reduced 
exercise capacity, engagements in sporting activities, and travelling. These 
limitations appeared to vary from day-to-day in some people. A previous qualitative 
study about the experiences of people with SV noted significant symptoms and 
physical limitations in relation to daily and social life (Overgaard et al., 2013). The 
authors also noted that most of these individuals managed to find their own pace and 
adjust to their limitations. The findings of the present study also suggest that the 
degree to which symptoms and subsequent physical and social limitations interfered 
with people’s lives depended on whether they managed to successfully incorporate 
them into their daily lives (see section 10.4.2, page 347). As mentioned earlier, 
adjustment to ACHD is a lifelong and dynamic process, dependent on changes in 
health and treatment. It may be important for people to have knowledge about 
potential changes in their physical functioning as lack of knowledge or even 
misconceptions may leave people with ACHD struggling to achieve normalcy 
although that may not be possible as they age and face further complications 
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(Rönning et al., 2008). Many participants in the study mentioned that changes in 
their health were unexpected and “weren’t really thought about before then”. In 
addition, although most people acknowledged that their health might deteriorate 
(further) in the future, they still felt uncertain about how it would impact their lives 
(see section 10.4.8, page 359).  
People with ACHD have previously expressed a desire for structured and timely 
information about potential changes in their health and treatment and the possible 
consequences to their physical and social functioning that may help them cope with 
the demands of their condition and treatment (Rönning et al., 2008). They have also 
described how receiving continuous information from healthcare professionals had 
previously helped their knowledge of what to expect and had provided them with 
tools to manage their symptoms and limitations (Rönning et al., 2008). Taken 
together, the findings of the present and previous studies suggest that continuous 
provision of timely information across people’s lifespan may help them form 
realistic expectations about their condition and illness progression. 
10.4.6. Occupational consequences of ACHD 
The physical impact of ACHD in the form of symptoms and physical limitations had 
a direct effect on the people’s ability to fulfil their occupational role. Most people 
appeared to be well educated and had skilled or professional jobs. However, their 
physical status seemed to have an increasing impact on their ability to work full-
time, their engagement in their usual job responsibilities, and early retirement due to 
family planning or reduced capacity. For a few people, their condition had 
influenced their choice of career or limited their ability to work in the first place. 
Claessens et al. (2005) also found that people with ACHD experienced employment 
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issues. Another large study of employment in people with ACHD found that 
although they did receive career advice, they found it less helpful than healthy 
individuals. This was attributed to inappropriate advice that was not specific to 
ACHD (Crossland et al., 2005). The authors suggested that educating employers 
about the physical challenges of people with ACHD might help these individuals’ 
chances of finding a job specific to their capabilities with an understanding 
employer. Together, these findings suggest that employment issues are persistent 
challenges even for people currently in employment, especially as they age and their 
physical limitations become more prominent. 
In addition, female participants appear to have particular needs in relation to 
balancing work and motherhood, which reflects the employment challenges 
experienced by women in general (Perrons, 2009). Some authors have suggested that 
adjustments such as working at home may be a practical way of helping people with 
ACHD that wish to stay in employment (Kamphuis et al., 2002c). However, it is also 
important that people with ACHD themselves are educated about how illness 
progression might influence their work life as it may help them take proactive steps 
towards disclosing their condition (section 10.4.7) and making arrangements with 
their employer or even early retirement. 
10.4.7. Illness disclosure 
The findings of this study indicated that people with ACHD did not generally 
experience problems with disclosing their condition to their close social circle. 
Disclosure was more difficult with new friends or acquaintances and people 
appeared to engage in cost-benefit decisions about whether to disclose their 
condition. This was also evident in a recent study, which suggested that people with 
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ACHD were unsure about when and how to disclose their condition (Cornett & 
Simms, 2014). Children and adolescents with CHD have also reported difficulties in 
disclosing their condition because of fear of discrimination and social exclusion 
(Horner et al., 2000; Tong et al., 1998). Disclosure challenges have been reported in 
other visible and invisible chronic conditions (Joachim & Acorn, 2000) and it 
appears that ACHD is no exception. The findings of the present study also suggest 
that disclosure within the social circle becomes less challenging for adults as they 
had managed to develop supportive social relationships.  
Most people currently working were comfortable with disclosing their condition to 
employers, particularly when there was a need for adjustments in work 
responsibilities. However, some of them expressed apprehension about fully 
disclosing their condition during job interviews because of fear of discrimination. A 
previous qualitative study with adolescents with CHD reported that they were 
concerned over discrimination from future employers mainly because they had 
already experienced discrimination in their lives (McMurray et al., 2001). In the 
present study it was apparent that some people carried these concerns through to 
their adult lives supporting findings from various chronic conditions (Joachim & 
Acorn, 2000). With the Disability Discrimination Act (DDA) 1995 in place in the 
UK, it is generally expected that people should not be concerned about 
discrimination and in turn employers should not discriminate against people with 
long-term disabilities. Some people with ACHD may not be fully aware of their 
rights for equal opportunities in employment and may still face discrimination. 
Hence, combining provision of information about employment laws for disabled 
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people with patient education about career and employment might help people with 
ACHD to pursue employment and encourage them to disclose their condition. 
10.4.8. Psychological consequences of ACHD 
Most people expressed feelings of “frustration” in relation to their physical 
limitations and not being able to fulfil their typical role at home, work, and within 
their social circle. The emotional burden of ACHD was most prominent during 
periods of health deterioration and interventions, where people described feeling 
depressed, anxious, and less confident in their capabilities. Furthermore, previous 
interventions were characterised as “dramatic”. These findings suggest that illness 
progression and changes in health status are accompanied by increased psychological 
consequences. Similar findings have been reported in a recent qualitative study about 
the psychological impact of ACHD (Cornett & Simms, 2014). The authors found 
that people with ACHD felt depressed over their condition and unexpected cardiac 
episodes and further operations left patients shocked and traumatised. The findings 
from both studies suggest that long-term complications and interventions during 
adulthood can have a significant emotional impact on people with ACHD. 
It is also important to note that female participants found pregnancy and family 
planning to be distressing. Claessens et al. (2005) also found that pregnancy was a 
particular concern for women with ACHD. Horner et al. (2000) reported that being 
informed that they were not able to have children was devastating for women with 
ACHD. In the present study women who did not have children were concerned about 
potential pregnancy issues in the future, whilst women who did have children 
described these experiences as being particularly emotional. One person, who did not 
understand doctors’ advice regarding pregnancy, emphasized the importance of 
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receiving clearer and timely information about her ability to withstand pregnancy. 
These findings suggest the need for more structured education about pregnancy and 
family planning for women with ACHD and potentially the provision of 
psychological support for women informed that they cannot bear children (Moons, 
De Geest, & Budts, 2002). 
The findings of the present study also indicated that the emotional consequences of 
ACHD were enhanced by a general feeling of uncertainty. Although most people 
acknowledged the possibility of health deterioration and further interventions and 
even though some of them had already experienced these changes, they still felt 
uncertain. This uncertainty left them feeling even more worried and anxious. 
Feelings of uncertainty have been reported multiple times in children and 
adolescents with CHD (Lee & Kim, 2012; Tong et al., 1998) and in the adult 
population (Claessens et al., 2005; Horner et al., 2000) suggesting that this is an 
ongoing issue for these individuals throughout their lifetime. Uncertainty has also 
been reported in other chronic conditions and evidence suggests it may be 
detrimental for people’s HRQoL and overall adjustment (Cleanthous, Newman, 
Shipley, Isenberg, & Cano, 2013). Feelings of uncertainty were enhanced by a “wait 
and see” attitude from healthcare professionals in the present study. These findings 
support the Uncertainty in Illness Theory (UIT; Mishel, 1988), which posits that the 
primary source of uncertainty is the underlying illness, whilst healthcare 
professionals are considered as a secondary source of uncertainty.   
As mentioned earlier, advising people about potential long-term health changes 
might help ameliorate these feelings of uncertainty and prepare them for the 
possibility that their health will deteriorate and that they will need to undergo further 
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interventions. However, a qualitative study with people with systemic lupus 
erythematosus and rheumatoid arthritis found that uncertainty may persist even when 
people are well informed about their condition, suggesting the distinction between 
the subjective perception of uncertainty and the objective lack of information 
(Cleanthous et al., 2013). Furthermore, some people in the present study sought 
professional psychological support to help them cope with uncertainty-related stress. 
Taken together, these findings suggest that provision of information needs to be 
accompanied by psychological support readily available for individuals who require 
it, as it might help them cope with the increasing emotional impact resulting from 
uncertainty. The need for psychological support is further supported by data which 
indicate that up to 40% of people with ACHD may seek mental health treatment at 
some point in their lives and generally favour the provision of psychological 
treatment (Kovacs et al., 2009a). However, a qualitative exploration of people’s 
educational needs highlighted that the provision of psychological support was an 
“unfulfilled” need for people with ACHD as they lacked knowledge about the 
availability of such resources (Rönning et al., 2008). Identification of individuals in 
need of psychological support by their clinicians might not be straightforward as 
people with ACHD do not always share their negative emotions with healthcare 
professionals (Cornett & Simms, 2014). In the present study most people reported 
seeking emotional support from family and friends and some reported contacting 
their healthcare professionals for reassurance. On the other hand, some appeared to 
be apprehensive about sharing their emotions in order to protect family and loved 
ones (section 10.4.4, page 352). This finding highlights the importance of not just the 
provision of psychological support but also the need to encourage people with 
ACHD to actively seek support. 
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10.5. Summary 
The present study explored the experiences of people with ACHD and the ways they 
adjust to living with ACHD. The overall narrative indicated that people with ACHD 
utilised coping strategies that helped them minimise the impact of ACHD on their 
HRQoL in terms of physical, social, occupational, and psychological functioning. 
People with ACHD had clear goals in relation to their health and managed to adjust 
to living with ACHD by accepting their condition and integrating their limitations 
and treatment into their daily lives. They sought to gain perspective over their 
experiences by comparing themselves to others in similar situations and maintaining 
a positive outlook. People’s social environment appeared to have an important role 
in helping them cope with their condition and it was these coping efforts that 
influenced the degree to which they experienced an impact on their physical, social, 
occupational, and psychological HRQoL. People with ACHD experienced 
limitations in their activities, impact on their work lives, and a number of negative 
emotions. Uncertainty about the future was a common concern amongst all people 
and for women family planning and pregnancy was particularly emotional. Health 
deterioration and changes in the treatment regimen over time appeared to be 
influencing both the coping attempts and the impact of living with the condition. The 
findings of this study could help inform patient education and psychological support 
especially in relation to illness and treatment progression. 
The following chapter will now bring together the findings from the quantitative and 
qualitative enquiries in order to discuss the contribution of the thesis to existing 
knowledge and the implications for research, theory, and practice.
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CHAPTER 11 – GENERAL DISCUSSION 
11.1. Prologue  
The findings of each study have been discussed in their corresponding chapters in 
the thesis. This final chapter offers a broad discussion of the key findings of the 
quantitative and qualitative studies reported in Chapters 7 to 10 and how these fit 
with previous research reported in Chapters 2 and 3 of the thesis. The discussion 
begins with the main aims of the thesis followed by a synthesis of the findings from 
the quantitative and qualitative studies. The overall aims are discussed in relation to 
how these studies make a contribution to the literature in the area. The chapter 
concludes with the strengths and weaknesses of the studies in the thesis, a discussion 
of the implications for practice, and recommendations for future research. 
11.2. Thesis aims 
The overall aim of the study was to investigate HRQoL and the factors associated 
with HRQoL in ACHD. It also sought to examine changes in HRQoL and 
psychosocial functioning over time. The qualitative study aimed to examine the 
experiences of people with ACHD and how they adjust to living with ACHD. The 
specific aims and hypotheses are described in more detail in section 4.3 (page 127). 
11.3. Synthesis of the findings from the quantitative and qualitative studies 
The following sections seek to integrate the findings from the quantitative and 
qualitative studies in this thesis and discuss the overarching conclusions within the 
existing literature and the main implications of the study as a whole. The integration 
of the findings from mixed methods at the interpretation stage of a research is 
considered important for achieving the full potential of this approach (O'Cathain, 
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Murphy, & Nicholl, 2010). The assimilated findings provided various insights with 
regards to the role of structural complexity in relation to HRQoL, the dynamic 
aspects of HRQoL, general methodological considerations, and the wider theoretical 
implications within the context of the SRM. 
11.3.1. The role of structural complexity in relation to HRQoL in ACHD 
As indicated in Chapter 1, ACHD consists of a heterogeneous group with differing 
structural changes in the heart. This heterogeneity coupled with the lack of a gold 
standard in the categorisation of ACHD in general and structural complexity in 
particular, has resulted in much research that has incorporated heterogeneous groups 
when examining HRQoL. In the systematic review of the literature in Chapter 2 it 
became evident that the lack of definition of these mixed samples produced 
inconsistent findings across studies that examined HRQoL in ACHD and limited the 
ability to draw clear inferences about the impact of ACHD on the HRQoL of various 
groups that fall under the umbrella ACHD. The present study sought to examine 
HRQoL using four diagnostic groups defined by the structural changes of their heart 
defect. Comparisons were made between these groups and to the general healthy 
population. 
The main findings from the quantitative study indicated that the SV group 
experienced reduced HRQoL in physical and psychosocial domains compared with 
both the general population and all the other groups of ACHD in the study. Impaired 
psychosocial HRQoL was also evident in the Simple group compared with the 
general population. These findings have important implications regarding the 
expected psychosocial impact of ACHD, especially in certain diagnostic groups. The 
significant physical and psychosocial morbidity may be expected in people with SV 
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due to the complexity of their condition. Both previous quantitative and qualitative 
studies in ACHD have supported this finding (e.g. Angeli et al., 2012; van den 
Bosch et al., 2004, Overgaard et al., 2013). The individuals with SV have increased 
illness and treatment demands with a higher risk of complications, need for frequent 
health monitoring, and multiple interventions throughout their lifetime which would 
be expected to have an impact on their HRQoL. 
In contrast, people in the Simple group require less frequent outpatient appointments 
and are generally expected to be free from disease burden and to have good HRQoL. 
Some previous studies that focused exclusively on people with ASD (Ternestedt et 
al., 2001) and CoA (Buys et al., 2014), both of which were included in the Simple 
group in the present study, also reported diminished psychosocial HRQoL in this 
group compared with the general population supporting the findings of the present 
study. These findings indicate that the relationship between structural complexity 
and HRQoL is not a simple linear relationship where decreasing structural 
complexity leads to better HRQoL.  
The issue for the Simple group may be more related to their perception driven by 
illness and treatment experiences, which may play a role in the evaluation of their 
HRQoL. Earlier experiences including surgery may shape people’s expectations 
about their future functioning. A study by Lane and colleagues (2002) found that 
people who were deemed surgically cured (a sample that consisted of people with 
ASD, VSD, PS, AS) reported poorer HRQoL compared with the general population 
and with other groups not considered to be cured. In light of this evidence, it is 
possible that people in the Simple group in this study tend to perceive that they have 
been “cured” early in their lives, thereby entering adulthood with unrealistic 
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expectations and misconceptions about their functioning and the extent to which they 
will remain as patients and their medical needs later in life. The use of surgical terms 
such as “total correction” by medical teams may further enhance these perceptions of 
cure (Warnes, 2005). The realisation later in life that their health will likely decline 
more rapidly than anticipated and that they may require further medical or surgical 
intervention may come as a shock (Saidi et al., 2007). They may have built up 
expectations that they will be like the general population and this may be their 
reference point when completing a HRQoL questionnaire.  
It is also the case that the Simple group are likely to have long periods of stability in 
functioning which may reinforce their belief that they are cured. Their emotional 
response to any deterioration and limitations and changes in their health may be 
more extreme (Saidi et al., 2007). It was evident from the qualitative data of the 
present study that people’s experiences of sudden health deterioration or receiving 
information from healthcare professionals about the possibility of further health 
decline and re-operation during their adulthood were not always congruent with their 
expectations resulting in uncertainty and increased negative emotional consequences. 
These findings suggest that it is possible that the mismatch between expectations 
about the illness course and experience may lead to significant emotional impact. It 
may be that the emotional consequences of ACHD are more salient for people in the 
Simple group because they may find it harder to adjust their expectations, especially 
since they are more likely to experience longer periods of health stability without 
symptoms and re-interventions.  
If this interpretation is correct, these findings are important considering the evidence 
that suggest that people may form misconceptions and lack clear understanding 
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about their condition during their childhood which they may carry into adulthood 
(Veldtman et al., 2000). A study of people with ACHD further identified gaps in 
their knowledge especially with regards to the physical restrictions and the purpose 
of the follow-up, suggesting that they may lack understanding about illness 
progression and may experience unnecessary self-imposed restrictions which may 
subsequently impact on their social integration (Moons et al., 2001). This was 
apparent in the interviews of the present study, where people noted that lack of clear 
information from doctors heightened uncertainty about their condition, its treatment, 
and its future impact on their lives.  
The pattern of quantitative and qualitative findings in the present study also indicated 
a lack of a coherent understanding of the illness as a whole as people did not 
attribute many severe symptoms and consequences to their ACHD, had an average 
understanding of their condition, felt unsure about the degree of personal control 
over their ACHD but believed that their treatment was beneficial. These perceptions 
along with negative emotions were found to be influential for people’s HRQoL in 
the quantitative study. More specifically, people who perceived more severe 
symptoms and greater consequences due to their ACHD, those with higher anxiety 
levels and those with depressive symptoms had poorer HRQoL. Furthermore, 
perceived uncertainty appeared to be related to increased negative emotions 
including frustration, stress, and anxiety in the qualitative study. These findings are 
in agreement with the wider chronic illness literature that has demonstrated the 
impact of negative illness perceptions and mood problems on HRQoL in heart 
failure, coronary heart disease, myocardial infarction, cancer, arthritis, diabetes, 
asthma, HIV, and epilepsy (Gaynes et al., 2002; Hagger & Orbell, 2003; Hallas et 
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al., 2011; Petrie et al., 2007, Ruo et al., 2003; Stafford et al., 2007). The findings 
also support the conclusions of Schoormans and colleagues (2014) who have 
reported that negative emotional and cognitive perceptions were significant 
determinants of poorer HRQoL outcomes two years later. Thus it appears that 
although there is some evidence of structural complexity driving HRQoL (e.g. SV 
group) people’s perceptions about their ACHD and their emotions also appear to 
have a significant influence on HRQoL.  
It may be expected that people with more complex ACHD hold more negative illness 
perceptions and mood problems. This was evident in the present study, where the SV 
group perceived their condition and its impact more negatively than the other groups 
and had a high percentage (27.3%) of people with depressive symptoms. This may 
help explain their poorer HRQoL compared with the general healthy population and 
the other groups in this study. For this group, such negative illness perceptions may 
therefore be accurate reflections of their poorer clinical state. However, the study by 
Schoormans and colleagues (2014) indicated that there were people with less 
complex conditions who also had unwarranted negative illness perceptions about 
their condition and its emotional impact which negatively influenced their HRQoL. 
In the present study, the Simple group had the highest percentage (28%) of people 
with depressive symptoms. People in the Simple group also had a more negative 
perception about illness curability and a more positive perception about illness 
chronicity (shorter duration) than other groups suggesting that they did not view 
their current treatment as helpful and did not believe that their illness would last as 
long as other groups, which appear to be contradictory. As discussed earlier, the 
expectations and perceptions people form following their treatment experiences may 
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explain the impaired psychosocial HRQoL in this group. It is possible that the lower 
scores in the curability subscale in these adults reflect the realisation that past 
treatments were not curative and that further problems and re-operations are likely 
after a long period of clinical stability. Alternatively, there may be people who 
perceive their current treatment as less helpful and potentially intrusive because they 
are physically well but they are still required to attend regular appointments. 
Although the study did not set out to examine the role of treatment perceptions in 
detail, this is an area of investigation that may be fruitful in accounting for the 
differences observed in this thesis. This will be discussed in the following section. 
11.3.1.1. Implications for the use of structural complexity in HRQoL research 
The findings discussed in this section raise the important question of the extent to 
which categorisation of ACHD based on structural complexity is of value when 
studying HRQoL. The ACHD population is highly diverse consisting of various 
diagnoses and structural changes. Guideline reports from various organisations 
around the world argue for their formulation for the classification of ACHD, each 
proposing their own in order to guide clinical practice and no gold standard exists. 
These categorisations are often broad and while they differ in the way they 
categorise specific diagnoses, all commonly attach labels like simple/mild, moderate, 
and complex/severe in order to describe the groups by disease complexity. Perhaps 
the most widely known is the Task Force 1 classification system of the American 
Heart Association, which is based on the underlying diagnosis and the need for 
regular monitoring (Warnes et al., 2001). 
The way in which such broad systems categorise various diagnoses has received 
criticism in recent publications for their inability to capture the true impact of illness 
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on people’s experiences (Jackson et al., 2015). According to the Task Force 1, TGA 
and SV are both categorised as complex. However, SV is associated with increased 
morbidity, mortality, and long-term complications (e.g. hemodynamic issues) that 
may not be typical in other diagnoses including TGA (Jackson et al., 2015). It is 
questionable the extent to which this and other similar broad categorisations 
sufficiently differentiate between the most complex and comparatively less complex 
diagnoses. Another way used to categorise ACHD is the use of the NYHA 
classification. However, this classification represents various levels of functional 
status and is not specific to ACHD, thus it does not take into account the underlying 
structural change in the heart and by extension the heterogeneity of ACHD.  
In view of the limitations of previous categorisation efforts, the present study 
followed an approach that allowed for clear distinction between various diagnostic 
groups defined by their structural changes in the heart. There were evident 
differences between the diagnostic groups and the general population providing 
some support for a categorisation based on structural complexity. However, the 
unexpected finding with regards to the impaired psychosocial HRQoL in the Simple 
group may suggest that this categorisation could be potentially expanded to include 
factors relating to expectations and illness and treatment experience. A more 
comprehensive evaluation of the treatment history (e.g. nature of treatment – 
curative operation, corrective operation, palliative operation, inoperable, medication) 
along with an assessment of expectations should be considered to supplement any 
use of the classification based on structural complexity. This will enable an 
examination of the classification based on structural complexity to be investigated in 
relation to expectations and perceptions about treatment and subsequently HRQoL.  
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Considering the importance of illness perceptions in relation to HRQoL in this study, 
the assessment of treatment perceptions may be useful in establishing whether these 
vary between the diagnostic groups. Evidence from cardiac disease have indicated 
that treatment perceptions are more complex than the single-item approach of the 
present study and qualitatively different than illness perceptions (Hirani, Patterson, 
& Newman, 2008).  
Measures have been developed to examine in more detail the various aspects of 
treatment perceptions (e.g. value, concerns, decision satisfaction, and cure). The 
assessment of treatment perceptions is particularly relevant in ACHD due to the fact 
that treatment is a major aspect of people’s experience of their condition. A variety 
of different treatment approaches may be followed even within a diagnostic group. A 
person in the Simple group who has received surgery deemed “total correction” and 
who experiences long periods of clinical stability and minimal limitations would 
likely perceive their current treatment differently to that of someone with SV who 
has received palliative surgery and continues to experience significant limitations. It 
would be expected that these differing perceptions are likely have an impact on their 
reports of HRQoL. In light of the evidence discussed above that suggested 
differences in HRQoL between treatment groups (cured, palliative, medical etc.) in 
ACHD (Lane et al., 2002) coupled with the differences observed between diagnostic 
groups in illness perceptions in the present study and their role in relation to HRQoL 
point to the need for further research in order to establish whether treatment 
characteristics interact with structural complexity to influence illness and treatment 
perceptions and subsequently HRQoL.  
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In summary, categorisation by structural complexity in the present study has 
provided some value in differentiation of ACHD and HRQoL along with illness 
perceptions and mood. This approach addressed some of the limitations of previous 
approaches in studying ACHD as a homogeneous group and has helped laid the road 
for future research. In terms of outcomes research the consideration of factors 
relating to treatment experience need to be considered in combination or alongside 
structural complexity in order to examine how their relationship with illness and 
treatment perceptions and mood may influence HRQoL in ACHD.  
11.3.2. The dynamic aspects of HRQoL in ACHD 
11.3.2.1. The life stage 
ACHD is a lifelong condition that for most people (>60%) is diagnosed early in their 
lives (Knowles & Hunter, 2014). People with ACHD are expected to go through the 
same life stages and developmental tasks as healthy individuals but they have to do 
so by adapting to illness-related, treatment-related, and life challenges at each stage. 
Guidelines have been published highlighting the need to consider the various life 
stages along with their relevant developmental tasks when helping people adjust to 
ACHD (Foster et al., 2001). 
The findings of the present study indicated that younger people have poorer 
psychosocial HRQoL and greater ACHD-specific worries (e.g. employment, family 
planning) compared with older individuals. This finding supports previous studies in 
ACHD that have found positive relationship between age and psychosocial HRQoL 
(Silva et al., 2011; Schoormans et al., 2014). In particular, people in the present 
qualitative study reflected on how earlier experiences during their young adulthood 
such as previous operations, challenges in family planning and pregnancies had been 
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particularly distressing. This is not surprising since young adulthood is a transitional 
life stage where establishing independence and social relationships, pursuing 
employment, and starting a family are pertinent issues as opposed to the relative life 
stability that characterises older adulthood (Sable et al., 2011).  
Comparisons between the longitudinal findings of the present study and previous 
studies in ACHD can provide further insight with regards to life stage and HRQoL. 
In the present study HRQoL remained stable over the period of the follow-up, 
whereas previous studies found changes in certain HRQoL domains. Ebenroth and 
Hurwitz (2007) reported decrease in vitality in people with TGA over a period of 9 
years, while van Rijen and colleagues (2005a) reported increase in negative emotions 
and decrease in social inhibition in a mixed sample over a period of 10 years. A 
potential explanation for the discrepancy is that previous studies captured changes in 
HRQoL over a much wider time span and during a transitional period in the people’s 
lives (from young to middle adulthood, 18 to 30 years of age) when their condition 
may be particularly salient due to the challenges associated with young adulthood.  
Whereas the present study examined participants on average from mid to late 30s 
which may be a relatively stable period of life for most of the participants. During 
their younger adulthood people with ACHD have to come to terms with their career 
choices, the timing issues and risks associated with pregnancy while also 
establishing independence and autonomy from their parents. This period may be 
particularly distressing because people with ACHD transitioned from adolescence 
where they may have experienced delay in developmental milestones because of 
their illness, including completing their education and choosing a career, increasing 
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their knowledge of their illness and responsibility for their medical care, and 
establishing independence from overprotective parents (Warnes et al., 2008). 
This is further supported by evidence from a recent meta-analysis of young adults 
with various paediatric chronic illnesses including CHD and healthy individuals. 
Young adulthood (18-30 years) appeared to be a critical period where young adults 
with chronic illness had difficulties finding employment, leaving the parental home, 
marrying, and becoming parents compared with their healthy counterparts (Pinquart, 
2014). However the fundamental limitation of the present study was the short 
follow-up time that was possible thereby limiting any longer term changes over time 
in HRQoL. 
The impact of ACHD on HRQoL was prominent in younger individuals but it 
appeared to subside as people grew older. This is interesting considering that as 
people get older and enter their third and fourth decade in life they may face other 
developmental challenges (e.g. maintaining rather than gaining employment, 
revising career goals, facing the prospect of premature death and its impact on the 
family) that may influence their HRQoL (Sable, 2011). 
These findings need to also be considered within the wider context and in relation to 
aging and HRQoL in the general population. A large cross-cultural study with over 
10,000 participants from the US and UK general population has found that age had a 
negative effect on physical HRQoL but a positive effect on psychosocial HRQoL 
(Franco et al., 2012). The authors attributed these findings to the deterioration of 
body functions and capabilities and better coping abilities and adaptation in people 
as they grow older respectively. Older age was not associated with a reduction in 
physical HRQoL in the present study possibly because people with ACHD would 
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have not have experienced “normal” health like an average healthy individual. It is 
also likely that as people with ACHD age they interpret emergent impairments in 
their functioning as part of the aging process (Bruto et al., 2001).  
On the other hand, the increase in psychosocial HRQoL with increasing age may be 
attributed to well-developed coping strategies and maturation processes. For 
example, research in healthy populations has indicated that HRQoL can increase 
with age due to adjustment in goals and personal growth (Netuveli & Blane, 2008). 
Studies in other chronic illnesses provided similar explanations. In a mixed methods 
study examining the impact of age on HRQoL in people with heart failure Moser and 
colleagues (2013) found that as people aged they gained perspective by appreciating 
their accomplishments (e.g. having a family), seeing the positive, and comparing 
themselves to other people in similar situations. The pattern of findings in the 
quantitative and qualitative studies in the present thesis indicated that people with 
ACHD engaged in adaptive coping strategies including acceptance, normalization, 
social comparisons, and maintaining a positive outlook. This is consistent with 
previous studies in ACHD (e.g. Claessens et al., 2005; van Rijen et al., 2004).  
Although the studies in this thesis cannot definitively answer the question whether 
the coping strategies people used had evolved since their young adulthood, 
comparisons with studies in younger populations do provide some suggestive 
evidence. In contrast to the more adaptive coping strategies used by people in the 
present study, denial and avoidance emerged as the dominant coping strategies in 
studies with children, adolescents and young adults with CHD (e.g. Zahmacioglu et 
al., 2011). This may suggest how maturing and growing up with ACHD can 
encourage the use of more adaptive coping strategies in people with ACHD. 
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Furthermore, the present study also revealed that the illness trajectory can 
significantly influence how people cope with their condition and adjust to living with 
ACHD. The next section will discuss the findings in relation to how illness 
progression can influence people’s experiences with living and adjusting to ACHD. 
11.3.2.2. The illness trajectory 
Despite the usual developmental challenges, people with ACHD also have to adapt 
and cope with the challenges caused by their underlying condition. According to the 
SRM changes in health over the course of a chronic illness can lead to a redefinition 
of the illness representation and the coping strategies people adopt to adjust to their 
illness (Leventhal et al., 2012). Periods of health deterioration or a change in the 
treatment may therefore redefine the illness experience. 
Changes in health and treatment over the course of the study were prominent in the 
narratives of some participants in the qualitative study and they influenced their 
perceptions about the impact of ACHD on their HRQoL as well as their coping 
efforts. People who reported a change in their health and treatment over time 
struggled to cope with this change and during these periods people strived to adjust 
to the changing demands of their illness by enhancing the use of coping efforts. On 
the other hand, there was evidence of clinical stability in the sample as a whole in the 
quantitative follow-up study, as measured by recorded clinical data on the number of 
interventions, hospitalizations, and medication during the follow-up study. While 
these are key indicators of illness progression, there are other clinical factors not 
measured in the follow-up study, which may signify a change in people’s clinical 
status over the period of the follow-up. For example, even more subtle changes such 
as a new symptom, new information from healthcare professionals, or further 
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diagnostic tests to detect health deterioration can often evoke a process of 
redefinition of the illness experience (Leventhal et al., 2012). These subtle changes 
may not be reflected in the clinical records. It is also possible that the stability in 
health and treatment observed in the follow-up study is due to the fact that illness 
progression as measured by clinical records is variable in people with ACHD. The 
observation of clinical stability as well as stability of HRQoL and psychosocial 
factors at the group level may be accounted for by the short length of follow-up and 
that people were not assessed in relation to any clinical event.  
This is in contrast to the qualitative study where the interviews focused on individual 
experiences and revealed the variability in illness experience amongst individuals. 
The interviews allowed people to reflect on their experiences, take and express a 
longer term perspective, and therefore captured the individual and dynamic 
processes in the illness experience. While HRQoL appeared to be relatively stable 
over time in the questionnaires, there was considerable ongoing readjustment taking 
place for people who experienced illness progression in the qualitative study. This 
may help explain why certain illness perceptions changed (e.g. increase in illness 
coherence) while all other factors remained stable during the quantitative follow-up 
study. 
Previous studies in chronic illnesses, including osteoarthritis and diabetes have also 
found that changes in illness perceptions over time were associated with illness 
progression (Bijsterbosch et al., 2009; Lawson et al., 2008). These changes may be 
part of people’s continuous efforts to make sense of new information and gain sense 
of coherence, establish a stable self-image, cope with the increasing demands of their 
condition and treatment, and maintain or restore their HRQoL. 
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Although coping strategies and social support had little or no contribution in 
explaining HRQoL in the quantitative study, the impact of the illness trajectory was 
evident in the use of coping strategies by people in the qualitative study. People’s 
coping efforts were influenced by illness progression, as the changing demands of 
their condition and treatment caused people to intensify their coping efforts. It may 
be that coping and social support become more influential for HRQoL when illness 
conditions show a marked change, when they encounter a situation where they need 
to re-evaluate their coping strategies and social support in order to maintain or 
restore their HRQoL. In the qualitative study, coping efforts, including social 
comparisons, positivity, and social support varied, even day-to-day, dependent on 
situational factors revealing the dynamic aspects of these processes in people with 
ACHD. In line with previous studies in ACHD (Berghammer et al., 2006; Claessens 
et al., 2005), the degree to which symptoms, limitations, and treatment demands 
interfered with people’s lives was dependent on whether they were able to accept 
and incorporate them into their daily lives. The qualitative study indicated that this 
was intensified during periods of illness progression and symptomatic flares. In an 
effort to cope with their illness and treatment as well as the increased uncertainty that 
accompanied changes in these aspects, people also attempted to gain perspective by 
comparing themselves to others in similar positions and viewing their illness and 
treatment in more positive terms. Furthermore, in order to cope with the loss of 
control caused by their illness some people re-prioritised and focused on the aspects 
they could control, for example their diet and exercise. 
Qualitative research in chronic illness have previously suggested that “letting go” of 
control was linked to sense of coherence, which included a search for meaning and 
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accepting that certain aspects of the illness are not controllable (Aujoulat, 
Marcolongo, Bonadiman, & Deccache, 2008). Similarly, embracing uncertainty and 
viewing it as opportunity rather than threat is believed to aid adjustment in chronic 
illness (Mishel & Clayton, 2008). Considerable research is now focused on 
examining the role of hope, benefit finding, sense making, personal growth, and 
other related concepts pertaining to the positive aspects of living with a chronic 
illness and how these may aid adjustment (de Ridder, Geenen, Kuijer, & van 
Middendorp, 2008). In view of this evidence, the present findings suggest that 
perceived uncertainty and lack of personal control may be viewed as a potential 
opportunity for personal growth and with the use adaptive coping strategies (e.g. 
social comparisons, positive re-interpretation, re-prioritisation) people can 
experience positive outcomes including improved HRQoL.  
In the qualitative study, social support was also an important coping resource that 
served various functions, ranging from instrumental (helping with responsibilities, 
adjusting social activities), emotional (encouragement, confidence-building, 
understanding), to informational (getting information from healthcare professionals) 
and played a significant role in people’s adjustment. In line with previous studies 
(Pike et al., 2012), the quantitative and qualitative findings of the study indicated that 
people perceived high levels of social support from their environment and support 
previous studies reporting that people with ACHD experience few inconsistencies 
between their preferred and received support (van Rijen et al., 2004). This may be 
due to the shared experiences of the illness between people with ACHD and their 
partner, family, and friends that resulted in social support practises becoming 
habitual or as one interviewee characterised it “just unsaid but brilliant”. 
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Especially during stressful periods of health deterioration people reported seeking 
informational support from healthcare professionals and turned to their social 
environment for emotional support in order to cope with their condition. This may 
suggest that the benefits of social support for HRQoL are situation-specific 
(DeLongis & Holtzman, 2005) and may explain why social support was not found to 
be associated with HRQoL in the quantitative analyses of the present study or 
previous studies in other chronic illnesses including heart failure (Luttik, Jaarsma, 
Moser, Sanderman, & van Veldhuisen, 2005) and stroke (Kruithof, van Mierlo, 
Visser-Meily, van Heugten, & Post, 2013).  
In summary, the findings from the qualitative study indicated that the way people 
coped with ACHD was influenced by illness progression as the changing demands of 
their condition and treatment caused them to intensify their coping efforts. This 
suggests that coping is an ongoing process that can vary in intensity depending on 
the illness trajectory perhaps making coping strategies and social support more 
influential for HRQoL during stressful periods of health deterioration and change in 
treatment. This is common in chronic illnesses where people continually need to 
readjust to the demands of their illness, cope with different facets of the illness, and 
adapt their coping strategies according to the stressor at hand and at particular 
timeframes (DeLongis & Holtzman, 2005).  
11.3.2.3. Implications for the study of change 
The discussion in this section indicated that HRQoL in ACHD needs to be viewed 
within people’s life stage as each is associated with various different developmental 
tasks which can pose additional challenges that people need to cope with in addition 
to illness-related issues. Much of the existing literature included mixed samples of 
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adolescents and adults which complicates the interpretation of the findings with 
regards to HRQoL in ACHD (Apers, Luyckx, & Moons, 2013a). Viewing the 
findings of the present study within the existing literature indicated that there are 
critical periods (i.e. transitional periods) in people’s lives when they may be 
vulnerable to experiencing reduced HRQoL. Furthermore, changes in HRQoL need 
to also be viewed within the broader life context of the individual as there are key 
transitional periods where these changes are more likely to occur (e.g. adolescence to 
adulthood, young to middle adulthood). These ongoing processes across people’s 
lives are important in the context of a long-term condition like ACHD as flexibility 
may be required in order for people to adjust.  
ACHD is a progressive illness and like other chronic illnesses is characterised by 
stressful periods of health deterioration, flare-ups, and changes in the treatment 
regimen which can make adjustment complex, with considerable variability across 
persons, time, and contexts (Hoyt & Stanton, 2012). More research is needed to 
study how HRQoL may change following such periods and what factors may predict 
HRQoL. Studies with targeted follow-ups (e.g. before or after interventions) may 
help determine the best timing for interventions targeting modifiable factors 
including illness perceptions and mood that aim to improve HRQoL. As the 
qualitative findings suggest the ways people mobilise their coping efforts can also 
evolve not just over people’s life course but also over the illness trajectory making 
their effects on HRQoL situation- and time-dependent. Compared with quantitative 
studies, qualitative studies as in the case of this thesis are important in capturing the 
dynamic aspects of coping and social support. 
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The period of follow-up may be extended in future longitudinal studies with multiple 
targeted follow-ups in order to capture trajectories of change (both individual and 
group) in these processes and how they may influence HRQoL. Another method that 
allows for the examination of the fluctuations in both an individual and group level 
are daily process methods which involve day-to-day monitoring of the study 
variables (DeLongis & Holtzman, 2005). This method may not only reduce recall 
error but may accurately capture daily variations in the use of coping strategies and 
social support and their influence in HRQoL and may detect more subtle changes 
that correspond to those observed in the present qualitative study. This may 
contribute to a better understanding of the role of coping and social support in 
relation to HRQoL in ACHD especially during critical periods in the illness 
trajectory. Furthermore, a different approach to studying coping, such as clustering 
people with ACHD on the basis of coping profiles may provide further insight about 
the relationship between coping profiles and HRQoL across the illness trajectory. 
11.3.3. General methodological considerations 
Some methodological points have been discussed in the previous sections in 
particular the categorisation of ACHD, sample definition, and methods to assess the 
dynamic aspects of the factors under study. The present study also raised some 
general methodological considerations with regards to the development of disease-
specific measures and the use of mixed methods.  
The present study utilised both generic and disease-specific measures to examine 
HRQoL in ACHD as their combination is believed to offer information on general 
HRQoL and disease-specific issues in the population under study (Fletcher et al., 
1992). The selection of a disease-specific HRQoL measure was limited as the CHD-
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TAAQOL is the only available measure for use in ACHD. However, as discussed in 
Chapter 7 of the thesis the CHD-TAAQOL had limited capacity in discriminating 
between the four diagnostic groups of the study. Significant group differences were 
only observed in the impact of cardiac surveillance but not in symptoms and worries 
subscales. Thus the measure was only able to discriminate between the groups in the 
more objective subscale (i.e. impact of cardiac surveillance). 
Taking into account the group differences observed in certain subscales of the 
generic SF-36 measure (e.g. physical functioning, vitality, social functioning), it was 
expected that group differences would be even more pronounced in the disease-
specific measure since it is concerned with issues more relevant to ACHD. 
Examining the mean scores in the subscales of the CHD-TAAQOL across the four 
diagnostic groups indicated that the measure may be able to discriminate between the 
most complex (SV) and the least complex (Simple) group but not between the 
intermediate groups (e.g. ToF, TGA). This is not surprising since in the initial 
validation study by Kamphuis et al. (2004) the measure was used to distinguish 
between mild (not requiring specialist follow-up) and complex (requiring specialist 
follow-up) ACHD. 
Considering the heterogeneity of ACHD and the fact that SV is substantially 
different from TGA and ToF (different symptomatology, residual issues, and long-
term complications) a disease-specific measure with more sensitivity is needed that 
has the ability to discriminate across the full spectrum of structural complexity in 
ACHD and not just between the relatively healthy and ill populations. 
Two main problems may have contributed to the limitations of this measure 
including the specific issues it tackles and the scoring of the subscales. The CHD-
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TAAQOL includes various symptoms like shortness of breath, palpitations, 
dizziness, and cyanosis but not the full range of symptoms in ACHD, thus excluding 
others like fatigue, pain and exercise capacity or long-term complications of having 
ACHD. Furthermore, it does not tackle the impact of ACHD on physical and social 
activities in much detail and although there is a whole subscale on cardiac 
surveillance, the impact of medication and side effects from treatment are not 
addressed. The emotional impact of ACHD is addressed by the worries subscale 
which focuses on the degree of worrying about various issues but not directly 
assessing negative emotions as a result of ACHD. Overall, the issues covered by the 
CHD-TAAQOL may be more relevant to younger adults as issues relevant to the 
older population are not included (e.g. maintaining employment, retirement, re-
operations, premature death) (Foster et al., 2001). Figure 11.1 depicts the domains 
currently tackled by the CHD-TAAQOL and the suggested additions.  
The response format (frequency and emotional impact) of the measure may also be 
considered problematic especially for the items in the worries subscale. For example, 
asking participants how much they are worried about a specific aspect of their lives 
and then asking them how much this worrying bothered them may be redundant and 
unnecessarily complicated. Furthermore, the scoring of the responses assumes that 
when a problem is absent then the person is not bothered about it. This may not 
always apply in the case of the cardiac surveillance scale where a person might be 
bothered even if they have not had a specific test because they may feel that they 
needed to. These are some of the limitations of the CHD-TAAQOL that need to be 
addressed when developing new disease-specific HRQoL measures.  
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There has been significant progress in the children and adolescent literature with the 
development of disease-specific measures for the paediatric population including the 
Congenital Heart Disease Quality of Life Questionnaire (ConQoL; Macran et al., 
2006) and the Pediatric Cardiac Quality of Life Inventory (PCQLI; Marino et al., 
2008). However, there is lack of development of disease-specific measures for the 
adult population and is being increasingly recognised by researchers calling for 
disease-specific PROMs in ACHD (Cedars & Spertus, 2014). A disease-specific 
HRQoL measure in ACHD would need to be comprehensive and cover issues 
relevant to a wide age range across people’s adult life and the ability to discriminate 
between ACHD groups. The development of psychometrically sound, disease-
specific HRQoL measures is necessary to evaluate the effects of randomized 
controlled trials of new treatment approaches and changes in HRQoL following 
interventions and over time (Marino et al., 2008). 
CHAPTER 11 – GENERAL DISCUSSION 
386 
 
 
Note. Highlighted boxes indicate the suggested additional domains 
Figure 11.1. Domains currently tackled by the CHD-TAAQOL and suggested additions 
 
In addition to HRQoL, research in other chronic illnesses has previously highlighted 
the various limitations of generic coping measures and the need for disease-specific 
measures of coping. Generic measures like the Brief COPE do not distinguish 
whether certain coping strategies are effortful or habitual for the individual (Steed et 
al., 1999), or if they are effective and how effective they are. If coping is successful 
or when people use habitual coping behaviours, they may not be able to identify 
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what strategies they use to cope with ACHD in general. This is particularly relevant 
in ACHD because people may have already developed effective (or ineffective) and 
habitual coping strategies once they reach adulthood (having lived with the condition 
for most of their lives).  
Furthermore, asking people to consider how they usually cope with the stress caused 
by ACHD may be simplistic because ACHD as a stressor envelops several other sub-
stressors. It is hard to discern which stressor (i.e. the context) influences a person’s 
responses on the measure as a whole or even individual items. The limitations of 
generic coping measures are believed to be addressed to some extent by disease-
specific coping measures. Some authors argue that due to the dynamic nature of 
coping it may be more important to assess whether a person copes in a flexible and 
complete way rather than the type of coping they use as assessed by generic coping 
measures (Maes, Leventhal, & de Ridder, 1996). For example, people with chronic 
illness may need a variety of strategies to cope with various different stressors 
related to their illness and thus situation-specific coping behaviour may need to be 
assessed. In addition to disease-specific measures, daily diary methods discussed in 
the previous section can provide more information about the process and evolution 
of coping in the everyday lives of people with ACHD.  
Qualitative methods are also useful in studying the way people cope with ACHD and 
the use of mixed methods is considered an appropriate methodology to study the 
complexity of coping (Tashakkori, Brown, & Borghese, 2010). Coping and social 
support were two areas where the use of a mixed methods approach in the present 
study contributed to a better understanding of these processes in ACHD. The 
quantitative component dealt with the generic aspects of coping and social support, 
CHAPTER 11 – GENERAL DISCUSSION 
388 
 
whereas the qualitative component provided depth with specific contextual examples 
and the processes underlying these constructs. 
While there are inherent challenges when attempting to compare inconsistent 
findings from two different methodologies, they are best viewed as complementary 
that provide various plausible explanations for a relationship and open new areas of 
investigation (Tashakkori et al., 2010). The fact that the qualitative rather than the 
quantitative data provided more detail about the importance of coping and social 
support in relation to HRQoL supports the relevance of mixed methods approach in 
ACHD. As opposed to explaining variance in HRQoL which was the purpose of the 
quantitative component, the qualitative study revealed the meaning behind people’s 
scale scores. The qualitative study also revealed the disease-specific coping 
strategies that people used, some of which were not captured in the generic measure 
used in the quantitative study. The use of social comparisons and re-prioritisation as 
coping strategies are examples of the qualitative findings complementing the 
quantitative. The interviews allowed people to provide the context of coping and the 
nature of the stressor. For example symptoms, limitations, treatment regimen, 
uncertainty, and lack of control were all ACHD-related stressors that guided people’s 
coping efforts to restore and maintain their HRQoL.  
Finally, the interviews captured the dynamic elements of coping and social support 
indicating that in addition to the day-to-day challenges that people had to cope with, 
changes in the illness and treatment demands over the illness trajectory also 
influenced people’s coping efforts making them more relevant for HRQoL as people 
needed to re-evaluate and enhance their coping efforts in order to restore or maintain 
their HRQoL. The mixed methods approach was valuable in studying these 
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processes thereby overcoming the logistical limitations of including multiple follow-
ups or daily diary assessments. 
The concurrent embedded design used in the present study allowed for key aspects 
of the quantitative component to be explored further with the qualitative component. 
Alternatively, a sequential design where the qualitative study is conducted first 
would have revealed the pertinent issues for people with ACHD (e.g. uncertainty) 
which could have been evaluated in the subsequent quantitative study to determine 
their influence on HRQoL at population level. However, the concurrent embedded 
design was deemed appropriate for the present study which used the well-established 
SRM as a framework for testable research questions. The findings from the 
qualitative study complemented the findings of the quantitative studies and revealed 
constructs including uncertainty which may be used to expand the SRM. The 
theoretical implications of the study findings within the context of the SRM are 
discussed in the following section. 
11.3.4. Theoretical implications  
The aim of this section is to discuss the findings within the context of the SRM and 
the extent to which other factors fit within the SRM to enhance understanding about 
HRQoL in ACHD. According to the SRM, people’s emotional and cognitive 
representations of their illness play a significant role for outcomes including HRQoL 
(Leventhal et al., 1992). The findings of the quantitative study in the present thesis 
also found that people’s illness perceptions were associated with HRQoL, supporting 
the key role of cognitive processing in relation to HRQoL.  
Further evidence for the importance of cognitive factors can be seen from the 
findings of the qualitative study relating to uncertainty. Uncertainty has been the 
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focus of the UIT by Mishel (1990) who conceptualized uncertainty as a cognitive 
state, with set antecedents (i.e. stimuli, healthcare professionals/social environment) 
and an appraisal process (i.e. appraised as danger vs opportunity) which influences 
coping and subsequently adaptation. Based on previous findings in chronic illness, 
uncertainty can negatively influence HRQoL and overall adjustment (Cleanthous et 
al., 2013). The findings of the present qualitative study further indicated that 
uncertainty in people with ACHD was associated with increased negative emotions 
especially during periods of health deterioration. This could be interpreted within the 
SRM in terms of parallel cognitive (uncertainty) and emotional (worry) 
representation of a health threat (health deterioration). Elements of the UIT and in 
particular uncertainty could be therefore incorporated into the cognitive 
representation component of the SRM and future research may establish whether it 
influences or is influenced by illness perceptions or interacts with them to influence 
outcomes using validated measures of uncertainty (e.g. Mishel uncertainty in illness 
scale).  
Another expansion for the SRM concerns the incorporation of treatment perceptions 
or beliefs. As mentioned earlier in the discussion the importance of treatment 
perceptions has been demonstrated in other chronic illnesses and evidence has 
suggested that when considered together with illness perceptions in coronary heart 
disease they explain greater variance in outcomes than when each is considered 
alone (Newman et al., 2012). Leventhal and colleagues (1997) suggested that 
because treatments are designed to treat the illness, treatment perceptions may be 
viewed along the same dimensions of illness perceptions (e.g. time for effectiveness, 
ability to cure/control, consequences, symptoms etc.). Measures of treatment 
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perceptions examine in more detail various dimensions including value (treatment 
benefit), concerns (anxiety and worry of undergoing treatment), decision satisfaction 
(informational needs, decision-making process, and suitability of treatment), and 
cure (Hirani et al., 2008). 
The findings of the present study indicated differences between diagnostic groups in 
illness perceptions and demonstrated their importance for HRQoL. These findings 
along with evidence of the impact of type of treatment on HRQoL in previous 
studies (e.g. Lane et al., 2002) suggest that treatment perceptions may be a useful 
addition to the study of HRQoL in ACHD. Irrespective of their label (e.g. correction, 
palliation, medication etc.), most treatments in ACHD are directed at controlling 
rather than curing the underlying defect (with various success levels and need for re-
intervention in the long-term). Yet treatments may be perceived as cures rather than 
controllers of the condition by people with ACHD (Saidi et al., 2007). 
Examining both illness and treatment perceptions may offer greater insight into 
people’s perspectives and expectations especially prior to re-intervention during their 
adult lives. Rather than the sequential examination approach followed in the present 
study (see figure 5.1, page 163), it would be valuable to study the interaction 
between clinical and cognitive factors; whether people in the four diagnostic groups 
perceive their treatment differently, particularly in the cure dimension, and how 
these perceptions relate to their illness perceptions and their HRQoL.  
The practical implications of the findings discussed in the previous sections are 
addressed in section 11.6 (page 406).  
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11.4. Strengths and weaknesses of the thesis 
As with all research, there are methodological factors that may have affected the 
results or areas that require further exploration. The strengths and weaknesses of the 
quantitative and qualitative components of the thesis are addressed next. 
11.4.1. Quantitative studies 
11.4.1.1. Sample size 
Firstly, with 314 participants included, the cross-sectional study is one of the largest 
to have examined the HRQoL of people with ACHD to date. This was an adequately 
powered sample to find an effect in the ANOVA and regression analyses presented 
in Chapters 7 and 8 respectively. Although power calculations for HLM analyses are 
complex, the sample size for the longitudinal study presented in Chapter 9 satisfied 
the criteria recommended by Tabachnick and Fidell (2007), whereby a minimum of 
120 participants is required for two-level models. Therefore, both studies had enough 
power to test the research questions and hypotheses stated in Chapter 4. 
11.4.1.2. Sample composition 
It should be acknowledged that certain diagnoses might have been under-
represented, for example some diagnoses in the Simple group, which consisted of a 
large percentage of people with CoA. This could potentially limit generalizability 
across the entire population of people with ACHD, especially people who are 
followed-up by their local GPs as opposed to those who attend specialist outpatient 
clinics. However, including a representative sample of the several different 
diagnoses would require a very large sample size, a problem acknowledged across 
the entire ACHD literature. Although the time frame and resources in the present 
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study did not allow for the inclusion of all possible ACHD diagnoses, the most 
common were well represented across the diagnostic groups.  
A strength of the current study compared with previous literature is the 
categorisation of participants in diagnostic groups which were clearly defined in 
their inclusion and exclusion criteria. This facilitated comparisons between four 
distinct diagnostic groups in Chapter 7.  
11.4.1.3. Selection and non-response bias 
The lack of an electronic records system of all individuals attending the GUCH 
clinic at The Heart Hospital, London influenced the recruitment strategies used in the 
study to identify potential participants, which might have inadvertently resulted in 
selection bias. Active patients were identified through paper forms, however not all 
of them were recorded in these forms. As discussed in Chapter 1 (section 1.9, page 
44), a common issue in ACHD clinics around the UK is the large number of people 
lost to follow-up, especially during the transition period from paediatric to adult 
clinics (Wray et al., 2013). It is likely that people who were lost to follow-up are in 
better health and have better HRQoL than those who are still followed-up at the 
GUCH clinic. Although not a limitation of the study itself, this has influenced the 
recruitment strategies used in the current study to identify potential participants and 
might have resulted in some selection bias. However, efforts have been made to 
include newly referred individuals identified from outpatients’ clinic lists, who 
would be otherwise missed if the recruitment was limited to paper forms (section 
5.4.3.2, page 134). 
As with many longitudinal studies, there is a question of whether sample attrition 
resulted in non-response bias. The response rate in the study was 60%. Participants 
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who completed the follow-up study were found to be similar to those who did not in 
all variables measured but depressive symptoms. As participants who did not 
complete both assessments were more likely to have depressive symptoms, it is 
possible that they represent a group who experienced significant change in either 
their HRQoL or psychosocial functioning. However, it should be noted that the 
effect size was rather small which is reassuring.  
11.4.1.4. Measures 
All studies described in this thesis relied on the use of self-report measures, which 
are believed to be subject to self-representation and recall bias. In order to minimise 
these bias, it was ensured that participants were aware that they were no right or 
wrong answers and that their responses were anonymous and confidential.  
The study did not include a composite measure of socioeconomic status. The 
common indicators of educational level and employment status were recorded, 
however income was not assessed as it can be volatile and fluctuate throughout the 
year/lifetime. A comprehensive and accurate assessment of socioeconomic status 
would require a large number of questions and coupled with the sensitivity of the 
topic (especially income), may result in a low response rate (Grundy & Holt, 2001). 
Since health inequalities was not the focus of the study, a comprehensive measure of 
SES was not deemed necessary, especially as education and employment were 
recorded.  
The selection of a disease-specific measure of HRQoL used in the present study was 
limited to the CHD-TAAQOL, which compared with the generic measure did not 
appear to be sensitive enough to detect differences between the four diagnostic 
groups (section 7.4.2.2, page 227 and section 11.3.3, page 382). This suggests that 
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the measure may be lacking discriminant validity. The CHD-TAAQOL is relatively 
new and the present study is the first to have used this ACHD-specific measure to 
study differences in HRQoL between diagnostic groups. Therefore, the validity of 
the measure needs to be further examined in future studies of people with ACHD. 
The use of brief versions of some measures may be considered a limitation. For 
example, in the Brief IPQ each of the illness perceptions dimensions is measured 
using a single item, thus the nature of some constructs may not have been fully 
captured within the items. The revised version of the IPQ (i.e. IPQ-R) might have 
provided more detailed evaluation of people’s illness perceptions. However, owing 
to the large number of constructs being examined, a pragmatic decision was made to 
include brief versions of measures, where available, in order to minimise participant 
burden.  
Although floor/ceiling effects are most commonly discussed within the context of 
experimental research, they can also influence non-experimental research. As 
reported in Chapter 5, a few subscales of the measures exhibited floor/ceiling effects, 
which may impact on the ability of a test to detect significant group differences 
(caused by heterogeneity of variance across groups) and may reduce measure 
responsiveness in longitudinal studies examining change. In the present study, 
heterogeneity of variance was taken into account in the ANOVA for group 
differences by employing the Welch test where appropriate, which is more robust 
against this violation. In addition, comparisons of the findings from parametric and 
non-parametric tests revealed the same differences, increasing the confidence in the 
findings reported in the thesis. Transformations may be conducted to deal with non-
CHAPTER 11 – GENERAL DISCUSSION 
396 
 
normality and ceiling/floor effects, however in the present study preliminary 
transformations failed to improve the distribution of the variables affected. 
It is possible that lack of change in the variables affected by floor/ceiling effects 
reflected the limited potential for improvement or deterioration during the follow-up. 
It is unclear what systematic impact these effects may have had on the results of the 
longitudinal study but their presence means that although there appeared to be no 
change in the affected variables over during the follow-up, there might have been 
little room for improvement/deterioration (Hessling, Traxel, & Schmidt, 2004). 
This may have greater implications for future intervention studies that aim to 
evaluate change in HRQoL and other psychosocial variables as the responsiveness of 
the measures may be compromised by floor and ceiling effects. However, it should 
be noted that generic HRQoL measures are often affected by these effects, as a result 
of using population-based measures in chronic illness samples. Substantial ceiling 
effects were observed only in two subscales of the SF-36 in the present study. As 
Bindman, Keane, and Lurie (1990) argue, ceiling effects are less of a concern 
because at a practical level researchers are less likely to search for improvements in 
HRQoL among those who already have excellent HRQoL. Thus, the SF-36 may still 
be an appropriate measure for use in future intervention studies, especially if it is 
accompanied by disease-specific HRQoL assessments. 
One strength of the thesis is the inclusion of a wide range of psychosocial measures, 
including illness perceptions, coping strategies, mood, and social support. This 
enabled a comprehensive evaluation of the relative contribution of psychosocial 
factors to HRQoL in ACHD. As with all studies, however, some measures were not 
included in the study. Some authors have suggested that, in addition to the factors 
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included in the SRM, dispositional factors such as personality traits may moderate 
people’s illness perceptions and coping strategies (e.g. dispositional optimism, 
Carver et al., 1989).  
11.4.1.5. Cross-sectional analysis 
The cross-sectional study found a range of demographic, clinical, and psychosocial 
factors that were associated with HRQoL in this sample of people with ACHD. 
However, there are inherent limitations in causality and directionality inferences 
based on cross-sectional data. Replication of the relationships between the factors 
studied is suggested in future longitudinal studies.  
11.4.1.6. Longitudinal analysis 
By adopting more advanced statistical analyses (HLM), the present study has 
overcome some of the limitations associated with traditional repeated measures 
approaches (ANOVA, paired t-tests, Wilcoxon signed rank test) used in previous 
studies. This statistical method takes into account the within-participant variation 
and the fact that assessments taken from the same participant at different time points 
are not independent (Quené & van den Bergh, 2004; West, 2009). The strengths of 
HLM over traditional methods have been discussed in more detail in section 5.6.8.4 
(page 165). 
It is well known that longitudinal studies require time and resources. In the present 
study the data collection for the follow-up study lasted a year compared with the 
cross-sectional study for which data collection lasted longer; this was done to 
maximise recruitment and thus achieve an adequate sample size for the analyses. 
This resulted in a variation in the length of follow-up, which could have influenced 
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the degree of change. However, efforts were made to minimise these effects by 
controlling for the variation in the analyses. 
Furthermore, with only two time-points, the longitudinal study was limited in 
examining trajectories of change in HRQoL and identification of crucial time points 
where changes in clinical and psychosocial status had taken place that might have 
influenced HRQoL. Although multiple assessments would have potentially provided 
valuable information, it was beyond the scope and the resources available for the 
present thesis.  
11.4.2. Qualitative study 
11.4.2.1. Bias 
Rapport with the participants was facilitated by the researcher’s involvement in 
conducting the quantitative component of the study. Participants may have been 
more inclined to participate in the study because of familiarity between them and the 
researcher. In addition, due to the researcher’s involvement in the questionnaire 
assessments, there might have been pre-conceptions regarding the interviewees’ 
HRQoL. However, efforts were made to disregard these pre-conceptions and 
preserve an open and inquisitive approach during the interviews. To some extent, 
pre-conceptions would have been overcome by the supervisory team reviewing the 
interview topic guide before the interviews and by keeping a reflective diary, which 
helped understand the researcher’s perspective. 
11.4.2.2. Interview setting 
Guidelines regarding interview settings are scarce but it is generally suggested that 
the setting is convenient and easily accessible by participants (Mack, Woodsong, 
MacQueen, Guest, & Namey, 2005). All participants in this study preferred the 
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interview to be conducted at the hospital as it was convenient to them. It was also 
ensured that interviews took place in a quiet room away from distractions. The 
choice of the clinical setting may have inadvertently influenced the participant’s 
responses, for example people who were awaiting test results and decisions 
regarding upcoming interventions. 
11.4.2.3. Generalisability 
Twelve people were interviewed for the present study, which may be criticised as 
insufficient for generalisability to the wider population of people with ACHD. 
However, generalisability in qualitative research refers to inferential and 
representational generalisation (Ritchie & Lewis, 2003). Representational 
generalisation was sought by including a diverse sample in terms of age, gender, and 
diagnostic group. Inferential generalisation, which involves presentation of the 
findings that allow the reader to assess whether the findings could be transferred to 
other settings, was ensured by providing a “thick” or rich description of the findings.  
The number of participants reflected the average typically included in qualitative 
studies in ACHD and it was enough to achieve data saturation. However, it should 
be acknowledged that some diagnostic groups were under-represented, in particular 
the Simple group which consisted of two cases. Time limitations did not allow for 
the inclusion of at least three cases per group, as it is generally recommended when 
comparing sub-groups in qualitative studies (Onwuegbuzie & Leech, 2007). 
11.4.2.4. Rigor and trustworthiness 
Rigor and trustworthiness was actively sought by the adoption of various strategies 
including the use of audit trail for the data analysis, the use of reflective accounts 
during data analysis, the process of external validation for the coding process, and 
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the inclusion of “thick” description for the presentation of findings. These 
approaches contributed towards the validity and reliability of the present study. 
11.4.2.5. Mixed methods 
The use of mixed method approach in this thesis provided an enriched understanding 
of HRQoL in ACHD with a synthesis of the findings from both approaches (section 
11.3, page 363). This facilitated triangulation of the study findings by highlighting 
both the similarities and differences from the two approaches. The mixed methods 
approach also painted a more complete picture of the impact of ACHD on HRQoL 
and how people adjust to living with ACHD.  
A challenge in the integration and interpretation of the findings from the quantitative 
and qualitative studies is making appropriate meta-inferences or generalisations, 
considering that the sample size of the qualitative component is less than 10% of the 
sample included in the quantitative component. The inclusion of a smaller sample 
size (n=  12) in the qualitative study may be justified by the concurrent embedded 
design, whereby the qualitative component is supplemental to the dominant 
quantitative component. Collins, Onwuegbuzie, & Jiao (2007) have argued that 
statistical generalisations that are interpretive consistent (consistency between the 
inferences made and the sampling design) may be justified if the dominant 
component is the one with the large sample, which is the case of the present thesis. 
Including large samples in both quantitative and qualitative studies would provide a 
stronger basis for interpretive consistency; however, the time constraints of the 
present study did not allow for the recruitment of a large number of participants in 
the qualitative study. 
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The concurrent embedded design of the study, whereby the quantitative component 
was dominant and the qualitative was supplemental is one of the many methods of 
mixed methods research. The synthesis of quantitative and qualitative methods is 
rapidly growing and new techniques are likely to arise in the future (Pope, Mays, and 
Popay, 2007). 
11.4.3. Public and patient involvement in research 
The present study did not involve the public and patients during the design and 
conduct. It is being increasingly recognised that public and patient involvement (PPI) 
in research can have multiple benefits including acquiring a different perspective on 
the research topic by people who live with ACHD and making the research more 
relevant by guiding it towards issues that interest and concern them. In addition PPI 
can improve the quality of the research through the choice of appropriate methods 
and materials and increase participation (INVOLVE, 2012). 
Consulting patients and their carers in the present study would perhaps help clarify 
the research questions and affirm their importance. It could also have improved 
participation rates through advice on recruitment strategies and data collection 
methods and provide patients’ perspective on the materials and information sheets. 
This is especially relevant with respect to the development of the topic guide of the 
qualitative study and the subsequent development of the themes. Although the time 
and financial constraints of the study did not allow for PPI during the design and 
conduct, there is potential for involving patients and carers during the dissemination 
stage. Specifically, the study findings will be discussed with patients and carers in 
order to get advice on producing coherent reports and lay summaries for the study 
participants and identify other relevant audiences such as ACHD patient networks. 
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Future studies, including interventions, may benefit from involving patients and 
carers early in the research process. Patients may offer advice on the ethical 
considerations, the focus of the intervention and its relevance, feasible recruitment 
strategies and help with the development of patient information materials. 
Furthermore, patients may help with the interpretation and dissemination of the 
findings. PPI can be especially beneficial for intervention studies in order to ensure 
their feasibility and acceptability by patients (Brett, Staniszewska, Mockford, Seers, 
Herron-Marx, & Bayliss, 2010). 
11.5. Directions for future research 
As the systematic review in Chapter 2 and the introduction in Chapter 3 highlighted, 
few studies have moved beyond the biomedical model in studying HRQoL in 
ACHD. This could be attributed to the fact that ACHD has been considered a novel 
area of study for years. However, there has been increasing interest towards studying 
the psychosocial factors that may influence HRQoL. 
The analyses conducted in Chapter 7 revealed that ACHD may result in significant 
emotional burden in the Simple group compared with the relatively more complex 
groups (i.e. ToF and TGA) who reported good HRQoL. An interesting avenue of 
future research is the in depth exploration of expectations in relation to HRQoL in 
ACHD, particularly across people in various diagnostic groups in order to test 
whether people form differing expectations especially following their treatment. 
The study discussed in Chapter 8 represents the first attempt to study the factors 
associated with HRQoL in ACHD by including a wide range of demographic, 
clinical, and psychosocial factors. Future studies may adopt similar approaches in 
order to examine whether the novel findings from the present study can be replicated 
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in other samples. Overall, illness perceptions were useful in explaining a large 
percentage of variance in HRQoL. As the Brief IPQ was identified as a potential a 
limitation in the present thesis, future studies could use more elaborated versions 
such as the IPQ-R to measure illness perceptions. In addition, measurement of sense 
of coherence could be extended to include the aspect of meaningfulness, which was 
identified as an important part of people’s experiences in the qualitative study. 
Antonovsky’s Sense of Coherence scale (SOC) (Antonovsky, 1993) includes a 
meaningfulness subscale, which could be potentially used in conjunction with illness 
perceptions measures in future studies. In addition, further studies need to be 
conducted in order to fully understand the role of coping and social support in 
relation to HRQoL in ACHD. 
Considering that the findings from regression analyses were based on cross-sectional 
data, future studies may adopt longitudinal designs to examine the temporal stability 
of the associations identified within the thesis. Furthermore, it is important that 
future studies use multiple follow-ups in order to explore trajectories of change in 
HRQoL and the psychosocial factors that influence such changes.  
Future research in ACHD investigating people’s illness perceptions might focus on 
developing an intervention to change negative illness perceptions and correct 
misconceptions. Petrie, Cameron, Ellis, Buick, and Weinman (2002) examined the 
effectiveness of a brief in-hospital intervention to alter strong negative illness 
perceptions in people with myocardial infarction. The intervention involved 
provision of information, challenge of negative illness perceptions, development of 
personalized action plans, and revision of action plans. Compared with the control 
group (standard care), the intervention group showed positive changes in their illness 
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perceptions, earlier return to work, and fewer angina symptoms at a 3-month follow-
up. Broadbent, Ellis, Thomas, Gamble, and Petrie (2009) designed a similar 
randomised controlled trial, which replicated the findings of Petrie and colleagues. 
The effectiveness of illness perceptions-based interventions has been demonstrated 
in other chronic populations, including haemodialysis (Karamanidou, Weinman, & 
Horne, 2008) and type 2 diabetes (Davies et al., 2008; Keogh et al., 2011). These 
interventions appeared to be successful in improving psychological and HRQoL 
outcomes and are a promising area for future research in ACHD.  
In addition, future research might focus on developing psychological interventions to 
treat depression in people with ACHD. Research has provided some support for the 
effectiveness of psychological interventions in minimising mood problems in cardiac 
populations (Newman, Hirani, Stygall, & Fteropoulli, 2012). In the ENRICHD 
study, the intervention group of people with myocardial infarction received cognitive 
behavioural therapy, which included active problem solving, behavioural activation, 
and challenge of depressive thoughts with antidepressant medication when required. 
This study indicated significant improvement in HRQoL (Carney et al., 2004).  
Intervention studies and cardiac rehabilitation programs in ACHD and the wider 
CHD population have predominantly focused on improving exercise capacity 
(Tikkanen, Oyaga, Riaño, Álvaro, & Rhodes, 2012). In addition, a recent review 
commissioned by Cochrane failed to identify any psychological interventions for 
depression in people with ACHD (Lane, Millane, & Lip, 2013). It has been argued 
that mood and HRQoL should also serve as endpoints in future interventions rather 
than clinical outcomes alone (Linden, 2000). Currently, one study is underway, 
which aims to assess the feasibility of a randomized controlled trial of a group 
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intervention aimed at improving psychosocial functioning, QoL, and resilience in 
people with ACHD (Kovacs & Irvine, 2013). This study could provide valuable 
insights for future intervention studies.  
Many of the interventions addressing illness perceptions took place during 
hospitalization, while those addressing mood generally took place after an acute 
episode or following diagnosis; these indicated the importance of timing in the 
delivery of interventions. Timing may be especially important for people with 
ACHD, many of whom will face health deterioration that may require further 
intervention during their adult lives. Interventions aimed at changing negative 
perceptions may be delivered at such key time points or “windows of opportunity” in 
order to improve the people’s HRQoL after hospital discharge. Delivering 
interventions during an acute illness phase may be more effective as individuals are 
more amenable to interventions (Petrie et al., 2002). 
In contrast to interventions targeting illness perceptions, interventions aimed at 
modifying mood may be more successful when delivered after rather than during an 
acute episode, due to emotional effects that may be situational (Whooley, 2006). 
Future intervention studies in ACHD need to assess crucial timings at which they 
may prove more beneficial for improving the people’s HRQoL. 
Another avenue for research is the possibility of addressing both negative illness 
perceptions and mood problems concurrently. A systematic review of randomised 
controlled trials, which aimed at changing negative illness perceptions in coronary 
heart disease, indicated that there is lack of high quality research that hinders the 
ability to draw conclusions (Goulding, Furze, & Birks, 2010). The authors 
highlighted that interventions that include a combination of cognitive behavioural 
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therapy and counselling are generally more successful in improving behavioural, 
functional, and psychological outcomes. 
11.6. Implications for practice 
The findings of the studies have a number of implications for clinical practice. A 
good starting point could be the routine assessment of people’s perceptions about 
their condition as negative illness perceptions can potentially have a detrimental 
impact on their HRQoL. The Brief IPQ, although not as comprehensive as the IPQ-
R, is a short and useful measure that can be used as part of routine care for a quick 
assessment of illness perceptions. This may help draw attention to misconceptions 
that individuals hold about their condition that could be tackled by clinicians or 
specialist nurses during routine outpatient appointments.  
A more challenging issue in patient education is the provision of clear and 
personalised information regarding health deterioration, changes in treatment, and 
further interventions. Due to the generally unpredictable nature of many chronic 
conditions including ACHD, clinicians often provide vague or insufficient 
information (Rönning et al., 2008). Indeed, the findings of the qualitative study in 
the present thesis indicated that people were struggling with uncertainty, which was 
enhanced by the “wait and see” attitude of their clinicians. Clinicians and health care 
professionals could routinely assess the people’s needs during their outpatient 
appointments and provide timely information regarding the illness and treatment 
course, education, employment, and family planning issues. This could help people 
with ACHD accept potential health changes, form realistic expectations especially 
after treatment, ameliorate uncertainty to some degree, and increase their sense of 
control (Rönning et al., 2008). 
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Furthermore, it is important to identify people who are in need of psychological 
support. The findings from the study indicated the importance of mood problems as 
a risk factor for poor HRQoL. Short, self-report measures such as the CES-D 10 
used in the present study, or other measures like the HADS and BDI are useful for a 
quick assessment of depressive symptomatology and could therefore be incorporated 
into the people’s routine care. This could be an effective way of identifying 
individuals at risk in a timely manner and referring them for professional 
psychological support. It is also important that psychological support is readily 
available as previous reports have highlighted that the provision of psychological 
support was an “unfulfilled” need for people with ACHD as they were unaware 
about the availability of such resources (Rönning et al., 2008). Another possibility 
for the provision of psychological support may be through peer support groups. As 
the qualitative study suggested, social comparisons helped people with ACHD cope 
with their condition and treatment. In another qualitative study, people with ACHD 
talked about the need of support services such as group therapy, mentorship 
programs, and patient conferences (Pagé et al., 2012). The Internet may also be a 
potential way to provide psychological support to these people (Kovacs et al., 
2009a). 
It is important to note that the findings of the longitudinal and qualitative studies in 
the present thesis indicated that the people’s educational and psychological needs 
can vary throughout their lives. Therefore, it may be beneficial for health care 
professionals to re-assess people’s perceptions and emotional status regularly, 
especially during crucial periods such as transition from child to adult clinics, health 
changes, introduction of new treatment regimens, and before or after re-
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interventions. This can help address people’s needs more effectively and minimise 
consultation times by providing only relevant information tailored to people’s 
individual needs during a particular stage in their lives and their journey with chronic 
illness.  
Despite the potential benefits of regular assessment of illness perceptions and 
emotional status there are still a number of barriers that need to be overcome before 
such PROMs are widely adopted in healthcare practice. A recent systematic review 
of professionals’ experiences identified several barriers in using PROMs including 
increase in workload, lack of clear guidelines about the data collection process, and 
lack of training in analysis and interpretation (Boyce, Browne, & Greenhalgh, 2014).  
Although there are also organizational challenges with regards to adopting PROMs 
in practice that need to be addressed, a number of facilitators have been identified for 
their implementation by healthcare professionals. Education of healthcare 
professionals about the use of PROMs and their interpretation is considered 
paramount (Antunes, Harding, & Higginson, 2014). Engaging healthcare 
professionals and patients in PROMs-related assessment strategies may enhance 
acceptability and understanding about their usefulness in clinical practice (Wray, 
Brown, Marino, & Franklin, 2011). 
Furthermore, it has been argued that workloads can be reduced if PROMs feedback 
is integrated naturally into the consultation process, especially with the use of data 
collection technology (Boyce et al., 2014). Specifically, the American Heart 
Association recommends the use of electronic systems for data collection (e.g. tablet 
computers or computer stations) in outpatient clinic waiting rooms, with built-in 
scoring algorithms which make the results immediately available to healthcare 
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professionals (Rumsfeld et al., 2013). Other electronic methods include web-based 
data collection that can take place in people’s homes (Black, 2013). These data may 
then be incorporated into electronic patient records. PROMs assessment within the 
NHS is currently being applied only with regards to some surgical procedures, 
however they are likely to be introduced across a wider range of NHS services, 
including routine clinical practice along with the introduction of financial incentives 
(Devlin & Appleby, 2010). Studies are therefore needed to assess the feasibility and 
acceptability of all the above PROMs data collection methods in ACHD clinics as 
well as their potential to improve HRQoL outcomes in ACHD. 
11.7. Overall conclusions 
The present thesis has made a number of contributions to the literature, specifically 
to the understanding of HRQoL in four distinct diagnostic groups and the factors 
associated with HRQoL in ACHD using a mixed methods approach. It demonstrated 
that people with ACHD experience HRQoL impairments, with the SV group 
experiencing reduced physical and psychosocial HRQoL and the Simple group 
experiencing reduced psychosocial HRQoL compared with the general healthy 
population. This has important implications about distinguishing between diagnostic 
groups when studying HRQoL in ACHD. With the inclusion of a wide range of 
factors in studying HRQoL in ACHD, the study demonstrated the relative 
importance of psychosocial factors, in particular negative illness perceptions about 
the symptoms and consequences of ACHD and mood problems in explaining 
(unique) variance in HRQoL. The qualitative study has added to the understanding 
of people’s experiences about the impact of ACHD and how they adjust to living 
with ACHD. Although HRQoL and other psychosocial factors remained stable over 
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a period of 3.3 years, the qualitative interviews revealed the dynamic day-to-day 
status of people living with ACHD. The impact of ACHD was evident by the various 
physical, psychological, social, and occupational consequences of ACHD. The 
coping process involved people accepting and adjusting to their condition, setting 
goals and priorities, and gaining perspective with the help of their social 
environment and was influenced by changes in health and treatment. The thesis 
offered important implications for clinical practice with regards to the provision of 
clear and timely information and the assessment of illness perceptions and mood 
problems during key periods in people’s lives and provided a basis for future 
longitudinal research in studying the role of psychosocial factors for HRQoL in 
ACHD across the illness trajectory and people’s life span. It also highlighted factors 
amenable to change that can potentially inform the development of intervention 
studies aiming to improve HRQoL in people with ACHD. 
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APPENDICES 
Appendix A. E-mail correspondence for image usage rights from Texas Heart 
Institute 
From: Ken Hoge [mailto:  
Sent: 24 July 2014 00:50 
To: Fteropoulli, Theodora 
Subject: RE: Use of website images for research 
  
Dear Theodora, 
  
The Texas Heart Institute is pleased to grant you conditional permission to use the following 
2 copyrighted graphics from our website at http://texasheart.org in your academic work as 
described in your request below. 
  
We require:  
1. The copyright must be noted and the Institute's website address must be listed 
accompanying all use of the images as follows: Image copyright Texas Heart Institute, 
www.texasheart.org   
2. No commercial gain may be derived from the sale or distribution of this publication by the 
author or the publisher.  
3. Texas Heart Institute reserves all rights and does not grant permission for any subsequent 
republication, commercial or otherwise, of these images in any media (print, web, video, 
etc.). 
  
Permission to reproduce this image is contingent upon acceptance of these terms. No rights 
to any further use beyond this one time are hereby granted.  
  
The authors are: Department of Scientific Publications, Texas Heart Institute: 
http://www.texasheart.org/AboutUs/Depart/scipub.cfm   
  
Thank you for your request. 
  
Ken 
 
Ken Hoge 
Manager, Visual Communication Services 
 |  | www.texasheart.org 
6770 Bertner Ave., MC 1-134, Houston, TX 77030 
Fax: | Pager:  
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Appendix B. E-mail correspondence for image usage rights from National 
Heart, Lung, and Blood Institute (NHLBI) 
NHLBI Web Manager (NIH/NHLBI) < >  
Mon 14/07/2014 16:53  
To: Fteropoulli, Theodora < >; NHLBI Web Manager 
(NIH/NHLBI) < >;  
 
Theodora, 
  
Thank you for your courtesy in requesting permission to use the information published by 
the National Heart, Lung, and Blood Institute (NHLBI).  No copyright exists on documents 
generated by the U.S. government, so please feel free to use any information that we 
provide. We simply request that you cite the NHLBI (as a part of the NIH and the U.S. 
Department of Health and Human Services), as well as the source document, and if you 
make any implications or draw any conclusions that are not in the original NHLBI 
document, that you make a clear statement to that effect in your publication. In addition, the 
material should not be used in any direct or indirect product endorsement. 
 
NHLBI Web Manager 
Center for Biomedical Informatics (CBI) 
National Heart, Lung, and Blood Institute (NHLBI) 
6705 Rockledge Drive, Room 6086 
Bethesda, MD 20892 
Phone  
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Appendix C. E-mail correspondence for image usage rights from British Heart 
Foundation 
From: Resources <resources@bhf.org.uk> 
Sent: 01 September 2014 14:51 
To: Fteropoulli, Theodora 
Subject: RE: Permission to use BHF Images for academic purposes 
Dear Ms Fteropoulli, 
 
Here is your copyright permission. We are happy to grant it on this occasion. Please let me 
know if you require the images in another format. 
 
Permission to Use illustrations: Hypoplastic left heart, Tricuspid atresia, 
Cavopulmonary shunt, Total cavopulmonary connection. 
 
I write to confirm that the British Heart Foundation (“BHF”) is willing to consent to the use 
of the copyright works listed below (the “Works”) by Theodora Fteropoulli (“You”) in your 
PhD publication and subsequently within your PhD publication on City Research Online 
digital archive, on the following conditions: 
1. No other use of the Works will be made by You without the prior consent of BHF. 
2. You may use the Works for the period of 1 year, commencing on today’s date and only in 
the UK, excepting the accepted use in the City Research Online digital archive. 
3. All use of the Works by You shall be in accordance with honest business practices and 
shall not in any way adversely affect or damage the Works or BHF. 
4. All goodwill or other rights accruing from the use of the Works by You shall belong to 
BHF. 
5. All future use of the Works by You shall cease within 7 days of receipt of notice of 
termination of the permission granted in this email from BHF by You. 
6. Any further use of the Works or any other material owned by BHF in any other 
publication or other manner shall require and be subject to the express written consent of 
BHF. 
7. BHF gives no warranties, indemnity or representation in respect of your reproduction or 
use of the Works and their use by you. 
8. All use of the Work by you shall be accompanied by the following statement: “© British 
Heart Foundation, 2014. Reproduced with kind permission of the British Heart Foundation.” 
 
Yours sincerely 
Dr Matthew McArdle  
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Appendix E. PRISMA 2009 checklist 
Section/topic  # Checklist item  Reported on page #  
 
Notes 
TITLE    
Title  1 Identify the report as a systematic review, meta-analysis, or both.  46  
ABSTRACT    
Structured 
summary  
2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; 
conclusions and implications of key findings; systematic review registration number.  
No  
INTRODUCTION    
Rationale  3 Describe the rationale for the review in the context of what is already known.  46-51  
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
51  
METHODS    
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
No  
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
53-55  
Information 
sources  
7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
52-53  
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
Appendix F  
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
55  
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Section/topic  # Checklist item  Reported on page #  
 
Notes 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
56-57  
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions 
and simplifications made.  
55-57  
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this 
was done at the study or outcome level), and how this information is to be used in any data synthesis.  
No Quality was assessed 
not risk of bias 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, difference in means).  No Not a meta-analysis 
Synthesis of 
results  
14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
55-57  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
No Quality was assessed 
not risk of bias 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
n/a  
RESULTS    
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
58-59,  
Figure 2.1 
 
Study 
characteristics  
18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
60-67,  
Table 2.2 
80-86,  
Table 2.6 
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Section/topic  # Checklist item  Reported on page #  
 
Notes 
Risk of bias within 
studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  No 
Quality was assessed 
not risk of bias 
Results of 
individual studies  20 
For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
67-80,  
Table 2.3 
Table 2.4 
Table 2.5 
87-91 
Table 2.7 
 
Synthesis of 
results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  n/a 
 
Risk of bias across 
studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  No 
Quality was assessed 
not risk of bias 
Additional 
analysis  23 
Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 
16]).  n/a 
 
DISCUSSION    
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
91-99  
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
100-102  
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
102  
FUNDING    
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders 
for the systematic review.  
No Provided in 
publication 
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Appendix F. Systematic review search strategy: ScienceDirect example 
Science Direct [all fields] 
{quality of life} OR 
{life satisfaction} OR 
{well being} 
 
AND 
 
GUCH OR 
ACHD OR 
{congenital heart disease} OR 
{congenital cardiac disease} OR 
{congenital heart defect} OR 
{congenital cardiac defect} AND adult 
 
Limit to journal articles 
 
Hits: 931 
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Appendix G. Data extraction form used for the systematic review 
General Information 
Article Title:  
Author(s): 
Source:  
Sample Characteristics 
Target Population:  
Inclusion Criteria:  
Exclusion Criteria: 
Sample Characteristics: CHD Group: 
                                       Norms/Control Group (if applicable): 
Study Characteristics 
Aim(s): 
Design:  
QoL/ HRQoL Definition: 
QoL/ HRQoL Measures: 
Other Measures:  
Statistical Analysis: 
Main Findings 
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Appendix H. Quality index used for the systematic review (adapted from Downs 
& Black, 1998) 
                             YES Partially NO Unable to 
determine 
REPORTING        
1. The hypothesis/ aim/ objective(s) of the study were clearly 
described 
2 1 0 0 
2. The main outcomes to be measured were clearly described in 
the Introduction or Methods section 
2 1 0 0 
3. The characteristics of the patients included in the study were 
clearly described 
2 1 0 0 
4. The  principal confounders in the sample were clearly 
described 
2 1 0 0 
5. The main findings of the study were clearly described 2 1 0 0 
6. Does the study provide estimates of the random variability in 
the data for the main outcomes? 
2 1 0 0 
7. Actual probability values have been reported (e.g. .035 rather 
than <.05) for the main outcomes except where the probability 
value was less than .001 
2 1 0 0 
EXTERNAL VALIDITY   
8. The persons asked to participate in the study were 
representative of the entire population from which they were 
recruited 
2 1 0 0 
9. The persons who were prepared to participate were 
representative of the entire population from which they 
recruited 
2 1 0 0 
10. The inclusion/exclusion criteria were made explicit 2 1 0 0 
INTERNAL VALIDITY- (Bias)  
11. The study design was appropriate for answering the research 
question(s) 
2 1 0 0 
12. The statistical tests used to assess the main outcomes were 
appropriate 
2 1 0 0 
13. The variable measures used were accurate (valid and 
reliable) 
2 1 0 0 
INTERNAL VALIDITY- (Selection Bias)  
14. The participants were similar in terms of prognostic factors 2 1 0 0 
15. There was a control group (2 for case-control, 1 for 
normative data, 0 for no control group)  
2 1 0 0 
16. There were adequate adjustment for confounding in the 
analyses from which the main findings were drawn 
2 1 0 0 
17. Potential differences between respondents and non-
respondents were reported  
2 1 0 0 
POWER  
18. The study had sufficient power to detect a clinically 
important effect where the probability value for a difference 
being due to chance was less than 5% 
2 1 0 0 
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Appendix I. Information sheet used in the cross-sectional study 
 
 
UCLH Project ID number : 08/0326 
 
CONFIDENTIAL 
INFORMATION SHEET (Version 2-12/08) 
 
Quality of life in GUCH patients. 
Investigators: Professor Stanton Newman, Professor John Deanfield, Dr Shay Cullen, Jan 
Stygall, Fiona Kennedy, Marie Francis, Nathalie Picaut, Katie Austin, Theodora 
Fteropoulli, Manavi Tyagi, Anna Davies. 
  
Contact 
details: 
GUCH Unit, Heart Hospital, 16-18 Westmoreland St., 
London W1G 8PH 
Tel: 020 7573 8889 
   
You are being invited to take part in a research study. Before you decide it is important for you to 
understand why the research is being conducted and what it will involve. Please take time to read 
the following information carefully and discuss it with others if you wish. Ask us if there is 
anything that is not clear or if you would like more information. Take time to decide whether or 
not you wish to take part.  
What is the purpose of the study? 
Although various studies have been conducted into the quality of life of children with congenital 
heart disease very little has been carried out with adults with congenital heart disease. In order 
to better plan our services to support long term care we would find it extremely valuable to have 
an understanding of how congenital heart disease affects quality of life. Therefore, we in the GUCH 
Unit at the Heart Hospital, UCLH, and the Unit of Behavioural Medicine at UCL would like to find 
out how your heart condition affects your life and your functioning. The information you give us 
will then be used to improve the long-term care of adults with congenital heart disease. 
  
Consultants:                                                                                     GUCH Office  
Dr Shay Cullen                                                                                                             The Heart Hospital 
Dr Fiona Walker        16-18 Westmoreland Street 
Prof Philipp Bonhoeffer       London W1G 8PH 
Prof John Deanfield       Tel: 020 7573 8808 
        Nurses: 020 7573 8872 
Surgeons:       Fax: 020 7573 8807 
Mr Victor Tsang        Email: guch.dept@uclh.org 
Ms Carin van Doorn      Website: www.uclh.org 
Mr Martin Kostolny       
 
Clinical Nurse Specialists:         
Ruth Brooks 
Marie Francis 
Fiona Kennedy 
Kerry Romer 
Nathalie Picaut 
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Why have I been chosen? 
You are being asked to take part in this study because you have a diagnosis of congenital heart 
disease. Approximately, 360 patients will take part in this study over the next 3 years. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be given 
this information sheet to keep and be asked to sign a consent form. If you decide to take part you 
are still free to withdraw at any time and without giving a reason. A decision to withdraw at any 
time, or a decision not to take part, will not affect the standard of care you receive. 
What is involved in the study? 
If you agree to take part in this study you will be asked to attend the Heart Hospital on the same 
day of your next outpatient appointment. During the research appointment a researcher will take 
you through some questionnaires aimed to find out how your heart condition has impacted upon 
your life. The appointment will take approximately 45 mins.  
What are the possible benefits of taking part? 
Whilst there are no immediate benefits for people participating in this study, it is hoped that this 
work will contribute to improving the long-term care of adults with congenital heart disease. 
Confidentiality of records 
We also need permission to access your medical records, which relate directly to this study. All 
the information we obtain will be strictly confidential. UCL will overview the collection, storage 
and handling of the data and Professor Newman, in his capacity of chief investigator, will be 
responsible for security and access to the data.  Only study investigators (named above) will have 
access to the data.  The information collected during the study, with exception of your name, will 
be stored and analysed confidentially in a computer. No identifiers on the data held by computer 
will enable a third party to link the data to you. A study ID number will be assigned to you and 
this will appear on all data including medical information and questionnaires. All data will be kept 
strictly confidential and secured under lock and key in UCL. The data will be stored for 5 years 
after the study has been completed. The results of this study may be published within the medical 
literature, however, no personal details will be revealed. Copies of the publications will be 
available to you from the researchers. A report of the findings of the research will be sent to all 
interested participants in approximately 3½ years from the start of the study. 
Comments or concerns during the study 
If you have a concern about any aspect of this study you should speak to the researchers who 
will do their best to answer your questions either at your appointment or on 020 7040 0878. 
If you remain unhappy and wish to complain formally you can do this through the Complaints 
Manager, UCLH, 2nd Floor West, 250, Euston Road, London NW1 2PQ. Please quote the UCLH 
project number at the top of this information sheet. 
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Ethics Committee Review 
All proposals for research using human subjects are reviewed by an ethics committee before they 
can proceed. This proposal was reviewed by the Joint UCL/UCLH Ethics Committee in Ethics of 
Human Research. 
Thank you for taking the time to read this. If you decide to take part you will be given a copy of 
this information sheet and a signed consent form to keep.  
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Appendix J. Information sheet used in the longitudinal study  
 
 
UCLH Project ID number : 08/0326 
CONFIDENTIAL 
INFORMATION SHEET (Version 3-11/11) 
Quality of life in GUCH patients, follow-up 
Investigators: Professor Stanton Newman, Professor John Deanfield, Dr Shay Cullen, Jan 
Stygall, Fiona Kennedy, Marie Francis, Nathalie Picaut, Theodora Fteropoulli, 
Manavi Tyagi. 
 
Contact 
details: 
GUCH Unit, Heart Hospital, 16-18 Westmoreland St., 
London W1G 8PH 
Tel: 020 7573 8889 
   
You are being invited to take part in a follow-up research study. Before you decide it is 
important for you to understand why the research is being conducted and what it will involve. 
Please take time to read the following information carefully and discuss it with others if you 
wish. Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part.  
What is the purpose of the study? 
Although various studies have been conducted into the quality of life of children with congenital 
heart disease very little has been carried out with adults with congenital heart disease. 
Moreover, there is little research examining how further treatment and disease progression 
affects the quality of life of GUCH patients. In order to better plan our services to support long 
term care we would find it extremely valuable to have an understanding of how congenital 
heart disease affects quality of life. Therefore, we in the GUCH Unit at the Heart Hospital, UCLH, 
and the Health Services Research Group at City University would like to find out how your heart 
condition affects your life and your functioning in the longer term, after your initial assessment. 
Consultants:                                                                                     GUCH Office  
Dr Shay Cullen                                                                                                             The Heart Hospital 
Dr Fiona Walker        16-18 Westmoreland Street 
Prof Philipp Bonhoeffer       London W1G 8PH 
Prof John Deanfield       Tel: 020 7573 8808 
        Nurses: 020 7573 8872 
Surgeons:       Fax: 020 7573 8807 
Mr Victor Tsang        Email: guch.dept@uclh.org 
Ms Carin van Doorn      Website: www.uclh.org 
Mr Martin Kostolny       
 
Clinical Nurse Specialists:         
Ruth Brooks 
Marie Francis 
Fiona Kennedy 
Kerry Romer 
Nathalie Picaut 
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The information you give us will then be used to improve the long-term care of adults with 
congenital heart disease. 
Why have I been chosen? 
You are being asked to take part in this follow-up study because you have a diagnosis of 
congenital heart disease and you have participated in the first phase of the study, about 2 years 
ago. Approximately, 220 patients will take part in this study over the next year. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If you decide to take 
part you are still free to withdraw at any time and without giving a reason. A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard of care you 
receive. Your contribution to the first phase of this study will also remain unaffected. 
What is involved in the study? 
If you agree to take part in this study you will be asked to attend the Heart Hospital on the same 
day of your next outpatient appointment. The same procedure applies as in the first phase of the 
study. During the research appointment a researcher will take you through some 
questionnaires aimed to find out how your heart condition has impacted upon your life. The full 
appointment will take approximately 45mins.  
What are the possible benefits of taking part? 
Whilst there are no immediate benefits for people participating in this study, it is hoped that 
this work will contribute to improving the long-term care of adults with congenital heart 
disease. 
Confidentiality of records 
We also need permission to access your medical records, which relate directly to this study. All 
the information we obtain will be strictly confidential. City University will overview the 
collection, storage and handling of the data and Professor Newman, in his capacity of chief 
investigator, will be responsible for security and access to the data.  Only study investigators 
(named above) will have access to the data. The information collected during the study, with 
exception of your name, will be stored and analysed confidentially in a computer. No identifiers 
on the data held by computer will enable a third party to link the data to you. A study ID 
number, assigned to you during the first phase of the study will appear on all data including 
medical information and questionnaires. All data will be kept strictly confidential and secured 
under lock and key in City University. The data will be stored for 5 years after the study has 
been completed. The results of this study may be published within the medical literature, 
however, no personal details will be revealed. Copies of the publications will be available to you 
from the researchers. A report of the findings of the follow-up research will be sent to all 
interested participants in approximately 3½ years from the start of the study. 
Comments or concerns during the study 
If you have a concern about any aspect of this study you should speak to the researchers who 
will do their best to answer your questions either at your appointment or on 020 7040 
0871/0878. If you remain unhappy and wish to complain formally you can do this through 
APPENDICES 
495 
 
the Complaints Manager, UCLH, 2nd Floor West, 250, Euston Road, London NW1 2PQ. Please 
quote the UCLH project number at the top of this information sheet. 
Ethics Committee Review 
All proposals for research using human subjects are reviewed by an ethics committee before 
they can proceed. This proposal was reviewed by the Joint UCL/UCLH Ethics Committee and 
NRES Committee London – Bentham in Ethics of Human Research. 
Thank you for taking the time to read this. If you decide to take part you will be given a copy of 
this information sheet and a signed consent form to keep.  
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Appendix K. Consent form used in the cross-sectional study  
 
 
 
 
 
 
UCLH Project ID number: 08/0326 
                                                
CONFIDENTIAL 
CONSENT FORM (Version 2-12/08) 
 
Quality of life in GUCH patients. 
  
Investigators: Professor Stanton Newman, Professor John Deanfield, Dr Shay Cullen, 
Jan Stygall, Fiona Kennedy, Marie Francis, Nathalie Picaut, Katie 
Austin, Theodora Fteropoulli, Manavi Tyagi. 
  
Contact 
details: 
GUCH Unit, Heart Hospital, 16-18 Westmoreland St., 
London W1G 8PH 
Tel: 020 7573 8889 
Please read the following statements and initial box 
 1. I confirm that I have read and understand the information sheet (version2-12/08) for the above study and have had the opportunity to ask questions. □ 
 
2.  I confirm that I have had sufficient time to consider whether or not I want to 
be included in the study. 
□ 
 
3. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights 
being affected. 
 
□ 
 
4. I understand that all data will be kept strictly confidential to this research and 
give permission for the above investigators to have access to my medical 
records. 
□ 
 
5. I agree to take part in the above study. □ 
 
 
Continued on next page/ 
GUCH Office  
The Heart Hospital 
16-18 Westmoreland Street  
London W1G 8PH 
Tel: 020 7573 8808 
Nurses: 020 7573 8872 
Fax: 020 7573 8807 
Email: guch.dept@uclh.org 
Website: www.uclh.org 
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UCLH Project ID number: 08/0326 
CONFIDENTIAL 
CONSENT FORM (Version 2-12/08) 
    
    
Signed:  Date:  
    
    
    
Full name in block letters:    
    
    
    
Signed 
(investigator): 
 Date:  
    
    
    
Full name in block letters:    
    
     
Comments or concerns during the study. 
 
If you have a concern about any aspect of this study you should speak to the researchers who 
will do their best to answer your questions either at your appointment or on (telephone 
number yet to be provided). If you remain unhappy and wish to complain formally you can 
do this through the Complaints Manager, UCLH, 2nd Floor West, 250, Euston Road, London 
NW1 2PQ. Please quote the UCLH project number at the top of this consent form. 
 
 
1 form for patient 
1 to be kept as part of the study documentation 
1 to be kept with hospital notes  
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Appendix L. Consent form used in the longitudinal study  
  
 
 
 
 
 
 
UCLH Project ID number: 08/0326 
                                                
CONFIDENTIAL 
CONSENT FORM (Version 3-11/11) 
 
Quality of life in GUCH patients, follow-up 
  
Investigators: Professor Stanton Newman, Professor John Deanfield, Dr Shay Cullen, 
Fiona Kennedy, Nathalie Picaut, Theodora Fteropoulli, Manavi Tyagi. 
  
Contact 
details: 
GUCH Unit, Heart Hospital, 16-18 Westmoreland St., 
London W1G 8PH 
Tel: 020 7573 8889 
Please read the following statements and initial box 
 1. I confirm that I have read and understand the information sheet (version 3-11/2011) for the above study and have had the opportunity to ask questions. □ 
 
2.  I confirm that I have had sufficient time to consider whether or not I want to 
be included in the study. 
□ 
 
3. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights 
being affected. 
 
□ 
 
4. I understand that data collected during the study, may be looked at by 
individuals from  UCLH NHS Foundation Trust, from regulatory authorities or 
from the NHS Trust, Where it is relevant to my part in this research, I give 
permission for these individuals to have access to my records. 
□ 
 
5. I agree to take part in the above study. □ 
 
 
Continued on next page/ 
GUCH Office  
The Heart Hospital 
16-18 Westmoreland Street  
London W1G 8PH 
Tel: 020 7573 8808 
Nurses: 020 7573 8872 
Fax: 020 7573 8807 
Email: guch.dept@uclh.org 
Website: www.uclh.org 
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UCLH Project ID number: 08/0326 
CONFIDENTIAL 
CONSENT FORM (Version 3-11/11) 
    
    
Signed:  Date:  
    
    
    
Full name in block letters:    
    
    
    
Signed 
(investigator): 
 Date:  
    
    
    
Full name in block letters:    
    
     
Comments or concerns during the study. 
 
If you have a concern about any aspect of this study you should speak to the researchers who 
will do their best to answer your questions either at your appointment or on (telephone 
number yet to be provided). If you remain unhappy and wish to complain formally you can 
do this through the Complaints Manager, UCLH, 2nd Floor West, 250, Euston Road, London 
NW1 2PQ. Please quote the UCLH project number at the top of this consent form. 
 
 
1 form for patient 
1 to be kept as part of the study documentation 
1 to be kept with hospital notes  
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Appendix M. Psychosocial questionnaire pack 
 
 
Quality of Life in GUCH patients 
 
Participant Questionnaire Booklet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participant ID 
 
  
Researcher Notes 
 
 
 
 
 
 
 
 
 
APPENDICES 
501 
 
Thank you for agreeing to take part in this study looking at 
quality of life in adults with congenital heart disease. The 
information you give us today will contribute to improving 
the long term care of adults with congenital heart disease. 
 
This booklet contains a number of questionnaires which 
you are kindly asked to complete. Please take time to read 
and understand the individual instructions for each 
questionnaire.  
 
There are no right or wrong answers; we are just interested 
in your opinions. If you do not understand any of the 
questions or the instructions provided, please do not 
hesitate to ask the researcher for assistance. 
 
Please mark the boxes with a cross      . . Should you make a 
mistake, please colour the box in completely and mark your 
correct selection. 
 
Thank you again for taking the time to complete this study. 
We assure you that your responses will be kept completely 
confidential. 
 
 
Many Thanks, 
The GUCH Team  
X 
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SF-36 HEALTH SURVEY 
 
 
INSTRUCTIONS:  This survey asks for your views about your health.  This information will help 
keep track of how you feel and how well you are able to do your usual activities. 
 
Answer every question by marking the answer as indicated.  If you are unsure about how to 
answer a question, please give the best answer you can. 
 
 
 
1. In general, would you say your health is: 
 
 (circle one) 
 
    Excellent ............................................................................................... 1 
 
    Very good ............................................................................................... 2 
 
    Good ....................................................................................................... 3 
 
    Fair .......................................................................................................... 4 
 
    Poor ........................................................................................................ 5 
 
 
 
 
 
2. Compared to one year ago, how would you rate your health in general now? 
 
 (circle one) 
 
    Much better now than one year ago ..................................................... 1 
 
    Somewhat better now than one year ago ............................................ 2 
 
    About the same as one year ago .......................................................... 3 
 
    Somewhat worse now than one year ago ............................................ 4 
 
    Much worse now than one year ago..................................................... 5 
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3. The following questions are about activities you might do during a typical day.  Does 
your health now limit you in these activities?  If so, how much? 
 
 (circle one number on each line) 
 
 ACTIVITIES 
Yes, 
Limited 
A Lot 
Yes, 
Limited 
A Little 
No, Not 
Limited 
At All 
 a. Vigorous activities, such as running, lifting heavy 
objects, participating in strenuous sports 1 2 3 
 b. Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or playing golf 1 2 3 
 c. Lifting or carrying groceries 1 2 3 
 d. Climbing several flights of stairs 1 2 3 
 e. Climbing one flight of stairs 1 2 3 
 f. Bending, kneeling, or stooping 1 2 3 
 g. Walking more than a mile 1 2 3 
 h. Walking half a mile 1 2 3 
 i. Walking one hundred yards 1 2 3 
 j. Bathing or dressing yourself 1 2 3 
 
 
 
4. During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of your physical health? 
 
 (circle one number on each line) 
 YES NO 
 a. Cut down on the amount of time you spent on work 
or other activities 1 2 
 b. Accomplished less than you would like 1 2 
 c. Were limited in the kind of work or other activities 1 2 
 d. Had difficulty performing the work or other activities 
(for example, it took extra effort) 1 2 
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5. During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of any emotional problems (such as feeling depressed 
or anxious)? 
 
 (circle one number on each line) 
 YES NO 
 a. Cut down on the amount of time you spent on work or other 
activities 1 2 
 b. Accomplished less than you would like 1 2 
 c. Didn't do work or other activities as carefully as usual 1 2 
 
 
 
 
6. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbours, or groups? 
 (circle one) 
 
    Not at all ................................................................................................. 1 
 
    Slightly ................................................................................................... 2 
 
    Moderately ............................................................................................. 3 
 
    Quite a bit .............................................................................................. 4 
 
    Extremely ............................................................................................... 5 
 
 
 
 
 
7. How much bodily pain have you had during the past 4 weeks? 
 
 (circle one) 
 
    None ...................................................................................................... 1 
 
    Very mild ................................................................................................ 2 
 
    Mild ......................................................................................................... 3 
 
    Moderate ................................................................................................ 4 
 
    Severe .................................................................................................... 5 
 
    Very severe ............................................................................................ 6 
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8. During the past 4 weeks, how much did pain interfere with your normal work (including both 
work outside the home and housework)? 
 (circle one) 
 
    Not at all ................................................................................................. 1 
 
    A little bit ................................................................................................. 2 
 
    Moderately ............................................................................................. 3 
 
     Quite a bit ............................................................................................... 4 
 
    Extremely ............................................................................................... 5 
 
 
 
9. These questions are about how you feel and how things have been with you during the 
past 4 weeks.  For each question, please give the one answer that comes closest to the way 
you have been feeling.  How much of the time during the past 4 weeks – 
 
 (circle one number on each line) 
 
All of 
the 
Time 
Most of 
the 
Time 
A Good 
Bit of 
the 
Time 
Some 
of the 
Time 
A Little 
of the 
Time 
None 
of the 
Time 
 a. Did you feel full of life? 1 2 3 4 5 6 
 b. Have you been a very 
nervous person? 1 2 3 4 5 6 
 c. Have you felt so down in 
the dumps that nothing could 
cheer you up? 
1 2 3 4 5 6 
 d. Have you felt calm and 
peaceful? 1 2 3 4 5 6 
 e. Did you have a lot of 
energy? 1 2 3 4 5 6 
 f. Have you felt downhearted 
and low? 1 2 3 4 5 6 
 g. Did you feel worn out? 1 2 3 4 5 6 
 h. Have you been a happy 
person? 1 2 3 4 5 6 
 i. Did you feel tired? 1 2 3 4 5 6 
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10. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting with friends, relatives, etc.)? 
 
 (circle one) 
 
    All of the time ......................................................................................... 1 
  
    Most of the time ..................................................................................... 2 
 
    Some of the time ................................................................................... 3 
 
    A little of the time ................................................................................... 4 
 
    None of the time .................................................................................... 5 
 
 
 
 
 
 
 
 
11. How TRUE or FALSE is each of the following statements for you? 
 
 (circle one number on each line) 
 Definitely 
True 
Mostly 
True 
Don't 
Know 
Mostly 
False 
Definitely 
False 
 a. I seem to get ill more easily 
than other people 1 2 3 4 5 
 b. I am as healthy as anybody I 
know 1 2 3 4 5 
 c. I expect my health to get worse 1 2 3 4 5 
 d. My health is excellent 1 2 3 4 5 
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The experience of symptoms, treatment, and emotions may be different for each person with 
congenital heart disease. In the following questionnaire we are interested to learn how your 
heart condition affects your quality of life. The questions relate to different aspects of your 
heart condition. 
 
Please answer the questions by putting a cross in the box which is most applicable to you. 
 
1a. How often in the last month were you short of breath after strolling 100 yards (91m)? 
 
 
 Never                                                     Occasionally                                                        Often 
 
1b. How much did that bother you? 
 
 
Not at all                              A little                                 Quite a lot                           Very much 
 
 
2a. How often in the last month were you short of breath after strolling between half a mile 
and ͵ miles ȋ0.8‐Ͷ.8kmȌ? 
 
 
 Never                                                      Occasionally                                                       Often 
 
2b. How much did that bother you? 
 
 
Not at all                              A little                                 Quite a lot                           Very much 
 
 
3a. How often in the last month did you have difficulty breathing while lying down? 
 
 
 Never                                                      Occasionally                                                       Often 
 
3b. How much did that bother you? 
 
 
Not at all                              A little                                 Quite a lot                            Very much 
 
 
4a. How often in the last month did you have to get up a lot at night to go to the toilet? 
 
 
 Never                                                     Occasionally                                                        Often 
 
4b. How much did that bother you? 
 
 
Not at all                              A little                                 Quite a lot                           Very much 
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5a. How often in the last month did you have excess fluid in your ankles, legs, and/or 
stomach? 
 
 
 Never                                                      Occasionally                                                       Often 
 
5b. How much did that bother you? 
 
 
Not at all                              A little                                 Quite a lot                            Very much 
 
 
6a. How often in the last month did you have palpitations? 
 
 
 Never                                                      Occasionally                                                       Often 
 
6b. How much did that bother you? 
 
 
Not at all                              A little                                 Quite a lot                            Very much 
 
 
7a. How often in the last month did you feel dizzy? 
 
 
 Never                                                     Occasionally                                                        Often 
 
7b. How much did that bother you? 
 
 
Not at all                              A little                                 Quite a lot                            Very much 
 
 
8a. How often in the last month did your lips turn blue when you exerted yourself? 
 
 
 Never                                                     Occasionally                                                        Often 
 
8b. How much did that bother you? 
 
 
Not at all                              A little                                 Quite a lot                            Very much 
 
 
9a. How often in the last month did you look pale? 
 
 
 Never                                                      Occasionally                                                       Often 
 
9b. How much did that bother you? 
 
 
Not at all                              A little                                 Quite a lot                            Very much 
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10a. How often in the last month were you worried about your study/training? 
 
 
 Never                                                       Occasionally                                                      Often 
 
10b. How much did that bother you? 
 
 
Not at all                              A little                                 Quite a lot                            Very much 
 
 
11a. How often in the last month were you worried about your job/future job? 
 
 
 Never                                                      Occasionally                                                       Often 
 
11b. How much did that bother you? 
 
 
Not at all                              A little                                Quite a lot                            Very much 
 
12a. How often in the last month were you worried about your working life? 
 
 
 Never                                                     Occasionally                                                        Often 
 
12b. How much did that bother you? 
 
 
Not at all                              A little                                 Quite a lot                            Very much 
 
 
13a. How often in the last month were you worried about being able to live independently? 
 
 
 Never                                                     Occasionally                                                        Often 
 
13b. How much did that bother you? 
 
 
Not at all                              A little                                 Quite a lot                            Very much 
 
 
14a. How often in the last month were you worried about being home alone? 
 
 
 Never                                                     Occasionally                                                        Often 
 
14b. How much did that bother you? 
 
 
Not at all                              A little                                 Quite a lot                            Very much 
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15a. How often in the last month were you worried about exertion or sports? 
 
 
 Never                                                     Occasionally                                                        Often 
 
15b. How much did that bother you? 
 
 
Not at all                              A little                                Quite a lot                            Very much 
 
16a. How often in the last month were you worried about having good friends? 
 
 
 Never                                                    Occasionally                                                         Often 
 
16b. How much did that bother you? 
 
 
Not at all                             A little                                 Quite a lot                             Very much 
 
 
17a. How often in the last month were you worried about a steady relationship? 
 
 
 Never                                                     Occasionally                                                        Often 
 
17b. How much did that bother you? 
 
 
Not at all                              A little                                 Quite a lot                            Very much 
 
 
18a. How often in the last month were you worried about being able to have children? 
 
 
 Never                                                     Occasionally                                                        Often 
 
18b. How much did that bother you? 
 
 
Not at all                              A little                                 Quite a lot                            Very much 
 
 
19a. How often in the last month were you worried about your health? 
 
 
 Never                                                     Occasionally                                                        Often 
 
19b. How much did that bother you? 
 
 
Not at all                              A little                                 Quite a lot                            Very much 
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20a. In the last twelve months have you had an ECG (heart trace)? 
 
 
    No                              Yes           
 
20b. How much did that bother you? 
 
 
Not at all                              A little                                Quite a lot                             Very much 
 
 
21a. In the last twelve months have you had an ultrasound heart test (echocardiograph)? 
 
 
   No                              Yes            
 
21b. How much did that bother you? 
 
 
Not at all                              A little                                Quite a lot                            Very much 
 
 
22a. In the last twelve months have you had a blood sample taken because of your heart 
condition? 
 
 
   No                              Yes            
 
22b. How much did that bother you? 
 
 
Not at all                              A little                                 Quite a lot                           Very much 
 
 
23a. In the last twelve months have you had an x‐ray of your heart and lungs because of 
your heart condition? 
 
 
   No                              Yes            
 
23b. How much did that bother you? 
 
 
Not at all                              A little                                Quite a lot                            Very much 
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24a. In the last twelve months have you had a flu jab because of your heart condition? 
 
 
   No                              Yes           
 
24b. How much did that bother you? 
 
 
Not at all                             A little                                  Quite a lot                           Very much 
 
25a. In the last twelve months have you seen a consultant for a check‐up because of your 
heart condition? 
 
 
   No                              Yes           
 
25b. How much did that bother you? 
 
 
Not at all                              A little                                Quite a lot                             Very much 
 
 
26a. In the last twelve months have you been admitted to hospital because of your heart 
condition? 
 
 
   No                              Yes            
 
26b. How much did that bother you? 
 
  
Not at all                              A little                                 Quite a lot                            Very much 
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When people experience a condition such as congenital heart disease, they form specific beliefs 
in order to make sense of that condition. In the following questionnaire we are interested to 
find out your own personal views of your heart condition NOT what you think other people 
believe. 
 
For the following questions, please put a cross in the box number that best corresponds to your 
views. 
 
1. How much does your illness affect your life? 
 
No 
affect 
at all 
    0 
 
 
 
 
 
   1 
 
 
 
   2 
 
 
 
    3 
 
 
 
    4 
 
 
 
    5 
 
 
 
   6 
 
 
 
 
    7 
 
 
 
 
   8 
 
 
 
    9 
Severely 
affects 
my life 
      10 
2. How long do you think your illness will continue? 
 
A 
very 
short 
time 
    0 
 
 
 
 
 
 
    1 
 
 
 
 
   2 
 
 
 
 
    3 
 
 
 
 
    4 
 
 
 
 
    5 
 
 
 
 
   6 
 
 
 
 
 
    7 
 
 
 
 
 
   8 
 
 
 
 
    9 
 
 
 
Forever 
     10 
3. How much control do you feel you have over your illness? 
 
 
Absolutely 
no control 
         0 
 
 
 
 
 
 
1 
 
 
 
 
2 
 
 
 
 
3 
 
 
 
 
4 
 
 
 
 
5 
 
 
 
 
6 
 
 
 
 
 
7 
 
 
 
 
 
8 
 
 
 
 
9 
 
Extreme 
amount of 
control 
10 
4. How much do you think your treatment can help your illness? 
 
Not 
at all 
    0 
 
 
 
 
    1 
 
 
   2 
 
 
    3 
 
 
    4 
 
 
    5 
 
 
   6 
 
 
 
    7 
 
 
 
   8 
 
 
    9 
Extremely 
helpful 
   10 
5. How much do you experience symptoms from your illness? 
 
No 
symptoms 
at all 
         0 
 
 
 
 
 
1 
 
 
 
2 
 
 
 
3 
 
 
 
4 
 
 
 
  5 
 
 
 
  6 
 
 
 
 
  7 
 
 
 
 
  8 
 
 
 
  9 
Many 
severe 
symptoms 
    10 
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6. How concerned are you about your illness? 
 
No at all 
concerned 
         0 
 
 
 
 
    1 
 
 
   2 
 
 
    3 
 
 
    4 
 
 
    5 
 
 
   6 
 
 
 
    7 
 
 
 
   8 
 
 
    9 
Extremely 
concerned 
       10 
7. How well do you understand your illness? 
 Don’t 
understand 
at all 
        0 
 
 
 
 
 
   1 
 
 
 
   2 
 
 
 
    3 
 
 
 
    4 
 
 
 
    5 
 
 
 
   6 
 
 
 
 
    7 
 
 
 
 
   8 
 
 
 
    9 
 
Understand 
very clearly 
         10 
8. How does your illness affect you emotionally? (e.g. does it make you angry, 
scared, upset, or depressed?) 
 
Not at all 
affected 
emotionally 
           0 
 
 
 
 
 
    1 
 
 
 
    2 
 
 
 
    3 
 
 
 
    4 
 
 
 
    5 
 
 
 
   6 
 
 
 
 
    7 
 
 
 
 
    8 
 
 
 
    9 
Extremely 
affected 
emotionally 
         10 
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We are interested in how people respond to having congenital heart disease. There are lots of 
ways to try to deal with problems which may arise due to your condition. This questionnaire asks 
you to indicate what you generally do and feel when you have problems related to your heart 
condition. Obviously, different events bring out somewhat different responses, but think about 
what you usually do when you are experiencing stress relating to your heart condition. 
 
Please respond to each of the following items by putting a cross in the box that best describes what 
you have been doing. There are no "right" or "wrong" answers, so choose the most accurate 
answer for YOU, not what you think "most people" would say or do. 
 
 I don’t do 
this at all 
I do this a 
little bit 
I do this a 
moderate 
amount 
I do this a lot 
1. I try to come up with a strategy 
about what to do. 
    
 
2. I concentrate my efforts on doing 
something about the situation I am 
in. 
 
 
 
 
 
 
 
 
 
3. I try to see it in a different light, 
to make it seem more positive. 
    
 
4. I accept the reality of the fact that 
it has happened. 
 
 
 
 
 
 
 
 
 
5. I make jokes about it. 
 
    
 
6. I pray or meditate. 
 
 
 
 
 
 
 
 
 
 
7. I get comfort and understanding 
from someone. 
    
 
8. I try to get advice or help from 
other people about what to do. 
 
 
 
 
 
 
 
 
 
9. I turn to work or other activities 
to take my mind off things. 
    
 
10. I say to myself "this isn't real". 
 
 
 
 
 
 
 
 
11. I say things to let my unpleasant 
feelings escape. 
   
 
 
12. I use alcohol or other drugs to help 
me get through it. 
 
 
 
 
 
 
 
 
 
13. I give up trying to deal with it. 
 
   
 
 
14. I blame myself for the things that 
happened. 
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 I don’t do 
this at all 
I do this a 
little bit 
I do this a 
moderate 
amount 
I do this a lot 
15. I take action to try and make 
the situation better. 
    
 
16. I think hard about what steps 
to take. 
 
 
 
 
 
 
 
 
 
17. I look for something good in 
what is happening. 
    
 
18. I learn to live with it. 
 
 
 
 
 
 
 
 
 
 
19. I try to find comfort in my 
religion or spiritual beliefs. 
    
 
20. I make fun of the situation. 
 
 
 
 
 
 
 
 
 
21. I do something to think about 
it less, such as going to movies, 
watching TV, reading, 
daydreaming, sleeping, or 
shopping. 
 
 
 
 
 
 
 
 
 
22. I get emotional support from 
others. 
 
 
 
 
 
 
 
 
 
23. I express my negative feelings. 
    
 
24. I refuse to believe that it is 
happening. 
 
 
 
 
 
 
 
 
 
25. I get help and advice from 
other people. 
    
26. I use alcohol or other drugs to 
make myself feel better. 
    
 
27. I give up the attempt to cope. 
 
 
 
 
 
 
 
 
 
 
28. I criticise myself. 
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A number of statements which people have used to describe themselves are given below. 
Read each statement and then put a cross in the appropriate box to indicate how you feel 
right now, at this moment. There are no right or wrong answers. Do not spend too much 
time on any one statement but give the answer that seems to describe your present feelings 
best. 
 
 Not at all Somewhat 
 
Moderately Very much 
 
1. I feel calm. 
 
    
2. I am tense. 
 
    
3. I feel upset. 
 
    
4. I am relaxed. 
 
    
5. I feel content. 
 
    
6. I am worried 
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Below is a list of some of the ways you may have felt or behaved. Please indicate how often you 
have felt this way during the past week (please put a cross in one box on each row). 
 
 Rarely or 
none of the 
time (less 
than 1 day) 
Some or a 
little of the time (ͳ‐ʹ 
days) 
Occasionally 
or a moderate 
amount of time (͵‐Ͷ 
days) 
All of the time (ͷ‐7 
days) 
1. I was bothered by things that 
don't usually bother me. 
    
 
2. I had trouble keeping my mind 
on what I was doing. 
 
 
 
 
 
 
 
 
 
3. I felt depressed. 
 
    
 
4. I felt that everything I did was 
an effort. 
 
 
 
 
 
 
 
 
 
5. I felt hopeful about the future. 
 
    
 
6. I felt tearful. 
 
 
 
 
 
 
 
 
 
 
7. My sleep was restless. 
 
    
 
8. I was happy. 
 
 
 
 
 
 
 
 
 
 
9. I felt lonely. 
 
    
 
10. I could not "get going". 
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We are interested in how much you feel you are supported by your friends, family, and a 
special person in your life. Please put a cross in the box of one of the five responses to indicate 
how much you agree with each statement. 
 
  
 
 
Strongly 
disagree 
Disagree 
 
 Neither  
disagree 
nor agree 
Agree 
 
Strongly agree 
1. There is a special person 
who is around when I am 
in need. 
     
 
2. There is a special person 
with whom I share my joys 
and sorrows. 
 
 
 
 
 
 
 
 
 
 
3. My family really tries to 
help me. 
     
 
4. I get the emotional help 
and support I need from 
my family. 
 
 
 
 
 
 
 
 
 
 
5. I have a special person 
who is a real source of 
comfort to me. 
     
 
6. My friends really try to 
help me. 
 
 
 
 
 
 
 
 
 
 
7. I can count on my 
friends when things go 
wrong. 
     
 
8. I can talk about my 
problems with my family. 
 
 
 
 
 
 
 
 
 
 
 
9. I have friends with 
whom I can share my joys 
and sorrows. 
     
 
10. There is a special 
person in my life who 
cares about my feelings. 
 
 
 
 
 
 
 
 
 
 
11. My family is willing to 
help me make decisions. 
     
 
12. I can talk about my 
problems with my friends. 
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Any other comments you would like to add regarding your quality of life: 
 
 
 
 
 
 
 
 
 
 
 
 
There are no more questions. 
 
Thank you very much for completing this booklet. 
 
 
Please make sure you have answered all relevant 
questions and hand the booklet back to the 
researcher. 
 
 
 
Thank you once again for your time. 
The GUCH team  
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Appendix N. License agreement for SF-36v1© 
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Appendix O. Missing value analysis for cross-sectional study  
Variables Missing Subscales (%§) 
DEMOGRAPHIC  
    Age 0 
    Gender 0 
    Marital status 0 
    Educational level 11 (3.5) 
    Employment status 11 (3.5) 
CLINICAL  
    Co-morbidities no. 3 (1) 
    Arrhythmias 3 (1) 
    Cyanosis days 12 (3.8) 
    Interventions no. 3 (1) 
    Hospitalization days 8 (2.5) 
    Medication no. 3 (1) 
    Current saturation 4 (1.3) 
    VO2 Max 0  
    Right ventricular function 0 
    Left ventricular function 0 
    NYHA class 3 (1) 
Total values: n= 5024 Missing values: n= 61 (1.2%)  
PSYCHOSOCIAL  
SF-36  
    Physical functioning 0 
    Role physical 1 (0.3) 
    Bodily pain 0 
    General health 0 
    Vitality 0 
    Social functioning 0 
    Role emotional 1 (0.3) 
    Mental health 0 
    Physical component summary 1 (0.3) 
    Mental component summary 1 (0.3) 
CHD-TAAQOL  
    Symptoms 2 (0.7) 
    Worries 0  
    Impact cardiac surveillance 1 (0.3) 
Brief IPQ  
    Consequences 1 (0.3) 
    Timeline 2 (0.7) 
    Controllability 1 (0.3) 
    Curability 9 (3) 
    Identity 0 
    Concern 0 
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Variables Missing Subscales (%) 
    Coherence 1 (0.3) 
    Emotional representation 1 
Brief COPE  
    Planning 2 (0.7) 
    Active coping 2 (0.7) 
    Positive reframing 2 (0.7) 
    Acceptance 2 (0.7) 
    Humour 2 (0.7) 
    Religion 2 (0.7) 
    Seeking emotional support 2 (0.7) 
    Seeking instrumental support 2 (0.7) 
    Self-distraction 2 (0.7) 
    Denial 2 (0.7) 
    Venting 2 (0.7) 
    Substance use 2 (0.7) 
    Behavioural disengagement 2 (0.7) 
    Self-blame 2 (0.7) 
STAI-6 0 
CES-D 10 2 (0.7) 
MSPSS  
    Family support 0 
    Friends support 0 
    Special person support 0 
Total values: n= 12120 Missing values: n= 52 (0.4%)  
§Percentage of values missing within the particular scale/subscale. 
Note. Missing value analysis for psychosocial questionnaires did not include the cases with incomplete 
psychosocial assessments (n=11) as these were not to be imputed.   
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Appendix P. Missing value analysis for longitudinal study  
Variables Missing Subscales (%§) 
CLINICAL  
    Interventions no. 0 
    Hospitalization days 0 
    Medication no. 0 
Total values: n= 564 Missing values: n= 0  
SF-36  
    Physical functioning 0 
    Role physical 0 
    Bodily pain 1 (0.5) 
    General health 0 
    Vitality 2 (1.1) 
    Social functioning 1 (0.5) 
    Role emotional 1 (0.5) 
    Mental health 2 (1.1) 
    Physical component summary 2 (1.1) 
    Mental component summary 2 (1.1) 
CHD-TAAQOL  
    Symptoms 0 
    Worries 0 
    Impact cardiac surveillance 0 
Brief IPQ  
    Consequences 0 
    Timeline 0 
    Controllability 0 
    Curability 2 (1.1) 
    Identity 1 (0.5) 
    Concern 0 
    Coherence 0 
    Emotional representation 0 
Brief COPE  
    Planning 0 
    Active coping 0 
    Positive reframing 0 
    Acceptance 0 
    Humour 0 
    Religion 0 
    Seeking emotional support 0 
    Seeking instrumental support 0 
    Self-distraction 0 
    Denial 0 
    Venting 0 
    Substance use 0 
  
APPENDICES 
525 
 
Variables Missing Subscales (%) 
    Behavioural disengagement 0 
    Self-blame 0 
STAI-6 0 
CES-D 10 0 
    Family support 0 
    Friends support 0 
    Special person support 0 
Total values: n= 7520 Missing values: n= 14 (0.2%)  
§Percentage of values missing within the particular scale/subscale.  
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Appendix Q. Correlation matrix of predictor variables 
 1  2 3 4 5 6 7 8 9 10 11 12 13 14 
1. Age -               
2. Gender§ .158**  -             
3. Marital status§ -.373**  -.137* -            
4. Education level§ -.135*  -.005 .090 -           
5. Employment 
status§ 
-.006 
 -.189** -.099 .101 -          
6. TOF§ .081  .039 -.043 -.013 .032 -         
7. TGA§ -.087  -.093 .073 -.090 .064 -.348** -        
8. SV§ -.232**  -.104 .007 .057 -.065 -.310** -.310** -       
9. Co-morbidities 
no. 
.315**  .014 -.077 -.042 -.161** -.050 .044 .087 -      
10. Arrhythmias§  .152**  -.047 -.086 .008 -.102 -.106 .208** .158** .552** -     
11. Cyanosis days .017  -.037 -.046 .102 -.033 .061 -.158** .433** .241** .163* -    
12. Interventions no. -.096  -.139* -.008 -.125* -.152** .010 .109 .304** .294** .401** .235** -   
13. Hospitalisation 
days 
.062  -.060 -.037 .016 -.158** .063 -.061 .291** .404** .256** .228** .445** -  
14. Medication no. .274**  -.054 -.099 -.096 -.114* -.193** .043 .227** .544** .433** .250** .328** .310** - 
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Continued 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
15. Current 
saturation 
.032 .002 .024 .005 .139* .170** .042 -.542** -.276** -.139* -.637** -.227** -.263** -.181** 
16. VO2 max -.283** -.264** .158** .158** .149** -.056 -.058 -.063 -.320** -.220** -.196** -.261** -.187** -.292** 
17. LVEF .031 .102 -.028 .019 .047 -.068 .134* -.361** -.172** -.205** -.288** -.271** -.237** -.210** 
18. RVEF .062 .125* -.021 .104 .053 -.109 -.213** -.109 -.133* -.297** -.168** -.384** -.220** -.169** 
19. NYHA class§ .190** .097 -.082 -.101 -.263** .021 -.001 .107 .457** .344** .246** .295** .365** .453** 
20. Consequences .055 .032 -.016 -.085 -.279** -.053 -.079 .223** .310** .194** .183** .220** .245** .350** 
21. Timeline -.118* -.085 .056 .013 .042 .013 .126* .073 .013 .069 -.066 .158** .089 -.003 
22. Controllability .071 -.045 -.053 -.032 .129* .066 .034 -.039 -.001 -.045 -.011 .078 .017 -.026 
23. Curability .066 -.123* -.038 -.045 .005 .214** -.022 .009 .024 .101 .065 .138 .096 .100 
24. Identity .135* .082 -.044 -.139* -.180** -.094 -.057 .253** .330** .243** .228** .213** .232** .361** 
25. Concern .031 -.015 .043 -.060 -.184** .045 -.066 .066 .227** .150** .105 .075 .143* .323** 
26. Coherence .169** .106 -.080 .144* -.114* -.003 .020 -.113* .147* .023 -.008 -.028 .066 .113* 
27. Emotional 
representation 
-.046 .109 .020 -.009 -.233** .006 -.081 .160** .247** .143*  .091 .076 .126* .224** 
28. Planning  .102 .117* -.116* .210** .096 .048 -.178** .104 .013 .005 .065 .042 .028 .071 
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Continued 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
29. Active coping .093 .101 -.099 .189** .061 .105 -.121* .031 .039 .013 .050 .037 .030 .014 
30. Positive 
reframing 
.124* .132* -.034 .021 .035 .016 -.037 -.046 -.048 -.048 .031 -.062 -.110 -.073 
31. Acceptance .106 .028 -.100 .069 .074 .033 -.115* .123* -.040 .091 .044 .054 -.010 -.006 
32. Humour .010 -.011 -.036 -.046 -.044 .002 -.072 .108 .010 -.004 .059 .060 -.036 .034 
33. Religion .126* .214** -.051 .085 -.047 .067 -.116* .043 .061 .048 .219** -.018 -.016 .021 
34. Emotional 
support 
-.053 .195** -.040 .061 -.032 .084 -.102 .044 .059 -.003 .027 .033 -.031 .093 
35. Instrumental 
support 
-.074 .105 -.005 .052 .008 .080 -.005 .007 .053 .016 .006 -.012 -.001 .057 
36. Self-distraction -.045 .165** .034 .068 .027 -.023 -.175** .133* .022 -.028 .119* -.043 .017 .089 
37. Denial .114* .104 .005 -.075 .004 -.021 -.016 .033 .025 .023 .095 -.029 .009 .113* 
38. Venting -.019 .064 -.012 -.029 -.094 -.001 -.126* .138* .116* .063 .049 .064 .068 .069 
39. Substance use .014 -.095 .121* .021 -.146* -.047 -.103 .068 .086 .099 -.011 .082 .081 .024 
40. Behavioural 
disengagement 
-.031 -.022 .077 -.090 -.086 -.075 -.048 .090 .082 .007 .051 .052 -.024 .093 
41. Self-blame .124* .093 -.026 -.023 -.085 -.074 -.017 .029 .130* .057 -.036 -.031 -.032 .087 
42. Anxiety .010 .157** .072 -.070 -.161** -.050 -.074 .118* .174** .061 .045 -.016 .114* .139* 
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Continued 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
43. Depression§ -.022 .079 .040 -.028 -.246** -.047 -.124* .075 .165** -.011 .098 -.052 .101 .117* 
44. Family support .059 .131* -.101 .041 .006 .109 -.010 -.084 -.009 .025 -.028 .038 -.137* .052 
45. Friends support .036 .185** -.028 -.011 .089 .003 .001 -.087 -.088 -.033 -.023 -.004 -.176** -.019 
46. Special person 
support 
.176** .224** -.390** -.062 .120* .112 -.038 -.134* -.005 .029 -.076 -.024 -.055 .022 
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Continued 
 15 16 17 18 19 20 21 22 23 24 25 26 27 28 
15. Current 
saturation 
-       
 
      
16. VO2 max .204* -             
17. LVEF .291** .151** -            
18. RVEF .169** .225** .566** -           
19. NYHA class§ -.299** -.291** -.149** -.191** -          
20. Consequences -.263** -.256** -.224** -.160** .331** -         
21. Timeline -.028 -.065 .056 -.089 .026 .092 -        
22. Controllability .040 -.038 .057 -.003 -.071 -.211** -.083 -       
23. Curability .027 -.045 -.078 -.168** .027 -.066 .036 .264** -      
24. Identity -.325** -.290** -.219** -.112 .375** .709** .064 -.159** -.075 -     
25. Concern -.147* -.149** -.149** -.128* .346** .582** .062 -.176** .019 .536** -    
26. Coherence .051 -.037 -.001 -.001 .011 -.005 -.030 .155** .141* -.068 -.026 -   
27. Emotional 
representation 
-.159** -.158** -.138* -.116* .247** .643** .002 -.221** -.077 .545** .646** -.020 -  
28. Planning  -.021 -.010 -.109 -.025 .008 .115* -.077 .076 .111 .104 .073 .128* .105 - 
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Continued 
 15 16 17 18 19 20 21 22 23 24 25 26 27 28 
29. Active coping .028 .006 -.006 -.024 .037 .104 .020 .185** .199** .081 .088 .105 .007 .750** 
30. Positive 
reframing 
.056 -.051 .015 -.012 .024 -.042 -.113 .219** .081 -.022 -.036 .041 -.056 .435** 
31. Acceptance -.008 -.067 -.074 -.101 -.037 .017 -.005 .038 .051 .028 -.095 .113* -.115* .198** 
32. Humour .003 -.010 -.042 -.002 .079 .092 -.107 .108 .141* .094 -.088 -.054 .057 .201** 
33. Religion -.089 -.166** -.087 -.018 .120* .099 -.141* -.004 .062 .129* .078 -.003 .137* .121* 
34. Emotional 
support 
-.035 -.115* -.091 -.101 .043 .120* -.047 .087 .116* .166** .119* .061 .153** .305** 
35. Instrumental 
support 
.002 -.023 -.089 -.078 -.015 .084 .002 .087 .119* .060 .165** .085 .106 .409** 
36. Self-distraction -.120* -.089 -.124* -.059 .057 .271** -.019 .010 .017 .209** .201** .006 .287** .381** 
37. Denial -.064 -.093 -.086 .006 .073 .118* -.082 .001 -.013 .128* .126* -.045 .182** .142* 
38. Venting -.113* -.089 -.019 -.016 .094 .345** .032 -.100 .017 .299** .316** .003 .511** .219** 
39. Substance use -.021 -.054 -.008 .034 .115* .187** -.029 -.079 -.065 .134* .169** -.161** .215** .077 
40. Behavioural 
disengagement 
-.142* -.070 -.054 .018 .043 .291** .031 -.177** -.148* .249** .259** -.219** .400** .085 
41. Self-blame -.019 -.087 -.002 .051 .091 .237** .039 -.108 -.053 .163** .162** -.008 .306** .208** 
42. Anxiety -.130* -.136* -.051 .013 .200** .365** -.036 -.283** -.256** .272** .316** -.129* .476** -.046 
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Continued 
 15 16 17 18 19 20 21 22 23 24 25 26 27 28 
43. Depression§ -.160** -.092 -.016 .000 .173** .400** -.007 -.205** -149** .333** .313** -.027 .518** .013 
44. Family support .043 -.093 .076 .015 -.023 -.133* -.032 .196** .163** -.075 -.068 .086 -.082 .131* 
45. Friends support .053 -.087 .041 .024 -.087 -.170** -.023 .186** .119* -.057 -.088 .030 -.132* .075 
46. Special person 
support 
.072 -.127* .093 .036 .071 -.107 -.048 .083 .145* -.035 -.071 .021 -.118* .198** 
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Continued 
 29 30 31 32 33 34 35 36 37 38 39 40 41 42 
29. Active coping -              
30. Positive 
reframing 
.516* -             
31. Acceptance .277** .382** -            
32. Humour .269** .358** .216** -           
33. Religion .067 .172** .133* .056 -          
34. Emotional 
support 
.259** .256** .150** .217** .238** -         
35. Instrumental 
support 
.379** .217** .054 .130* .150** .637** -        
36. Self-distraction .319** .216** .185** .216** .087 .390** .359** -       
37. Denial .066 .008 -.131* .119* .090 .075 .105 .242** -      
38. Venting .156** .037 .017 .122* .074 .251** .306** .339** .190** -     
39. Substance use .005 .007 -.033 .072 -.100 -.017 .001 .169** .012 .207** -    
40. Behavioural 
disengagement 
-.070 -.074 -.162** .040 .105 .015 .046 .174** .339** .320** .277** -   
41. Self-blame .057 -.035 -.108 .098 .020 .109 .189** .254** .226** .396** .154** .402** -  
42. Anxiety -.178** -.244** -.245** -.133* .047 -.036 -.020 .073 .182** .271** .208** .357** .307** - 
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Continued 
 29 30 31 32 33 34 35 36 37 38 39 40 41 42 
43. Depression§ -.106 -.181** -.173** -.022 .071 .042 .035 .169** .185** .354** .215** .411** .356** .508** 
44. Family support .135* .151** .145* .081 .090 .351** .196** .064 -.022 -.011 -.210** -.133* -.093 -.259** 
45. Friends support .079 .185** .144* .126* .164** .277** .158** .078 -.014 .017 -.172** -.104 -.091 -.235** 
46. Special person 
support 
.231** .197** .127* .094 .049 .267** .133* .065 .054 -.009 -.154** -.062 -.062 -.166** 
 
Continued 
 43 44 45 46 
43. Depression§ -    
44. Family support -.176** -   
45. Friends support -.169** .454** -  
46. Special person 
support 
-.158** .413** .322** - 
*p<.05, **p<.01. 
§ Gender: 0= male, 1= female, Marital status: 0= married/in relationship, 1= single, Educational level: 0= school level, 1= university level, Employment status: 0= unemployed, 1= employed, 
TOF, TGA, SV: dummy-coded diagnostic group, Arrhythmias: 0= no arrhythmias, 1= arrhythmias, NYHA class: 0= Class I, 1= Classes II, III, IV, Depression: 0= no depressive symptoms, 1= 
with depressive symptoms.
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Appendix R. Bivariate regressions: factors associated with generic physical and psychosocial and disease-specific HRQoL  
Predictor 
Variable 
Physical HRQOL Psychosocial HRQOL Disease-specific HRQoL 
 Ph
ysi
cal
 
Co
mp
on
ent
 
Su
mm
ary
 
Ph
ysi
cal
 
Fu
nct
ion
ing
 
Ro
le P
hys
ica
l 
Bo
dil
y P
ain
 
Ge
ner
al H
eal
th 
Me
nta
l 
Co
mp
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ent
 
Su
mm
ary
 
Vit
ali
ty 
So
cia
l 
Fu
nct
ion
ing
 
Ro
le E
mo
tio
na
l 
Me
nta
l H
eal
th 
Sym
pto
ms
 
Im
pac
t C
ard
iac
 
Su
rve
illa
nce
 
Wo
rri
es 
Age -.153* -.125 -.060 -.056 -.013 .160* -.033 .101 .065 .164* -.108 -.008 .153* 
Gender§ -.112 -.163* -.049 -.138 -.019 -.056 -.170* -.037 -.056 -.075 -.155* .004 -.030 
Educational 
level§ 
.156* .124 .054 .135 .181* -.001 .032 .053 -.010 .061 .112 .033 -.069 
Employment 
status§ 
.212** .290** .287** .126 .211** .261** .284** .256** .251** .261** .289** .111 .147 
ToF§ .118 .103 .101 .129 .096 .099 .151* .151* .056 .098 .072 .092 .099 
SV§ -.170* -.238** -.144 -.083 -.133 -.098 -.097 -.214** -.075 -.116 -.196* -.188* -.186* 
Co-morbidities 
no. 
-.312** -.381** -.182* -.178* -.269** -.095 -.227** -.205** -.138 -.083 -.318** -.268** -.171* 
Arrhythmias§ -.135 -.198* -.015 -.008 -.138 .043 -.029 -.022 .018 .016 -.166* -.290** -.057 
Cyanosis days -.261** -.289** -.242** -.093 -.113 .021 -.068 -.143 .005 -.039 -.180* -.102 -.101 
Intervention no. -.131 -.182* -.050 .059 -.152* .059 .019 -.069 .060 .022 -.124 -.222** -.034 
Hospitalization 
days 
-.235** -.294** -.149 -.111 -.195* -.048 -.094 -.182* -.063 -.075 -.183* -.146 -.145 
Medication no. -.305** -.340** -.143 -.171* -.322** -.076 -.209** -.194* -.073 -.093 -.305** -.295** -.133 
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Continued 
Predictor 
Variable 
Physical HRQOL Psychosocial HRQOL Disease-specific HRQoL 
 Ph
ysi
cal
 
Co
mp
on
ent
 
Su
mm
ary
 
Ph
ysi
cal
 
Fu
nct
ion
ing
 
Ro
le P
hys
ica
l 
Bo
dil
y P
ain
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al H
eal
th 
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eal
th 
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pto
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Im
pac
t C
ard
iac
 
Su
rve
illa
nce
 
Wo
rri
es 
Current O2 
saturation 
.334** .411** .279** .152* .214** .087 .198* .270** .072 .137 .323** .215** .205** 
VO2 max .266** .331** .130 .124 .224** .022 .136 .139 .034 .073 .320** .193* .114 
RVEF .090 .098 .042 -.071 .157* -.061 -.056 .021 -.070 -.010 .120 .125 .134 
LVEF .137 .209** .085 .029 .114 .028 .016 .124 .025 .056 .192* .084 .142 
Brief IPQ 
consequences 
-.553** -.614** -.499** -.426** -.545** -.426** -.544** -.581** -.378** -.425** -.615** -.432** -.557** 
Brief IPQ 
controllability 
.155* .145 .158* .192* .232** .227** .238** .183* .183* .243** .166* .138 .186* 
Brief IPQ 
curability 
.073 .085 .062 .103 .154* .165* .171* .113 .141 .140 .072 .016 .161* 
Brief IPQ 
identity 
-.677** -.667** -.512** -.541** -.597** -.332** -.587** -.555** -.288** -.344** -.698** -.444** -.480** 
Brief IPQ 
concern 
-.406** -.441** -.316** -.365** -.474** -.352** -.411** -.415** -.272** -.386** -.508** -.416** -.476** 
Brief IPQ 
emotional 
representation 
-.362** -.405** -.374** -.392** -.504** -.527** -.512** -.493** -.415** -.539** -.550** -.455** -.550** 
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Continued 
Predictor 
Variable 
Physical HRQOL Psychosocial HRQOL Disease-specific HRQoL 
 Ph
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eal
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t C
ard
iac
 
Su
rve
illa
nce
 
Wo
rri
es 
Brief COPE 
planning 
-.061 -.041 -.052 -.109 -.011 -.037 -.064 -.046 -.062 -.013 -.056 -.168* -.154* 
Brief COPE 
positive 
reframing 
-.056 -.011 .027 -.044 .137 .224** .146 .062 .152* .212** .007 .069 .103 
Brief COPE 
acceptance 
-.015 .050 .000 .057 .107 .222** .166* .101 .152* .218** .047 .061 .068 
Brief COPE 
religion 
-.156* -.153* -.101 -.168* -.049 -.007 -.044 -.077 -.047 -.022 -.133 -.108 -.110 
Brief COPE 
self-distraction 
-.118 -.147 -.124 -.147 -.140 -.212** -.240** -.199** -.172* -.175* -.214** -.094 -.258** 
Brief COPE 
denial 
-.133 -.205** -.110 -.207** -.072 -.188* -.214** -.154* -.136 -.229** -.190* -.145 -.117 
Brief COPE 
venting 
-.170* -.174* -.244** -.251** -.255** -.361** -.319** -.280** -.297** -.357** -.294** -.253** -.285** 
Brief COPE 
substance use 
-.108 -.197* -.139 -.039 -.171* -.202** -.185* -.191* -.192* -.175* -.165* -.150* -.234** 
  
APPENDICES 
538 
 
Continued 
Predictor 
Variable 
Physical HRQOL Psychosocial HRQOL Disease-specific HRQoL 
 Ph
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Ge
ner
al H
eal
th 
Me
nta
l 
Co
mp
on
ent
 
Su
mm
ary
 
Vit
ali
ty 
So
cia
l 
Fu
nct
ion
ing
 
Ro
le E
mo
tio
na
l 
Me
nta
l H
eal
th 
Sym
pto
ms
 
Im
pac
t C
ard
iac
 
Su
rve
illa
nce
 
Wo
rri
es 
Brief COPE 
behavioural 
disengagement 
-.192* -.264** -.232** -.239** -.272** -.374** -.339** -.289** -.301** -.396** -.307** -.290** -.280** 
Brief COPE 
self-blame 
-.072 -.178* -.194* -.155* -.179* -.419** -.352** -.217** -.372** -.401** -.253** -.125 -.303** 
MSPSS family 
support 
.084 .103 .074 .143 .082 .136 .105 .146 .085 .160* .091 .040 .170* 
MSPSS friend 
support 
.033 .106 .107 .051 .097 .220** .127 .165* .212** .194* .075 .072 .189* 
MSPSS 
significant other 
support 
-.031 .014 .052 -.026 .079 .180* .087 .117 .142 .151* .043 .013 .146 
STAI-6 anxiety -.243** -.364** -.313** -.333** -.317** -.525** -.447** -.420** -.429** -.550** -.422** -.342** -.402** 
CES-D 10 
depression§ 
-.261** -.361** -.444** -.327** -.427** -.686** -.598** -.513** -.585** -.652** -.510** -.274** -.507** 
Note. Values represent standardised beta coefficients.  
*p<  .01, **p<  .001. §Gender: 0=  male, 1=  female, educational level: 0=  school, 1=  university, employment status: 0=  unemployed, 1=  employed, ToF, SV: dummy-coded- reference group was 
Simple, arrhythmias: 0=  no arrhythmias, 1=  arrhythmias, CES-D 10: 0=  no depressive symptoms, 1=  with depressive symptoms. 
Note. Beta coefficients are standardized. Marital status, TGA, brief IPQ timeline, brief IPQ coherence, brief COPE active coping, brief COPE humour, brief COPE emotional support, and brief 
COPE instrumental support were excluded from the table because they did not have a significant relationship with any of the outcome variables. 
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Appendix S. Full hierarchical multiple regressions 
Physical component summary of the SF-36 (n= 301) 
Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
1  .079 .069 .079   <.001 
 
Education level    .117 .115 .040 
 
Employment status    .203 .202 <.001 
 
Age    -.119 -.118 .036 
2  .195 .172 .116   <.001 
 
Education level    .146 .141 .008 
 
Employment status    .153 .149 .005 
 
Age    -.065 -.057 .283 
 
ToF    .109 .087 .098 
 
TGA    .010 .008 .884 
 
SV    -.046 -.032 .537 
 
Cyanosis days    -.185 -.156 .003 
 
Co-morbidities no.    -.213 -.191 <.001 
3  .202 .178 .008   .094 
 
Education level    .150 .144 .006 
 
Employment status    .143 .139 .008 
 
Age    -.061 -.053 .316 
 
ToF    .135 .105 .047 
 
TGA    .024 .019 .721 
 
SV    -.007 -.005 .926 
 
Cyanosis days    -.185 -.157 .003 
 
Co-morbidities no.    -.177 -.149 .005 
 
Hospitalization days    -.103 -.088 .094 
4  .235 .203 .033   .007 
 
Education level    .121 .115 .026 
 
Employment status    .113 .107 .038 
 
Age    -.017 -.014 .783 
 
ToF    .125 .095 .065 
 
TGA    .071 .054 .294 
 
SV    .091 .057 .273 
 
Cyanosis days    -.076 -.054 .295 
 
Co-morbidities no.    -.084 -.062 .227 
 
Hospitalization days    -.092 -.078 .130 
 
Current O2 saturation    .183 .122 .019 
 
Medication no.    -.125 -.095 .066 
 
VO2 max    .104 .091 .078 
5  .510 .481 .275   <.001 
 
Education level    .062 .059 .158 
 
Employment status    .050 .046 .272 
 
Age    -.016 -.013 .761 
 
ToF    .104 .078 .061 
 
TGA    .025 .019 .651 
 
SV    .119 .073 .080 
 
Cyanosis days    -.084 -.060 .153 
 
Co-morbidities no.    -.032 -.024 .570 
 
Hospitalization days    -.065 -.055 .187 
 
Current O2 saturation    .069 .046 .272 
 
Medication no.    .009 .006 .880 
 
VO2 max    .026 .022 .589 
 Brief IPQ consequences    -.126 -.077 .067 
 Brief IPQ controllability    .046 .044 .296 
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Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
 
Brief IPQ identity    -.517 -.334 <.001 
 
Brief IPQ concern    -.055 -.038 .356 
 
Brief IPQ emotional 
representation 
   .073 .048 .246 
6  .515 .481 .005   .418 
 
Education level    .068 .063 .129 
 
Employment status    .046 .042 .312 
 
Age    -.011 -.009 .835 
 
ToF    .102 .077 .066 
 
TGA    .023 .017 .676 
 
SV    .115 .070 .092 
 
Cyanosis days    -.065 -.045 .276 
 
Co-morbidities no.    -.033 -.025 .555 
 
Hospitalization days    -.071 -.060 .150 
 
Current O2 saturation    .076 .050 .235 
 
Medication no.    .007 .005 .905 
 
VO2 max    .018 .015 .711 
 
Brief IPQ consequences    -.129 -.078 .061 
 
Brief IPQ controllability    .044 .042 .311 
 
Brief IPQ identity    -.513 -.331 <.001 
 
Brief IPQ concern    -.057 -.040 .341 
 
Brief IPQ emotional 
representation 
   .067 .041 .330 
 
Brief COPE religion    -.063 -.059 .160 
 
Brief COPE venting    .042 .035 .401 
 
Brief COPE behavioural 
disengagement 
   -.017 -.015 .719 
7  .516 .478 .001   .747 
 
Education level    .066 .061 .143 
 
Employment status    .045 .041 .323 
 
Age    -.010 -.008 .840 
 
ToF    .099 .074 .077 
 
TGA    .020 .015 .720 
 
SV    .114 .069 .101 
 
Cyanosis days    -.066 -.046 .274 
 
Co-morbidities no.    -.032 -.023 .578 
 
Hospitalization days    -.069 -.058 .167 
 
Current O2 saturation    .075 .049 .242 
 
Medication no.    .006 .004 .921 
 
VO2 max    .015 .013 .753 
 
Brief IPQ consequences    -.126 -.076 .068 
 
Brief IPQ controllability    .038 .035 .403 
 
Brief IPQ identity    -.517 -.332 <.001 
 
Brief IPQ concern    -.057 -.040 .340 
 
Brief IPQ emotional 
representation 
   .081 .047 .264 
 
Brief COPE religion    -.064 -.060 .154 
 
Brief COPE venting    .042 .035 .400 
 
Brief COPE behavioural 
disengagement 
   -.010 -.008 .841 
 
STAI-6 anxiety    -.037 -.030 .479 
 
CES-D 10 depression    -.003 -.003 .951 
Note. Gender: 0=  male, 1=  female, educational level: 0=  school, 1=  university, employment status: 0=  
unemployed, 1=  employed, ToF, TGA, SV: dummy-coded- reference group was Simple, arrhythmias: 0=  no 
arrhythmias, 1=  arrhythmias, CES-D 10: 0=  no depressive symptoms, 1=  with depressive symptoms. 
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Physical functioning subscale of the SF-36 (n= 301) 
Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
1  .099 .093 .099   <.001 
 
Gender    -.104 -.102 .064 
 
Employment status    .279 .274 <.001 
2  .273 .253 .174   <.001 
 
Gender    -.139 -.134 .008 
 
Employment status    .210 .202 <.001 
 
ToF    .043 .034 .490 
 
TGA    -.028 -.022 .663 
 
SV    -.151 -.108 .030 
 
Cyanosis days    -.134 -.115 .022 
 
Co-morbidities no.    -.329 -.267 <.001 
 
Arrhythmias    .044 .035 .483 
3  .283 .258 .009   .151 
 
Gender    -.145 -.139 .006 
 
Employment status    .198 .189 <.001 
 
ToF    .072 .055 .269 
 
TGA    -.011 -.008 .865 
 
SV    -.107 -.070 .158 
 
Cyanosis days    -.134 -.114 .022 
 
Co-morbidities no.    -.286 -.218 <.001 
 
Arrhythmias    .044 .034 .493 
 
Intervention no.    -.012 -.009 .854 
 
Hospitalization days    -.110 -.090 .070 
4  .346 .314 .064   <.001 
 
Gender    -.115 -.103 .032 
 
Employment status    .167 .156 .001 
 
ToF    .063 .047 .330 
 
TGA    .036 .026 .588 
 
SV    .016 .010 .841 
 
Cyanosis days    .016 .010 .829 
 
Co-morbidities no.    -.145 -.100 .038 
 
Arrhythmias    .037 .028 .558 
 
Intervention no.    .038 .029 .541 
 
Hospitalization days    -.103 -.084 .079 
 
Current O2 saturation    .241 .159 .001 
 
Medication no.    -.157 -.120 .012 
 
VO2 max    .125 .106 .027 
 
LVEF    .080 .071 .140 
5  .573 .546 .227   <.001 
 
Gender    -.102 -.090 .021 
 
Employment status    .099 .090 .021 
 
ToF    .044 .032 .415 
 
TGA    -.009 -.007 .860 
 
SV    .014 .008 .832 
 
Cyanosis days    -.004 -.003 .940 
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Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
 
Co-morbidities no.    -.112 -.076 .050 
 
Arrhythmias    .050 .038 .333 
 
Intervention no.    .044 .034 .387 
 
Hospitalization days    -.078 -.063 .105 
 
Current O2 saturation    .137 .089 .022 
 
Medication no.    -.017 -.013 .745 
 
VO2 max    .059 .049 .209 
 
LVEF    .026 .023 .549 
 
Brief IPQ consequences    -.234 -.142 <.001 
 
Brief IPQ identity    -.374 -.244 <.001 
 
Brief IPQ concern    -.094 -.065 .095 
 
Brief IPQ emotional 
representation 
   .102 .068 .083 
6  .605 .571 .032   .001 
 
Gender    -.106 -.091 .017 
 
Employment status    .091 .082 .030 
 
ToF    .016 .011 .766 
 
TGA    -.032 -.022 .554 
 
SV    -.013 -.008 .837 
 
Cyanosis days    .015 .011 .778 
 
Co-morbidities no.    -.123 -.082 .030 
 
Arrhythmias    .061 .046 .229 
 
Intervention no.    .039 .030 .433 
 
Hospitalization days    -.081 -.065 .085 
 
Current O2 saturation    .140 .089 .018 
 
Medication no.    -.015 -.011 .771 
 
VO2 max    .041 .034 .365 
 
LVEF    .013 .011 .767 
 
Brief IPQ consequences    -.231 -.139 <.001 
 
Brief IPQ identity    -.375 -.244 <.001 
 
Brief IPQ concern    -.093 -.064 .092 
 
Brief IPQ emotional 
representation 
   .119 .071 .061 
 
Brief COPE religion    -.045 -.041 .282 
 
Brief COPE denial    -.107 -.097 .011 
 
Brief COPE venting    .104 .083 .028 
 
Brief COPE substance use    -.109 -.099 .009 
 
Brief COPE behavioural 
disengagement 
   -.046 -.037 .333 
 
Brief COPE self-blame    -.025 -.021 .583 
7  .618 .581 .012   .014 
 
Gender    -.096 -.081 .030 
 
Employment status    .083 .074 .048 
 
ToF    .010 .007 .842 
 
TGA    -.037 -.026 .484 
 
SV    -.013 -.008 .833 
 
Cyanosis days    .016 .011 .768 
 
Co-morbidities no.    -.116 -.078 .037 
 
Arrhythmias    .056 .041 .270 
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Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
 
Intervention no.    .019 .015 .696 
 
Hospitalization days    -.066 -.053 .159 
 
Current O2 saturation    .132 .084 .025 
 
Medication no.    -.014 -.010 .786 
 
VO2 max    .038 .031 .400 
 
LVEF    .018 .015 .680 
 
Brief IPQ consequences    -.216 -.130 .001 
 
Brief IPQ identity    -.381 -.246 <.001 
 
Brief IPQ concern    -.096 -.066 .079 
 
Brief IPQ emotional 
representation 
   .172 .098 .009 
 
Brief COPE religion    -.049 -.045 .231 
 
Brief COPE denial 
 
  -.102 -.093 .013 
 
Brief COPE venting    .102 .082 .029 
 
Brief COPE substance use    -.099 -.089 .018 
 
Brief COPE behavioural 
disengagement 
   -.020 -.015 .681 
 
Brief COPE self-blame    -.004 -.003 .929 
 
STAI-6 anxiety    -.103 -.082 .029 
 
CES-D 10 depression    -.064 -.047 .204 
Note. Gender: 0=  male, 1=  female, educational level: 0=  school, 1=  university, employment status: 0=  
unemployed, 1=  employed, ToF, TGA, SV: dummy-coded- reference group was Simple, arrhythmias: 0=  no 
arrhythmias, 1=  arrhythmias, CES-D 10: 0=  no depressive symptoms, 1=  with depressive symptoms. 
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Role physical subscale of the SF-36 (n= 301) 
Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
1  .085 .082 .085   <.001 
 
Employment status    .291 .291 <.001 
2  .140 .131 .055   <.001 
 
Employment status    .270 .266 <.001 
 
Cyanosis days    -.196 -.192 <.001 
 
Co-morbidities no.    -.093 -.089 .098 
3  .148 .137 .009   .082 
 
Employment status    .253 .246 <.001 
 
Cyanosis days    -.122 -.094 .081 
 
Co-morbidities no.    -.079 -.075 .165 
 
Current O2 saturation    .124 .093 .082 
4  .342 .322 .194   <.001 
 
Employment status    .168 .157 .001 
 
Cyanosis days    -.111 -.085 .075 
 
Co-morbidities no.    .043 .039 .412 
 
Current O2 saturation    .019 .014 .774 
 
Brief IPQ consequences    -.203 -.125 .009 
 
Brief IPQ controllability    .041 .040 .403 
 
Brief IPQ identity    -.305 -.203 <.001 
 
Brief IPQ concern    .051 .037 .443 
 
Brief IPQ emotional 
representation 
   -.062 -.042 .375 
5  .351 .324 .009   .275 
 
Employment status    .171 .160 .001 
 
Cyanosis days    -.118 -.091 .057 
 
Co-morbidities no.    .045 .041 .392 
 
Current O2 saturation    .012 .009 .850 
 
Brief IPQ consequences    -.194 -.119 .013 
 
Brief IPQ controllability    .035 .033 .484 
 
Brief IPQ identity    -.306 -.203 <.001 
 
Brief IPQ concern    .044 .031 .509 
 
Brief IPQ emotional 
representation 
   -.010 -.006 .898 
 
Brief COPE venting    -.033 -.027 .574 
 
Brief COPE behavioural 
disengagement 
   -.051 -.044 .355 
 
Brief COPE self-blame    -.057 -.049 .302 
6  .398 .369 .047   <.001 
 
Employment status    .140 .130 .005 
 
Cyanosis days    -.113 -.086 .061 
 
Co-morbidities no.    .048 .044 .342 
 
Current O2 saturation    .001 .001 .984 
 
Brief IPQ consequences    -.176 -.108 .020 
 
Brief IPQ controllability    .009 .009 .850 
 
Brief IPQ identity    -.304 -.201 <.001 
 
Brief IPQ concern    .027 .020 .669 
 
Brief IPQ emotional 
representation 
   .089 .052 .254 
 
Brief COPE venting    -.022 -.018 .694 
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Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
 
Brief COPE behavioural 
disengagement 
   .001 .000 .999 
 
Brief COPE self-blame    -.013 -.011 .811 
 
STAI-6 anxiety    -.058 -.046 .313 
 
CES-D 10 depression    -.249 -.190 <.001 
Note. Gender: 0=  male, 1=  female, educational level: 0=  school, 1=  university, employment status: 0=  
unemployed, 1=  employed, ToF, TGA, SV: dummy-coded- reference group was Simple, arrhythmias: 0=  no 
arrhythmias, 1=  arrhythmias, CES-D 10: 0=  no depressive symptoms, 1=  with depressive symptoms. 
  
APPENDICES 
546 
 
Bodily pain subscale of the SF-36 (n= 303) 
Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
1  .032 .029 .032   .002 
 
Co-morbidities no.    -.178 -.178 .002 
2  .051 .041 .019   .052 
 
Co-morbidities no.    -.095 -.078 .169 
 
Current O2 saturation    .110 .106 .061 
 
Medication no.    -.100 -.084 .138 
3  .317 .299 .266   <.001 
 
Co-morbidities no.    -.019 -.016 .745 
 
Current O2 saturation    -.023 -.021 .660 
 
Medication no.    .044 .035 .469 
 
Brief IPQ consequences    -.005 -.003 .948 
 
Brief IPQ controllability    .090 .087 .072 
 
Brief IPQ identity    -.462 -.307 <.001 
 
Brief IPQ concern    -.051 -.036 .449 
 
Brief IPQ emotional 
representation 
   -.093 -.063 .194 
4  .344 .314 .027   .041 
 
Co-morbidities no.    -.030 -.024 .614 
 
Current O2 saturation    -.035 -.033 .494 
 
Medication no.    .053 .042 .383 
 
Brief IPQ consequences    -.011 -.007 .883 
 
Brief IPQ controllability    .096 .092 .054 
 
Brief IPQ identity    -.448 -.296 <.001 
 
Brief IPQ concern    -.057 -.040 .400 
 
Brief IPQ emotional 
representation 
   -.030 -.019 .696 
 
Brief COPE religion    -.086 -.084 .077 
 
Brief COPE denial    -.120 -.111 .021 
 
Brief COPE venting    -.037 -.030 .529 
 
Brief COPE behavioural 
disengagement 
   -.027 -.022 .638 
 
Brief COPE self-blame    .002 .002 .970 
5  .365 .332 .021   .009 
 
Co-morbidities no.    -.019 -.015 .749 
 
Current O2 saturation    -.045 -.041 .382 
 
Medication no.    .048 .038 .417 
 
Brief IPQ consequences    .006 .004 .936 
 
Brief IPQ controllability    .067 .063 .182 
 
Brief IPQ identity    -.455 -.300 <.001 
 
Brief IPQ concern    -.061 -.043 .358 
 
Brief IPQ emotional 
representation 
   .040 .024 .617 
 
Brief COPE religion    -.090 -.088 .061 
 
Brief COPE denial    -.110 -.102 .031 
 
Brief COPE venting    -.038 -.031 .515 
 
Brief COPE behavioural 
disengagement 
   .003 .002 .961 
 
Brief COPE self-blame    .030 .025 .590 
 
STAI-6 anxiety    -.138 -.110 .020 
 
CES-D 10 depression    -.077 -.059 .207 
Note. Gender: 0=  male, 1=  female, educational level: 0=  school, 1=  university, employment status: 0=  
unemployed, 1=  employed, ToF, TGA, SV: dummy-coded- reference group was Simple, arrhythmias: 0=  no 
arrhythmias, 1=  arrhythmias, CES-D 10: 0=  no depressive symptoms, 1=  with depressive symptoms.  
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General health subscale of the SF-36 (n= 303) 
Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
1  .071 .064 .071   <.001 
 
Education level    .162 .161 .004 
 
Employment status    .195 .194 .001 
2  .125 .116 .054   <.001 
 
Education level    .156 .155 .004 
 
Employment status    .156 .154 .005 
 
Co-morbidities no.    -.237 -.233 <.001 
3  .133 .118 .008   .271 
 
Education level    .159 .157 .004 
 
Employment status    .147 .143 .009 
 
Co-morbidities no.    -.198 -.178 .001 
 
Intervention no.    -.013 -.012 .827 
 
Hospitalization days    -.090 -.076 .160 
4  .191 .167 .059   <.001 
 
Education level    .134 .130 .014 
 
Employment status    .138 .134 .011 
 
Co-morbidities no.    -.059 -.046 .383 
 
Intervention no.    .069 .057 .281 
 
Hospitalization days    -.061 -.051 .333 
 
Current O2 saturation    .115 .108 .041 
 
Medication no.    -.216 -.176 .001 
 
VO2 max    .063 .056 .286 
 
RVEF    .079 .072 .169 
5  .465 .437 .273   <.001 
 
Education level    .113 .108 .013 
 
Employment status    .043 .040 .359 
 
Co-morbidities no.    .001 .001 .991 
 
Intervention no.    .027 .022 .616 
 
Hospitalization days    -.047 -.039 .368 
 
Current O2 saturation    .007 .006 .881 
 
Medication no.    -.093 -.072 .095 
 
VO2 max    .014 .013 .772 
 
RVEF    .069 .062 .152 
 
Brief IPQ consequences    -.064 -.039 .367 
 
Brief IPQ controllability    .080 .074 .089 
 
Brief IPQ curability    .122 .113 .009 
 
Brief IPQ identity    -.319 -.208 <.001 
 
Brief IPQ concern    -.093 -.065 .131 
 
Brief IPQ emotional 
representation 
   -.155 -.104 .017 
6  .468 .432 .003   .769 
 
Education level    .111 .106 .015 
 
Employment status    .040 .037 .398 
 
Co-morbidities no.    .003 .002 .956 
 
Intervention no.    .033 .026 .544 
 
Hospitalization days    -.050 -.041 .344 
 
Current O2 saturation    .007 .006 .885 
 
Medication no.    -.096 -.074 .089 
 
VO2 max    .013 .011 .799 
 
RVEF    .077 .068 .119 
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Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
 
Brief IPQ consequences    -.058 -.035 .418 
 
Brief IPQ controllability    .076 .070 .106 
 
Brief IPQ curability    .116 .107 .014 
 
Brief IPQ identity    -.322 -.209 <.001 
 
Brief IPQ concern    -.091 -.064 .143 
 
Brief IPQ emotional 
representation 
   -.138 -.084 .053 
 
Brief COPE venting    .009 .007 .868 
 
Brief COPE substance use    -.044 -.041 .341 
 
Brief COPE behavioural 
disengagement 
   -.030 -.025 .569 
 
Brief COPE self-blame    -.015 -.013 .766 
7  .488 .449 .020   .005 
 
Education level    .112 .106 .013 
 
Employment status    .017 .016 .712 
 
Co-morbidities no.    .004 .003 .939 
 
Intervention no.    .004 .003 .935 
 
Hospitalization days    -.036 -.030 .485 
 
Current O2 saturation    -.001 -.001 .986 
 
Medication no.    -.095 -.073 .088 
 
VO2 max    .017 .015 .732 
 
RVEF    .073 .065 .131 
 
Brief IPQ consequences    -.049 -.030 .486 
 
Brief IPQ controllability    .075 .068 .110 
 
Brief IPQ curability    .111 .101 .019 
 
Brief IPQ identity    -.313 -.202 <.001 
 
Brief IPQ concern    -.105 -.073 .087 
 
Brief IPQ emotional 
representation 
   -.093 -.054 .205 
 
Brief COPE venting    .020 .016 .713 
 
Brief COPE substance use    -.038 -.035 .409 
 
Brief COPE behavioural 
disengagement 
   -.002 -.001 .975 
 
Brief COPE self-blame    .005 .004 .919 
 
STAI-6 anxiety    .037 .029 .498 
 
CES-D 10 depression    -.186 -.140 .001 
Note. Gender: 0=  male, 1=  female, educational level: 0=  school, 1=  university, employment status: 0=  
unemployed, 1=  employed, ToF, TGA, SV: dummy-coded- reference group was Simple, arrhythmias: 0=  no 
arrhythmias, 1=  arrhythmias, CES-D 10: 0=  no depressive symptoms, 1=  with depressive symptoms.  
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Mental component summary of the SF-36 (n= 302) 
Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
1  .095 .089 .095   <.001 
 
Age    .165 .165 .003 
 
Employment status    .264 .264 <.001 
2  .345 .327 .249   <.001 
 
Age    .143 .139 .004 
 
Employment status    .126 .121 .011 
 
Brief IPQ consequences    -.123 -.076 .111 
 
Brief IPQ controllability    .058 .054 .251 
 
Brief IPQ curability    .101 .097 .042 
 
Brief IPQ identity    -.017 -.012 .807 
 
Brief IPQ concern    .005 .004 .939 
 
Brief IPQ emotional 
representation 
   -.385 -.260 <.001 
3  .465 .435 .121   <.001 
 
Age    .160 .149 .001 
 
Employment status    .125 .117 .007 
 
Brief IPQ consequences    -.090 -.055 .209 
 
Brief IPQ controllability    .019 .017 .699 
 
Brief IPQ curability    .088 .083 .056 
 
Brief IPQ identity    -.041 -.028 .521 
 
Brief IPQ concern    -.010 -.007 .872 
 
Brief IPQ emotional 
representation 
   -.232 -.142 .001 
 
Brief COPE positive 
reframing 
   .143 .126 .004 
 
Brief COPE acceptance    .083 .072 .098 
 
Brief COPE self-distraction    -.055 -.046 .286 
 
Brief COPE denial    -.047 -.042 .332 
 
Brief COPE venting    -.043 -.034 .429 
 
Brief COPE substance use    -.037 -.034 .431 
 
Brief COPE behavioural 
disengagement 
   -.039 -.031 .469 
 
Brief COPE self-blame    -.244 -.205 <.001 
4  .472 .438 .006   .190 
 
Age    .156 .144 .001 
 
Employment status    .124 .116 .008 
 
Brief IPQ consequences    -.071 -.042 .327 
 
Brief IPQ controllability    .011 .010 .825 
 
Brief IPQ curability    .083 .077 .074 
 
Brief IPQ identity    -.051 -.034 .426 
 
Brief IPQ concern    -.012 -.009 .843 
 
Brief IPQ emotional 
representation 
   -.226 -.138 .002 
 
Brief COPE positive 
reframing 
   .134 .116 .008 
 
Brief COPE acceptance    .077 .067 .121 
 
Brief COPE self-distraction    -.064 -.054 .213 
 
Brief COPE denial    -.046 -.041 .348 
 
Brief COPE venting    -.053 -.042 .334 
 
Brief COPE substance use    -.022 -.020 .641 
 
Brief COPE behavioural 
disengagement 
   -.041 -.033 .443 
 
Brief COPE self-blame    -.237 -.198 <.001 
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Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
 
MSPSS friends support    .081 .073 .093 
 
MSPSS significant other 
support 
   .012 .011 .794 
5  .605 .577 .134   <.001 
 
Age    .164 .151 <.001 
 
Employment status    .074 .068 .070 
 
Brief IPQ consequences    -.040 -.024 .524 
 
Brief IPQ controllability    -.008 -.007 .858 
 
Brief IPQ curability    .034 .031 .407 
 
Brief IPQ identity    -.036 -.024 .521 
 
Brief IPQ concern    -.036 -.026 .493 
 
Brief IPQ emotional 
representation 
   -.065 -.038 .311 
 
Brief COPE positive 
reframing 
   .070 .060 .111 
 
Brief COPE acceptance    .044 .038 .309 
 
Brief COPE self-distraction    -.059 -.050 .186 
 
Brief COPE denial    -.027 -.024 .527 
 
Brief COPE venting    -.019 -.015 .693 
 
Brief COPE substance use    .000 .000 .998 
 
Brief COPE behavioural 
disengagement 
   .029 .023 .545 
 
Brief COPE self-blame    -.172 -.142 <.001 
 
MSPSS friends support    .056 .050 .179 
 
MSPSS significant other 
support 
   -.006 -.005 .888 
 
STAI-6 anxiety    -.131 -.099 .008 
 
CES-D 10 depression    -.421 -.319 <.001 
Note. Gender: 0=  male, 1=  female, educational level: 0=  school, 1=  university, employment status: 0=  
unemployed, 1=  employed, ToF, TGA, SV: dummy-coded- reference group was Simple, arrhythmias: 0=  no 
arrhythmias, 1=  arrhythmias, CES-D 10: 0=  no depressive symptoms, 1=  with depressive symptoms. 
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Vitality subscale of the SF-36 (n= 303) 
Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
1  .095 .089 .095   <.001 
 
Employment status    .261 .257 <.001 
 
Gender    -.123 -.121 .029 
2  .177 .160 .082   <.001 
 
Employment status    .215 .207 <.001 
 
Gender    -.113 -.109 .040 
 
ToF    .223 .185 .001 
 
TGA    .197 .161 .002 
 
SV    .047 .039 .458 
 
Co-morbidities no.    -.195 -.191 <.001 
3  .201 .179 .024   .013 
 
Employment status    .201 .193 <.001 
 
Gender    -.112 -.108 .039 
 
ToF    .225 .184 <.001 
 
TGA    .228 .183 .001 
 
SV    .165 .113 .031 
 
Co-morbidities no.    -.098 -.078 .135 
 
Current O2 saturation    .165 .130 .013 
 
Medication no.    -.119 -.096 .067 
4  .491 .466 .290   <.001 
 
Employment status    .104 .097 .022 
 
Gender    -.049 -.046 .271 
 
ToF    .228 .179 <.001 
 
TGA    .208 .166 <.001 
 
SV    .232 .155 <.001 
 
Co-morbidities no.    -.009 -.007 .862 
 
Current O2 saturation    .078 .061 .151 
 
Medication no.    .011 .009 .839 
 
Brief IPQ consequences    -.117 -.071 .091 
 
Brief IPQ controllability    .068 .064 .130 
 
Brief IPQ curability    .045 .041 .326 
 
Brief IPQ identity    -.361 -.237 <.001 
 
Brief IPQ concern    .014 .010 .813 
 
Brief IPQ emotional 
representation 
   -.210 -.140 .001 
5  .544 .510 .053   <.001 
 
Employment status    .107 .097 .017 
 
Gender    -.040 -.036 .371 
 
ToF    .195 .151 <.001 
 
TGA    .194 .152 <.001 
 
SV    .195 .129 .001 
 
Co-morbidities no.    -.005 -.004 .920 
 
Current O2 saturation    .064 .049 .228 
 
Medication no.    .018 .014 .737 
 
Brief IPQ consequences    -.108 -.065 .108 
 
Brief IPQ controllability    .067 .062 .125 
 
Brief IPQ curability    .042 .038 .347 
 
Brief IPQ identity    -.381 -.248 <.001 
 
Brief IPQ concern    .014 .010 .807 
 
Brief IPQ emotional 
representation 
   -.111 -.066 .101 
 
Brief COPE acceptance    .129 .119 .003 
 
Brief COPE self-distraction    -.047 -.039 .332 
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Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
 
Brief COPE denial    -.058 -.052 .195 
 
Brief COPE venting    .000 .000 1.000 
 
Brief COPE substance use    -.014 -.013 .749 
 
Brief COPE behavioural 
disengagement 
   -.019 -.015 .711 
 
Brief COPE self-blame    -.150 -.126 .002 
6  .609 .577 .065   <.001 
 
Employment status    .079 .071 .059 
 
Gender    -.036 -.032 .391 
 
ToF    .175 .135 <.001 
 
TGA    .147 .114 .003 
 
SV    .157 .102 .007 
 
Co-morbidities no.    -.003 -.002 .949 
 
Current O2 saturation    .030 .023 .542 
 
Medication no.    .022 .017 .659 
 
Brief IPQ consequences    -.078 -.047 .211 
 
Brief IPQ controllability    .046 .042 .265 
 
Brief IPQ curability    .012 .011 .773 
 
Brief IPQ identity    -.376 -.245 <.001 
 
Brief IPQ concern    -.009 -.006 .864 
 
Brief IPQ emotional 
representation 
   .008 .005 .898 
 
Brief COPE acceptance    .091 .082 .029 
 
Brief COPE self-distraction    -.062 -.051 .172 
 
Brief COPE denial    -.047 -.042 .267 
 
Brief COPE venting    .018 .014 .700 
 
Brief COPE substance use    .005 .004 .913 
 
Brief COPE behavioural 
disengagement 
   .026 .021 .583 
 
Brief COPE self-blame    -.099 -.082 .028 
 
STAI-6 anxiety    -.076 -.057 .128 
 
CES-D 10 depression    -.302 -.226 <.001 
Note. Gender: 0=  male, 1=  female, educational level: 0=  school, 1=  university, employment status: 0=  
unemployed, 1=  employed, ToF, TGA, SV: dummy-coded- reference group was Simple, arrhythmias: 0=  no 
arrhythmias, 1=  arrhythmias, CES-D 10: 0=  no depressive symptoms, 1=  with depressive symptoms. 
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Social functioning subscale of the SF-36 (n= 303) 
Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
1  .065 .062 .065   <.001 
 
Employment status    .256 .256 <.001 
2  .138 .124 .073   <.001 
 
Employment status    .213 .209 <.001 
 
ToF    .121 .100 .064 
 
TGA    .065 .054 .318 
 
SV    -.132 -.111 .040 
 
Co-morbidities no.    -.159 -.156 .004 
3  .142 .124 .004   .265 
 
Employment status    .207 .202 <.001 
 
ToF    .137 .111 .040 
 
TGA    .074 .060 .262 
 
SV    -.107 -.084 .118 
 
Co-morbidities no.    -.133 -.121 .026 
 
Hospitalization days    -.070 -.060 .265 
4  .162 .139 .020   .032 
 
Employment status    .192 .187 .001 
 
ToF    .143 .115 .033 
 
TGA    .104 .084 .118 
 
SV    .004 .003 .962 
 
Co-morbidities no.    -.064 -.049 .362 
 
Hospitalization days    -.065 -.056 .297 
 
Current O2 saturation    .169 .133 .013 
 
Medication no.    -.071 -.057 .286 
5  .430 .405 .269   <.001 
 
Employment status    .076 .072 .108 
 
ToF    .161 .128 .004 
 
TGA    .078 .063 .158 
 
SV    .057 .037 .400 
 
Co-morbidities no.    .015 .011 .805 
 
Hospitalization days    -.055 -.046 .298 
 
Current O2 saturation    .086 .067 .134 
 
Medication no.    .073 .055 .213 
 
Brief IPQ consequences    -.261 -.159 <.001 
 
Brief IPQ controllability    .029 .028 .535 
 
Brief IPQ identity    -.235 -.155 .001 
 
Brief IPQ concern    -.027 -.019 .675 
 
Brief IPQ emotional 
representation 
   -.159 -.106 .017 
6  .439 .401 .009   .626 
 
Employment status    .076 .070 .117 
 
ToF    .149 .117 .009 
 
TGA    .069 .055 .222 
 
SV    .049 .032 .472 
 
Co-morbidities no.    .016 .012 .794 
 
Hospitalization days    -.060 -.050 .262 
 
Current O2 saturation    .082 .063 .161 
 
Medication no.    .076 .057 .200 
 
Brief IPQ consequences    -.254 -.153 .001 
 
Brief IPQ controllability    .026 .024 .585 
 
Brief IPQ identity    -.236 -.156 .001 
 
Brief IPQ concern    -.029 -.020 .654 
 
Brief IPQ emotional 
representation 
   -.126 -.077 .086 
 
Brief COPE self-distraction    .001 .001 .978 
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Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
 
Brief COPE denial    -.049 -.045 .316 
 
Brief COPE venting    .013 .011 .810 
 
Brief COPE substance use    -.038 -.035 .428 
 
Brief COPE behavioural 
disengagement 
   -.038 -.030 .499 
 
Brief COPE self-blame    -.038 -.032 .470 
7  .442 .403 .004   .184 
 
Employment status    .077 .071 .111 
 
ToF    .151 .119 .008 
 
TGA    .072 .057 .204 
 
SV    .054 .036 .422 
 
Co-morbidities no.    .018 .013 .765 
 
Hospitalization days    -.050 -.041 .352 
 
Current O2 saturation    .083 .064 .154 
 
Medication no.    .070 .053 .236 
 
Brief IPQ consequences    -.242 -.145 .001 
 
Brief IPQ controllability    .016 .015 .732 
 
Brief IPQ identity    -.246 -.161 <.001 
 
Brief IPQ concern    -.029 -.020 .651 
 
Brief IPQ emotional 
representation 
   -.121 -.073 .100 
 
Brief COPE self-distraction    -.007 -.006 .894 
 
Brief COPE denial    -.047 -.043 .338 
 
Brief COPE venting    .004 .004 .937 
 
Brief COPE substance use    -.029 -.026 .555 
 
Brief COPE behavioural 
disengagement 
   -.037 -.030 .507 
 
Brief COPE self-blame    -.032 -.027 .542 
 
MSPSS friends support    .064 .059 .184 
8  .499 .459 .056   <.001 
 
Employment status    .055 .051 .231 
 
ToF    .116 .091 .033 
 
TGA    .022 .017 .685 
 
SV    .002 .001 .977 
 
Co-morbidities no.    .015 .011 .795 
 
Hospitalization days    -.030 -.025 .555 
 
Current O2 saturation    .048 .037 .389 
 
Medication no.    .070 .052 .217 
 
Brief IPQ consequences    -.224 -.134 .002 
 
Brief IPQ controllability    -.012 -.011 .800 
 
Brief IPQ identity    -.242 -.159 <.001 
 
Brief IPQ concern    -.049 -.034 .422 
 
Brief IPQ emotional 
representation 
   .006 .003 .939 
 
Brief COPE self-distraction    -.030 -.026 .542 
 
Brief COPE denial    -.030 -.027 .525 
 
Brief COPE venting    .017 .013 .755 
 
Brief COPE substance use    -.014 -.013 .762 
 
Brief COPE behavioural 
disengagement 
   .012 .009 .825 
 
Brief COPE self-blame    .019 .016 .708 
 
MSPSS friends support    .034 .031 .463 
 
STAI-6 anxiety    -.119 -.093 .029 
 
CES-D 10 depression    -.249 -.187 <.001 
Note. Gender: 0=  male, 1=  female, educational level: 0=  school, 1=  university, employment status: 0=  
unemployed, 1=  employed, ToF, TGA, SV: dummy-coded- reference group was Simple, arrhythmias: 0=  no 
arrhythmias, 1=  arrhythmias, CES-D 10: 0=  no depressive symptoms, 1=  with depressive symptoms.  
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Role emotional subscale of the SF-36 (n= 302) 
Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
1  .063 .060 .063   <.001 
 
Employment status    .251 .251 <.001 
2  .218 .202 .155   <.001 
 
Employment status    .135 .129 .013 
 
Brief IPQ consequences    -.167 -.103 .047 
 
Brief IPQ controllability    .074 .072 .166 
 
Brief IPQ identity    -.003 -.002 .973 
 
Brief IPQ concern    .054 .039 .448 
 
Brief IPQ emotional 
representation 
   -.292 -.199 <.001 
3  .301 .270 .084   <.001 
 
Employment status    .131 .124 .013 
 
Brief IPQ consequences    -.135 -.082 .096 
 
Brief IPQ controllability    .040 .037 .448 
 
Brief IPQ identity    -.021 -.014 .770 
 
Brief IPQ concern    .040 .029 .561 
 
Brief IPQ emotional 
representation 
   -.164 -.100 .043 
 
Brief COPE positive 
reframing 
   .099 .088 .076 
 
Brief COPE acceptance    .069 .060 .221 
 
Brief COPE self-distraction    -.048 -.042 .394 
 
Brief COPE venting    -.036 -.028 .565 
 
Brief COPE substance use    -.050 -.047 .338 
 
Brief COPE behavioural 
disengagement 
   -.045 -.038 .440 
 
Brief COPE self-blame    -.214 -.183 <.001 
4  .312 .278 .010   .041 
 
Employment status    .132 .124 .012 
 
Brief IPQ consequences    -.111 -.067 .174 
 
Brief IPQ controllability    .027 .025 .603 
 
Brief IPQ identity    -.034 -.023 .641 
 
Brief IPQ concern    .036 .026 .599 
 
Brief IPQ emotional 
representation 
   -.155 -.095 .053 
 
Brief COPE positive 
reframing 
   .089 .078 .112 
 
Brief COPE acceptance    .061 .054 .271 
 
Brief COPE self-distraction    -.059 -.051 .299 
 
Brief COPE venting    -.048 -.038 .437 
 
Brief COPE substance use    -.033 -.031 .529 
 
Brief COPE behavioural 
disengagement 
   -.046 -.039 .429 
 
Brief COPE self-blame    -.207 -.177 <.001 
 
MSPSS friends support    .108 .101 .041 
5  .420 .387 .108   <.001 
 
Employment status    .087 .081 .075 
 
Brief IPQ consequences    -.085 -.051 .259 
 
Brief IPQ controllability    .004 .003 .939 
 
Brief IPQ identity    -.014 -.010 .832 
 
Brief IPQ concern    .007 .005 .909 
 
Brief IPQ emotional 
representation 
   -.011 -.006 .888 
 
Brief COPE positive 
reframing 
   .033 .029 .527 
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Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
 
Brief COPE acceptance    .030 .027 .556 
 
Brief COPE self-distraction    -.052 -.045 .317 
 
Brief COPE venting    -.021 -.017 .710 
 
Brief COPE substance use    -.013 -.012 .786 
 
Brief COPE behavioural 
disengagement 
   .025 .020 .654 
 
Brief COPE self-blame    -.146 -.123 .007 
 
MSPSS friends support    .080 .075 .100 
 
STAI-6 anxiety    -.098 -.076 .093 
 
CES-D 10 depression    -.384 -.291 <.001 
Note. Gender: 0=  male, 1=  female, educational level: 0=  school, 1=  university, employment status: 0=  
unemployed, 1=  employed, ToF, TGA, SV: dummy-coded- reference group was Simple, arrhythmias: 0=  no 
arrhythmias, 1=  arrhythmias, CES-D 10: 0=  no depressive symptoms, 1=  with depressive symptoms. 
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Mental health subscale of the SF-36 (n= 303) 
Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
1  .096 .090 .096   <.001 
 
Age    .168 .168 .002 
 
Employment status    .264 .264 <.001 
2  .351 .336 .255   <.001 
 
Age    .152 .148 .002 
 
Employment status    .125 .119 .012 
 
Brief IPQ consequences    -.082 -.051 .280 
 
Brief IPQ controllability    .102 .098 .037 
 
Brief IPQ identity    -.041 -.028 .557 
 
Brief IPQ concern    -.030 -.022 .642 
 
Brief IPQ emotional 
representation 
   -.386 -.262 <.001 
3  .463 .435 .112   <.001 
 
Age    .178 .167 <.001 
 
Employment status    .125 .118 .007 
 
Brief IPQ consequences    -.064 -.039 .367 
 
Brief IPQ controllability    .061 .057 .186 
 
Brief IPQ identity    -.057 -.038 .376 
 
Brief IPQ concern    -.046 -.033 .449 
 
Brief IPQ emotional 
representation 
   -.239 -.146 .001 
 
Brief COPE positive 
reframing 
   .116 .102 .019 
 
Brief COPE acceptance    .064 .056 .198 
 
Brief COPE self-distraction    .006 .005 .908 
 
Brief COPE denial    -.097 -.086 .047 
 
Brief COPE venting    -.034 -.027 .528 
 
Brief COPE substance use    -.012 -.011 .800 
 
Brief COPE behavioural 
disengagement 
   -.074 -.060 .169 
 
Brief COPE self-blame    -.224 -.188 <.001 
4  .467 .433 .004   .567 
 
Age    .177 .163 <.001 
 
Employment status    .128 .120 .006 
 
Brief IPQ consequences    -.049 -.029 .501 
 
Brief IPQ controllability    .051 .047 .279 
 
Brief IPQ identity    -.063 -.042 .332 
 
Brief IPQ concern    -.048 -.035 .426 
 
Brief IPQ emotional 
representation 
   -.237 -.144 .001 
 
Brief COPE positive 
reframing 
   .111 .097 .026 
 
Brief COPE acceptance    .059 .051 .242 
 
Brief COPE self-distraction    -.002 -.001 .973 
 
Brief COPE denial    -.095 -.084 .052 
 
Brief COPE venting    -.042 -.033 .447 
 
Brief COPE substance use    .001 .001 .980 
 
Brief COPE behavioural 
disengagement 
   -.074 -.060 .169 
 
Brief COPE self-blame    -.219 -.183 <.001 
 
MSPSS friends support    .053 .045 .295 
 
MSPSS family support    .028 .023 .603 
 
MSPSS significant other 
support 
   -.009 -.008 .855 
APPENDICES 
558 
 
Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
5  .587 .558 .120   <.001 
 
Age    .186 .172 <.001 
 
Employment status    .082 .076 .048 
 
Brief IPQ consequences    -.019 -.011 .768 
 
Brief IPQ controllability    .020 .018 .629 
 
Brief IPQ identity    -.050 -.033 .384 
 
Brief IPQ concern    -.076 -.054 .157 
 
Brief IPQ emotional 
representation 
   -.070 -.041 .288 
 
Brief COPE positive reframing    .047 .040 .295 
 
Brief COPE acceptance    .024 .021 .592 
 
Brief COPE self-distraction    .001 .001 .984 
 
Brief COPE denial    -.075 -.067 .081 
 
Brief COPE venting    -.015 -.012 .763 
 
Brief COPE substance use    .021 .019 .626 
 
Brief COPE behavioural 
disengagement 
   -.004 -.004 .926 
 
Brief COPE self-blame    -.156 -.129 .001 
 
MSPSS friends support    .039 .033 .385 
 
MSPSS family support    -.018 -.014 .709 
 
MSPSS significant other 
support 
   -.019 -.016 .667 
 
STAI-6 anxiety    -.192 -.148 <.001 
 
CES-D 10 depression    -.356 -.270 <.001 
Note. Gender: 0=  male, 1=  female, educational level: 0=  school, 1=  university, employment status: 0=  
unemployed, 1=  employed, ToF, TGA, SV: dummy-coded- reference group was Simple, arrhythmias: 0=  no 
arrhythmias, 1=  arrhythmias, CES-D 10: 0=  no depressive symptoms, 1=  with depressive symptoms.  
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Symptoms scale of the CHD-TAAQOL (n= 302) 
 
Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
1  .094 .088 .094   <.001 
 
Gender    -.104 -.102 .064 
 
Employment status    .270 .266 <.001 
2  .207 .185 .113   <.001 
 
Gender    -.132 -.128 .015 
 
Employment status    .212 .204 <.001 
 
ToF    .020 .016 .761 
 
TGA    -.008 -.007 .900 
 
SV    -.147 -.106 .043 
 
Cyanosis days    -.078 -.067 .199 
 
Co-morbidities no.    -.272 -.221 <.001 
 
Arrhythmias    .036 .029 .581 
3  .207 .182 .000   .996 
 
Gender    -.132 -.127 .015 
 
Employment status    .212 .203 <.001 
 
ToF    .020 .016 .766 
 
TGA    -.008 -.006 .901 
 
SV    -.147 -.101 .053 
 
Cyanosis days    -.078 -.067 .200 
 
Co-morbidities no.    -.272 -.208 <.001 
 
Arrhythmias    .036 .029 .582 
 
Hospitalization days    .000 .000 .996 
4  .278 .246 .071   <.001 
 
Gender    -.102 -.092 .066 
 
Employment status    .176 .166 .001 
 
ToF    .025 .019 .711 
 
TGA    .053 .040 .425 
 
SV    -.006 -.004 .943 
 
Cyanosis days    .069 .050 .317 
 
Co-morbidities no.    -.124 -.085 .091 
 
Arrhythmias    .044 .033 .506 
 
Hospitalization days    .021 .018 .719 
 
Current O2 saturation    .234 .154 .002 
 
Medication no.    -.162 -.124 .014 
 
VO2 max    .145 .125 .013 
 
LVEF    .086 .076 .131 
5  .581 .555 .303   <.001 
 
Gender    -.061 -.054 .160 
 
Employment status    .093 .085 .028 
 
ToF    .027 .020 .599 
 
TGA    .015 .011 .773 
 
SV    .026 .016 .678 
 
Cyanosis days    .032 .023 .545 
 
Co-morbidities no.    -.062 -.042 .279 
 
Arrhythmias    .058 .044 .251 
 
Hospitalization days    .030 .025 .513 
 
Current O2 saturation    .118 .077 .046 
 
Medication no.    -.012 -.009 .819 
 
VO2 max    .085 .072 .063 
 
LVEF    .029 .025 .509 
 
Brief IPQ consequences    -.088 -.053 .166 
 
Brief IPQ controllability    .014 .014 .725 
 
Brief IPQ identity    -.428 -.278 <.001 
 
Brief IPQ concern    -.088 -.061 .115 
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Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
 
Brief IPQ emotional 
representation 
   -.134 -.088 .023 
6  .593 .558 .011   .257 
 
Gender    -.062 -.053 .169 
 
Employment status    .092 .083 .032 
 
ToF    .014 .010 .794 
 
TGA    .008 .006 .876 
 
SV    .017 .010 .788 
 
Cyanosis days    .032 .023 .547 
 
Co-morbidities no.    -.058 -.039 .309 
 
Arrhythmias    .058 .044 .251 
 
Hospitalization days    .022 .018 .636 
 
Current O2 saturation    .118 .076 .048 
 
Medication no.    -.008 -.006 .878 
 
VO2 max    .078 .065 .090 
 
LVEF    .026 .023 .557 
 
Brief IPQ consequences    -.081 -.049 .207 
 
Brief IPQ controllability    .010 .009 .815 
 
Brief IPQ identity    -.431 -.280 <.001 
 
Brief IPQ concern    -.093 -.064 .097 
 
Brief IPQ emotional 
representation 
   -.104 -.063 .104 
 
Brief COPE self-distraction    .009 .008 .833 
 
Brief COPE denial    -.054 -.049 .205 
 
Brief COPE venting    .031 .025 .523 
 
Brief COPE substance use    -.028 -.025 .516 
 
Brief COPE behavioural 
disengagement 
   -.028 -.022 .564 
 
Brief COPE self-blame    -.075 -.063 .103 
7  .634 .599 .041   <.001 
 
Gender    -.051 -.043 .239 
 
Employment status    .075 .067 .069 
 
ToF    -.010 -.007 .847 
 
TGA    -.022 -.016 .669 
 
SV    -.012 -.007 .841 
 
Cyanosis days    .042 .030 .414 
 
Co-morbidities no.    -.047 -.032 .385 
 
Arrhythmias    .031 .023 .528 
 
Hospitalization days    .042 .035 .339 
 
Current O2 saturation    .096 .062 .092 
 
Medication no.    -.007 -.005 .896 
 
VO2 max    .078 .066 .072 
 
LVEF    .038 .033 .370 
 
Brief IPQ consequences    -.060 -.035 .332 
 
Brief IPQ controllability    -.018 -.017 .640 
 
Brief IPQ identity    -.431 -.279 <.001 
 
Brief IPQ concern    -.107 -.074 .045 
 
Brief IPQ emotional 
representation 
   .001 .001 .987 
 
Brief COPE self-distraction    -.015 -.013 .724 
 
Brief COPE denial    -.039 -.035 .339 
 
Brief COPE venting    .038 .030 .409 
 
Brief COPE substance use    -.008 -.007 .854 
 
Brief COPE behavioural 
disengagement 
   .013 .010 .781 
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Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
 
Brief COPE self-blame    -.029 -.024 .518 
 
STAI-6 anxiety    -.097 -.075 .042 
 
CES-D 10 depression    -.215 -.160 <.001 
Note. Gender: 0=  male, 1=  female, educational level: 0=  school, 1=  university, employment status: 0=  
unemployed, 1=  employed, ToF, TGA, SV: dummy-coded- reference group was Simple, arrhythmias: 0=  no 
arrhythmias, 1=  arrhythmias, CES-D 10: 0=  no depressive symptoms, 1=  with depressive symptoms. 
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Impact of cardiac surveillance scale of the CHD-TAAQOL (n= 303) 
Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
1  .126 .111 .126   <.001 
 
ToF    -.002 -.002 .973 
 
TGA    -.056 -.045 .412 
 
SV    -.171 -.140 .011 
 
Co-morbidities no.    -.164 -.137 .012 
 
Arrhythmias    -.163 -.130 .017 
2  .129 .112 .003   .292 
 
ToF    .016 .013 .811 
 
TGA    -.036 -.027 .613 
 
SV    -.141 -.106 .052 
 
Co-morbidities no.    -.155 -.128 .019 
 
Arrhythmias    -.148 -.114 .036 
 
Intervention no.    -.069 -.057 .292 
3  .154 .128 .024   .040 
 
ToF    .011 .009 .870 
 
TGA    -.017 -.013 .813 
 
SV    -.064 -.041 .450 
 
Co-morbidities no.    -.046 -.033 .540 
 
Arrhythmias    -.145 -.110 .041 
 
Intervention no.    -.043 -.035 .515 
 
Current O2 saturation    .102 .079 .143 
 
Medication no.    -.139 -.108 .045 
 
VO2 max    .066 .060 .266 
4  .322 .292 .168   <.001 
 
ToF    .033 .026 .594 
 
TGA    -.045 -.034 .489 
 
SV    -.031 -.019 .694 
 
Co-morbidities no.    .013 .009 .850 
 
Arrhythmias    -.133 -.100 .039 
 
Intervention no.    -.064 -.052 .285 
 
Current O2 saturation    .047 .035 .465 
 
Medication no.    -.039 -.029 .550 
 
VO2 max    .020 .018 .716 
 
Brief IPQ consequences    -.040 -.024 .616 
 
Brief IPQ identity    -.136 -.089 .067 
 
Brief IPQ concern    -.129 -.090 .064 
 
Brief IPQ emotional 
representation 
   -.232 -.156 .001 
5  .347 .309 .025   .027 
 
ToF    .019 .015 .759 
 
TGA    -.075 -.054 .258 
 
SV    -.042 -.026 .584 
 
Co-morbidities no.    .002 .002 .971 
 
Arrhythmias    -.138 -.103 .032 
 
Intervention no.    -.051 -.041 .390 
 
Current O2 saturation    .038 .028 .552 
 
Medication no.    -.031 -.023 .638 
 
VO2 max    .022 .020 .681 
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Block Predictor Variables R2
  
Adjusted R2 ΔR2   β sr2 Sig. 
 
Brief IPQ consequences    -.030 -.018 .701 
 
Brief IPQ identity    -.131 -.086 .075 
 
Brief IPQ concern    -.134 -.093 .053 
 
Brief IPQ emotional 
representation 
   -.185 -.113 .019 
 
Brief COPE planning    -.119 -.114 .018 
 
Brief COPE venting    .015 .013 .792 
 
Brief COPE substance use    -.009 -.009 .855 
 
Brief COPE behavioural 
disengagement 
   -.117 -.103 .033 
6  .365 .323 .018   .020 
 
ToF    .016 .012 .802 
 
TGA    -.079 -.057 .228 
 
SV    -.034 -.021 .661 
 
Co-morbidities no.    .014 .010 .834 
 
Arrhythmias    -.141 -.105 .027 
 
Intervention no.    -.070 -.056 .241 
 
Current O2 saturation    .037 .028 .558 
 
Medication no.    -.029 -.021 .651 
 
VO2 max    .011 .010 .832 
 
Brief IPQ consequences    -.011 -.006 .892 
 
Brief IPQ identity    -.142 -.093 .051 
 
Brief IPQ concern    -.135 -.093 .050 
 
Brief IPQ emotional 
representation 
   -.132 -.077 .106 
 
Brief COPE planning    -.138 -.130 .006 
 
Brief COPE venting    .019 .016 .739 
 
Brief COPE substance use    .003 .002 .959 
 
Brief COPE behavioural 
disengagement 
   -.088 -.074 .117 
 
STAI-6 anxiety    -.159 -.127 .008 
 
CES-D 10 depression    -.005 -.004 .939 
Note. Gender: 0= male, 1= female, educational level: 0= school, 1= university, employment status: 0= 
unemployed, 1= employed, ToF, TGA, SV: dummy-coded- reference group was Simple, arrhythmias: 0= no 
arrhythmias, 1= arrhythmias, CES-D 10: 0= no depressive symptoms, 1= with depressive symptoms.  
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Worries scale of the CHD-TAAQOL (n= 303) 
Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
1  .023 .020 .023   .008 
 
Age    .153 .153 .008 
2  .104 .089 .081   <.001 
 
Age    .221 .196 <.001 
 
ToF    .102 .084 .126 
 
TGA    .132 .106 .054 
 
SV    -.045 -.036 .517 
 
Co-morbidities no.    -.241 -.223 <.001 
3  .116 .098 .012   .044 
 
Age    .229 .203 <.001 
 
ToF    .114 .094 .085 
 
TGA    .157 .124 .024 
 
SV    .042 .028 .609 
 
Co-morbidities no.    -.214 -.194 <.001 
 
Current O2 saturation    .138 .110 .044 
4  .437 .414 .321   <.001 
 
Age    .197 .170 <.001 
 
ToF    .096 .076 .084 
 
TGA    .104 .082 .065 
 
SV    .083 .054 .222 
 
Co-morbidities no.    -.031 -.027 .545 
 
Current O2 saturation    .057 .044 .314 
 
Brief IPQ consequences    -.246 -.153 .001 
 
Brief IPQ controllability    -.002 -.002 .966 
 
Brief IPQ curability    .089 .082 .064 
 
Brief IPQ identity    -.116 -.076 .087 
 
Brief IPQ concern    -.122 -.087 .050 
 
Brief IPQ emotional 
representation 
   -.224 -.150 .001 
5  .480 .447 .043   .001 
 
Age    .235 .198 <.001 
 
ToF    .077 .061 .157 
 
TGA    .089 .068 .112 
 
SV    .093 .060 .160 
 
Co-morbidities no.    -.025 -.022 .610 
 
Current O2 saturation    .079 .061 .157 
 
Brief IPQ consequences    -.215 -.132 .002 
 
Brief IPQ controllability    -.001 -.001 .990 
 
Brief IPQ curability    .091 .083 .053 
 
Brief IPQ identity    -.135 -.088 .042 
 
Brief IPQ concern    -.130 -.092 .032 
 
Brief IPQ emotional 
representation 
   -.203 -.124 .004 
 
Brief COPE planning    -.090 -.080 .061 
 
Brief COPE self-distraction    -.004 -.003 .940 
 
Brief COPE venting    .085 .067 .117 
 
Brief COPE substance use    -.092 -.087 .044 
 
Brief COPE behavioural 
disengagement 
   .046 .038 .375 
 
Self-blame    -.180 -.151 .001 
6  .487 .450 .006   .173 
 
Age    .233 .196 <.001 
 
ToF    .082 .064 .136 
 
TGA    .093 .071 .097 
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Block Predictor Variables R2
  
Adjusted R2 ΔR2  β sr2 Sig. 
 
SV    .104 .067 .116 
 
Co-morbidities no.    -.023 -.020 .641 
 
Current O2 saturation    .080 .062 .149 
 
Brief IPQ consequences    -.197 -.120 .005 
 
Brief IPQ controllability    -.013 -.012 .782 
 
Brief IPQ curability    .083 .075 .079 
 
Brief IPQ identity    -.145 -.094 .029 
 
Brief IPQ concern    -.130 -.092 .032 
 
Brief IPQ emotional 
representation 
   -.201 -.122 .004 
 
Brief COPE planning    -.097 -.086 .044 
 
Brief COPE self-distraction    -.014 -.012 .775 
 
Brief COPE venting    .075 .060 .164 
 
Brief COPE substance use    -.075 -.069 .108 
 
Brief COPE behavioural 
disengagement 
   .047 .039 .359 
 
Self-blame    -.171 -.142 .001 
 
MSPSS friend support    .061 .052 .221 
 
MSPSS family support    .041 .035 .410 
7  .523 .486 .037   <.001 
 
Age    .218 .183 <.001 
 
ToF    .061 .048 .250 
 
TGA    .048 .036 .384 
 
SV    .060 .038 .361 
 
Co-morbidities no.    -.014 -.012 .765 
 
Current O2 saturation    .049 .037 .365 
 
Brief IPQ consequences    -.179 -.109 .009 
 
Brief IPQ controllability    -.023 -.021 .606 
 
Brief IPQ curability    .067 .060 .150 
 
Brief IPQ identity    -.137 -.089 .033 
 
Brief IPQ concern    -.146 -.103 .013 
 
Brief IPQ emotional 
representation 
   -.106 -.061 .138 
 
Brief COPE planning    -.117 -.103 .013 
 
Brief COPE self-distraction    -.024 -.020 .626 
 
Brief COPE venting    .090 .071 .087 
 
Brief COPE substance use    -.066 -.060 .147 
 
Brief COPE behavioural 
disengagement 
   .084 .069 .094 
 
Self-blame    -.126 -.103 .013 
 
MSPSS friend support    .047 .040 .330 
 
MSPSS family support    .021 .018 .659 
 
STAI-6 anxiety    -.061 -.047 .261 
 
CES-D 10 depression    -.224 -.168 <.001 
Note. Gender: 0=  male, 1=  female, educational level: 0=  school, 1=  university, employment status: 0=  
unemployed, 1=  employed, ToF, TGA, SV: dummy-coded- reference group was Simple, arrhythmias: 0=  no 
arrhythmias, 1=  arrhythmias, CES-D 10: 0=  no depressive symptoms, 1=  with depressive symptoms.
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Appendix T. Multivariate outliers in regression analyses 
Regression Model (DV)  Case ID Standardized 
Residual 
Cook’s 
Distance 
Physical component 
summary 
 
Case 272 -4.62 0.03 
Physical functioning 
     
 
 
Case 272 -4.90 0.04 
Case 179 -4.22 0.03 
Case 112 -4.10 0.12 
Role physical 
     
 
 
Case 24 -3.73 0.02 
Case 252 -3.70 0.03 
Case 272 -3.51 0.02 
Bodily pain  n/a n/a n/a 
General health  n/a n/a n/a 
Mental component 
summary 
 n/a n/a n/a 
Vitality  Case 92 -3.43 0.03 
Case 123 -3.51 0.06 
Social functioning 
     
 
 
Case 30 -3.71 0.07 
Case 179 -3.80 0.03 
Role emotional 
     
 
 
Case 29 -3.32 0.02 
Case 131 -3.41 0.06 
Mental health  Case 136 3.68 0.09 
Case 305 -3.60 0.03 
Symptoms  Case 135 -3.62 0.03 
Worries  Case 10 -3.61 0.09 
Case 12 -3.48 0.11 
Impact cardiac 
surveillance 
 n/a n/a n/a 
Note. ±3.29 threshold  
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Appendix U. Graphical representation of clinical factors over time 
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Appendix V. Graphical representation of illness perceptions over time 
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Appendix W. Graphical representation of coping strategies over time 
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Appendix X. Graphical representation of social support over time 
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Appendix Y. Graphical representation of depression over time 
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Appendix Z. Information sheet used in the qualitative study  
 
 
UCLH Project ID number : 08/0326 
CONFIDENTIAL 
INFORMATION SHEET (Version 4-11/11) 
Quality of life in GUCH patients, qualitative study 
Investigators: Professor Stanton Newman, Professor John Deanfield, Dr Shay Cullen, Fiona 
Kennedy, Nathalie Picaut, Theodora Fteropoulli, Manavi Tyagi. 
Contact 
details: 
GUCH Unit, Heart Hospital, 16-18 Westmoreland St., 
London W1G 8PH 
Tel: 020 7573 8889 
   
You are being invited to take part in a qualitative study. Before you decide it is important for 
you to understand why the research is being conducted and what it will involve. Please take 
time to read the following information carefully and discuss it with others if you wish. Ask us if 
there is anything that is not clear or if you would like more information. Take time to decide 
whether or not you wish to take part.  
 
What is the purpose of the study? 
Although various studies have been conducted into the quality of life of children with congenital 
heart disease very little has been carried out with adults with congenital heart disease. Moreover, there is little research examining the patients’ personal experiences about their 
quality of life. In order to better plan our services to support long term care we would find it 
extremely valuable to have an understanding of how congenital heart disease affects quality of 
life. Therefore, we in the GUCH Unit at the Heart Hospital, UCLH, and the Health Services 
Research Group at City University would like to find out how you feel your heart condition 
affects your quality of life. The information you give us will then be used to improve the long-
term care of adults with congenital heart disease. 
 
Why have I been chosen? 
You are being asked to take part in this study because you have a diagnosis of congenital heart 
disease and you have participated in the first/second phase of the study. 
 
Consultants:                                                                                     GUCH Office  
Dr Shay Cullen                                                                                                             The Heart Hospital 
Dr Fiona Walker        16-18 Westmoreland Street 
Prof Philipp Bonhoeffer       London W1G 8PH 
Prof John Deanfield       Tel: 020 7573 8808 
        Nurses: 020 7573 8872 
Surgeons:       Fax: 020 7573 8807 
Mr Victor Tsang        Email: guch.dept@uclh.org 
Ms Carin van Doorn      Website: www.uclh.org 
Mr Martin Kostolny       
 
Clinical Nurse Specialists:         
Ruth Brooks 
Marie Francis 
Fiona Kennedy 
Kerry Romer 
Nathalie Picaut 
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Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If you decide to take 
part you are still free to withdraw at any time and without giving a reason. A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard of care you 
receive. Your contribution to the other phases of this study will also remain unaffected. 
 
What is involved in the study? 
If you agree to take part in this study you will be asked to attend the Heart Hospital on a day and 
at a time that suit your schedule. The meeting will involve an interview with the researcher 
which will be audio taped. You will be asked a few questions about your experiences with living 
with congenital heart disease. The conversation will largely be guided by what and how much 
information you want to share with us. Please note that you will be free to share only as much 
information as you wish. It is anticipated that the process will take approximately 60 minutes.  
 
What are the possible benefits of taking part? 
Whilst there are no immediate benefits for people participating in this study, it is hoped that 
this work will contribute to improving the long-term care of adults with congenital heart 
disease.  
 
Confidentiality of records 
We also need permission to access your medical records, which relate directly to this study. All 
the information we obtain will be strictly confidential. City University will overview the 
collection, storage and handling of the data and Professor Newman, in his capacity of chief 
investigator, will be responsible for security and access to the data. Only study investigators 
(named above) will have access to the data. The information collected during the study, with 
exception of your name, will be stored and analysed confidentially in a computer. No identifiers 
on the data held by computer will enable a third party to link the data to you. A study ID 
number, assigned to you during the first phase of the study will appear on all data including 
medical information and questionnaires. All data will be kept strictly confidential and secured 
under lock and key in City University. The data will be stored for 5 years after the study has 
been completed. The results of this study may be published within the medical literature, 
however, no personal details will be revealed. Copies of the publications will be available to you 
from the researchers. A report of the findings of the research will be sent to all interested 
participants in approximately 2 years from the start of the study. 
 
Comments or concerns during the study 
If you have a concern about any aspect of this study you should speak to the researchers who 
will do their best to answer your questions either at your appointment or on 020 7040 
0871/0878. If you remain unhappy and wish to complain formally you can do this through 
the Complaints Manager, UCLH, 2nd Floor West, 250, Euston Road, London NW1 2PQ. Please 
quote the UCLH project number at the top of this information sheet. 
 
Ethics Committee Review 
All proposals for research using human subjects are reviewed by an ethics committee before 
they can proceed. This proposal was reviewed by the Joint UCL/UCLH Ethics Committee 
(Bentham) in Ethics of Human Research. 
 
Thank you for taking the time to read this. If you decide to take part you will be given a copy of 
this information sheet and a signed consent form to keep. 
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Appendix AA. Consent form used in the qualitative study  
 
 
 
 
 
 
 
UCLH Project ID number: 08/0326 
                                                
CONFIDENTIAL 
CONSENT FORM (Version 4-11/11) 
 
Quality of life in GUCH patients, qualitative study 
  
Investigators: Professor Stanton Newman, Professor John Deanfield, Dr Shay Cullen, 
Fiona Kennedy, Nathalie Picaut, Theodora Fteropoulli, Manavi Tyagi. 
  
Contact 
details: 
GUCH Unit, Heart Hospital, 16-18 Westmoreland St., 
London W1G 8PH 
Tel: 020 7573 8889 
Please read the following statements and initial box 
 1. I confirm that I have read and understand the information sheet (Version 4, 11/11) for the above study and have had the opportunity to ask questions. □ 
 
2.  I confirm that I have had sufficient time to consider whether or not I want to 
be included in the study. 
□ 
 
3. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights 
being affected. 
 
□ 
 
4. I understand that all data will be kept strictly confidential to this research and 
give permission for the above investigators to have access to my medical 
records. 
□ 
 
5.  I agree for the interview to be audio recorded and the recordings will be 
destroyed and only an anonymous written copy of my interview will be kept for 
research purposes. 
 
□ 
 
6. I agree to take part in the above study. □ 
Continued on next page/ 
GUCH Office  
The Heart Hospital 
16-18 Westmoreland Street  
London W1G 8PH 
Tel: 020 7573 8808 
Nurses: 020 7573 8872 
Fax: 020 7573 8807 
Email: guch.dept@uclh.org 
Website: www.uclh.org 
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UCLH Project ID number: 08/0326 
CONFIDENTIAL 
CONSENT FORM (Version 4, 11/11) 
    
    
Signed:  Date:  
    
    
    
Full name in block letters:    
    
    
    
Signed 
(investigator): 
 Date:  
    
    
    
Full name in block letters:    
    
     
Comments or concerns during the study. 
 
If you have a concern about any aspect of this study you should speak to the researchers who 
will do their best to answer your questions either at your appointment or on 020 7040 
0871/0878. If you remain unhappy and wish to complain formally you can do this through 
the Complaints Manager, UCLH, 2nd Floor West, 250, Euston Road, London NW1 2PQ. Please 
quote the UCLH project number at the top of this consent form. 
 
 
1 form for patient 
1 to be kept as part of the study documentation 
1 to be kept with hospital notes  
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Appendix BB. Reflective account for qualitative study 
My PhD rests on a pragmatic paradigm, guided by “what” the research problem is and 
“how” it can be researched (Creswell & Plano Clark, 2011). It is a paradigm that embraces 
and values the contribution of both qualitative and quantitative approaches to research. 
During my qualitative enquiry, I was concerned about how I can objectively interpret and 
present people’s experiences. I understand that the subjectivity of the researcher is 
recognised in qualitative research because it not only guides the selection of topic and 
formulation of questions but also the methodology and interpretation of the data. Therefore, 
the researcher needs to reflect on their values and assumptions they bring to the study in 
order to recognise their subjectivity and facilitate objective comprehension of the world 
(Ratner, 2002). What follows is a reflection on my own background, the methods and data 
collection, and the data analysis and interpretation. 
Researcher background 
I am female, educated to postgraduate level, and from a Greek cultural background. This 
study was not just an academic endeavour but also reflects my personal and academic 
interests. My research interests have always revolved around the impact and adjustment to 
chronic illness, with particular focus on cardiovascular disease. My father’s diagnosis of 
coronary heart disease and his subsequent coronary artery bypass surgery played a 
significant role in my choice of a career in health psychology and informed the subject of 
both my undergraduate and postgraduate theses. My undergraduate thesis focused on the 
role of self-regulation in Cypriot cardiac patients. My postgraduate thesis examined the 
relationship between dispositional optimism, illness perceptions, and coping in patients 
undergoing treatment for cardiovascular disease. After completing my MSc in health 
psychology I wished to keep my research focus on cardiovascular disease. I worked on a 
large study of cognitive and psychosocial functioning in ACHD for three years. This work 
enhanced my interest in this understudied population and influenced my decision to pursue a 
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PhD on the subject. I was hoping that the study would contribute to our understanding of 
HRQoL in ACHD and how we can help people adjust to this chronic condition. 
I had little prior experience interviewing participants for qualitative research in health 
psychology. However, during my PhD I attended a two-day workshop at the NatCen which 
involved a “hands-on” approach to conducting face-to-face interviews. This workshop had 
proved very helpful and made me feel confident in my ability to conduct the qualitative 
interviews. Further workshops in qualitative data analysis using framework analysis 
(developed by the NatCen) provided me with sufficient skills to conduct the research, 
including practical exercises in the analysis of actual data using framework analysis. 
My experience during recruitment and data collection for the quantitative studies provided 
me with invaluable experience on how to approach and talk to people about their HRQoL. 
After completing the questionnaires, many people were very keen to discuss their 
experiences with living with ACHD beyond the questions in the psychosocial measures. 
This experience of informal conversations with participants taught me how to maintain an 
objective yet friendly position and be reflective on my thoughts and feelings about the 
experiences that they shared with me.  
Reflection on the methods and data collection 
I appreciate that my pre-conceptions about people’s experiences regarding their HRQoL 
derived from the informal chats might have influenced my interview guide. However, I 
made every effort in setting these pre-conceptions aside when finalising the interview guide. 
I believe some of these pre-conceived notions were overcome by having the interview guide 
reviewed and revised by the supervisory team and two independent experts in qualitative 
research. In addition, none of the participants in the interviews were part of the earlier 
informal chats I had during the quantitative studies which minimised the effects of my pre-
conceptions. 
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During the interviews I introduced myself as PhD student at City University London. I 
explained the aims of the study to participants and ensured that they understood that they 
could terminate the interview if they felt uncomfortable. I was aware of the emotional 
burden that ACHD can cause and I tried to approach topics with sensitivity and compassion. 
I generally approached this study with the understanding that qualitative data is rich in detail 
and felt it was inappropriate to interrupt participants even if they were going slightly off-
topic. I did not push participants to give more detail where they did not wish to or where 
they found it difficult to articulate their views. This explains the short or long length of some 
interviews. 
During the interviews, two female participants became upset when they described particular 
experiences relating to pregnancy and uncertainty. I paused the tape recorder and gave them 
the opportunity to have a break. I asked them whether they wanted to terminate the interview 
but on both occasions participants wished to continue. I did not feel uncomfortable at all and 
remained calm and empathetic, knowing that pregnancy is a very sensitive topic for women 
with ACHD. I provided water and tissues for the participants and the interviews continued. 
On reflection, me being a female researcher, may have influenced what participants were 
willing to share with me. Specifically, the challenges of family planning and pregnancy 
discussed by female participants may not have come up with a male researcher. On the other 
hand, male participants discussed in much detail how their ACHD had influenced (or not 
influenced) their occupational life. This resonated with my experiences of growing up in a 
primarily patriarchal culture, where the father is the main bread-winner in the family. 
Furthermore, it is possible that my gender made some male participants more hesitant in 
sharing negative emotional experiences because they may have thought I would view them 
as vulnerable.  
One particular interview with a male participant made me feel uncomfortable; he provided 
short yes/no answers despite my various attempts to prompt him. This interview was 
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therefore very short in duration. On occasion, I found myself asking one or two questions in 
a closed-ended way. As I became aware of that, I rectified it quickly. This participant had a 
Simple defect which did not have a significant impact on his HRQoL. This experience 
initially led me to think carefully about my interview topic guide in relation to people who 
generally did not experience impact on their HRQoL as a result of their ACHD. However, 
subsequent interviews with people with similar experiences had proved to be quite insightful 
in the ways they coped with their condition. In addition, studying my reflective notes from 
that interview suggested to me that the particular participant found it difficult to articulate 
his views and experiences and was generally not open about sharing details.  
Overall, I was able to establish rapport with most of the participants quite quickly. This was 
not surprising since the participants were already familiar with the study and its purpose and 
had already met me during the quantitative studies. I got the impression that the participants 
felt that they were part of the research team instead of being researched and I was moved by 
their commitment to the study, and their praises about its significance. From my part I felt 
very lucky to be able to get such an insight of their experiences.  
At the end of each interview I ensured that participants were not left in an emotional state 
and assured them about confidentiality. Overall, participants were very keen to sharing their 
experiences. The variety of experiences acquired from the interviews provided some 
reassurance in relation to potential bias in participant selection.  
On reflection, I now realise that during the interview process I was perhaps viewed not as an 
“insider” but rather a “bridge” or a “medium” between the participants and the healthcare 
system. For many of them, there weren’t many opportunities to discuss their experiences and 
feelings about living with ACHD in such depth. As a result, I felt a responsibility towards 
the participants to be able to translate their experiences in an accurate and objective manner.  
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Reflection on data analysis and interpretation 
The overall approach I took for the data analysis was to search for common themes or 
patterns across the participants’ narratives. Since there are no rules regarding what 
constitutes a theme, within the present study a theme needed to “capture something 
important about the data in relation to the research question, and represent some level of 
patterned response or meaning within the data set” (Braun & Clarke, 2006). This meant that 
themes were not considered only in terms of occurrence but also in terms of their importance 
to the research questions. Since framework analysis enables both inductive and deductive 
approaches, my data analysis was based on specific questions and drew on previous research 
but also allowed for new themes to emerge.  
There are two points which I believe are particularly relevant in my analysis and 
interpretation. Coming into this study and as a health psychology student, I was already 
familiar with the literature in ACHD before data collection and analysis. I was aware that 
people with ACHD face various challenges and I was prepared for themes to emerge about 
physical limitations, emotional impact, uncertainty, and social relationships; these themes 
were apparent in the participants’ narratives. Moreover, I share the view of most researchers 
in this field that HRQoL is a multidimensional concept. This has likely influenced my 
analysis and structure of the findings with regards to the impact of ACHD on the various 
areas of people’s lives. Participants who described a negative impact of ACHD on their lives 
were perhaps given particular weight during data analysis partly because their experiences 
resonated with the theoretical literature I was familiar with. However, I made sure to present 
positive or opposing narratives where it was relevant. My background in psychology may 
have also influenced my focus on narratives highlighting psychosocial processes that helped 
people cope and adjust to living with ACHD, in particular acceptance and the role of social 
support. It is possible that participants might have focused on other issues (e.g. satisfaction 
with healthcare) had I not somehow guided the conversation towards this direction.  
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Furthermore, the qualitative interviews were supplemental and designed to complement the 
dominant quantitative component of the thesis, thus the analysis and interpretation of the 
interview data were influenced by the quantitative study. Although it was not the aim of the 
qualitative study to look at the experiences of people within various diagnostic groups 
separately from each other, there were some data that suggested the differing ways ACHD 
had an impact on these groups of people. I discussed these differing experiences but I have 
not explored them in much depth due to the limitations of the study in terms of time and 
resources to allow for data saturation within groups. It is possible that these observations 
were influenced by my assumptions that the four diagnostic groups would experience 
challenges to differing degrees. 
Throughout the analysis and interpretation I was influenced by my knowledge of the field. I 
drew from existing literature and concepts from theories (normalization and uncertainty are 
two examples) to make sense of the data. During the final stages, I realised that there was a 
need to consciously choose the data that I was going to present, which were relevant to the 
research questions of the study. I understand that these decisions were influenced by various 
factors such as writing an interesting and coherent story to be presented to the wider 
academic community that remained true to the participants’ experiences. Thus, I selected 
quotes that were more illustrative of the point I wanted to get across, ensuring that all 
participants were represented. Overall, I recognise that my research background may have 
had an impact on the interpretation and the presentation of the participants’ experiences. 
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Appendix CC. Stage 2 of framework analysis: grouping categories thematically and developing an initial conceptual framework (example 
of initial themes & sub-themes that were later developed into the overarching theme of coping) 
Key theme Sub-themes Description Example of indexed data 
C
o
pi
ng
 
Adjusting to 
physical 
limitations 
Process of accepting the condition and their 
limitations and how they incorporate them into 
their lives. 
“just focusing on certain house chores I would do, but I will do it 
and I’ll have a rest afterwards so I just... pace myself to do it and the 
jobs really in the house” 
Adjusting to 
treatment 
 
Accepting and adjusting to their treatment 
regimen. 
“So used to them [hospital visits] now, it’s no, no problem at all. 
You’re sort of used to the people, what, you know, the various things 
that you have to do. Sort of, sort of it’s like a routine” 
Being positive 
 
Positive feelings of luck, positive 
outlook/optimism, and gaining perspective. 
“I suppose just emotionally...just that the fact that, yeah, that the, 
the realisation that “I am here” and that I was a lucky one” 
Seeking 
support 
 
Actively seeking practical support, advice, and 
emotional support from family, friends, and 
HCPs. Also includes deliberately hiding facts and 
feelings from others. 
“Sharing it helps you eem but sometimes, you know, actually “Do I 
want her to worry as much as I’m worrying about it?” Probably not 
so, you know, you keep that bit inside you” 
Social 
comparisons 
Comparisons with other people including those in 
worse and better condition. 
“There’s people in the world with much worse heart conditions than 
me but travel the world…It’s like I’m gonna have to put things into 
perspective” 
Pe
rs
o
n
a
l 
co
n
tr
o
l n/a Whether (or not) they feel that they have control over their QoL and what they think they can do to 
change it. 
“I don’t think, I’m not in control. Your health’s in control isn’t it? 
You can’t control your health, well you can...but obviously I can’t 
control it. If my heart wants to go...funny or...what, I can’t control 
that” 
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Key theme Sub-themes Description Example of indexed data 
So
ci
a
l s
u
pp
or
t 
Support from 
partner  
Ways their partner provides support.  “he [husband] really pushes me to do all of those things. So he 
might remind me to take my tablets” 
Support from 
parents 
 
Ways their parents provide support. “I think my mum is more physical support for when I’m too ill to do 
things. She will come over and, like I said previously help me cook 
dinner” 
Support from 
friends 
 
Ways their friends provide support. “I was, got really upset, my friend was straight round after work, 
saying “Right if we can’t do this, we can’t do it. There’s no point 
you making yourself all over it or having your plan” and I needed 
that then” 
Support from 
employer and 
colleagues 
Ways their employer and colleagues provide 
support. 
“we’ve got a good team at work, there’s a good team of us 
so...there’s always some support there” 
Support from 
healthcare 
professionals 
Ways HCPs provide support. “N [nurse] gave me one of these...sort of relaxation CDs, you know, 
with the breathing and the visualisation and stuff. And that actually 
helped quite a lot” 
Preferred 
support 
Type of support they want/need. “I like to think I’m quite tough emotionally. So when I physically 
can’t do things it’s the physical things that I need help with” 
Qo
L 
m
ea
n
in
g Good QoL meaning 
What good QoL means for them. “It’s got to be your health comes first. Eeh and then just enjoying 
your family, enjoying your social life, and again work” 
Priorities Life domains they prioritise and/or give particular 
attention to. 
“I think my health is more important. Eem...looking after myself and 
looking after....my partner is more important” 
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Appendix DD. Stage 3 of framework analysis: developing and refining themes and sub-
themes from stage 2 (example of coping) 
 
Key theme Sub-themes Description 
Gaining perspective  Social comparisons 
 
Gaining perspective was developed as a main 
theme under which positivity and social 
comparisons were coded as sub-themes. Both 
were directed towards gaining perspective 
based on the coded data. 
Positivity 
Acceptance & 
adjustment  
n/a Formed by merging adjustment to physical 
limitations and adjustment to treatment. 
Treatment was not independent of disease 
impact. 
Social influence 
 
Receipt of social support  
 
Social influence was developed as a main 
theme under which receipt of social support 
and seeking social support were coded as sub-
themes. Seeking social support as a coping 
mechanism was not independent of the 
availability of social support. 
Seeking social support 
 
Priorities & goals  
 
n/a QoL meaning and personal control themes 
were merged into this theme as coded data 
reflected how people prioritise and how they 
try to control and improve aspects of their 
lives.  
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Appendix EE. Stages 4 & 5 of framework analysis: creating case by theme charts and interpretation (example of acceptance & 
adjustment) 
Theme: Acceptance & adjustment   
Case* Summary Illustrative quotations Notes/comments on patterns, 
relationships, explanations 
Ron 
male, 54, 
TGA 
Knowledge and acceptance of his limitations, 
getting on with it, avoiding activities he can’t 
do, adjusting speed/time for chores, leading 
normal life, hospital appointments part of his 
life, planning. 
“I know my limits if you know what I mean. I don’t 
run around, I can’t play football or I don’t go to the 
gym or anything like that but yeah I get by[…] there 
are certain things you sort of limit yourself, you know 
what yourself you can do” 
 Acceptance of ACHD as 
part of life and identity, 
acknowledging 
limitations, adjusting to 
limitations, and 
achieving normalcy.  Similar to normalization 
concept in previous 
studies – ongoing 
process?   Evident impact of health 
deterioration and change 
in treatment regimen on 
attempts to adjust – 
dynamic adjustment.  Degree of successful 
adjustment related to 
degree of consequences 
(see theme physical 
consequences)  
 
Janis 
female, 35, 
SV 
Avoiding activities she can’t do, concentrates 
on what she can do, acknowledging limits. 
“There’s always gonna be limits. That’s just parts of 
living with a heart condition. And it’s just finding 
ways of them not being a problem. So we don’t go to 
India for holiday. We go somewhere closer. That’s, 
to me that’s just common sense.” 
Peter 
male, 39, 
Simple 
Thinking strategies around his condition, 
avoiding activities that may cause problems, 
planning ahead. 
“[…] I guess if you take going to a holiday of 
altitude, rather than sort of pushing on through it and 
seeing how I go, I would just not really go on that 
holiday, cause it might be a problem and I don’t 
wanna get into a problem situation.” 
Robert 
male, 40, 
TGA 
Thinking ahead about activities, pacing himself 
for chores, plan the day, knowledge of his 
limits, not pushing himself. 
“just focusing on certain house chores I would do, 
but I will do it and I’ll have a rest afterwards so I just 
pace myself to do it…” 
Jim 
male, 36, 
ToF 
Always lived with it, accept it, dealing with 
issues as they come, acceptance of possible 
interventions, hospital appointments and tests 
as second nature, part of his life, normal life. 
“…you can make a big deal out of it if you want to or 
you just accept it as being there and you deal with it 
if issues come up. And I think that’s what I’ve tried to 
do with my life…” 
*Example chart includes only a subset of cases. 
